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Summary 
Role of EFA6B, Exchange Factor of Arf6, in epithelial morphogenesis and 
collective invasion of human mammary cells 
Epithelial tissue homeostasis is fundamental for the survival and maintenance of a healthy 
organism. During mammary gland morphogenesis, epithelial cells communicate with their 
surrounding stroma in order to orchestrate the formation of a functional organ by undergoing 
multiple cycles of controlled proliferation, epithelial-mesenchymal transition (EMT) and 
mesenchymal-epithelial transition, migration and invasion. In cancer cells, these processes are 
dysregulated. Thus, understanding how normal mammary cells preserve their homeostasis 
during development is crucial to identify the molecular events inducing breast cancer. 
Homeostasis of epithelia relies on key specific features: apico-basal polarity, cell cohesion and 
lumen formation. Here stands our protein of interest, EFA6B, exchange factor for Arf6, hence 
my interest in studying its role in mammary epithelial cells. During my PhD work, I investigated 
the role of EFA6B on epithelial integrity. 
Using CRISPR/Cas9 EFA6B knock-out cells, I showed that the loss of EFA6B deregulates the 
homeostasis of normal mammary epithelial cells at different levels. First, deleting EFA6B 
allows the formation of invadopodia rich in integrin ITGB1 and metalloprotease MMP14. My 
results indicate that EFA6B KO cells invasion is Cdc42-dependent, supported by increased cell 
contractility and the formation of protrusive branched structures through the 
Cdc42/MRCK/pMLC and Cdc42/N-WASP/Arp2/3 signaling pathways. Second, we showed 
that the loss of EFA6B is associated with the engagement of cells into EMT, revealed by a 
cadherin switch and an upregulation of EMT transcription factors. Third, coherently with 
EFA6B roles on junction assembly, its depletion prevented cells from polarizing and forming 
normal acini with central lumens. Collectively, our data are in agreement with previous results 
showing a correlation between the loss of EFA6B and the breast cancer claudin-low subtype 
defined by EMT properties, invasion capacities and a decrease in TJ proteins expression. 
I also contributed to the characterization of the role of α-actinin1 as an effector of EFA6A in 
normal epithelial cells (MDCK), and of EFA6B in a tumorigenic mammary cell line (MCF7). 
I show that EFA6B and α-actinin1 by regulating together the apical cellular contractility 
coordinate the establishment of apico-basal polarity and luminogenesis, two essential processes 
for functional epithelia. 
Altogether, these results demonstrate that the loss of EFA6B triggers invasive potentials in 
normal epithelial cells, and modifies their microenvironment (contractility, degradative 
invadopodia, alteration of the matrisome). We propose the gene PSD4 encoding for EFA6B as 
an invasion-suppressor gene that will preserve cells from losing their epithelial features in order 
to maintain tissue integrity. 
Key words: EFA6B, epithelial homeostasis, breast cancer, invasion, invadopodia, Cdc42. 
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 Résumé 
 
Rôle de EFA6B, facteur d'échange d’Arf6, dans la morphogenèse 
épithéliale et l'invasion collective de cellules mammaires humaines 
 
L'homéostasie des tissus épithéliaux est fondamentale à la survie et au maintien d'un organisme 
sain. Au cours de la morphogenèse des glandes mammaires, les cellules épithéliales 
communiquent avec leur stroma environnant afin d'orchestrer la formation d'un organe 
fonctionnel en passant par de multiples cycles régulés de prolifération, de transitions épithélio-
mésenchymateuse (TME) et mésenchymateuse-épithéliale, de migration et d’invasion. Dans les 
cellules cancéreuses, ces processus sont dérégulés. Il est donc important d’étudier comment les 
cellules mammaires normales conservent leur homéostasie au cours du développement pour 
appréhender les événements moléculaires induisant le cancer du sein. L’homéostasie de 
l'épithélium repose sur le contrôle de propriétés spécifiques : polarité apico-basale, cohésion 
cellulaire et formation de lumen. Notre protéine d’intérêt EFA6B, facteur d'échange d’Arf6, se 
trouve au cœur de ces caractéristiques structurelles, d’où mon intérêt à étudier son rôle dans les 
cellules épithéliales mammaires. Au cours de mes travaux de thèse, j'ai étudié l'impact de la 
perte d'EFA6B sur l'intégrité épithéliale.  
 
En utilisant des cellules épithéliales normales mammaires invalidées pour EFA6B par la 
technique de CRISPR/Cas9, j'ai démontré que la perte d’EFA6B dérégule fortement 
l'homéostasie épithéliale à différents niveaux. Premièrement, sa déplétion entraîne la formation 
d'invadopodes riches en intégrine ITGB1 et en métalloprotéase MMP14. Mes résultats 
indiquent que l'invasion des cellules EFA6B knock-out dépend de l’activation de Cdc42. Elle 
est soutenue par une contractilité accrue des cellules et la formation de structures branchées 
protrusives contrôlées par les voies de signalisation Cdc42/MRCK/P-MLC et Cdc42/N-
WASP/Arp2/3. Deuxièmement, nous avons montré que la perte d'EFA6B est associée à 
l'engagement des cellules EFA6B knock-out dans une TME, révélée par un échange de 
cadhérine et une augmentation de l’expression de facteurs de transcription mésenchymateux. 
Troisièmement, conformément au rôle d’EFA6B dans l'assemblage des jonctions serrées, sa 
déplétion empêche les cellules de se polariser et de former des acini avec un lumen central. 
Collectivement, nos données sont en accord avec des résultats précédemment publiés montrant 
une corrélation entre la perte d’EFA6B et le sous-type de cancer du sein invasif Claudin-low 
défini par une signature TME et une perte d’expression des protéines des jonctions serrées. 
 
J'ai aussi contribué à la caractérisation du rôle de l’α-actinine 1 comme effecteur d’EFA6A dans 
des cellules épithéliales normales (MDCK) et d’EFA6B dans une lignée cellulaire mammaire 
tumorigène (MCF7). Je montre qu’EFA6B et l’α-actinine 1, en régulant la contractilité 
cellulaire apicale, coordonnent l'établissement de la polarité apico-basale, la formation des 
jonctions serrées et du lumen. 
 
L'ensemble de ces résultats démontre que la perte d'EFA6B stimule les propriétés invasives de 
cellules épithéliales normales et impacte leur microenvironnement (contractilité, dégradation 
de la matrice, altération du matrisome). Nous proposons que le gène PSD4 codant pour EFA6B 
est un gène suppresseur d’invasion qui contribue à préserver l'intégrité des tissus épithéliaux. 
 
Mots clés : EFA6B, homéostasie épithéliale, cancer du sein, invasion, invadopodes, Cdc42. 
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“Prayer indeed is good, but while calling on the gods a man should himself lend a hand.” 
Hippocrates 
“Be realistic, Plan for a miracle.” 
Osho 
“…Another moment of discovery -its antithesis- that is rarely recorded: the discovery of 
failure. It is a moment that a scientist often encounters alone” 
-Dr.S.Mukherjee,
 The Emperor of All Maladies 
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Preface 
 
A brief walk with cancer: History and actuality 
 
“thus for 3000 years and more, this disease has been known to the medical profession. And for 3000 
years and more, humanity has been knocking at the door of the medical profession for a cure”. 
-Fortune, March 1937 
 
This disease is cancer and what else could it be! Described for the first time in 1600 BC, in an ancient 
Egyptian papyrus (the oldest medical report), a breast cancer case was stated among 47 cases of injuries 
and trauma, and was the only one to be considered untreatable at the time. Here we are in the 21st century 
and cancer is still a major threat to our societies. Global cancer estimations have risen to 18.1 million 
new cases and 9.6 million deaths in 2018. In other words, one in 5 men and one in 6 women worldwide 
will develop cancer during their lifetime, and one in 8 men and one in 11 women will die because of it. 
Cancer is also an economic disease where about 170 billion dollars are spent for the management of 
cancer patients. 
 
From radical surgeries and mastectomy to the discovery of chemotherapy and radiotherapy, cancer has 
witnessed some improvement at the treatment level but not enough to considerably reduce cancer 
mortality rate. The aggressiveness and heterogeneity of this disease makes it hard to target or control. 
Thus, more research is needed to better understand the process of cancer initiation and progression, and 
thus, propose more personalized and effective treatments. 
 
Who is behind this giant?! 
 
“It’s a bad bile. It’s bad habits. It’s bad bosses. It’s bad genes” 
-Mel Greaves,  
Cancer: The Evolutionary Legacy, 2000 
 
After Hippocrates suggestion that all illness have humoral causes, Galen proposed that cancer is caused 
by stagnating black bile. Then with the trend of viruses’ discovery, researchers claimed that all cancers 
are induced by viruses; this theory is still true for some cancers. Nowadays, we know that behind cancer 
initiation and progression stands an accumulation of gene alterations that will disrupt the homeostasis 
of normal cells. Some key mutations are capable of giving cells the capacity to proliferate and escape 
cell death and therefore to form a primary tumor. Additional mutations will allow hyperproliferative 
cells to become aggressive and invasive in order to colonize new organs and form tumors at distant sites. 
Heterogeneous, complex and resistant to treatment, it would be interesting to identify genes important 
for protecting normal cells from losing their integrity and becoming cancerous. 
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 My PhD thesis: A step towards better understanding Cancer 
 
My PhD objective was to study the role of EFA6B, our protein of interest, on normal mammary 
epithelial cell homeostasis. Interestingly, the loss of EFA6B solely disrupted normal epithelial cell 
behavior (polarity and luminogenesis) and provided cells with powerful invasive capacities. This thesis 
allowed the identification of EFA6B as a new guardian of epithelial cells characteristics, and an 
important gene for preserving cells from becoming invasive.  
 
In the hope that the results I present in this PhD thesis will open up new horizons for cancer research 
and bring us a step closer to conquering the so-called “Emperor of All Maladies”, Cancer
28
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 Introduction 
 
This is not an exhaustive summary of the literature. In my introduction, I will try to set a context for my 
PhD work and to highlight research studies and knowledge relevant to it. 
 
I. Mammary Gland: Physiology and Pathology 
1. Physiology 
1. 1. Mammary gland morphogenesis: key developmental steps 
Mammary gland is one of the main differential organs characterizing mammals; it evolved over 300 
million years most probably from sweat glands. This apocrine gland is responsible for producing milk 
during lactation required to support newborns’ survival and development.  
For developmental biologists, the mammary gland has always been an interesting model of study; unlike 
other exocrine organs, its development starts during embryogenesis but continues after birth through 
different stages of life: embryonic, pubertal and reproductive stages (Macias and Hinck, 2012). Our 
knowledge of the mammary gland morphogenesis is provided primarily from studies conceived in 
mouse models and extrapolated to human (Figure 1). 
 
Figure 1: Schematic representation of human and mouse mammary gland.  
Some structural differences exist: Rodents develop five pairs of mammary glands at reproducible 
locations with a fatty stroma rich in adipocytes while human’ only pair contains more fibrous connective 
tissue. Adapted from Visvader, 2009. 
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Overall, at the cellular level, the mammary gland is similar in human and rodents, and therefore data 
presented hereafter mostly from rodent models are relevant to the understanding of human breast 
development and disease. 
 
 
Figure 2: Morphological changes associated with the post-natal stages of mammary gland 
development.  
At birth, mice have few small branches that will grow slowly until hormone-stimulation at puberty. Then, 
a tremendous growth of the ductal tree occurs. Upon pregnancy alveologenesis is observed with the 
stimulation of prolactin. Involution is triggered by milk stagnation and consists of two stages. Stage 1 
consists of a reversible step where cells start engaging into apoptosis accompanied by alveolar cell 
detachment. At 48h, cells transition to stage 2 of the involution and alveoli breakdown by a second wave 
of apoptosis stimulated by the ECM and the proteolytic enzymes. At this stage, milk is definitely lost. 
The mammary gland is remodeled to its original architecture, and gain a new transcriptional signature. 
Adapted from Macias and Hinck, 2012 and Schedin et al., 2007. 
1. 1. 1. Embryonic development of the mammary gland 
Mammary gland derives from the ectoderm germ layer that later differentiates into the epithelial 
compartment and forms the rudimentary mammary bud present at birth.  
First, mammary placodes emerge defining the position of future mammary glands. Placodes are 
defined by ectoderm thickenings consisting of several shaped layers of ectoderm cells and are formed 
by physiological cell migration and aggregation, but not proliferation. 
Interestingly, already at this stage, the mammary gland is surrounded by a stromal compartment 
composed of cells deriving from the mesoderm. This embryonic mesenchyme plays a crucial role in 
orienting the differentiation of the epithelial layer into mammary precursors. This information has been 
proven by combining epithelial mammary cells with different types of mesenchyme. For example, 
combining salivary mesenchyme with embryonic mammary line produced an epithelium 
morphologically close to salivary gland (Kratochwil, 1969; Sakakura et al., 1976). In parallel, the 
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mammary epithelial line releases inductive signals stimulating the differentiation of the close 
mesenchyme layer into fibroblasts while more distant mesenchyme differentiates into fat pad precursors 
and adipocytes.  
At the end of the fetal development, the mammary gland precursor consists of a small network of 
polarized bilayered epithelia organized in simple ducts. 
 
1. 1. 2. Puberty & branching morphogenesis 
Until puberty, the mammary bud with its few rudimentary branches will remain in a quiescent state and 
grows proportionally to the body. With hormones and growth factors (growth hormone, Estrogen, 
insulin-like growth factor…) release, epithelial cells will fill the fat pad with extensive proliferation and 
will present growing ducts characterized by elongated tubes with multilayered cells forming at the tip 
the so-called terminal end buds (TEBs)***. TEBs are round shaped structures that will penetrate the 
stroma by dividing their outer cell layer (later differentiated in myoepithelial cells) as well as the 
underlying multilayer of luminal precursor cells (Ewald et al., 2008, 2012; Williams and Daniel, 1983). 
From these primary ducts, secondary branches sprout laterally to form a more complex tubular network.  
 
***Together with biochemical signals (growth factors, hormones, morphogens, etc.), mechanical cues 
(cellular contractility, matrix stiffness, intercellular cohesion, etc.) may trigger the activation of several 
signaling pathways in cells and seem to play an important role in branching morphogenesis, especially 
in defining the branching sites (Gjorevski and Nelson, 2010; Nerger and Nelson, 2018). In addition, 
mechanical forces have been shown to stimulate the expression of mesenchymal transcription factors 
(e.g. Twist1, Snail…) and therefore induce an epithelial-mesenchymal transition of leader cells 
important for mammary morphogenesis (Gjorevski and Nelson, 2010). It has as well been implicated in 
increasing extracellular matrix remodeling and the thinning of the basement membrane (physical 
barriers) by activating metalloproteases that will allow normal epithelial cells to invade the adjacent 
extracellular matrix, ECM (Mori et al., 2013; Wiseman et al., 2003). For more in-depth information, 
the following reviews present extensively the roles of mechanical forces in mammary morphogenesis : 
(Fata et al., 2003; Spurlin and Nelson, 2017; Varner and Nelson, 2014; Xu et al., 2009).*** 
 
The final pubertal tree pattern will increase tremendously the area of lobular structures to fill up to 60% 
of the fat pad and therefore prepare it for lactation when pregnancy occurs. Of note, the quiescent 
mammary gland of rodents contains ramified ducts only, comprising small lateral or tertiary branches 
that give rise to alveoli at pregnancy, whereas adult human mammary gland, even in the absence of 
pregnancy, consists of variable amounts of lobulo-alveoli (Anbazhagan et al., 1998; Naccarato et al., 
2000). 
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 1. 1. 3. Pregnancy, lactation and involution: a more complex ductal network 
Pregnancy hormones (mainly progesterone and prolactin) will prepare the mammary gland for another 
round of morphogenesis, and an increase in secondary and tertiary branching. These hormones will 
stimulate epithelial cell proliferation, angiogenesis and a decrease in the mammary adipose tissue. At 
this stage, terminal lobular structures will give rise to alveolar buds composed of into differentiated 
bilayered alveoli. During lactation, these alveoli will become milk secreting lobules, characterized by a 
central lumen and a single layer of secretory luminal cells enclosed in a layer of myoepithelial contractile 
cells.  
 
When weaning occurs and milk stagnate in the lobules, involution begins bringing back the quiescent 
ductal mammary architecture and a modified gene expression profile. Apoptosis, stimulated in part by 
the breakdown of ECM, will play a major part in reducing the excess of branching and replacing it with 
adipocytes. Besides apoptosis, the crosstalk between ECM and epithelial mammary cells have its role 
in the involution; as the important remodeling of the stroma by the metalloproteases (Figure 2) (Macias 
and Hinck, 2012). 
 
Conclusion 
Mammary gland morphogenesis is a finely tuned complicated process in which different cell types have 
to integrate external and internal signals to multiple different cycles of proliferation, migration and 
invasion. The different cellular components of the mammary tissue interact with their surrounding 
stroma or mesenchyme in order to orchestrate the formation of a functional organ. Identifying the 
molecular control and the spatiotemporal regulation of these events is key to further understand the 
cellular homeostasis of this tissue but also for a better interpretation of molecular events inducing and 
promoting breast cancer. 
 
1. 2. Mammary gland architecture: key components 
As presented in paragraph I-a, the mammary gland is composed of stromal tissue in which mammary 
epithelium develops. Along with external signals (hormones, growth factors…), these two 
compartments interact and exchange information continuously to ensure a normal and functional gland 
development. 
In this section, we will delve into cell types and constituents of the epithelium and the mesenchyme of 
mammary gland: characteristics, origin, and interaction. 
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 Figure 3: Ductal and TEB cellular composition and branching regulation at the TEBs.  
Branching is ensured by TEB collective migration facilitated by MMPs dependent degradation of the 
ECM. In addition, ECM remodeling by MMPs generates functional peptides which stimulate the 
proliferation of cells at the TEBs essential for sustaining the ductal elongation. Myoepithelial cells with 
the turn-over of basal membrane allow the migration of TEB cells but restrain any formation of cellular 
protrusion. In the lower panel, green indicates the immunostaining of keratin 5 in myoepithelial cells of 
mice mammary gland. The ductal myoepithelial cells of a 10 weeks old virgin mouse show a continuous 
monolayer while alveolar myoepithelial cells (2-day lactating mouse mammary gland) show a stellate 
architecture. Adapted from Moumen et al., 2011; Spurlin and Nelson, 2017. 
1. 2. 1. Epithelium compartment 
The mammary epithelium is composed of two main epithelial cell types: luminal and basal cells. 
Luminal cells are Keratin 8 & 18 positive cells facing the lumen and secreting milk during lactation, 
surrounded by basal/myoepithelial cells (Keratin 5 & 14 positive) characterized by their contractile 
capacity (smooth muscle α positive) and are in direct contact with the stroma (basement membrane and 
extracellular matrix). 
Luminal and basal epithelial cells are connected within the same layer or between each other through 
adhesion complexes and will adopt different architectural and functional characteristics depending on 
the stage of morphogenesis of the mammary gland as well as the functional unit they are composing 
(ducts, TEB/alveoli). 
 
Luminal cells: 
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Within the ductal unit (Figure 3), luminal cells are in direct contact with myoepithelial cells and form 
a monolayer of cuboidal polarized cells connected through strongly expressed adhesion complexes: 
tight junctions, adhesion junctions, gap junctions and desmosomes. In particularly, luminal cells express 
two specific desmosomal cadherins (desmocollin 2 & desmoglein 2), and one of the most studied 
adherens junction proteins, E-cadherin (Daniel et al., 1995; Deugnier et al., 2002; Faraldo et al., 2005; 
Kendrick et al., 2008; Muschler and Streuli, 2010; Pitelka et al., 2009; Runswick et al., 2001; Shamir 
and Ewald, 2015). 
 
In the TEB (Figure 3), cell proliferation drives the ductal elongation and establishment of multi-
layered luminal cells (Lu et al., 2008). At this dynamic level, in 3D culture and in mice, stratification 
occurs when luminal cells of the duct give rise to less polarized daughter cells, expressing fewer 
adhesion molecules (Huebner and Ewald, 2014). This asymmetric cellular division takes place in an 
apical vertical manner, placing new cells between the polarized luminal cells and the myoepithelial 
layer.  
 
Besides proliferation, ductal elongation uses collective migration to drive mammary branching (Ewald 
et al., 2008, 2012). Collective migration requires cells to stay connected and hence the importance of 
adhesion proteins. Consistent with these findings, in an in vitro model of dissemination, mammary cells 
expressing Twist1 (a mesenchymal transcription factor) can migrate through a 3D matrix while 
preserving their adhesive properties (E-cadherin*** expression required) and proliferation capacities 
(Shamir et al., 2014, 2016). In addition, some studies have revealed the importance of E-cadherin 
expression at different stages of mammary morphogenesis. Shamir et al, in vivo, showed that E-cadherin 
expression is important for ducts formation and homeostasis; noting that cells negative for E-cadherin 
have been extruded from the elongating ducts (Shamir et al., 2014). E-cadherin is as well crucial for 
normal milk secretion during lactation; a reduced amount of milk proteins have been reported in alveoli 
structures deleted for E-cadherin (Boussadia et al., 2002). 
 
I mentioned that ductal elongation occurs through a collective migration combined to an invasion of the 
extracellular matrix without sending cellular or membrane protrusions (Ewald et al., 2008, 2012; 
Huebner et al., 2016). In 1983, Williams & Daniel noticed, using phase real-time phase contrast images, 
that luminal cells of the TEB are in a dynamic state of extension and retraction (Williams and Daniel, 
1983). More recently, in silico, these extensions have been seen as attempts to prepare luminal cells for 
intercalating into the basal layer, and therefore elongating the pubertal ducts (Neumann et al., 2018). 
One major difference with invading carcinomas that duct elongation of normal mammary adopts 
collective cell migration with no cellular dissemination. It is interesting to understand in normal 
mammary models in vitro and in vivo the mechanisms and signals ruling epithelial homeostasis not only 
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to understand epithelial tissue development but to also have more insights on which mechanisms might 
be disrupting the epithelial homeostasis and causing tumor initiation and progression. 
 
***Cadherins are transmembrane proteins that develop calcium-dependent intercellular homophilic 
interactions via their extracellular domain. E-cadherin is the main cadherin expressed by epithelial 
cells. Its cytoplasmic domain is associated with β-catenin and p120-catenin. The α-catenin binds to β-
catenin and other actin-binding proteins such as vinculin and α-actinin, thus allowing the anchoring of 
adherens junctions to the actin cytoskeleton. Many additional proteins can then be recruited such as 
Arp2/3, cortactin, and small Rho-GTPases (Rac1, Cdc42 and RhoA) responsible for organizing the actin 
cytoskeleton associated to E-cadherin*** 
 
Basal cells: 
 
The basal layer consists of myoepithelial cells forming a continuous monolayer around ducts and a 
loose layer (stellate shaped) around alveoli enclosing luminal cells that are rarely in direct contact with 
the basement membrane (Figure 3) (Moumen et al., 2011). Structurally, myoepithelial cells are 
connected to ECM through hemidesmosomes (the integrins) and some non-integrin receptors such as 
dystroglycan, syndecan, galactosyl transferase and to luminal cells through desmosomes. They are 
characterized by the expression of P-cadherin and alpha smooth muscle actin, a marker of their 
contractility function (Daniel et al., 1995; Moumen et al., 2011).  
 
During development, myoepithelial cells play an essential role regulating the overall homeostasis as 
well as ductal morphogenesis of the developing mammary gland and in establishing luminal cell polarity 
(Adriance et al., 2005). 
 
Homeostasis of developing mammary gland: 
The communication of myoepithelial cells with their luminal neighbor cells is in part ensured by 
differential expression of ligand-receptor. For example, the exclusive expression of Ephrin receptor 
EphB4 by myoepithelial cells whereas its ligand Ephrin 2 expression is restricted to luminal cells  
(Andres and Ziemiecki, 2003). An imbalance of this distribution alters the survival and proliferation of 
mammary epithelium. Other examples are reviewed by Moumen et al., 2011.  
Another crucial function is that myoepithelial cells participate to ECM production by expressing 
components of the basal membrane (as laminin-1, laminin-5, collagen IV and fibronectin) (Warburton 
et al., 1982) and remodeling of the latter by secreting matrix metalloproteases (Dickson and Warburton, 
1992). 
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The integrity of myoepithelial layer is a major criterion for maintaining a normal tissue as well as 
preventing cancer cells of disseminating. In patients, a damaged basal layer correlats with poor 
prognosis and helps distinguish Invasive Ductal Carcinoma from Ductal Carcinoma In Situ (Man and 
Sang, 2004; Man et al., 2003; Sternlicht and Barsky, 1997). In mice, P-cadherin (mainly expressed by 
myoepithelial cells) deficient mammary glands develop late in life hyperplasia lesions in the epithelium 
(Radice et al., 1997). 
 
Ductal morphogenesis: 
Myoepithelial cells are partially responsible for restricting the protrusive potential of TEBs cells during 
their collective migration. They form a barrier retaining luminal cells from dissemination during TEB 
progression (Figure 3) (Hu et al., 2008; Sirka et al., 2018). Recently, Sirka et al showed that normal 
myoepithelial cells restrain Twist1+ disseminating luminal cells and prevent them from invading the 
collagen of 3D organotypic culture (Sirka et al., 2018). On the other hand, myoepithelial cells take part 
in producing laminins (especially laminin-1), main components of the basal lamina that have been 
strongly correlated with the inhibition of epithelial cell invasion, especially in malignant contexts 
(Nguyen-Ngoc et al., 2012).  
 
Luminal cell polarity: 
This capacity of secreting laminin-1 stands behind the role of myoepithelial cells in maintaining the 
apico-basal polarity of luminal cells (Bissell and Bilder, 2003; Gudjonsson et al., 2002). Indeed, luminal 
cells cultured in 3D collagen matrix have reverted polarity and lack a central lumen, a main characteristic 
of normal acini. However, when co-cultured with myoepithelial cells in the same matrix, luminal cells 
display a normal polarity with the apical side of the cells facing the lumen (Gudjonsson et al., 2002). 
 
During lactation, under the stimulation of oxytocin hormone, myoepithelial cells contract and expulse 
milk from acini into collector ducts, and to the nipple (Reversi et al., 2005). Here, gap junctions and 
cadherin interaction function as mechanical regulators of the smooth milk ejection. 
 
1) Stem cells 
Mammary gland undergoes an extensive remodeling during its development. This characteristic 
suggests an important regenerative capacity of a stem cell subpopulation. This hypothesis has been 
demonstrated especially by stem cell enrichment followed by transplantation assays. Epithelial 
mammary cells, sorted on the basis of various cell surface markers and transplanted into cleared fat pads 
were capable of generating normal branching epithelia (Daniel, 1975; Faulkin and Deome, 1960; 
Kordon and Smith, 1998; Plaks et al., 2013; Shackleton et al., 2006; Spike et al., 2012; Stingl et al., 
2006; Zeng and Nusse, 2010). 
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These different studies (reviewed in detail by Inman et al., 2015) used variable markers which generated 
inconsistencies in the definition of the stem cell or progenitor sub-populations residing in the epithelial 
compartment of the mammary gland. For instance, whether this sub-population is present in the basal 
or in both luminal and basal layers is still a subject of controversy. A limiting experimental factor is the 
fact that manipulating cells in vitro and removing them from their environment before injections can 
affect their behavior and stimulate some stem cell characteristics. 
 
As of today, several markers are used to define mammary stem cells and progenitors. In human breast 
tumors, a high CD44 and low CD24 expression is believed to mark a sub-population of cells bearing 
stem cell characteristics (Al-Hajj et al., 2003). However, in 2007, C. Ginestier et al have challenged this 
notion. In fact, CD44high/CD24low normal and cancer cells were not able of generating a mammary gland 
when implanted in mice mammary fat pad. They suggested instead the use of aldehyde dehydrogenase 
1 (ALDH1) as a more specific marker for stem and progenitor cells (Ginestier et al., 2007).] 
 
In the last decade, lineage tracing techniques allowed researchers to follow cells’s origin, segregation, 
and differentiation, in situ, in their physiological contexts. A recent study by C.Blanpain’s lab have 
shown that multipotent stem cells exist only during embryonic mammary development unlike other 
epithelial tissues. They have also demonstrated that postnatal mammary development is supported by 
distinct unipotent progenitors of basal and luminal cells (Wuidart et al., 2018). 
 
Nevertheless, limitations and variability related to this new technique exist as well: choice of the right 
promoters, as well as specific markers to trace and confirm these lineages at different developmental 
stages of the mammary gland. Therefore, other studies have demonstrated the presence of bipotent 
mammary epithelial cells in the basal layer  (Shackleton et al., 2006; Stingl et al., 2006; Visvader and 
Stingl, 2014). They suggest that these bipotent cells are capable of generating both luminal and basal 
cells in the post-natal development (Rios et al., 2014; Wang et al., 2015). An interesting discussion 
related to these controversies was addressed in the review of L.Seldin, A.Le Guelte and I.Macara, 
(Seldin et al., 2017). 
 
1. 2. 2. Microenvironment compartment 
The microenvironment surrounding cells establishes a part of the tissue architecture and has been 
implicated in diverse developmental processes as well as diseases. It is mainly composed of: 1) a 
basement membrane delineating the epithelium compartment and 2) a stroma called extracellular matrix 
(ECM) adjacent to the latter, homing different cells important for the homeostasis of the mammary gland 
(as fibroblasts, adipocytes, immune cells, etc.). This pleiotropic aspect comes from the rich diversity of 
microenvironment components (proteins and their isoforms) and their 3D pattern organization.  
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 The basement membrane (BM) is a highly organized structure lying directly underneath the epithelia. 
It adopts different morphologies depending on the structural unit of the mammary gland: basement 
membrane surrounding the ducts is thicker than the layer outlining TEBs which can be a functional 
consequence supporting growing ducts (measured first by (Williams and Daniel, 1983)). It is mainly 
constituted of laminins, collagen IV, nidogen and proteoglycans like perlecan (Maller et al., 2010). 
Laminins, the major BM proteins, are a family of multidomain heterodimers (α, β and δ chains) with 
the most expressed in developing mammary gland being: Laminin-111, Laminin-332, Laminin-511, 
Laminin-521 (Aumailley et al., 2005; Prince et al., 2002). 
 
Different integrin receptors will recognize these laminins and play a major role in sensing extracellular 
composition, density and architecture and translate it into intracellular signals required for epithelial 
morphogenesis, mainly cell polarity and cell migration. They can also perceive growth factors and 
cytokine signaling and control morphogenesis (Eyckmans et al., 2011, 2011; Glukhova and Streuli, 
2013; Katz and Streuli, 2007). In both rodents and human, various integrin dimers were revealed by 
immunohistochemistry: collagen receptors (α1β1, α2β1 integrin), fibronectin receptor (α5β1, αvβ3 
integrin) and high levels of laminin receptors (α3β1, α6β1 and α6β4 integrins binding respectively 
laminins 511/521/332, laminins 511/521/332/111 and laminins 332, 511, 521) (Moumen et al., 2011; 
Ramovs et al., 2017; Raymond et al., 2012).  
 
A great number of studies aimed at understanding the role of these different isoforms and dimers of 
integrins and their substrates. For instance, the major laminin of the BM, Laminin 111, helps polarizing 
luminal cells in the alveolar structures (Alcaraz et al., 2008; Gudjonsson et al., 2002). To investigate the 
role of integrins, KO mice have been established, and revealed that the mammary gland requires the α2 
subunit for branching morphogenesis but not the α3, α4 or α6 subunits (Chen et al., 2002; Kass et al., 
2007; Klinowska et al., 2001). Homozygous KO of integrin β1 was shown to be lethal for mouse 
embryos (Fässler and Meyer, 1995), which reflects its importance in early developmental processes. For 
mammary gland development, integrin β1 has an interesting role in regulating the branching 
morphogenesis by binding to the metalloprotease MMP14 and remodeling the ECM (Mori et al., 2013). 
It also acts during lactation on relaxing the focal adhesion tensions in response to myoepithelial 
contractility (Raymond et al., 2011) and on stimulating mammary epithelial differentiation and milk 
synthesis (Li et al., 2005; Naylor et al., 2005). 
 
Further information on the role of integrins in mammary gland development can be found in these two 
reviews : (Glukhova and Streuli, 2013; Kass et al., 2007).  
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2) Adjacent to the BM lies the stroma, a fibro and fatty collagen I-rich structure, harboring different 
cell types indispensable for the homeostasis, development, and immunological protection of a 
normal mammary gland.  
The stroma or extracellular matrix (ECM)*** is composed of fibroblasts, adipocytes, 
vascular and immune cells embedded in a matrix of collagen I, fibronectins, tenascins, SPARC 
(secreted protein acidic and rich in cysteine), decorins, proteoglycans, among other proteins 
such as ECM-remodeling enzymes and their regulators (Inman et al., 2015; Maller et al., 2010). 
 
***ECM protein families: 
Collagens a family of 27 distinct members is grouped into two large subfamily fibrillar collagens 
and non-fibrillar collagens (Myllyharju and Kivirikko, 2004).  
Proteoglycans (PGs) superfamily contains more than 30 large protein chains often linked to one 
or more glycosaminoglycan (GAGs) chains, such as heparin sulphate (Casu et al., 2010; Iozzo, 
1998, 2005). 
Elastin fibers are essential ECM macromolecules comprising an elastin core surrounded by a 
mantle of fibrillin-rich microfibrils and fibulin (structural glycoproteins) (Kielty et al., 2002). 
Glycoproteins  are proteins comprising short chains of carbohydrates covalently attached to 
amino acid side chains (Chothia and Jones, 1997). Some of the members of glycoprotein family 
are fibronectin, laminin, tenasin-C, etc.*** 
 
It has unique biophysical and biomechanical characteristics essential to support a wide variety 
of cell behaviors such as migration, mechanosensing and signaling. Depending on the 
developmental stage of mammary gland, the ECM will be modified to stimulate and enable a 
normal morphogenesis including epithelial branching and differentiation. 
 
The matrix density as well as 3D macromolecules arrangement will dictate the biophysical 
features of the stroma that recently emerged as a key player in affecting morphogenesis. For 
instance, during ductal branching, several ECM remodeling enzymes are expressed by both 
epithelial and stromal cells (like fibroblasts) and play an important role in epithelial branching. 
Among these enzymes, the most dominant are metalloproteases represented by two major 
families MMPs and ADAMs (reviewed by (Lu et al., 2011)). To further investigate their role in 
mammary branching, several mouse models were established with dysregulated MMP 
expression. An overexpression of MMP3 or MMP14 has shown an increase in lateral branching 
suggesting that a partial degradation of the ECM is sufficient to increase or facilitate mammary 
gland branching (Gomes et al., 2015; Mori et al., 2013; Wiseman et al., 2003).  
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Other interesting enzymes are lysyl oxidases (LOX) responsible for collagen cross-linking 
which can increase the stiffness of the stroma and thus alveolar morphogenesis (Bonnans et al., 
2014). The stiffness reflects the rigidity of the ECM, a biophysical feature that depends on the 
size and length of fibrillary collagen bundles. The degree of rigidity of the ECM dictates in part 
the differentiation of mammary epithelial cells (Engler et al., 2006; Schedin and Keely, 2011). 
 
ECM proteins were as well found essential to regulate branching. In a KO mouse model of 
fibronectin, ductal outgrowth was delayed in virgin mice and alveologenesis was absent in 
pregnant mice suggesting an interesting role of fibronectin in proliferation and differentiation 
of mammary epithelial cells (Liu et al., 2010). Similarly, loss of collagens and laminins, in other 
developing glands (as salivary gland) disrupted branching morphogenesis (Fukuda et al., 1988; 
Rebustini et al., 2007). 
 
Finally, ECM cellular components play a role in regulating various functions indispensable for 
mammary gland morphogenesis. For example, fibroblasts, main actors of ECM, will synthesize 
stromal proteins such as collagens, fibronectins, proteoglycans and many enzymes and 
communicate with the epithelium through growth factor and proteases (Howard and Lu, 2014; 
Inman et al., 2015). In turn, adipocytes exhibit an endocrine function; they release hormones 
regulating the mammary gland function (such as VEGF important for angiogenesis). They also 
consist of the energy stock needed for milk production, a metabolically demanding process 
(Gregor et al., 2013; Hovey and Aimo, 2010). Immune cells like macrophages and eosinophils 
were as well implicated in mammary epithelial branching; they were localized to branching sites 
where invasion into the fat pad occurs (Gouon-Evans et al., 2000). 
 
A full description of the numerous roles of the stroma and its components is beyond the scope 
of this thesis, but further information are covered in details in the following reviews: (Howard 
and Lu, 2014; Huebner and Ewald, 2014; Inman et al., 2015; Kass et al., 2007; Maller et al., 
2010; Schedin and Keely, 2011; Shamir and Ewald, 2015). 
 
Conclusion:  
ECM is a highly dynamic structure modulated constantly by enzymes secreted by both the 
epithelial and the stromal cells and is crucial to ensure a normal mammary gland morphogenesis. 
 
However, besides the fibronectin  KO mouse model (Liu et al., 2010), studies investigating the 
functions of other stromal components are held in vitro in cell lines. Therefore, research on 
animal models is needed to further understand the role of stroma in normal morphogenesis in 
an attempt to have a better understanding of its pathological implication. 
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 2. Breast Cancer 
2. 1. Epidemiology, Evolution and Causes 
 
Figure 4: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 
countries (2018). 
Breast cancer shows the highest rates of new cases emergence and death cases in women worldwide. 
Adapted from Bray et al., 2018. 
 
Breast cancer, the first cancer to be described in history, is still the most frequent cancer among women 
(Figure 4). In 2018, it is accountable for around 25% of all cancers with 2.1 million newly diagnosed 
cases worldwide. Breast cancer is considered the leading cause of death of women, with a majority 
(60%) occurring in economically developed countries (Bray et al., 2018). 
In France, more than 49 000 new cases and 12 000 death cases are estimated in 2018. This high incidence 
rate is attributed in majority to de novo breast cancer form, characterized by sporadic mutations. Several 
risk factors can increase the prevalence of these mutations:  age (aging population especially in 
developed countries), reproduction (having a late pregnancy at first birth, or nulliparity), hormone 
treatment after menopause, early menstruation, nutrition (alcohol, obesity…) (Bray et al., 2018; Britt et 
al., 2007). To note, only 5 to 10% of breast cancer are linked to hereditary factors with germinal 
mutations of genes involved in DNA and cell cycle control (like BRCA1, BRCA2 genes or other cancer 
susceptibility genes). 
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 2. 2. Heterogeneity and Treatments 
 
Figure 5: Intrinsic and extrinsic factors causing tumor heterogeneity. 
Various factors can contribute to the heterogeneity observed even within the same tumor. The ECM has 
been largely associated with tumor progression and it can vary depending on the molecular components 
and their architecture (stiffness, density, etc.) and in its cellular components with cancer-associated 
fibroblasts, immune cells, and endothelial cells. Hypoxia, cell metabolism, angiogenesis and epigenetics 
can play a major part in influencing the state of cancer cells (Lawson et al., 2018). 
Over the last few years, European countries have seen a notable decrease in breast cancer death 
incidence. The mammography screening has improved the survival rates by allowing to take in charge 
patients at earlier stages of the disease. Besides early detection, breast cancer is one of the most 
treatment-responsive solid tumors. Numerous treatments exist and can vary depending on the subtype 
and stage of cancer at diagnosis, one can cite: hormone therapy, chemotherapy, radiation therapy, 
immunotherapy, and surgery. Nevertheless, the total death number of breast cancer patients is still 
considerable.  
 
This reality lies behind the highly heterogeneous aspect of this disease, more specifically breast cancer 
(Figure 5). Mostly induced by sporadic mutations, breast tumors arise from an endless possible 
combination of altered genes and pathways. This plethora of causes is reflected by a variability of 
clinical outcomes and by the different evolution of the tumor in response to treatment. From resistance 
to relapses, the existing therapies have proven not sufficient to target all breast cancers.  
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 In fact, for early-stage cancer, clinicians usually proceed by removing the tumor surgically. This early 
management of the tumor has, in parallel, increased the prescription of chemotherapy. Around 60% of 
patients undergo combine surgery with an adjuvant chemotherapy in order to eradicate disseminated 
micrometastasis (Andre and Delaloge, 2009; Schmidt et al., 2009; Weigelt and Reis-Filho, 2010). 
 
Even with more effective therapies, up to 25 % of patients develop distant metastasis recurrence and no 
improvement in survival rates over the last 30 years (Tevaarwerk et al., 2013). It may be that the primary 
tumor and the metastatic sites do not require the same treatments. Indeed, gene profiling of primary 
tumors and distant metastasis have demonstrated that secondary tumors acquire new somatic mutations 
while progressing (Yates et al., 2017). Thus, it might be interesting to sequence tumors at all sites in 
order to suggest more adapted treatments. Besides the cellular heterogeneity of cancer, the stromal 
compartment plays an important role in dictating the tumor subtype and its aggressiveness. The 
exchange of extracellular matrix with epithelial cells has been demonstrated crucial for the development 
and progression of cancer (Place et al., 2011). Analysis of stroma components by matrisome profiling 
analysis can give correlations between clinical outcomes and specific treatments. Having this 
information will help to further stratify the classification of cancer and push towards more personalized 
treatments. I can refer to the interesting initiative launched by MIT university “The Matrisome Project” 
aiming to create a data base related to proteins constituting the Extracellular Matrix which can help 
cumulate data about the tumors’ matrisome as well. 
 
For now, therapeutic decisions and prediction of tumor progression are mainly based on breast cancer 
subtypes which are determined by different prognostic markers (tumor size, hormone receptors’ 
expression, histological grade, invasion, etc.), and more recently by large scale genomic profiling of 
primary tumors. Therefore, refining the classification of tumors will result in better predictions of the 
efficiency of a specific therapy, and optimize treatment decisions (Colombo et al., 2011). 
 
2. 3. Breast Cancer Classification 
Although pathologists and genomic data analysts have all agreed on breast cancer heterogeneity, they 
managed to establish common traits in order to classify tumors into clinically meaningful subgroups. 
For breast cancer, two main methods among others are used to categorize patients’ tumors: histological 
and molecular classifications.  
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 2. 3. 1. Histological Method: 
Histological grade 
The grading of tumors is based on a semi quantitative evaluation of three morphological 
criteria: percentage of tubule formation, degree of nuclear pleomorphism and mitotic index 
(Elston and Ellis, 1991; Weigelt and Reis-Filho, 2010). These features give an estimation of 
the differentiation state and the proliferative activity of a tumor. The different grades have 
been strongly correlated with prognosis: better survival rate is attributed to patients with grade 
I tumors than grade II or III. This grading method combined with an assessment of tumor size 
and the number of involved lymph nodes form the Nottingham prognostic index, a prognostic 
tool for breast cancer. 
 
Histological type 
The histological classification separates tumors according to their anatomo-pathological 
nature and is used by the World Health Organization (WHO). Most of breast lesions are 
initiated in mammary lobules or ducts, and are known as carcinomas. Depending on their 
location, they will be qualified as ductal (70 to 80% of cases) or lobular (10 to 15%) 
carcinomas (Weigelt et al., 2010). 
Two main carcinomas exist: 
a) The non-invasive carcinomas, mainly ductal carcinoma (DCIS) and lobular carcinoma 
(LCIS) in situ: They form cellular masses that will proliferate without overcoming the 
basement membrane or invading the stromal conjunctive tissue.  
b) The invasive carcinomas: They breach the endogenous physical barrier and are usually 
associated with poor prognosis. Unequal prognosis exists for the different types of infiltrating 
cancers indicating that they require different therapeutic management. They are classified 
according to their morphological aspects. Under the invasive carcinomas, we find different 
types with variable frequencies: invasive ductal carcinomas (80%), invasive lobular 
carcinomas (10%), and other rarer types including tubular (2%), medullary (1-3%), mucinous 
(3%), papillary (2%) carcinomas. 
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2. 3. 2. Molecular subtypes 
 
Figure 6: Breast cancer molecular subtypes.  
A. Breast cancers are classified into six subtypes: normal-like, Luminal A, Luminal B, HER2-
enriched, Basal-like and claudin-low, showing different epithelial status. B. TNBCs are a 
heterogeneous group primarily composed of Basal-like breast tumors. Claudin-low tumors 
constitute a significant proportion of TNBCs. Adaptef from Prat and Perou, 2009, 2011. 
Classical classification: Receptor status 
Up to date, classic clinical tumor classification is based mainly the expression of three hormone-
receptors: estrogen, progesterone and Her2 receptors, established by immunohistochemistry on 
patients biopsies (Torregrosa et al., 1997; Vollenweider-Zerargui et al., 1986). Combined with the 
histological methods, breast cancer has been classified into the five classical subtypes described 
below: Luminal A, Luminal B, normal-like, Her2 and basal-like subtypes. This classification is 
currently used by clinicians to give a diagnosis and decide on the treatment. 
 
Modern classification: Genomic signature 
 
In the beginning of the 21st century, genomic analysis came to refine the classification of this 
heterogeneous disease by proposing a new molecular classification (Figure 6) (Perou et al., 2000; 
Sorlie et al., 2001). Based on patient tumor samples, six subtypes were defined: two belonging to 
the positive estrogen receptors ER+ and three that are negative for ER (ER-). More recently a 
subtype called Claudin-low was added to ER- group (Hennessy et al., 2009; Herschkowitz et al., 
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2007; Prat and Perou, 2011b). Surprisingly, this more complex and modern classification did not 
really differ from the classical classification except for the Claudin-low subtype. 
In the positive estrogen receptors branch, two luminal subtypes are distinguished according to the 
activation of the estrogen pathway and some luminal epithelial characteristics: Luminal A 
expressing high levels of ER and PR receptors with a low proliferation index and Luminal B 
expressing a lower level of PR with a strong Ki67 and have worse prognosis when compared to 
luminal A. Both Luminal A and B are negative for HER2 receptors (Weigelt and Reis-Filho, 2010). 
For subtypes negative for ER, four have been separated: normal-like, HER2, basal-like and 
Claudin-low. 
The normal-like tumors are still poorly characterized: they share close signature with normal 
breast tissue and fibroadenoma but they need to be studied further to have their prognosis state and 
clinical relevance. HER2 subtype encloses tumors overexpressing HER2 receptors. This 
aggressive cancer is characterized by hyperproliferation and bad prognostics.  
 
The basal-like tumors are usually of a high grade and associated with poor prognosis. They 
comprise invasive ductal carcinomas and a high risk of metastasis. They express basal keratins 5 
and 14, and other basal markers such as the transcription factor p63, P-cadherin, integrin beta 4, 
etc. (Review of (Bertucci et al., 2012)). These tumors are often mutated for TP53 or PTEN (Sorlie 
et al., 2001). BRCA1 mutated tumors fall as well in this subtype. Up to 80% of basal tumors are 
classified as Triple Negative Breast Cancers (TNBC), related to the lack of ER, PR, or HER2 
receptors expression. However, even though tumors are for now called basal-like tumors, one 
should not confuse then with triple negative ones (Prat et al., 2013). The proposed stratification 
shows that 70 to 80 % of TNC are basal-like (Figure 6).  
 
Claudin-low, the latest classified subtypes, was discovered in 2007 by Herschkowitz et al 
(Herschkowitz et al., 2007). It is distinguished by a low expression of tight junction proteins 
(Claudins 3, 4, 7, occluding, etc.), a mesenchymal signature (increase in vimentin and N-cadherin 
expression, and a downregulation of E-cadherin) and some stem cell features. It accounts for 7-
14% of invasive breast cancers. The majority of Claudin-low tumors is TNC, and correlates with 
large tumor size, young patients, and immune cells infiltration (Prat and Perou, 2011b)(Prat and 
Perou, 2011b). However, they did not show an important local recurrence rate but they have worse 
overall survival than luminal A, the most benign subtype (Dias et al., 2017). 
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 II. The Strategies of Cancer 
 
1. Hallmarks of cancer 
 
As mentioned in paragraph I-A, mammary gland is a highly plastic organ that undergoes intense 
remodeling during different stages of life, which makes it more susceptible to accumulate errors in their 
genome and therefore encounter tumorigenesis. Tumorigenesis is basically linked to somatic mutations 
acquired by cells, and providing them with survival and proliferative advantages to escape regulatory 
mechanisms (immune system, DNA repair system, apoptosis, etc.) and resist to various stresses. 
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 Figure 7: DNA damages and cancer. 
A. Various damaging agents (chemical agents, radiations, intrinsic DNA stress) can cause different 
types of lesions in the genome (base mismatches, DNA breaks, DNA adducts). In normal cells, DNA 
repair mechanisms are put in place in order to maintain normal genes expression B. Once these 
mechanisms fail to repair gene alterations, cells will accumulate a number of mutations leading to a 
deregulation of the homeostatic state of cells (metabolism, balance of proliferation/apoptosis, escaping 
the immune system…) leading to cancer. Adapted from Hanahan and Weinberg, 2011; Helena et al., 
2018. 
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The last quarter of the 20th century has revealed a set of mutated genes that drastically predispose cells 
to cancer and drive tumor initiation and progression (Figure 7). Mainly, we witnessed the discovery of 
two major classes of altered genes: oncogenes found up-regulated or over-activated by gain-of-function 
mutations (such as Ras, myc, cyclin D1, ERBB2 etc.) and tumor suppressor genes that are 
downregulated or modified by loss-of-function mutations (such as TP53, PTEN, etc.) (Hanahan and 
Weinberg, 2000). These two gene classes have been identified first in cancer cell models, and later found 
to be equally altered in patient-derived tumors. In breast cancer, the most frequent oncogenes found 
altered are HER2 oncogene amplified or overexpressed in 20 to 30% of invasive BC and in majority of 
high grade DCIS, Cyclin D1 overexpressed in 40 to 50% of invasive BC and amplified in 10-20% of 
cases, and c-myc amplified or overexpressed in 15 to 25 % of BC cases.  Concerning tumor suppressors, 
TP53 and Rb (retinoblastoma) genes are mutated in 20 to 30% of breast cancers (Osborne et al., 2004). 
Other mutations were found in the germline and are responsible for increasing the risk of developing 
breast cancer (such as BRCA1, BRCA2, etc.) (Thompson, 1994). 
 
But one is not sufficient! In vitro, transforming rodent cells requires at least two mutations in order to 
acquire tumorigenic capacities, and it is even more complex to transform their human counterparts 
(Elenbaas et al., 2001; Hahn et al., 1999). In reality, cancer initiation and progression lies behind an 
accumulation of a multiplicity of impactful mutations. It was suggested that a normal cell turns into a 
cancer cell after a succession of four to seven genetic changes. It is important to note that only the so-
called driver mutations targeting genes regulating vital processes for cell homeostasis, but eventually 
cells will carry numerous silent or passenger mutations targeting marginal non-coding sequences or 
redundant functional genes. After the trend of driver mutations, an increased interest by the research 
community and pharma companies was given to a set of genes that we will call secondary driver 
mutations. Some gene alterations, even though incapable of transforming a normal cell, are providing 
important advantages for tumor cells to evolve towards malignancy (Nik-Zainal and Morganella, 2017). 
For instance, new attempts in curing cancer by targeting secondary driver genes exist such as in Rho 
GEFs, the activators of Rho GTPases implicated in cancer cells migration (Cardama et al., 2017), or 
metalloproteases implicated in the degradation of tumor cells extracellular matrix and their invasion 
(Cathcart et al., 2015). 
 
To add to the complexity of cancer, gene expression can be equally altered by modified epigenetic 
regulators (e.g. methylation, chromatin state) as well as non-coding RNAs (Flavahan et al., 2017). 
 
Cancer can then be defined by an unlimited number of altered genes combinations. But despite the 
heterogeneity of this disease, cancer cells seemed to share some acquired common capabilities. 
Vogelstein et al have considered the altered signaling pathways in a cancer cell to regulate three vital 
functions: genome maintenance, cell fate and cell survival (Vogelstein et al., 2013). Using a more 
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detailed approach, Hanahan and Weinberg proposed originally six common traits: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis. With further 
understanding of the disease, four common features were added: changes in cellular metabolism, 
genomic instability, escaping the immune system and tumor inflammation (Figure 7) (Hanahan and 
Weinberg, 2011). 
*** 
Compiling the impact of these mutations on cell physiology will lead normal cells through the labyrinth 
of the metastatic cascade. 
1. 1. From tumorigenesis to malignancy: the metastatic cascade 
From hyperplasia (defined by an unusual increase in tissue size resulting from cell proliferation), up to 
invasive metastatic tumors, cells have to climb a ladder of successive genome and cell transformations. 
Before diving into the molecular regulators, here’s a brief walk through cancer sequential progression 
(Figure 8). 
 
Figure 8: The metastatic cascade. 
The metastatic process involves a series of steps that allow a tumor cell to migrate, integrate another 
tissue and develop a secondary tumor. To this end, invasive cells of the primary tumor degrade the 
basement membrane, escape into the connective tissue and, penetrate into blood vessels (intravasion). 
In the circulating system, tumor cells interact with immune system cells and the platelets that protect 
them during transport. In order to leave the vessels, circulating tumor cells adhere to the inner vascular 
wall of vessels, and escape through extravasation to the neighboring tissue. Arrived at the secondary 
site, tumor cells can encounter three different destinies. First, tumor cells can directly adapt to their 
new microenvironment, proliferate and form a tumor at a distant site, so-called metastasis. Second, they 
might stay as dormant cells for a certain period of time, a quiescent non-proliferative state requiring a 
mesenchymal to epithelial transition. Third, tumor cells can fail at this last step to survive the new 
microenvironment or escape the attacks of the immune system. Adapted from Yap, 2015. 
  
52
1. 1. 1. Initiation 
It is the first phase of tumorigenesis where a normal cell acquires one or several mutations that will be 
transmitted to daughter cells. These mutations can occur due to an error in DNA duplication during cell 
division or can be induced by genotoxicity (DNA damage caused by chemical agents) or other toxic 
factors (such as stress, radiation…). Cells have developed DNA repair mechanisms that will consistently 
proofread DNA sequence and make sure to either suspend the cellular division in order to fix any 
possible errors to stop the whole process by initiating apoptotic signals. Since it is a matter of fidelity, 
it happens that DNA damage will not be accurately repaired leading to genetic alterations (Nikolaev and 
Yang, 2017; Wood, 2018). Since half a century, a deficiency in DNA repair was linked to disease, in 
particular cancer. 
At each division cycle, more mutations can add up to the existing ones until resulting dysregulated 
pathways are sufficient to transform the cells carrying them. The transformation is primarily an 
immortalization, where cells will have the capacity of proliferating at high rates. This will result in a 
small benign mass, mostly not detectable clinically.  
 
1. 1. 2. Progression 
It is an irreversible state where hyper-proliferating cells will gain in autonomy to escape cell death as 
well as the defense of the immune system. At this stage, cells will undergo mitosis and accumulate a 
diversification of new mutations. The formation of a tumor can be compared to the theory of species 
evolution, with the selection of cells benefiting from survival advantages and malignant potentials and 
resulting in waves of clonal expansion (Merlo et al., 2006). 
In support to primary tumor growth, blood vessels and lymphatic systems will be developed by processes 
called respectively angiogenesis and lymphogenesis in response to signals from stroma and cancer cells. 
These vessels make it possible to provide nutrients and oxygen necessary for tumors and to remove their 
metabolic waste (Nishida et al., 2006). Along with the increase of cancer size, tumor cells are likely to 
go through morphological and functional modifications resumed as the epithelial mesenchymal 
transition EMT (detailed in 2. Epithelial mesenchymal transition). They will also modify the components 
of their extracellular matrix and its biomechanical properties, all of which prepare cells to reach the last 
stage of this cascade by invading and metastasizing. 
 
1. 1. 3. Invasion and Metastasis 
The clinical manifestation of metastasis appears when cancer cells successfully initiate detectable 
tumors at secondary sites of the body. The process of metastasis usually starts by a local invasion of the 
surrounding tissue, which is followed by some primary cancer cells getting to the blood stream through 
the endothelial basal membrane (Figure 8). Surviving tumor cells have then to adhere to vessels’ 
membrane, exit the periphery and form new metastatic foci. However, how tumor cells succeed to adapt 
53
and proliferate in the new tissue remain ambiguous. This question definitely needs to be further 
investigated in order to understand and control the metastatic phase, responsible for 90% of cancer 
patients’ death (Ribelles et al., 2014; Wan et al., 2013).  
Of note, using available sorting techniques and markers, around 50 circulating tumor cells only are 
collected per milliliter of cancer patients blood (Yu et al., 2011). Dissemination is therefore considered 
a rare event, guaranteed only for cells that bypass apoptotic signals and the immune system. In breast 
cancer, about 25 % of patients develop distant tumors targeting preferentially some organs more than 
others ***. For instance, bone is the most metastatic site with an occurrence rate of 40 to 60 %, followed 
by the liver and lungs (occurrence ranging from 19 to 30 %) and finally the brain with 10% occurrence 
rate (Feng et al., 2018; Weigelt et al., 2005).  
 
 ***The metastatic organotropism is an old theory known as the “seed and soil theory”, proposed in 
1889 by Stephen Paget (Fidler, 2003; Ribelles et al., 2014). Looking at 900 biopsy records, he noticed 
that metastasis does not have a random pattern and suggested that this phenomenon can be based on a 
cross-talk between cancer cells (seed) and the microenvironment of the recipient organ (soil). But the 
mechanistic by which disseminated cells choose their secondary metastatic sites is still unclear. Recent 
papers suggest that a communication between cancer cells and their pre-metastatic niche can occur 
through chemokines and/or exosomes (Borsig et al., 2014; Paolillo and Schinelli, 2017). Notably, in 
breast cancer, organ-specific homing process was shown to be based on the expression of the chemokine 
receptor 4 (CXCR4) by tumor cells, while its ligand CXCL12 is predominantly expressed in the lymph 
nodes, lungs, liver and bone marrow, and weakly expressed in the other organs such as small intestine, 
kidneys, brain, skin and muscles (Borsig et al., 2014). A recent work by Hoshino et al shows that tumor-
derived exosomes can direct cells to specific future metastatic site (Hoshino et al., 2015). For instance, 
exosomal integrins α6β4 and α6β1 were linked to lung metastasis, while exosomal integrin αvβ5 was 
associated with liver metastasis.*** 
 
Besides how tumor disseminate, timing is still a notion that we cannot easily approach when dealing 
with cancer. To answer the question “when do cells leave the primary tumor?”, correlations were 
established between tumor size and metastasis. For instance, patients with large primary tumors are at 
higher risk of dying from metastasis. But recent studies are challenging this concept of late dissemination 
and have shown that, in DCIS in women, dissemination takes place as soon as the primary tumor is 
formed. In murine models of breast cancer, epithelial cells were shown to disseminate in the 
premalignant phase to the bone marrow (Hosseini et al., 2016; Hüsemann et al., 2008). After 
dissemination, cancer cells usually stay for a certain time in a quiescent state, called dormancy, defined 
by a mitotic arrest where cells exit the cell cycle and enter the G0 state. 
54
In the continuity of this work, further investigations are required to determine how and why do early-
disseminated cells survive in a dormant state for a considerable time and what factors release them from 
this dormancy.  
 
These two interesting reviews cover the latest discoveries that have unraveled many signaling pathways 
and characteristics of the tumorigenic process: (Balani et al., 2017; Wan et al., 2013). 
 
*** 
 
In the following sections, we will be focusing on two major biological processes driving this complicated 
metastatic cascade: the epithelial mesenchymal transition and invasion.  
 
 2. Epithelial mesenchymal transition  
 
The epithelial mesenchymal transition (EMT) was first described in the 1980s by Elizabeth Hay during 
chick embryogenesis as a transformation that accords to epithelial cells a high plasticity crucial for 
morphogenesis (Hay, 1995). Indeed, the formation of embryonic sheets requires cell migration and 
therefore, a loss of adhesion proteins and an activation of motility programs, two main characteristics of 
EMT. 
 
Besides embryogenesis and organ development, EMT has been detected in two other biological 
contexts: tissue regeneration and fibrosis, and cancer progression (Kalluri and Weinberg, 2009). 
We are going to focus on the latter, and try to cover the following questions:  
 
2. 1. What is the role of EMT in cancer progression? 
 
EMT is a dynamic process during which cells will lose major epithelial characteristics and gain 
mesenchymal properties. This is in response to driver mutations that will cause a change in their 
transcriptional program and induce complex functional and architectural modifications of the cells 
providing them with advantages required for cancer development. 
It is considered a major first step towards tumorigenesis, but has also been shown to intervene at 
advanced stages of cancer progression by favoring metastasis and resistance to therapy (Brabletz et al., 
2018). However, it is important to keep in mind the plasticity aspect of EMT and the potential cycles of 
EMT/MET (mesenchymal to epithelial transition***) occurring throughout the process of 
tumorigenesis. Metastatic cells may recover an epithelial state through MET after encountering the 
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normal stroma of a dissemination site, a signal suggested to be important to enter dormancy (Bloushtain-
Qimron et al., 2008; Chaffer et al., 2007). 
 
 ***Mesenchymal to epithelial transition-MET: 
An interesting notion worthy to note is the reversible aspect of the epithelial-mesenchymal transition. 
Mesenchymal cancer cells are capable of taking a mesenchymal-epithelial transition in order to gain 
back some epithelial features crucial for succeeding their invasive strategies. Indeed, an Australian 
research group have used a bladder cancer cell line that can switch between both status to show that, 
in mice, mesenchymal-type cells were more apt to leave the primary tumor while the epithelial-type cells 
were better at colonizing new organs (to adapt and proliferate in a new microenvironment) (Garber, 
2008).*** 
 
 
Figure 9: Morphological and gene expression changes of cells undergoing the epithelial-to-
mesenchymal transition (EMT). 
Epithelial cells are characterized by an apico-basal polarity and express several epithelial markers (E-
cadherin, ZO-1). During EMT, cells lose their cuboidal polarized shape and adopt an elongated 
mesenchymal form. This state is characterized by the expression of mesenchymal transcription factors 
(EMT-TFs) like Snail, Slug and Twist and other specific markers listed above. This transition is 
reversible and cells can gain back their epithelial state through MET. Adopted from (Kalluri and 
Weinberg, 2009; Micalizzi et al., 2010). 
 
Molecular markers associated to EMT have been established in cancer cell models and for the majority 
validated in animal cancer models (Figure 9). The relevance of these biomarkers for human cancer is 
still under discussion and need thorough research. Yet, some EMT-related markers have shown clinical 
significance in specific contexts and were summarized by Wu et al. (Wu et al., 2016). 
 
*** 
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 The findings presented below are not an extensive summary of EMT, but rather studies relevant for this 
PhD thesis. I am going to expose the main morphological and functional changes during EMT and the 
key transcription factors orchestrating the majority of these changes. 
 
2.1.1 There is a first step to everything: loss of polarity and adhesion proteins 
 
Epithelial cells are mainly defined by two features that are crucial to the function of epithelial tissues: 
cellular adhesion and apico-basal polarity. Thus, the disruption of these epithelial characteristics during 
EMT alters the whole tissue integrity and have been shown to boost cancer progression at several levels: 
increasing tumor growth, facilitating invasion and metastasis, as well as modifying the immune-response 
of tumor cells. 
 
During early steps of EMT, the disassembly of adhesion complexes such as tight and adherens junctions 
occurs in epithelial cells. First descriptions of EMT were mainly focused on the loss of E-cadherin, a 
major epithelial adherens junction protein. E-cadherin function can be regulated through different 
mechanisms. Transcriptional silencing, gene mutation, or hypermethylation of CDH1  (the gene 
encoding E-cadherin) promoter have been reported in breast cancer (Conacci-Sorrell et al., 2002). 
Likewise, the same mechanisms apply to the downregulation of claudins, occludins and ZO1 (Zonula 
Occludens 1) molecules concordant to tight junctions’ disassembly during EMT (Ozdamar et al., 2005; 
Viloria-Petit and Wrana, 2010). 
 
E-cadherin, is a transmembrane glycoprotein of 120KDa forming homotypic interactions through their 
extracellular domains and bridging two neighboring epithelial cells. Immunohistochemistry on tumor 
biopsies has shown that low expression of E-cadherin correlated with cancer metastasis and patients 
death (Birchmeier and Behrens, 1994). Similarly, in human cell lines, E-cadherin negative cells were 
characterized by a mesenchymal morphology and the acquisition of migratory and invasive capacities 
(Frixen et al., 1991). This was followed by an in vitro validation; overexpressing E-cadherin in 
mammary mouse cells resulted in blocking invasion (Vleminckx et al., 1991). Other studies as well 
classified E-cadherin as an invasion suppressor molecule (reviewed by (Shamir and Ewald, 2015)). 
 
Surprisingly, the loss of E-cadherin that was first attributed to invasive lobular carcinoma, has later  been 
reported in benign lobular carcinoma in situ (Vos et al., 1997). As the latter suggests, loss of E-cadherin 
might not always lead to invasion. Concomitantly, Kowalski shows that often primary breast tumors and 
their distant metastasis express E-cadherin (Kowalski et al., 2003). In other contexts, its expression has 
even been considered advantageous for invasion. For instance, in vitro knockdown of E-cadherin 
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inhibited twist1-induced dissemination in primary murine mammary epithelial cells (Shamir et al., 2014, 
2016). Thus, in the midst of several studies stating a correlation between E-cadherin levels and 
metastasis, some did not detect any clear relation linking E-cadherin status with tumor aggressiveness 
(Shamir and Ewald, 2015).  
 
All these data reveal that E-cadherin is an important protein for maintaining tissue integrity and 
homeostasis, nevertheless in BC its absence is not a pre-requisite to acquire invasive capacities essential 
for metastasis. Knowing that cancer cells can take many alternative pathways to reach invasion, 
variabilities that we just presented can be explained by tumor heterogeneity. It can as well be related to 
the plasticity aspect of the EMT process with detection bias generated by potential transient modulation 
of E-cadherin expression levels. This controversy can be linked to the association of E-cadherin with 
different signaling pathways. Indeed, an additional level of complexity comes from the pleiotropic 
feature of E-cadherin. Loss of E-cadherin does not only disrupt cell-cell adhesion but it is as well 
implicated in activating different signaling pathways (contact-inhibition, apoptosis, etc.). In normal 
cells, E-cadherin is connected to the actin cytoskeleton by their cytoplasmic tail through the catenins 
adaptor proteins (mainly β-catenin). Once E-cadherin is removed from the membrane, catenins will be 
released in the cytoplasm, transferred to the nucleus and modify gene transcription. However, catenins 
are not E-cadherin’s only mediators. In cancer cells, E-cadherin-related EMT modifications can be 
induced by Twist1 mesenchymal transcription factor (Onder et al., 2008) as well as by E-cadherin 
interactions with transmembrane receptors (EGFR, TGF-β-R, ERBB2), and cytosolic proteins (APC, 
Rho-GTPases) (Perrais et al., 2007). 
 
During EMT, the strong adhesion ensured by E-cadh is usually replaced by weaker homotypic 
interactions provided by other cadherins (N-cadherin, P-cadherin), allowing the transition from a pro-
adhesive to a pro-migratory state of collective invading cells (Cavallaro and Christofori, 2004; Cavallaro 
and Dejana, 2011). N-cadherin, the most commonly expressed in cancer cells, has been shown to 
contribute to invasiveness in human cell lines and metastasis in vivo in nude mice (ElMoneim and 
Zaghloul, 2011; Nakajima, 2004). Yet, in other cellular and animal models, N-cadherin was not 
sufficient to induce invasion (Shamir and Ewald, 2015). Thus, N-cadherin used extensively as a 
mesenchymal marker does not always reflect an invasive advantage. It is more appropriate to use it as 
an indicator of less polarized migratory epithelial cells. 
The same applies to P-cadherin. Found in luminal originating breast cancer, it was first correlated with 
poor clinical outcomes. However, later on, P-cadherin did not really show any major advantages or 
disruption when expressed in mice mammary gland (Daniel et al., 1995; Radice et al., 2003).  
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Figure 10: Epithelial polarity complexes.  
The epithelial phenotype is characterized by the presence of cell junctions of several types including 
tight junctions, adherent junctions, desmosomes and GAP junctions. These 
structures are lost during the first steps of EMT and replaced by structures more adequate for migration 
and invasion. The actin cytoskeleton rearrangement will form stress fibers facilitating the migration, 
and different protrusive structures like lamellipods, filopods and invadosomes. In addition, the 
expression profile integrins is modified, thus regulating cellular adhesion to the ECM. Adapted from 
Lamouille et al., 2014. 
 
Nevertheless, acquiring a mesenchymal status takes more than disrupting adhesion proteins. Besides 
their effect on cell-cell-contact, the loss of adhesion proteins disrupts cellular polarity crucial for normal 
epithelial cell functioning. In fact, epithelial cells establish their polarity after receiving two adhesion 
cues: the cell-cell contact and cell-extracellular matrix contact. Upon E-cadherin and integrins 
engagement, cells are polarized along the apico-basal axis through an extensive rearrangement of the 
cortical actin cytoskeleton and the positioning of three polarity complexes (partitioning defective 
(PAR3), crumbs (CRB) and scribble (SCRIB)) (Figure 10). Each of these polarity complexes determine 
a plasma membrane domain: PAR3 defining tight junctions, CRB defining the apical domain and SCRIB 
defining the basolateral domain. During EMT, polarity complexes are downregulated or not found at the 
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right sites. For example, the loss of E-cadherin blocks the recruitment of SCRIB to the basolateral 
membrane (Navarro et al., 2005).  
 
In parallel, a switch in the cytoskeleton components from cytokeratin to vimentin filaments can occur 
and alter membrane proteins trafficking and distribution, such as E-cadh (Hanada et al., 2005; Toivola 
et al., 2005). It will also affect the cytoskeleton architecture. Epithelial cells transfected with vimentin 
adopt an elongated morphology and acquire other mesenchymal characteristic like an increase in 
motility and a high turnover of focal adhesion*** molecules as well as a loss of desmosomes (Mendez 
et al., 2010). 
 
***Focal adhesions are cell-ECM adhesion complexes in which integrins are the core receptors forming 
mechanical links between actin cytoskeleton and the stroma in many cell types. Focal adhesions are in 
constant remodeling (dynamic assembly and disassembly) that is important for cell motility during 
migration. They also act as mechanosensors of extracellular tensions that will be translated into cellular 
modifications through different signaling proteins like talins (e.g. reinforcing cell adhesion). More than 
60 focal adhesion proteins have been described in mammals including catalytic proteins like protein 
tyrosine kinases such as FAK and Src, protein serine/threonine kinases such as ILK and p21-activated 
kinase (PAK), and phosphoinositide 3-kinase, as well as other enzymes like proteases and phosphatases. 
In addition, several adaptor proteins are found associated to focal adhesions like paxillin, vinculin and 
tensin. In cancer, an increased activity of FAK and Src have been reported and correlated with 
malignancy; oncogenic focal adhesions can contribute to resistance to apoptosis, increase in 
proliferation and elevated cell motility and invasion (Wehrle-Haller, 2012; Wu, 2007).*** 
 
Conclusion: 
Normal epithelial cells have a stable polarized architecture and a mobility limited within their 
monolayers. By disrupting adhesion and polarity, EMT provides cells with motility advantages as well 
as morphological ones, as elongated cells have less contact with their microenvironment and therefore 
less retention. The remaining challenge is to overcome inconsistencies related to the existing markers of 
EMT. We need to better understand the heterogeneity of tumors, in addition to their stochastic gradual 
evolution, and find targetable common molecules expressed in a transitioning epithelial cell. The 
emerging techniques of spatial single cell sequencing (Satija et al., 2015; Shapiro et al., 2013; Wang et 
al., 2018) will help to a certain extent in assessing the variabilities seen intra- and inter-tumors and to 
discriminate in which contexts specific markers are expressed and which state of the epithelial-
mesenchymal transition they reflect. This will give us as well more insights about the temporal 
expression of mesenchymal transcription factors ruling a major part of EMT as well as other functions 
detailed in the following section. 
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2.1.2 Roles of Mesenchymal transcription factors: EMT and beyond  
 
As described above, EMT is mainly detected by the loss of critical epithelial characteristics (polarity, 
adhesion junctions) and the gain of mesenchymal properties (mobility, migration, invasion). Behind 
these functional and morphological changes lies a panel of transcriptomic changes led by a group of 
master regulators of the EMT: the mesenchymal transcription factors (EMT-TFs). Three major families 
of EMT-activating transcription factors have been the focus of cancer research: SNAIL (containing 
Snai1 and Snai2/slug), ZEB (with two factors Zeb1 and Zeb2) and basic Helix Loop Helix or TWIST 
(with Twist1 and Twist2) families (Polyak and Weinberg, 2009; Puisieux et al., 2014a; Yang and 
Weinberg, 2008). EMT-TFs can modulate the expression of their target genes by directly binding to 
DNA or by cooperating with other transcriptional regulators. While Twist1 induces the expression of 
N-cadherin by binding to its promoter, downregulating E-cadherin requires the interaction of TWIST1 
with the NURD (Nucleosome Remodeling Deacetylase) complex (Alexander et al., 2006; Cheng et al., 
2007) 
 
During the last ten years, several reports have provided evidence that EMT-TFs regulate the expression 
of core polarity proteins during EMT (Thiery et al., 2009). Zeb1 was shown to bind key polarity genes 
promoters including the E-cadherin and repress their expression in tumor cells thus reducing epithelial 
differentiation (Aigner et al., 2007; Graham et al., 2010; Spaderna et al., 2008). Similarly, Snai1 alters 
cell polarity by repressing the transcription of Crumb3 and modifying the location of Par3 and Crumbs 
at the junctions (Moreno-Bueno et al., 2008) as well as repressing E-cadherin (Peinado et al., 2005). 
Even in collective migration where cell clusters express adhesion proteins, leader cells have usually 
undergone a partial EMT and express EMT-TFs; for instance SNAIL was found at the invasive front of 
a mammary tumor model (Ye et al., 2015). It was noted that disassembled adhesion complexes can 
induce EMT-TFs up-regulation. It is hard to tell which stimuli comes first, however feedback loops exist 
between these two phenomena.  
 
Upregulation of EMT-TFs has been detected in numerous cancers and correlated with poor prognosis 
of patients. Upregulation of Slug correlated with poor prognosis in human breast cancer patients (Guo 
et al., 2012). The expression of Snai1 in a transient way was shown necessary for metastatic competence 
in breast cancer (Tran et al., 2014). ZEB1 is aberrantly present in numerous invasive tumors: breast 
cancer (Graham et al., 2010; Soini et al., 2011), pancreatic cancer (Kurahara et al., 2012), hepatocellular 
carcinoma (Zhou et al., 2012), lung cancer (Gemmill et al., 2011), and many others. Zeb2 was found 
upregulated in the majority of tumors expressing Zeb1. TWIST is overexpressed in breast cancer and 
correlated with invasion, metastasis and poor survival (Ansieau et al., 2008; Puisieux et al., 2006; Soini 
et al., 2011; Yang et al., 2004). Likewise, in vitro, exogenous expression of EMT-TFs in solid tumors 
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induced cancer cell motility and invasion (Comijn et al., 2001; Olmeda et al., 2007, 2008; Puisieux et 
al., 2006; Shamir et al., 2014).  
 
More importantly, tumor suppressor genes act in part by downregulating these EMT-TFs. In breast, 
pancreatic and hepatocellular carcinoma cancers, TP53 expression inhibits the mesenchymal phenotype 
acquisition and the invasive capacities of these cancer cells by inducing microRNAs expression (mir-
200 and mir-192) that downregulate ZEB transcription factors (Chang et al., 2011; Kim et al., 2011). 
 
According to Thomas Brabletz, in a recent Nature Reviews Cancer publication, all tumor cells make use 
of a program induced by EMT-TFs, but to different extents (Brabletz et al., 2018). EMT is perceived as 
a reversible coordinated complex cell program and therefore, it is not surprising that EMT-TFs 
expression and roles will differ according to various cell contexts and conditions. For instance, ZEB1 
up-regulation in breast cancer does not promote metastasis while in pancreatic cancer, overexpression 
of ZEB1 and not SNAIL or TWIST can induce tumor metastasis (Krebs et al., 2017). However, it is 
interesting to note that its downregulation reduced 70% of metastasis but metastatic lesions were still 
observed meaning that not all the invasive potential of cancer cells relies on the expression of EMT-TFs 
and that other factors might be ruling this phenomenon as well (Krebs et al., 2017). 
This being said, are EMT-TFs only roles to induce EMT properties? Do they participate to the metastatic 
cascade by activating other cancer programs?  
EMT-TFs’ roles have lately been re-evaluated after many studies raveling their various intrinsic 
activities related to cancer initiation and progression (Garber, 2008). Besides activating common EMT 
properties, mesenchymal TFs play different roles that have been proven to be tissue specific: 
 • EMT-TFs have been detected in the premalignant stages of tumors acting as a survival signal 
against various stresses. EMT-TFs would allow cancer cells to avoid senescence or apoptotic 
signals induced by oncogenes (Goossens et al., 2017; Puisieux et al., 2014a). • EMT-TFs activation will support the dedifferentiation of epithelial cells and maintenance of 
stemness properties usually linked to high proliferative capacity, plasticity as well as resistance 
to therapy (Morel et al., 2008; Puisieux et al., 2014a). In mammary epithelial cancer cells, Slug 
acts as the main contributor to cells’ stem plasticity features (Scheel and Weinberg, 2012). • TFs can increase the expression of metalloproteinases important for matrix degradation and 
invasion (detailed in 4. 3. 3. Proteases & ECM degradation). 
 • EMT-TFs have been as well detected in non-epithelial tumors which support the statement of 
Brabletz about the non-EMT programs that can be stimulated by EMT-TFs in tumor cells 
(Kahlert et al., 2017). 
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The fact that these TFs are implicated in ensuring other functions adds a layer on the complexity and 
heterogeneity of this disease. 
 
We have to note that other transcription factors are involved in EMT. We can mention the transcription 
factors belonging to the families FOX (forkhead box), SOX (SRY box) or GATA (reviewed in (Golson 
and Kaestner, 2016; Tremblay et al., 2018)). 
 
Conclusion 
 
The aberrant activation of EMT-TFs provides cells with a great plasticity, and the capacity to grow and 
invade.  
 
2. 2. Which stimuli do activate EMT? One extra level of complexity 
 
Figure 11: Stimuli and signaling pathways regulating epithelial-mesenchymal transition. 
This overview shows the complexity and variety of signaling networks that can participate to the EMT 
process. Depending on the cell origin and context, several combinations of these pathways can be seen. 
Some receptors can induce direct effects on adhesion complexes while other will change the 
transcriptional program of cells and alter protein expression; for instance, the composition of the ECM 
can be one of the targets. Transcriptional shift is in majority mediated by an upregulation of 
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mesenchymal transcription factors (Twist, Slug, Snail, Zeb, etc.). RTK: receptor tyrosine kinase, ETAR: 
endothelin A receptor. Adapted from Polyak and Weinberg, 2009. 
 
EMT-TFs are not the only actors in driving tumor growth and metastasis (Figure 11).  
 
EMT is a complex process resulting from the combination of extracellular and intracellular stimuli, 
translated into various modifications of the cells and their microenvironment. A second level of 
regulation comes from feedback mechanisms crucial for pushing forward the initial transition from an 
epithelial state to a more mesenchymal state.  
 
More than 20 signaling pathways have been described to enhance EMT in various cell types during 
physiological and pathological contexts (Thiery et al., 2009). Puisieux et al grouped these pathways 
under five stresses associated with tumorigenesis (physical constraints, hypoxia, inflammation, 
metabolic stress, oncogenic stress) (Puisieux et al., 2014b). Stimulating pathways capable of reactivating 
EMT during tumorigenesis include the TGFβ superfamily, Wnts, Notch, tyrosine kinase receptors 
ligands (EGF, HGF, FGF), HIF, and many other hypoxia factors.  
 
These pathways have been shown to prompt EMT in major part by inducing new transcriptional 
programs and more specifically, by upregulating or activating EMT-TFs. For instance, hypoxia, the 
anaerobic condition that tumor cells can encounter, induces EMT by activating the Notch pathway. 
Notch activation drives HIF-1a (hypoxia-inducible factor 1a) that will be recruited on the LOX (Lysyl 
Oxydase) promoter. In turn, increased levels of LOX stabilize EMT-TFs and activate a set of other genes 
related to EMT. High expression of different Notch receptors was also correlated to Zeb1 and vimentin 
expression in invasive breast cancer (Han et al., 2011; Lamy et al., 2017). Taking another example, the 
well characterized transforming growth factor-β (TGFβ) hass been described, among many other 
EMT-related functions, to induce SNAIL and ZEB genes and alter cell polarity. Further detailed 
examples can be found in the subsequent reviews (Polyak and Weinberg, 2009; Yang and Weinberg, 
2008). 
 
TGFβ and many other EMT inducing factors are in part produced by fibroblasts which can lead us to 
another level of regulation: the extracellular matrix. Manipulating cells in different conditions in vitro 
has shown that ECM can induce an entry in EMT of normal cells.  
Interestingly, as we will see in paragph “4. 3. 3. Proteases & ECM degradationextracellular” proteases 
can release growth factors and cytokines from the matrix or even increase indirectly EMT-TFs 
expression.  
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Having different external stimuli on top of feedback loops and internal signals makes it hard to determine 
what is leading the cells to EMT. Classifying these triggering events by order of importance or 
emergence is still not possible and needs further studies in vivo.  
 
2.3 Does EMT really occur in vivo in cancers? A subject of controversy 
The numerous regulatory pathways of EMT add to the complexity of this process and therefore to the 
overall divergence of scientific opinions. As a matter of fact, EMT was well documented in numerous 
cancer cell lines, but in vivo reporting of EMT showed up very late and did not always validated the in 
vitro observations. Numerous pathologists showed their disagreement on EMT as a cancerous-process. 
David Tarin published in 2005 an article questioning the existence of EMT and supporting his doubts 
by mainly lack of  relevant markers as well as elongated epithelial cells in cancer tissues (Tarin, 2005).  
 
In patients, claudin-low breast cancer subtype has been characterized by a pronounced EMT signature 
with high expression of EMT-TFs associated with an increased aggressiveness, a resistance to drugs and 
high metastatic potential (Feng et al., 2018; Prat and Perou, 2011a). Additionally, L. Chodosh group 
showed that in breast cancer, upregulation of Snail predicted lower relapse-free survival. Snail was also 
seen overexpressed in a transgenic mice model for HER/neu-induced mammary tumors, and induced 
EMT in a primary tumor cell line (Garber, 2008; Moody et al., 2005). A pool of other studies showing 
EMT in vitro, and correlations in vivo can be added to the previous examples (Chaffer et al., 2016; 
Heerboth et al., 2015). However, having different criteria and interpretations for EMT did not make the 
results very consistent. As we previously seen, EMT was associated with elongated morphological 
criteria, a downregulation and upregulation of epithelial and mesenchymal markers respectively, but 
also with an activation of EMT-TFs and some stem cell characteristics. EMT markers soon appeared 
not applicable to all the different contexts and cancer types. E-cadherin the most used epithelial marker 
turns out that it is not decreased in every disseminating cell, but rather co-expressed with mesenchymal 
makers (such as Vimentin) (Yamashita et al., 2018). 
 
Defining EMT general lines by which this process commonly occurs in tumors is a hard task and one of 
the main subjects of controversy in cancer biology. To add to this complexity, besides the wide panel 
EMT-TFs that can be stimulated in an epithelial cell, the origin of the epithelial cell in which these 
programs are triggered is drastically important. TGF-β activation in basal mammary cells induces 
rapidly and efficiently an EMT phenotype, however luminal epithelial breast cancer were not responsive 
to TGF-β (Chaffer et al., 2016). The difference here can be set by the chromatin status of different cells. 
For example, basal cells keep Zeb1 promoter in an open conformation ready (Chaffer et al., 2013).  
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However, taking into consideration the complexity of cancer, even within the same tumors, different 
extents of EMT can occur. The radical EMT is now an old concept; today the scientific community talks 
more about a partial or heterogeneous EMT where cells will be engaged in this transition but not fully 
and in different ways.  
 
*** 
About EMT and Invasion  
 
A large amount of work has been done in an attempt to investigate the link between EMT or EMT-TFs 
and metastasis frequency in vivo, migration speed of tumor cells, and invasion capacities. 
 
After all, a partial activation of EMT gives tremendous advantages to cells to invade which makes it 
hard for now to decide to what extent the engagement in EMT is a pre-requisite for invasion (Heerboth 
et al., 2015). I consider cancer progression and invasion as a feedback loop process where every signal 
will be amplified by stimulating other changes that will alter the cell homeostasis, therefore every 
modification in the cell even in early stages may give some invasive advantages used in further steps of 
the disease progression.  
 
One of the remaining questions, as defined by Fidler, is : “how many of the steps of the invasion–
metastasis cascade can be achieved by an activated EMT program?” (Fidler, 2003) 
 
3. Collective Invasion: 
 
3. 1. Invasion in general 
 
Invasion is the central step of the metastatic cascade comprising several mechanisms adopted by the 
cells to breach physical barriers (BM, ECM, endothelium) and eventually grow secondary-site tumors. 
Besides cell-cell interactions, tumor cells will use Cell-ECM interactions and ECM remodeling to 
complete a successful invasion that will result from a continuum of different interdependent steps. 
In vitro, two main types of invasion have been observed: single-cell invasion (including mesenchymal 
and amoeboid invasion) and collective invasion. The degree of EMT engagement can reflect on the 
invasion strategy used, thus the least differentiated the more likely cells are going to invade individually. 
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3. 1. 1. Cellular invasion 
 
Figure 12: Migration strategies of cancer cells and their molecular programs. 
A. Mesenchymal-type migration. B. Amoeboid migration. C. Collective migration. At the invasion front, 
cells set up membrane protrusions. they interact with the ECM and establish focal adhesion points rich 
in integrins. The activation of integrins triggers the recruitment of many proteins by their intracellular 
domain, this allows the anchoring of the cytoskeleton of the cell to the ECM and the transmission of 
external signals to cells. Surface proteases, such as MMPs, are recruited at the invasion front to degrade 
the ECM and allow cells to move forward. Contraction of the cellular body generates forces necessary 
to move the cellular body forward. The disassembly of adhesions sites on the rear of cells allows cells 
to move forward and start again a new migration cycle. Integrins are then recycled via endoplasmic 
vesicles to the cells’migration front. Adapted from Sahai, 2005. 
 • Single-cell invasion 
 
Individual cell invasion has been reported in vitro and in animal models. Based on cell type, two variants 
of individual invasion can exist: mesenchymal and amoeboid (Friedl and Wolf, 2003; Sahai, 2005) 
(Figure 12). 
 
Mesenchymal migration: this type of migration consists in having spindle-shape morphology cells 
mainly ruled by integrin-mediated interactions with ECM, traction forces, and proteases expression to 
degrade the surrounding matrix. Mesenchymal migration is mostly found in some models of 
fibrosarcomas and gliomas. 
This type of invasion has been associated with increased tumor aggressiveness, increased resistance to 
apoptosis and an important ECM remodeling (Heerboth et al., 2015; Kalluri and Weinberg, 2009). 
Disrupting this mechanism is possible by inhibiting RhoGTPases, integrins, MMPs or MLCK (myosin 
light-chain kinase) (Friedl and Wolf, 2010; Hegerfeldt et al., 2002). 
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 Amoeboid migration: Cells adopting amoeboid migration have a round-shape and low affinity to their 
ECM. In order to advance within the tissue, they will use high morphological deformability by rapidly 
juggling cycles of contraction and expansion in order to move between the fibers of the ECM. This 
migration pattern can be induced by the inhibition of proteolysis in mesenchymal cells, which may 
explain the failure of anti-cancer therapies blocking metalloproteases (Paňková et al., 2010; Wolf et al., 
2003). Used by leucocytes, amoeboid migration is found in some epithelial carcinomas like metastatic 
rat breast cancer cell line MTLn3 injected in female Fischer 344 rats (Farina et al., 1998).  
 
By reconstructing breast human tissue from cancer patients, a recent study proposes collective migration 
as the migration strategy of cancer cells and claims an absence of single cell leaving the tumors (Bronsert 
et al., 2014). 
 • Collective invasion 
 
Collective migration was well described in normal embryonic development during neural tube formation 
(Davidson and Keller, 1999) as well as different organ morphogenesis especially of the mammary gland 
(Ewald et al., 2008). In cancer, it consists of a cluster of cells leaving the primary tumor to invade the 
surrounding tissue or even further organs (Figure 12). Main criteria defining this type of invasion are 
the adhesion complexes preserved between cells during migration, protrusive structures creating the 
traction forces crucial for movement, and lastly modifications of the ECM by degrading, remodeling or 
deposing new components (Friedl and Gilmour, 2009). Epithelial tumors commonly migrate in bulks, 
and it has been shown that circulating tumor cell clusters have 23-50 times increased potential of seeding 
secondary tumors and therefore are the main precursors of breast cancer metastasis (Aceto et al., 2014).  
 
However, studies have shown a clear heterogeneity within this cellular migrating cohort. As presented 
in the EMT section, cells at the invasive front leading the migration seems to undergo a partial EMT and 
to express EMT-TFs while the rest of cells keep a less-mesenchymal phenotype. In the same line of 
thoughts, in vivo and in 3D culture of primary human breast tumors, only leading cells of the cluster 
have activated a dedifferentiation mechanism and expressed basal epithelial markers (as tumor protein 
p63, and cytokeratin 14) (Cheung et al., 2013). Leader cells will also have to concentrate proteases, 
mainly MT1MMP in the case of breast cancer, that will allow matrix degradation, creating galleries for 
follower cells to be dragged behind passively [proteases families and roles are described in the following 
sections]. Through a specific reorganization of cortical actin and adhesion complexes, the cell cluster 
will become a contractile large body. By interacting with the ECM (mainly integrins) and pulling on the 
collagen fibers, a reorganization of the ECM will occur to optimize their motility. Of note, in some 
cases, tip cells leading the cluster can be stromal fibroblasts (Gaggioli et al., 2007).  
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 Conclusion 
In conclusion, the invasion process is the result of the degrading properties of malignant cells and a 
“tumor microenvironment” (TME) that will provide a fertile soil for tumor development, progression 
and metastasis. 
 
*** 
 
In the EMT description, I have focused on the importance of cell-cell interaction and adhesion for tumor 
development. Throughout the following section, I will discuss the inreraction of cells with their 
microenvironment by focusing on the molecular details of Cell-ECM interactions, ECM remodeling, 
and ECM degradation. 
 
4. Tumor Microenvironment  
 
A collaborative interaction between cancer cells and their stroma is crucial for tumor cell proliferation, 
invasion and metastases in most human cancers (Hanahan and Coussens, 2012)(Hanahan and Coussens, 
2012). During cancer progression, it is conceived that ECM is continuously reshaped on a molecular 
and structural level and that it may promote metastatic spread. R. Hynes group showed that the high 
metastatic potential of primary tumors of human mammary carcinoma xenografts derives from distinct 
stromal composition when compared to less metastatic tumors (Naba et al., 2014). Furthermore, the 
clinical outcome of breast cancer patients was shown to be strongly linked to ECM characteristics 
(Bergamaschi et al., 2008). Moreover, Provenzano et al (2006) defined three Tumor Associated Collagen 
Signatures (TACS) by using environmental collagen density and collagen fiber organization and 
corresponded them to stages of mammary carcinoma with correlations on tumor burden, invasion and 
metastasis (Provenzano et al., 2006). Thus, a deregulation of extracellular matrix (ECM) dynamics is 
recognized widely as a hallmark of cancer. 
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 Figure 13: ECM modifications occurring during tumoral progression. 
The tumor microenvironment (TME) is connected to every step of tumorigenesis and will undergo 
various modifications that will affect tumoral progression. It will activate fibroblasts into the so-called 
cancer associated fibroblasts (main cellular players), recruit immune cells that will increase the 
inflammation, and increase growth factor and cytokines release. The stroma will also have a different 
density and assembly of the molecular components like collagen and fibronectin which will provide new 
physical properties for the ECM enabling tumor migration and invasion (e.g. stiffness). A continuous 
crosstalk is maintained between cells and TME by reciprocal mechanosensing of the applied tensions. 
Adapted from Butcher et al., 2009. 
 
4. 1. General composition 
 
TME is composed in majority of the same ECM components of normal mammary gland (presented in 
“1. 2. 2. Microenvironment compartment”). However, main differences lie behind the variants or 
isoforms of ECM cells and molecules, the distinct expression ratios, the activity levels of some enzymes 
70
as well as distinct 3D structure assembly of the matrix. And on the basis of these differences, ECM 
elements will acquire pro-tumorigenic properties (Figure 13) (Whiteside, 2008). 
Tumor stroma can be divided into two major components: cellular components or stromal cells (e.g. 
adipocytes, endothelial cells, fibroblasts, immune cells, myofibroblasts, cancer associated fibroblasts) 
and non-cellular connective extracellular matrix (ECM) composed of proteoglycans, hyaluronic acid, 
fibrous proteins (e.g. fibronectin, collagen and laminin). 
Among the cellular components (Figure 13): • Fibroblasts, the most abundant cell type of connective tissue, regulate in physiological contexts 
several roles. They secrete and assemble major components of ECM: collagen (notably I, III 
and V), elastin, fibronectin, fibrillin, proteoglycans, etc., enzymes such as proteases and their 
regulators (MMPs, ADAMs, TIMPs, etc.) to maintain the balance between ECM degradation 
and deposition, and cytokines and growth factors that participate to the differentiation of 
surrounding cells. Activated fibroblasts, called myofibroblasts, will secrete an ECM with altered 
architecture, as well as different cytokines helping the recruitment of immune cells  (Kalluri and 
Zeisberg, 2006). 
 • CAFs or cancer associated fibroblasts are activated fibroblasts that display similar roles as 
myofibroblasts with a main difference that their epigenetic regulation can limit the regression 
of this activated state .They usually do not undergo apoptosis and support all along the 
tumorigenesis process (LeBleu and Kalluri, 2018; Tao et al., 2017). CAFs are mainly implicated 
in architectural modifications of TEM as well as tumors’ resistance to therapy. They are also 
responsible in part of the biophysical characteristics of the matrix such as stiffness discussed in 
“4. 3. 1. ECM Stiffness”. 
 • Adipocytes, described first as an energy storage, have been described to have a paracrine role 
by secreting growth factor (such as hepatocyte growth factor) important for the progression of 
breast cancer (Dirat et al., 2011). 
 • Immune cells are found infiltrated in the TME indicating a strong inflammation at the tumor 
site. We can find lymphocytes (T cells, B cells and natural killer cells), macrophages and 
neutrophils originating from two different lineage of bone marrow. In contrast to their immune 
role, they have been enrolled in promoting angiogenesis, increasing proliferation, resisting cell 
death and activating invasion (Condeelis and Pollard, 2006; Hanahan and Coussens, 2012; 
Murdoch et al., 2008). 
 
The ECM of breast cancer is reviewed in (Insua-Rodríguez and Oskarsson, 2016; Lu et al., 2012). 
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*** 
While some authors believe cancer is mainly the result of a complex cancerous microenvironment 
surrounding cells (Whiteside, 2008), I think that cancer is the resultant of back and forth interactive 
crosstalk between tumor cells and their TME. Therefore, metastasis occurs only when their cooperation 
results in cells overcoming the physical barriers as well as resisting to various threats like the immune 
system. 
 
4. 2. Crosstalk between Cells and their ECM: Role of Integrins 
 
Figure 14: Integrin family and their ligands. 
This figure represents the mammalian subunits and their αβ associations. Each heterodimer has a ligand 
specificity marked here by different arrow colors. In the normal mammary gland, the most expressed 
integrin receptors are collagen receptors (α1β1, α2β1), fibronectin receptors (α5β1, αvβ3) and laminin 
receptors (α3β1, α6β1 and α6β4). Some subunits have alternatively spliced cytoplasmic domains like 
α6, α3, β3 and β4. Adapted from resources.rndsystems.com 
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ECM-Cell interactions are mainly mediated by specific receptors, such as integrins, DDRs (Discoidin 
Domain Receptor), and syndecans (Hynes, 2002; Raymond et al., 2012). I will mostly be discussing the 
role of the major receptors, integrins, tackled in this thesis work. 
 
In mammals, 18 alpha subunits and 8 beta subunits, capable of forming 24 dimers of integrin, have been 
identified. The association determines the specificity of integrin for its substrate and they can be 
classified into four main groups according to their ligand (Figure 14, Figure 15). 
 
In fact, during tumor transformation, cancer cells modify the repertoire of integrins expressed on their 
surface in order to adapt to their changing tumoral environment and to activate proliferation and pro-
invasive signaling pathways (Figure 15) (Desgrosellier and Cheresh, 2010; Guo and Giancotti, 2004; 
Seguin et al., 2015). In breast cancer, integrins β1 and β4 play a key role in breast tumorigenesis. Indeed, 
the loss of function of β1 or β4 integrins, in different mouse models, inhibited tumor initiation and 
progression (Huck et al., 2010; Lahlou and Muller, 2011; White et al., 2004). Additionally, integrin α3β1 was involved in tumor progression and metastatic migration in many studies and solely, integrin α3 was detected in aggressive breast cancer cells undergoing EMT (Shirakihara et al., 2013). In contrast, 
integrin β1combined to integrin α2 was reported to suppress the formation of metastases from primary 
breast tumors (Ramirez et al., 2011). 
 
Altered integrin expression patterns have been linked to many types of cancer. Correlation between 
specific integrins expression and patient survival or response to therapy were summarized in the 
supplementary of Hamidi and Ivaska review (Hamidi and Ivaska, 2018). Different roles of integrins 
were also seen in breast cancer mouse models (Raymond et al., 2012). 
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 Figure 15: Integrin structure and activation mechanism. 
Integrins are on-off switches that allow anchoring cells to ECM and controlling different processes of 
mammary gland morphogenesis (proliferation, differentiation, migration, survival, etc.). They are also 
mechanotransducers that can convert tension forces generated by the ECM into intra-cellular signals. 
Generally, the affinity of integrins to their ligands is controlled by an inside-out signal mediated mainly 
by talins. Talin activated by PIP2 or FAK (focal adhesion kinase) bind the cytoplasmic tail of integrins 
and induce conformational changes that can modify integrins’ affinity to their ligands (Hynes, 2002). 
After binding to their ligand, an outside-inside integrin mediated signaling is triggered and can involve 
the recruitment of Focal Adhesion Kinase (FAK) and its downstream target SRC, or the activation of 
RAS-MAPK or PI3K-AKT signaling pathways. Less emphasized in the literature is the role of talin in 
the outside-inside signaling. Some data suggest that once integrins bind to their ligand, talin will change 
conformation and it will be dissociated so that other effectors can bind the activated C-terminal of 
integrins (Das et al., 2014).  Adapted from Cheah and Andrews, 2018. 
 
It is important to stress that, integrins are crucial as well for mechanical sensing, stiffening and 
remodeling of the ECM, and they intervene at different levels of tumor progression including invasion, 
metastases and drug resistance (Glukhova and Streuli, 2013; Hamidi and Ivaska, 2018). Furthermore, 
many studies indicate that signaling molecules activated upon engagement of integrins, such as FAK 
and ILK, play a key role during tumorigenesis (Lahlou et al., 2012). 
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4. 3. ECM remodeling 
Tumor ECM influences tumor progression when architectural and biochemical features are altered (level 
of expression of ECM components and/or fiber alignment) (Bissell et al., 1982). Here I would like to 
clarify on one hand the effect of ECM remodeling, more specifically stiffness, on cancer cells through 
the process of mechanotransduction and on the other hand the effect of cancer cells contractility in 
restructuring the collagen matrix to facilitate migration (Simi et al., 2018). 
 
4. 3. 1. ECM Stiffness 
 
 
Figure 16: ECM stiffness in patients and associated signaling pathways 
A. ECM stiffness and contractility are two related characteristics of the ECM and cells respectively. 
This panel shows that matrix stiffness applies an external force that stimulates the clustering of integrins. 
Integrins are mechanotransducers that will in turn increase intracellular signaling and activate Rho 
associated pathways. As a result, cellular contractility will increase and an inside-outside signaling will 
allow cells to remodel the ECM (e.g. by aligning collagen fibers) B. Mammographic density of breast 
showing 0% dense tissue on the first panel on the left and increasing density with more than 75% dense 
tissue in the last panel on the right. Increased density was associated with higher risk of breast cancer. 
Adapted from Boyd et al., 2002; Kass et al., 2007. 
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 Somewhat counterintuitive to ECM degradation used by tumor cells to disseminate, dense fibrotic 
stroma has been correlated with poor prognosis in breast cancer (Figure 16) (Wan et al., 2013). In 
diagnostic, patients with an increased breast density revealed by palpation and measured by 
mammography have a greater risk for breast cancer (Boyd et al., 2002). Increased deposition of collagen 
in mouse model of breast cancer significantly increases tumor formation and has been causally linked 
to tumor metastasis (Provenzano et al., 2008). 
 
Rigid matrix is perceived and translated by cells as mechanical forces measured in Pascal (Pa) and are 
usually integrate by cells through mechanotransduction. Stiffness has been shown to increase cancer cell 
proliferation, resistance to apoptosis, and angiogenesis (Pickup et al., 2014). Binding of cells to a tumor 
matrix inhibits the expression of some tumor suppressors such as BRCA1 or PTEN (tumor suppressor 
phosphatase and tensin homolog). Moreover, matrix stiffness contributes to the formation of invadopods 
and focal adhesions required for cell invasion (Menon and Beningo, 2011). Additionally, in recent 
studies, increased crosslinking of collagen by lysyl oxidase (LOX) family promotes tumor invasion and 
metastasis by engaging integrin signaling (Kirschmann et al., 2002; Levental et al., 2009; Wan et al., 
2013). The LOX prepeptides were capable of inhibiting branching structures formation in Matrigel and 
to suppress tumor size by more than 60% in xenografts mice model of Her-2 driven breast cancer 
(Johnston and Lopez, 2018). Lately, preclinical studies involve trials on inhibiting LOX in tumors which 
shows for now positive results (blocks metastasis, and no toxic side effects reported) (Barker et al., 2012; 
Bondareva et al., 2009) 
 
In line with the role of integrins, stiffness was linked to tumors aggressiveness by translating the 
mechanotensions into biochemical cues through integrins (Butcher et al., 2009; Kumar and Weaver, 
2009). The group of V. Weaver has suggested a mechanism of action of how matrix stiffness alter 
epithelial homeostasis. In fact, an increased rigidity of the surrounding stroma will activate integrin 
clusters in order to enhance ERK signaling, focal adhesion formation in addition to ROCK-mediated 
contractility (Paszek et al., 2005a). This integrin-dependent mechanotransduction may imply several 
signaling pathways such as Rho GTPases, FAK/SRC and YAP/TAZ (Figure 16) (Dupont et al., 2011; 
Paszek et al., 2005b; Provenzano et al., 2009). 
 
A recent review covers more details on the impact of altered tumors mechanics (Mohammadi and Sahai, 
2018) 
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4. 3. 2. Contractility 
 
Figure 17: Contractility and collagen fibers alignment. 
A. This panel shows that in normal epithelial cells, the collagen fibers adopt a random architecture. 
When the radial stress increase, cells increase their contractility and in result tend to align their 
collagen fibers. B. Confocal image of 4T1 mouse mammary tumor cells (in red) presenting a high 
percentage of aligned collagen fibers (in white) . Adapted from Ahmadzadeh et al., 2017; Piotrowski-
Daspit et al., 2017. 
 
Alongside the stiffness of ECM, cancer cells need to use contraction to pull on the extracellular matrix 
and move forward. This results in aligned collagen fibers organized in parallel structures implicated in 
determining the migration direction, as well as increase the efficiency and persistence of migrating cells 
(Figure 17) (Piotrowski-Daspit et al., 2017). 
 
Besides migration, contractility of tumor cells has been linked to invasion and metastasis. Two studies 
have shown that actomyosin-based contractility drives invasion in 3D Matrigel using MDA-MB-231 
human breast adenocarcinoma cells by generating forces on β1 integrin adhesion (Mierke et al., 2011; 
Poincloux et al., 2011).  
 
In mammary cancer cell lines, contractility is mainly mediated by Rho GTPases and enhanced by 
propagation of tension through intercellular adhesions (Haga and Ridley, 2016; Parri and Chiarugi, 
2010; Piotrowski-Daspit et al., 2017). The Rho GTPases signaling pathways will be described in: III. 
A. RhoGTPases 
 
Conclusion 
The biomechanical properties of ECM and their interaction with epithelial cells can drastically affect 
cancer progression. The evidences aforementioned underscore the importance of ECM dynamic 
remodeling and ECM-Cell interactions for migration, invasion and metastasis. 
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4. 3. 3. Proteases & ECM degradation 
 
Besides pulling the ECM fibers and modifying its density, collective migration requires the degradation 
of ECM by remodeling enzymes, firstly the basal membrane which confine cells in a limited physical 
space. Different families of matrix modifying proteases have been described: matrix metalloproteinases 
(MMPs), heparanase, cathepsins, urokinase plasminogen activator (uPa), etc. They are often found 
aberrantly upregulated in breast cancer and enhance significantly tumoral progression and metastasis 
(Bonnans et al., 2014; Gomes et al., 2013; Oskarsson, 2013). These enzymes will generate least 
resistance tracks used by following cells of the migrating cluster. They also serve to release growth 
factors associated to ECM. 
  
Extracellular Matrix degradation: A focus on MMPs 
 • Family of MMPs 
 
Human have 23 MMPs, with 17 soluble and secreted enzymes and 6 membrane-associated enzymes. 
They consist of a polypeptide sequence comprising a cysteine residue that contains a Zinc atom (Zn), 
hence their generic name of metalloproteases. They differ by their tissue specific expression, substrates 
affinity and their structural architecture (Radisky and Radisky, 2010). Despite the complexity of their 
regulatory mechanisms, it is possible to identify three major levels: transcriptional regulation, activation 
of proenzymes and inhibition of their enzymatic activity. The latter is mainly mediated by tissue 
inhibitor of metalloproteinases (TIMP) family members. They inhibit MMPs in a stoichiometric 
reversible way through binding to the catalytic site of MMPs and thus mimicking their substrate. A 
redundancy can be found between different members of this family. Surprisingly, TIMP-1, one of the 
four natural TIMPs, was shown to be upregulated in breast cancer and in some cases correlated with 
poor patient prognosis (Nakopoulou et al., 2002; Ree et al., 1997). Besides acting as an endogenous 
inhibitor of matrix metalloproteinases, TIMP1 has been recognized for its role in promoting 
proliferation, inhibiting apoptosis in cancer cells and in the accumulation of cancer associated fibroblasts 
(CAFs) that in turn enhance tumor progression (Gong et al., 2013; Würtz et al., 2005). 
 
MMPs have also their ways to favor tumor progression in different ways in breast cancer. For instance, 
MMP3 triggers EMT by increasing the cellular levels of reactive oxygen species, which in turn induces 
Snail1 expression (Radisky and Radisky, 2010). During metastasis, MMP-2 and MMP-9 are the main 
MMPs activated in order to digest the collagen type IV, major component of the basement membrane 
(Duffy et al., 2000). In patients, some important MMPs for mammary gland involution are found 
upregulated during breast cancer such as MMP-2,-3, -9 and -14 (McDaniel et al., 2006; Oskarsson, 
2013). 
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 We are going to focus on MMP14 also previously called MT1MMP, the founding member of 
membrane-associated MMPs, implicated in the core work of this thesis. 
 • MT1-MMP/MMP14 
 
MMP14 has been reported to play several roles (in adhesion and motility, proliferation, activating 
growth factors, senescence, etc.) with an emphasis on their role in invasion (Feinberg et al., 2016). In 
vitro, in both normal mammary gland branching and breast cancer invasion, MMP14 has been shown to 
be particularly important for collective migration by degrading the extracellular matrix and favoring 
motility. MMP14 also participates to pro-migratory positive feedback loop by activating MMP-2 known 
to induce invasive behaviors. In vitro, several studies were able to confirm the degrading capacity of 
MMP14 in collagenous matrix. 
 
Expressed at tip cells, MMP14 allows cancer cells to sculpt a track facilitating clusters invasion (Friedl 
and Gilmour, 2009; Poincloux et al., 2009; Wolf et al., 2007). More specifically, MMP14 proteins are 
concentrated in membrane extensions called invadopodia*** which optimize their action (Poincloux et 
al., 2009). In mice, KO of MMP14 has shown many bone abnormalities, suggesting a strong 
involvement of this MMP in normal collagen metabolism and therefore was considered a major 
collagenase. In addition, mouse models of breast cancer downregulated for MMP14 developed fewer 
tumors (Andarawewa et al.; Masson et al., 1998).  
 
However, downregulation of MMP14 in mouse epithelial cells did not show any major alteration of 
normal mammary development in vivo (Feinberg et al., 2016). These surprising observations show 
inconsistency with the in vitro experiments carried to examine mammary morphogenesis. A recent study 
has succeeded to explain these confusing results by showing that during normal mammary branching, 
the active MMP14 responsible for degrading the matrix is expressed by the cells of the periductal stroma 
while during cancer invasion, MMP14 expression and activity is expressed on the plasma surface of 
tumor epithelial cells (Figure 18) (Feinberg et al., 2016, 2018). 
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 Figure 18: MMP14 intercellular trafficking 
MMP14/MT1-MMP is synthetized as a proenzyme and its activation occur in a post-golgi compartment. 
In normal cells, it is sometimes transported with TIMP2, a metalloprotease inhibitor. It is usually 
recycled in a clathrin-dependant vesicles and send in part to degradation in the lysosome. In cancer 
cells, MMP14 is directed from late endosomes to invadopodia (degradative structures enabling 
invasion) and from the post-golgi compartment. This will allow the concentration of MMP14 in 
invadopodia and will increase the degradation of the ECM essential for collective migration. Adapted 
from Poincloux et al., 2009. 
 
***Invasive cells grow membrane extensions in order to migrate and metastasize. There are four types 
of protrusions including: blebs, filopods, lamellipods, invadopodia (Friedl and Wolf, 2003).  
Invadopodia are actin-dependent structures that function in ECM remodeling and invasion. The 
formation of these structures was linked to src signaling; different substrates of src have been localized 
to invadopodia (N-WASP, cortactin, Arp 2/3, etc.). Invadopodia will ensure adhesion and cell signaling 
roles as well as the secretion of MMPs to promote invasion. Through cytoskeleton organization and 
Arf6-dependent exocytosis mechanisms, MT1MMP is concentrated and activated in invadopodia (Clark 
and Weaver, 2008; Marchesin et al., 2015a; Poincloux et al., 2009).*** 
 
Conclusion 
Invasion, after all, is the resultant of continuous cross-talks between cells and TME. It is a combination 
of several deregulated signaling pathways, aberrant protein expression as well as biomechanical and 
structural modifications. What was presented in this part of the introduction is a brief overview of few 
of the possible mechanisms enhancing invasion and metastasis. 
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III. Support system of tumorigenesis: the Ras SUPERFAMILY 
 
The Ras superfamily of small guanine triphosphate (GTP)-binding proteins comprises over 160 human 
member and, according to their similar structure and function, can be divided into five major families: 
Ras, Rho, Ran, Arf/Sar and Rab families (Takai et al., 2001). Discovered in the 1980s, they belong to a 
class of protein called small G proteins capable of binding guanylyl nucleotides. These monomeric 
proteins act as binary molecular switches cycling between a so-called inactive state in GDP form and an 
active state in GTP form. Although they have intrinsic GTPase activity, with the exception of Arf 
proteins, they exhibit low GDP/GTP exchange activities. Thus, to pass from one state to the other, their 
intrinsic activities are catalyzed by by GEFs (Guanines nucleotides Exchanges Factor) and GAPs 
(GTPase Activating Protein) proteins (Bos et al., 2007). The regulation of Ras superfamily proteins by 
various GEFs and GAPs besides other post-translational modifications as well as space localization 
leads to a regulation of a broad range of cell processes (cell differentiation and proliferation, actin 
cytoskeleton reorganization and vesicular trafficking) (Wennerberg et al., 2005). 
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III. A. RhoGTPases 
 
1. Generalities & Regulators 
 
 
Figure 19: Rho GTPase family and their regulation process 
A. Dendogram of the family of Rho GTPases. B. Regulation process of Rho GTPases. Rho GTPases are 
activated at the membrane level by GEF proteins which will allow the binding and activation of 
downstream effectors. Their deactivation is mediated by the hydrolysis of GTP by releasing the third 
phosphate. GAPs and GDIs have shown to mediate the passage of Rho GTPase proteins from a GTP 
active state to a GDP inactive one. Adapted from Ellenbroek and Collard, 2007. 
 
Rho GTPases belong to the Ras superfamily of GTP binding proteins. They are small binary molecular 
switches (21KDa) activated by different signaling cascades. These signals are mainly transduced from 
transmembrane receptors like integrins, growth factor receptors, G-protein coupled receptors etc. The 
Rho genes were first isolated, in 1985, from the abdominal ganglia of Aplysia, a marine snail (Madaule 
and Axel, 1985). Subsequently, 23 members of the Rho GTPases family have been identified and were 
divided into  subfamilies, based on their sequence identity, structure, and function (Figure 19) 
(Ellenbroek and Collard, 2007). These 6 subfamilies are Rho BTB, Rnd, Miro proteins and the three 
classical subfamilies Rho, Rac and Cdc42 proteins that we will be focusing on. 
 
The active GTP form of Rho GTPases can bind more than 70 effector proteins and thus, they regulate a 
variety of cell functions particularly cytoskeleton reorganization, cell adhesion, proliferation, 
differentiation and vesicular trafficking (Bishop and Hall, 2000; Bustelo et al., 2007). 
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This diversity of RhoGTPases roles is related to cell types by which they are expressed, and the 
subcellular location of their activation (Nalbant, 2004). The spatio-temporal regulation of Rho GTPases 
can be moderated by three main regulators. First, the guanine nucleotide exchange factor proteins 
(GEFs) are responsible for catalyzing the exit of GDP to allow the spontaneous binding of a guanosine 
triphosphate (GTP) from an excess of existing GTP pool and therefore the activation of Rho GTPases 
(Schmidt, 2002). This GTP bound will modify the conformation of Rho GTPases, thus increasing the 
affinity to their effectors. Second, though Rho GTPases have an intrinsic GTPase activity, GTPase 
activating proteins (GAPs) are needed to facilitate the switch to an inactive GDP state (Moon, 2003; 
Tcherkezian and Lamarche-Vane, 2007). The third regulators are the guanine nucleotide dissociation 
inhibitors (GDIs). GDIs bind to the inactive GDP conformation of Rho GTPases, and sequester them as 
soluble complexes in the cytoplasm in order to prevent spontaneous activation and other functions that 
are not yet well defined (DerMardirossian and Bokoch, 2005; Olofsson) 
 
To date more than 70 GEFs, and 60 GAPs were described; many more than Rho GTPases family 
members. Therefore, the amount of activated Rho GTPases at a specific site of the cell will strongly 
depend on the expression, localization and activity of their regulators. 
 
2. General Roles of Rho GTPases 
 
After 5 years of Rho genes discovery, Hall and Ridley’s work revealed some functions of Rho GTPases 
in the regulation of membrane ruffling, assembly of focal adhesions and stress fibers in human 
fibroblasts (Ridley and Hall, 1992; Ridley et al., 1992). In parallel to this, the role of Cdc42 on cell 
polarity was established in yeast (Adams, 1990; Johnson, 1990). Rho GTPases are major regulators of 
actin cytoskeleton organization in mammalian cells (Tapon and Hall, 1997), and it did not take long to 
discover their roles in a wide range of other cellular functions: proliferation and apoptosis, vesicular 
traffic, cell adhesion, and gene expression (Hall, 2005; Olson et al., 1995; Ridley, 2001a). 
 
3. Rho GTPases and cancer 
 
These cellular functions mentioned above are often disrupted during cancer, and therefore several 
studies have found the small G proteins of Rho family playing major roles in cell transformation and 
cancer progression (Karlsson et al., 2009; Ridley, 2001b; Sahai and Marshall, 2002). It has been clearly 
shown that Rho-GTPases participate in cell transformation induced by the oncogene Ras (Avraham and 
Weinberg, 1989). Indeed, the expression of negative dominant mutants of RhoA, Rac1 or Cdc42 inhibits 
Ras-induced malignant transformation (Khosravi-Far et al., 1995; Qiu et al., 1995a, 1995b, 1997).  
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Unlike Ras family GTPases, no activating mutations have been detected in genes encoding Rho-
GTPases in cancer, with the exception of Rho H, whose gene is rearranged or mutated in B-cell 
lymphoma cases (Pulgar et al., 2005; Rihet et al., 2001). However, some Rho-GTPases are 
overexpressed in a number of cancers and this high expression rate is often correlated with tumor 
progression (Fritz et al., 1999; Sahai and Marshall, 2002). 
 
RhoA is overexpressed in carcinomas of the neck and head, breast cancer, as well as in tumors of the 
lungs and colon. RhoC expression is increased in pancreatic cancers and melanomas with high metastatic 
potential. Breast and colon cancers are also associated with overexpression of Rac1 and Cdc42 (Sahai 
and Marshall, 2002). In addition, Rac1b, a splicing variant of Rac1, and Rac3 were found strongly 
expressed and overactivated in these two types of cancers (Schnelzer et al., 2000). Besides Rho GTPases, 
a deregulation of the activity or expression of their regulators has been observed in different cancers 
(Wennerberg and Der, 2004; Wennerberg et al., 2005). Finally, some of the Rho-GTPase effectors have 
been identified as inducing cell transformation. For example, the expression and activity of PAK (p21-
Activated Kinase), an effector of Rac1 and Cdc42, are increased in breast cancers and correlated with 
tumor invasiveness (Kumar et al., 2006; Ridley, 2004; Vadlamudi and Kumar, 2003). These multiple 
roles of Rho GTPases in tumor progression have been validated by some small molecular inhibitors. I 
can cite the work of Zins et al. where they show that inhibiting Rac1 and Cdc42 reduced tumor growth 
of prostate tumor xenografts (by blocking cell cycle and migration and increasing apoptosis) (Zins et 
al., 2013). 
 
3. 1. 1. Rho GTPases and Invasion 
 
Rho GTPases play an important role in the reorganization of the actin cytoskeleton and microtubules 
allowing the formation of membrane protrusions at the migration front and the contraction of the cell 
body as well as the turn-over of cell-cell and cell-ECM adhesion, all of which jointly contribute to the 
efficacy of cell migration (Ridley, 2015). And therefore, aberrant activation of these signaling pathways 
can promote migration and subsequently act as a major contributor to invasion and metastases formation. 
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3. 1. 2.Regulation of actin cytoskeleton and Protrusion formation 
 
Figure 20: Rho GTPases and protrusion formation.  
Taken a single migrating cell, filopodia and lamellipodia will be formed at the leading edge. The polarity 
in this case implies the activation of Cdc42. Cdc42 contributes to filopodium extension through mDia 
and formins. Lamellipodium extension recruits Rho and Rac proteins. Contractility of the cell body 
drives cells forward and is mediated by Rho/ROCK or Cdc42/MRCK. A sustained activation of Cdc42 
and Rac allows the formation of invadopodia important for collective migration. Cdc42 maintains the 
WASP/Arp2/3 complex and promotes invadopodia extension and helps transporting MMP14 to the 
plasma membrane of these structures. Adapted from Lawson and Ridley, 2018; Spuul et al., 2014. 
 
RhoA, Rac1 and Cdc42 coordinate the dynamics of the cytoskeleton of actin and tubulin and are, 
therefore, a turning point in cell migration, both under normal physiological conditions as well as 
pathological context, such as tumor progression (Evers et al., 2000; Ridley, 2001b; Tapon and Hall, 
1997). 
 
For instance, inhibiting Cdc42 in swiss 3T3 fibroblasts or neuronal cells decreased migration, abolished 
microspikes formation and disrupted golgi structure. In tumor cells, Cdc42 inhibition blocked actin-
based motility and migration in a metastatic prostate cancer cell line (Friesland et al., 2013). In vivo, 
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Rho and its effector ROCK have been implicated in tumor-cell dissemination (Clark et al., 2000; Itoh et 
al., 1999; Murata et al., 2001; Somlyo et al., 2000). 
 
Many other examples will be presented while briefly explaining the different membrane extensions that 
can participate to cell migration.  
In migrating cells, four types of protrusions have been reported to be mediated by Rho GTPases (Ridley, 
2011). 
 
Lamellipodia are sheet-like protrusions usually observed at the front-rear of collective migrating cells. 
Activated Rac is required to drive lamellipodia formation (Faroudi et al., 2010; Montell et al., 2012), 
and will mainly recruit Wiskott-Aldrich syndrome protein-family verpolin-homologous protein 
(WAVE) that in turn activates Arp 2/3 in charge of actin nucleation and branching. Even though Rac is 
sufficient for creating these protrusions, Cdc42 and Rho have been found active and contributed to the 
extension of lamellipodia (Machacek et al., 2009). Other essential actors in this migration type are 
integrins in part due to their activation of Rac proteins (Lawson and Burridge, 2014). Of note, cells can 
use other means to migrate, therefore lamellipodia are not considered essential for cell motility however 
they will provide cells with faster migration when present. For instance, fibroblasts downregulated for 
Arp2/3 or Rac will use filopodia to migrate (Li et al., 2011; Wu et al., 2012). 
 
Filopodia are implicated in directed cell migration and can be seen in leader cells. They are thin 
membrane extensions of parallel actin bundles important for mechanosensing the microenvironment, 
and predominantly organized by Cdc42 (Pichot et al., 2010; Yang et al., 2006). The latter acts through 
the activation of the Mammalian Diaphanous-related formin (mDia2) that can nucleate and elongate 
actin filaments (Peng et al., 2003). Cdc42 also targets the insulin-receptor substrate p53 (IRSp53) that 
will contribute to filopodia formation by curving the membrane and bundling actin filaments (Cory and 
Cullen, 2007; Lim et al., 2008). Wiskott-Aldrich syndrome protein (WASP) was initially considered one 
of the main effectors of Cdc42-induced filopodia, but cells lacking both WASP isoforms were able to 
form filopodia (Snapper et al., 2001).  
 
Blebs, unlike lamellipodia, requires a loss of actin filament interaction with the membrane and therefore 
they are mostly used in low adhesion situations (Charras and Paluch, 2008). They are formed when 
plasma membrane detaches from the cortical actin network and cytoplasm flow will push it outwards 
(Bovellan et al., 2010). The hydrostatic pressure created is supported by Myosin II-induced actomyosin 
contraction (Tinevez et al., 2009) led in majority by Rho and its target ROCK which phosphorylates the 
myosin light chain MLC. It is suggested that this is followed by the E-cadherin dependant recruitment 
of Rac1 to stimulate actin polymerization at the front stabilizing membrane blebbings (Yap and Kovacs, 
2003). 
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 Invadopodia are rich actin protrusions important for degrading the extracellular matrix (ECM) specially 
to allow cells to breach the basal membrane during invasion (Buccione et al., 2009). Cdc42 is the 
essential Rho GTPases contributing to invadopodia formation through WASP/N-WASP and Arp2/3 
complexes. It coordinates the assembly of actin filaments with matrix degradation. Besides Cdc42, 
tyrosine kinases of Src family appear important for actin bundling with several Src substrates located in 
invadopodia such as cortactin and WASP/N-WASP (Dovas and Cox, 2010). Reactive oxygen species 
(ROS) generated by NADPH oxidases (Nox) and Nox organizers, the tyrosine kinase substrate proteins 
(as Tks5) were shown to be important for invadopodia formation as well as its function by targeting and 
keeping MMP14 in invadopodia (Diaz et al., 2009; Weaver, 2009).  Besides having common actin 
regulators with other membrane protrusions, the main difference of invadopodia is their capacity to 
modify and degrade the ECM of tumors by ensuring the trafficking of vesicles containing proteolytic 
enzymes mainly MMP14 (Poincloux et al., 2009). Microtubules may be  important for vesicles delivery 
and participate with intermediate filaments to the elongation of invadopods (Figure 20) (Schoumacher 
et al., 2010). 
 
3. 2. Polarity and adhesion  
 
In collective migration, leader cells establish a bipolar state where the leading-edge is in contact with 
the ECM and the rear is connected to neighboring cells by cell-cell adhesion. This new polarity is not a 
static new state of migrating cells but instead a dynamic cyclic process during which a continuous 
remodeling of adhesion complexes or the actin network stabilizing them occur. 
 
Some studies argue for a role of Rho-GTPases in the establishment and maintenance of intercellular 
junctions, in particular by promoting the polymerization of actin at the level of adhesion complexes 
(Evers et al., 2000; Malliri and Collard, 2003). For example, inhibition of Rac1 or RhoA contributes to 
the loss of cell polarity and intercellular junctions, and thus to the acquisition of a motile phenotype. 
Concerning Cdc42, it was first found to be crucial for establishing and maintaining cell polarity in yeast 
and drosophila models (Drubin, 1991; Etienne-Manneville, 2004; Murphy and Montell, 1996). Later, in 
mammalian cells, overexpression of Cdc42 and its effector Pak4 was shown to regulate apical junction 
formation in human bronchial epithelial cells. Similarly in MCF7 cells, a weakly tumorigenic mammary 
cell line identifying Cdc42/Pak4 importance in establishing epithelial polarity during directed cell 
migration (Melendez et al., 2011; Selamat et al., 2015; Wallace et al., 2010). 
 
On the contrary, other studies show that the activation of Rho-GTPases contributes directly or indirectly 
to the loss of adhesion complexes (Lozano et al., 2003; Sahai and Marshall, 2002). Indeed, it has been 
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shown that an aberrant activation of Rac1 and RhoA resulted in decreased adherence intercellular, thus 
contributing to tumor progression (Akhtar and Hotchin, 2001; Sahai and Marshall, 2002). In collagen 
matrix, constitutive activation of Cdc42 or Rac1 has been demonstrated to induce an increased integrin-
mediated migration and invasion and suggested to help the disruption of the polarization of T47D 
mammary epithelial cells in 3D culture (Keely et al., 1997).  
 
Similarly, activated Cdc42 and Rac1 by p120 catenin drive cell migration and invasion of the aggressive 
metastatic Her2/ErbB2 breast cancer; this was shown in vitro as well as in vivo in a xenograft mouse 
model of ErbB2-dependent breast cancer cell line (Johnson et al., 2010). In addition, Cdc42 plays a 
crucial role in targeting Pak6 to cell-cell adhesions. Pak6 isoform (serine/threonine kinases in the p21-
activated) has recently been found to regulate epithelial cell adhesion and to induce Cdc42-mediated 
epithelial colony escape. Pak6 is often found overexpressed in prostate cancer (Morse et al., 2016). 
 
However, these antagonistic roles may be explained by taking into consideration the fact that Rho-
GTPases may have different functions depending on the cell types and stage of the tumor development 
as well as the effectors implicated. 
 
3. 3. Contractility 
 
Cell body actomyosin contraction was first described regulated by the Rho/ROCK pathway. Activated 
ROCK can phosphorylate the myosin-light chain (MLC) and/or can desactivate the phosphatase function 
of myosin binding subunit (Mbs) responsible for the dephosphorylation of MLC which will overall 
induce cell contraction (Riento and Ridley, 2003). Contractility is important for several physiological 
functions, and is required to drive focal adhesion and stress fiber formation (Olson, 2004). It was also 
shown to regulate breast epithelial differentiation in 3D collagen culture (Wozniak et al., 2003). In 
addition, upregulating Cdc42 activity disrupted mammary gland branching leading to an increase in cell 
contractility and migration in association with stromal alterations (Bray et al., 2013). 
 
During migration, contractility and tail retraction are essential for cells motility. In 2005, Wilkinson et 
al have discovered that elongated cell migration is mediated by Cdc42 through the activation of MRCK 
that in turn phosphorylates MLC, stimulating contraction  and subsequently invasion (Wilkinson et al., 
2005). Similarly, in fibroblast-led invasion models, follower carcinoma cells require the activation of 
Cdc42/MRCK in order to migrate (Gaggioli et al., 2007) 
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3. 4. Collective migration and Spatio-temporal regulation 
 
Collective migration is a complex cyclic process that may require the activation of different Rho 
GTPases in the same cell at different locations. A fine regulation of these Rho GTPases allows leader 
cells to invade and degrade the ECM at the leading edge while keeping a connected rear with following 
cells and pulling them forward (Zegers and Friedl, 2014).  
 
In 2004, a new technique of biosensors allowed the visualization of Cdc42 activity in living cells and 
the monitoring of its spatiotemporal activity (Nalbant, 2004). This study showed that activity and 
localization of Cdc42 fluctuated according to the retraction/extension cycles found during migration. A 
more recent paper monitored the activity and subcellular location of Rho, Rac and Cdc42  with a second 
generation biosensors and suggested that the different Rho GTPases regulate different cytoskeleton 
rearrangements in highly plastic edge dynamics (Martin et al., 2016). 
 
The integration of all these modifications (from cell adhesion and polarity to cytoskeleton organization, 
protrusion formation and contractility) besides the fast dynamics of these events highlight the complex 
and important roles of Rho GTPases during collective migration and invasion. Further studies in vitro 
and in vivo will allow us to better understand the activation cascade of Rho GTPases, the dynamics of 
their regulators (the GEFs and GAPs), as well as what induces the upstream signaling pathways observed 
in human tumors. 
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III. B. Arfs , EFA6 and Cancer  
1. Arfs family 
1. 1. Generalities  
ADP-ribosylation factors (ARFs) are a family of small guanine nucleotide binding proteins, first 
discovered as co-factors of cholera toxin (Moss and Vaughan, 1995). The mammalian Arf family 
consists of six related genes divided into three subgroups according to primary sequence homology: 
class I includes Arf1, Arf2 (not expressed in human) and Arf3, class II Arf4 and Arf5, and class III Arf6 
(Tsuchiya et al., 1991). The membrane localization of Arf proteins is ensured by the myristoylated 
amphipathic N-terminal helix exposed upon GDP to GTP exchange, called N-terminal  helix GDP/GTP 
switch (Antonny et al., 1997; Franco et al., 1993, 1995, 1996). 
 
I am going to highlight the roles of Arf1 and Arf6, the two most studied members, in physiological 
contexts and in more details in cancer (Donaldson and Jackson, 2011). 
 
1. 2. Roles 
Arf1 
 
Arf1 was originally found in the Golgi apparatus where it regulates the formation of protein-coated 
vesicles important for exocytosis and intracellular vesicular trafficking pathways, comprising the 
retrograde Golgi-to-endoplasmic reticulum transport and intra-Golgi anterograde transport. 
Additionally, it has been shown that activated Arf1 may be located at the plasma membrane where it 
regulates endocytosis by controlling Cdc42 activity through the recruitment of a RhoGAP, ARHGAP10 
protein (Kumari and Mayor, 2008). Studies have also shown that Arf1 is able to trigger actin assembly 
polymerization through the Arp2/3 complex. This mechanism is dependent on the Cdc42 GTPase and 
its N-WASP effector. Here as well, Arf1 regulated this mechanism through its interaction with the 
ARHGAP10 (Dubois et al., 2005; Heuvingh et al., 2007; Stamnes, 2002). Of note, ARHGAP10 
described here as an effector of the activated form of Arf1 and Arf6 can act as the GAP of Cdc42 and 
therefore represent a possible link between the activation of Arf6 and the inhibition of Cdc42 activity 
(Dubois et al., 2005). 
Ar6 
 
Arf6 is the least conserved member of Arfs and shares 66% of sequence identity with Arf1. It is 
ubiquitously expressed and found mostly at the plasma membrane or endosomal compartment. It plays 
pivotal roles in a wide panel of cellular events including cell surface trafficking, phagocytosis, and cell–
90
cell adhesion. For example, Arf6 is implicated in the internalization of G-proteins coupled receptors 
(GPCRs) in both clathrin dependent and independent endocytosis (Houndolo et al., 2005; Hunzicker-
Dunn et al., 2002; Montagnac et al., 2011; Naslavsky et al., 2004) and plays important roles in the 
internalization of some of these GPCRs and the EGF receptor either for recycling or proteolysis (Macia 
et al., 2012; Montagnac et al., 2011). Additionally, Arf6 participates to the remodeling of actin 
cytoskeleton, mainly mediated by the activation of Rac1 and lipids-modifying enzymes (as PIP5K type 
I and phospholipase D) (Béglé et al., 2009; Caumont et al., 1998; Jovanovic et al., 2005), and mostly 
seen by monitoring membrane extension formation (Franco et al., 1999; Klein et al., 2006). 
 
In epithelial cells, Arf6 uses its different functions (membrane trafficking, cell-cell adhesion, and actin 
remodeling) to regulate cell polarity. It was initially shown to regulate vesicular trafficking to the apical 
domain of the cell, and later to mediate the turnover of AJ, the assembly of TJ as well as cyst 
morphogenesis, and HGF-induced tubulogenesis (Luton et al., 2003; Palacios et al., 2001; Sabe, 2003; 
Tushir and D’Souza-Schorey, 2007; Tushir et al., 2010). 
 
In vivo, a ubiquitous knock out of Arf6 was carried out in mice to further study its roles but exhibited a 
lethal phenotype due to liver development abnormalities caused by abnormal cell migration and 
increased apoptosis (Suzuki et al., 2006). 
 
We should note that these individual functions described above ranging from endocytosis and recycling 
to actin remodeling and lipid modifications will have, when altered, major effects on a wide range of 
cellular activities (as cell motility and invasion, cell division, cholesterol homeostasis, etc.). C. D’Souza-
Schorey group has an interesting review on Arf6-mediated functions (Schweitzer et al., 2011a). 
 
Of note, a molecular cascade was suggested linking Arf6 activation to Arf1. Once activated by EFA6, 
Arf6 can stimulate the activity of ARNO which in turn will allow GTP binding to Arf1 (Cohen et al., 
2007; Stalder et al., 2011). This notion emphasizes the complexity of Arfs’ acitivities, and the 
importance of keeping in mind the possible crosstalk between different isoforms of Arfs (DiNitto et al., 
2007). 
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1. 3. Arfs in Cancer 
 
 
Figure 21: Role of Arf proteins and their regulators in cancer cell migration.  
A. Arfs proteins are implicated in the maintenance of adhesion complexes, and the turnover of E-
cadherin with different Arf GEFs/GAPs. B. After adhesion complexes disassembly (first step of the EMT 
process), Arf proteins and their regulators will participate to the formation of new focal adhesions 
required for cell migration. C. In invasive cells, Arf proteins will be implicated in the recycling of 
integrins from the trailing edge and they will participate to the formation of different protrusive 
structures by remodeling the actin cytoskeleton and regulating vesicular trafficking. It is important to 
note that each step requiring Arf protein’s activity is directly bound to the presence of specific Arf 
regulators. CDR, circular dorsal ruffle; EE, early endosome; LE, late endosome; MP, macropinosome; 
RE, recycling endosome. .Adapted from (Casalou et al., 2016). 
 
Arf proteins are implicated in key physiological functions of cell homeostasis and therefore it is not 
surprising to find them dysregulated in cancer.  
 
As we have previously seen, in cancer, EMT will give many advantages to tumor cells, ranging from 
motility to invasiveness. One of the earliest and main step of this process is the disassembly of adhesion 
proteins followed by an important remodeling of the cortical actin cytoskeleton. Epithelial cancer cells 
are strongly affected by any modification of these two components that are direct and indirect targets of 
Arf proteins (Casalou et al., 2016; Schweitzer et al., 2011b).  
 
1.3.1 Arf1 
 
Arf1 has been shown to act at different levels of tumor progression. In a series of studies of A. Claing 
group, Arf1 activity was correlated to cell proliferation. In fact, lowering the active levels of Arf1 
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reduced the proliferation of MDA-MB-231 cells through mechanisms involving the retinoblastoma 
protein (pRB) hyperphosphorylation limiting gene transcription (Boulay et al., 2011). They have also 
shown that Arf1 may act upstream Rac1 to control migration  (Lewis-Saravalli et al., 2013). In the same 
line of thoughts, Arf1 was found in complex with ß1-integrin, paxillin, talin and FAK. Its knockdown 
impaired focal adhesion formation, highlighting its role in migration (Schlienger et al., 2015). 
Furthermore, Arf1 knockdown impaired invadopodia formation and decreased cell invasion. The 
suggested mechanism by which Arf1 mediated MDA-MB-231 invasion is through the activation of Rho 
activity affecting in turn the myosin light-chain (MLC) phosphorylation (Schlienger et al., 2013). The 
latter constitute the main regulator of contractility often used by cancer cells to pull on the extracellular 
matrix, reorganize the collagen fibers, and facilitate the migration process (Figure 21). 
 
1.3.2 Arf6 
 
 Arf6 and polarity 
 
Arf6 has been shown to exhibit important roles in cell-cell adhesion and cell polarity. In breast cancer, 
it has been described as an important regulator of the assembly and disassembly of adherens junctions 
by controlling the internalization of E-cadherin in mammary cancer cells (MCF7 and T47D) treated with 
EGF (Xu et al., 2015). Indeed, E-cadherin is constitutively recycled between the basolateral membrane 
and the endosomes, and the activation of Arf6 induces a stimulation of its clathrin-dependent 
endocytosis. Studies conducted on MDCK cells (Madin-Darby Canine Kidney), this time treated with 
HGF, have shown that Arf6-GTP is able to recruit, at the cellular junctions, the enzyme Nm23-H1 
capable of catalyzing endocytosis and to negatively regulate Rac1 protein activity, thus facilitating the 
disassembly of adherens junctions (Figure 21) (Palacios et al., 2001, 2002, 2005). 
 
 Arf6 and migration  
 
Endocytosis can play an important role in the migration process as well. In fact, motile cells need to 
redistribute their integrins at the migrating front. Stimulated by HGF, Arf6 was shown essential for the 
recycling of integrin β1 in migrating Hela cells (Hongu et al., 2015; Powelka et al., 2003). Similarly, in 
MDA-MB-231, silencing Arf6 altered the migration of this breast cancer cell line upon stimulation 
(Hashimoto et al., 2005; Marchesin et al., 2015b). 
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Arf6 and invasion 
 
The group of H. Sabe in Japan delivered most of the research work presented below describing the 
involvement of Arf6 in regulating cancer cell invasion using as a model the MDA-MB2311 mammary 
cell line. 
In 2004, they showed for the first time an evidence of the role of Arf6 in breast cancer invasion. In the 
aggressive mammary tumor cell line MDA-MB231, they demonstrated that Arf6 is localized at 
invadopodia concordant with the sites of matrix degradation. The knockdown of Arf6 reduced matrix 
degradation, invadopodia formation and migration through a matrigel barrier. Interestingly, both the 
expression of dominant-negative (Arf6(T27N)) and the constitutively active (Arf6(Q67L)) blocked 
invasion. Authors emphasized the importance of Arf6 cycling between active and inactive states, thus 
regulatory Arfs’ GEFs and GAPs can also be possible targets for cancer invasion (Hashimoto et al., 
2004). Shortly after, Arf GAPs and GEFs have been investigated. For instance, GEP100 GEF and 
AMAP GAPs have been implicated in controlling Arf6 mediated invasive activities of breast cancer 
cells upon EGF stimulation (Hashimoto et al., 2005; Morishige et al., 2008; Onodera et al., 2005). 
AMAP1 was found overexpressed in invasive breast cancer cells. However, several lines of evidence 
have demonstrated that AMAP1 binds Arf6 by a non-catalytic domain and acts as an effector of Arf6 
rather than as a GAP enzyme. Upon binding to Arf6-GTP, AMAP1 is recruited at the plasma membrane 
and will bind paxillin and cortactin and modify the actin cytoskeleton, mainly in invadopodia where it 
was located in MDA-MB231 (Hashimoto et al., 2005; Klein et al., 2006; Morishige et al., 2008; Onodera 
et al., 2005).  
It must be noted that Arf GAPs are the largest group of Arf binding proteins (Randazzo and Hirsch, 
2004; Sabe et al., 2006). Having multiple domains, Arf GAPs exhibit enzymatic GAP function but also 
can bind Arfs as effectors and therefore should be further considered when investigating the pathways 
by which Arfs mediate their activities. 
 
Moreover, recently a complementary study to the one localizing Arf6 at invadopodia showed that Arf6 
together with c-Jun NH2-terminal kinase–interacting protein 3 and 4 (JIP3 and JIP4) effectors may be 
controlling the quantity and activity of MT1MMP concentrated in these structures and crucial for 
degrading the matrix. Arf6 was revealed important for enzymatic recovery of MT1MMP by trafficking 
it from late endosomes to invadopodia (Marchesin et al., 2015a). 
 
In the same line of studies, in triple negative breast cancer cell models, downregulation of an anti-
tumorigenic micro-RNAs resulted in Arf6 upregulation and an increase of invasion. In clinical samples, 
they found that lymph node metastasis showed higher levels of Arf6 when compared to primary tumors, 
suggesting an important role for Arf6 in acquiring invasive capacities (Eades et al., 2015). 
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 The pro-tumorigenic role of Arf6 was confirmed in other types of cancer. For instance, in vitro and in 
mouse models, Arf6 was shown to mediate Wnt-induced melanoma invasion and metastasis. Here Arf6 
stabilized adherens junctions and thus blocked β-catenin signaling driving cells to malignancy 
(Grossmann et al., 2013).  
 
Together, these results suggest that Arf6 play an important role in the metastatic process and may be an 
interesting therapeutic target. 
 
However, we should note that most of the studies aforementioned used mostly one mammary cancer 
cell line, the MDA-MB-231. Using such highly transformed and aggressive cancer cell line does not 
allow us to investigate the role of Arf6 in the early stages of the disease where some proteins can have 
antagonistic roles (such as TGFβ). Besides this, the correlation with human breast cancer done by the 
group of Hisataka Sabe in Japan who investigated the role of Arf6 in cancer was done on a small number 
of patients and did not show any clear correlations between Arf6 and breast cancer aggressiveness. 
Another interesting remark is that studies showing a pro-tumorigenic or pro-invasive capacity of 
activated Arf6 in breast cancer had to stimulate their cells with EGF or HGF in order to see these effects. 
It is important to keep in mind that a deregulation of the Arf6 mediated receptor cycling will abrogate 
the vesicle trafficking and endocytosis mechanisms in which it is implicated. This will have serious 
effect on the desensitization of pro-oncogenic activated receptors like EGFR which will obviously give 
tumorigenic advantages to cells. 
Interestingly, a recent study shows opposing results to the pro-tumorigenic proclaimed role of Arf6. 
Indeed, the depletion of NEDD9, a maker of invasive and metastatic cancers, increased the Arf6-
dependent MMP14 targeting to late endosomes and thus decreased it at the cell membrane. The 
downregulation of Arf6 is capable of restoring the MMP14 amount present at the plasma membrane. In 
vivo, blocking NEDD9 has shown less tumor growth and metastasis in xenograft models of breast 
cancer (Loskutov et al., 2015). 
These results suggest that Arf6 may have different roles depending on the cellular context (adhesion 
status of cells), Arf6 regulators and the stage of cancer studied. 
 
*** 
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2. ARF GEFs: After all it is regulation that matters 
One of the fundamental highlights of Arfs activity in most scenarios remains the necessity of cycling 
between both active and inactive state in order to be functional. Arfs activities are tightly governed by 
their activators, GEFs, facilitating the binding of GTP and negative regulators, GAPs, enhancing GTP 
hydrolysis. GEFs and GAPs will also play an important role in spatiotemporal regulation of Arfs and 
thus the amplitude of Arfs-induced cellular behavior. Besides their role in regulating Arfs, some GEFs 
and GAPs can directly bind proteins and affect some cellular functions; for instance, Arf GAPs are 
considered a major group of potential Arfs’ effectors. Hence, Arf GEFs and GAPs may seem as 
attractive therapeutics targets. 
 
The core of my PhD thesis consists of studying the role of EFA6B, a member of EFA6 GEFs family, in 
cancer progression, and therefore I will present in the following section an overview of Arf GEFs family, 
with a focus on EFA6 GEFs: 
 
2. 1. The Arfs Exchange Factors 
 
Figure 22: Members of the Sec7 exchange factor families.  
The large number of Arf GEFs compared to the number of Arf suggests that Arf functions are under 
important regulation. Adapted from Casanova, 2007; Jackson and Casanova, 2000. 
 
In human, 15 genes encode members of the family of exchange factors specific to small G Arf proteins, 
also known as the Sec 7 Domain family, subdivided into two groups according to their sequence 
homology and molecular weight (Figure 22). 
 
The first group is composed of exchange factors of high molecular weight. This sub-family includes 
Gea1p and Gea2p yeast proteins, GNOM/Emb30p and GBF1, BIG1 and BIG2 proteins, and Syt1p. The 
majority of these proteins are located in the Golgi apparatus. The second group consists of proteins with 
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low molecular weight composed of three subfamilies : 1) ARNO and Cytohesins 2) BRAGs and 3) 
EFA6 proteins, all having a PH domain allowing them to bind to the plasma membranes via 
phosphoinositides (Casanova, 2007; Jackson and Casanova, 2000). 
 
2. 2. EFA6: genes, distribution and structure 
 
Figure 23: Structures of EFA6 isoforms.  
The four isoforms of EFA6 are composed of a variable N-terminal domain, a Sec7 catalytic domain, a 
PH domain responsible for plasma membrane localization and a C-terminal domain involved in the 
interaction with different partners.  
 
In 1999, the first member of EFA6 (exchange factor for Arf6) family was cloned by M. Franco and 
identified as a specific exchange factor for Arf6 (Franco et al., 1999). Since, four isoforms were 
identified EFA6A, EFA6B, EFA6C and EFA6D encoded by different genes (PSD, PSD4, PSD2 and 
PSD3, respectively). Additional isoforms resulting from alternative splicing have been described for 
EFA6A, EFA6B, and EFA6C (Derrien et al., 2002; Luton et al., 2003; Sakagami, 2008; Sironi et al., 
2009). 
  
As determined by in situ hybridization, they have various patterns of tissue distribution. EFA6A, EFA6C 
and EFA6D are widely expressed in neuronal cells showing distinct expression sites with some overlaps 
in brain regions (Sakagami, 2008). EFA6A was also found in small intestine and colon whereas EFA6D 
is ubiquitously expressed (Franco et al., 1999; Sakagami et al., 2006). EFA6B was found abundantly 
expressed in epithelial tissues with high levels in lungs, spleen and thymus (Derrien et al., 2002). 
 
The general structure of EFA6 family comprises a variable N-terminal domain, a Sec7 catalytic domain 
shown to be sufficient for GDP/GTP nucleotide exchange of Arf proteins (Chardin et al., 1996), a PH 
domain allowing membrane localization (Macia et al., 2008) and a C-terminal region composed of a 
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coiled-coil and two proline rich domains mediating the interaction with several partners (such as actin, α-actinin, etc.) (Figure 23) (Franco et al., 1999; Milanini et al., 2018).  
 
This GEFs’ structure highlights the dual means by which EFA6 proteins can intervene in cellular 
functions. It suggests that EFA6 could function by coordinating the activation of Arf6 together with the 
recruitment of effectors through its C-terminal domain. 
 
2. 3. EFA6 Roles: 
 
Since its discovery, 44 articles were published on EFA6 family describing their roles, in majority in 
vitro with the two most studied isoforms being EFA6A and EFA6B. 
 
Consistent with the roles of Arf6, EFA6A was involved in the internalization and recycling mechanisms 
of different membrane proteins. Thus, the overexpression of EFA6 or an Arf6 mutant blocked in the 
GTP form leads to a drastic decrease in transferrin internalization (Franco et al., 1999). It was also 
implicated in the recycling of the β2 adrenergic receptor (Macia et al., 2012). In vesicle trafficking, 
EFA6A recruits endophilin was also shown to control the activation of Arf6 and clathrin-mediated 
endocytosis (Boulakirba et al., 2014a). 
 
Besides their activities on remodeling the actin cytoskeleton, some direct roles of EFA6 on microtubule 
cytoskeleton remodeling were described in Caenorhabidits elegans. Independently of Arf6, EFA6 
inhibited microtubule growth at the cell cortex of yeast affecting functions like mitosis (O’Rourke et al., 
2010). Similarly, EFA6 in C.elegans altered axon regeneration by regulating the microtubules dynamics 
(Tang and Chisholm, 2016). 
 
Being more relevant to my PhD work, the physiological functions of EFA6 proteins like remodeling the 
actin cytoskeleton and establishment of epithelial cell polarity as well as some recent roles in cancer will 
be presented in detail below: 
 
2. 3. 1. EFA6 in actin cytoskeleton remodeling  
 
EFA6, like Arf6, is involved in the reorganization and assembly of the actin cytoskeleton (Derrien et al., 
2002; Franco et al., 1999). Indeed, Hela cells overexpressing the wild-type form of EFA6A accumulate 
filamentous actin that co-localize with EFA6A at the level of membrane ruffles. By using different 
mutants, the C-terminal domain of EFA6A was identified responsible for this remodeling. The 
overexpression in cells of EFA6AE242K or EFA6AΔsec7 mutants, which do not possess a catalytic activity, 
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leads to the formation of actin-rich membrane extensions. Concomitantly, cells overexpressing the 
mutant that do not have the C-terminal domain had no effect in particular. At least a part of the effect of 
EFA6A on actin has been suggested to be mediated by the activation of Rac1 (Franco et al., 1999). The 
localization of EFA6 by the PH domain was shown to be crucial for the C-terminus induced cytoskeleton 
remodeling. It has been demonstrated that cells overexpressing the C-terminal domain alone which is 
cytosolic, or the PH domain alone located at the folds of the plasma membrane have a similar 
morphology to that of control cells. On the other hand, when the C-terminal domain is coupled to the 
PH domain, it localizes to the plasma membrane and induces changes in the actin cytoskeleton. This 
means that actin remodeling is mainly mediated by the C-terminal domain of EFA6 only when recruited 
by the PH domain at the plasma membrane. Another evidence to this role is the capacity of EFA6A to 
interact directly with actin and α-actinin*** (Macia et al., 2008; Sakagami et al., 2007).  
 
 ***α-actinin is a cross-linking protein capable of binding and maintaining two actin microfilaments 
parallel to each other in order to form, in collaboration with myosin II, contractile actin filaments. It 
participates among other to the formation of stress fibers and in the regulation of actomyosin 
cytoskeleton supporting the TJs.*** 
 
It is interesting to note that actin cytoskeleton rearrangement can also be seen in the regulation of 
membrane extensions formation. EFA6A has been shown critical for the development of neuronal 
protrusions. For instance, in cultured hippocampal neurons, a GEF-defective mutant of EFA6A 
increased significantly the formation and stability of dendritic spines which are small actin rich 
extensions important for synapse neuronal signaling (Choi et al., 2006; Sakagami et al., 2004). 
Interestingly, even though EFA6A is important for neuronal protrusions, a constitutively active Arf6 
decreased spine density while its dominant negative increased it. This information proves once again 
that the regulation of Arf6 by EFA6, which can modulate Arf6 function through its C-terminal domain, 
is critical to normal cellular functions. 
 
Conclusion 
EFA6 coordinates Arf6 activation and recruits effectors to the C-terminal domain that can modulate 
Arf6 functions. 
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2. 3. 2. EFA6 in epithelial cell polarity 
 
Figure 24: Model for EFA6B regulation by ubiquitinylation/de-ubiquitinylation during epithelial cell 
polarization. 
In non-polarized epithelial cells, EFA6 is submitted to a constitutive ubiquitinylation by the E3 ligase 
Siah followed by its degradation through the proteasome. As soon as cells engage in the cell polarization 
program EFA6 is protected from degradation by the de-ubiquitinylase USP9, this leads to a rapid 
accumulation of EFA6, which will contribute to the reorganization of the actin cytoskeleton and the 
formation of the TJ. Once the latter is formed, EFA6 is no longer protected from the proteasome and its 
protein expression level drops down due to the activity of Siah. Since USP9 leaves very rapidly from the 
contact zone where EFA6 remains concentrated, EFA6 is probably protected from Siah or its 
degradation by the proteasome, by a USP9- independent mechanism (Théard et al., 2010). 
 
Polarized epithelial cells are defined by two distinct domains at the plasma membrane level: an apical 
domain facing the lumen and a basolateral domain facing the basal membrane. These two membrane 
domains are separated by tight junctions (TJs). Our research group has shown the importance of EFA6 
in TJs assembly and elucidated by which molecular mechanisms the actin cytoskeleton modulates TJs 
functions (Figure 24) (Klein et al., 2008a; Luton, 2005; Luton et al., 2003). In Madin-Darby canine 
kidney (MDCK) cells, after E-cadherin engagement, EFA6 is recruited at the cell-cell junctions where 
it controls the assembly of tight junctions and contribute to the development of epithelial polarity. EFA6 
maintains TJs by stabilizing the apical actin ring that supports them and promoting the retention of TJs 
proteins (Luton et al., 2003). The use of catalytically inactive mutants or mutants without the C-terminal 
domain demonstrated that Arf6 activation by EFA6 Sec7 domain and regulating this activity by its C-
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terminal domain of EFA6 were necessary (Klein et al., 2008a).  Here again we show that the cooperation 
between Arf6 activation and the C-terminal domain activity are important for EFA6-mediated effects. 
 
The levels of EFA6 are critical for TJs biogenesis and are controlled by the deubiquitinating enzyme 
USP9x. In polarized cells, a low level of EFA6 is maintained by constitutive ubiquitination and turned 
over by the proteasome. However, while establishing new contacts, epithelial cells require higher levels 
of EFA6 guaranteed by the USP9x-mediated deubiquitination that protects EFA6 from proteosomal 
degradation at the nascent cell-cell contact where TJs are assembled (Figure 24) (Théard et al., 2010). 
 
Conclusion 
EFA6 and its substrate Arf6 favor the development of cell polarity and stabilize the apical actin ring and 
adhesion complexes. The purpose of the second article presented in this thesis will be to elucidate the 
role and mechanism of action of EFA6 in lumen formation, a crucial step for having functional normal 
endocrine glands as the mammary gland. 
 
2. 3. 3. EFA6 in cancer 
 
Even though EFA6 family was shown to be implicated in important physiological roles, it was rarely 
investigated in pathological contexts. On the basis of transcriptomic data, some papers have suggested 
correlations between the level of expression of EFA6 and some cancer types in patients. For instance, 
the mRNA levels of PSD3 (EFA6D) have been found increased in colon and hepatocellular carcinoma 
tissues and downregulated in esophageal, breast and ovarian cancer (Hu et al., 2005; Pils et al., 2005; 
Thomassen et al., 2009; Wang et al., 2002). For ovarian cancer, the downregulation of PSD3 on the 
transcriptomic level observed in patient tissues has been linked to poor prognosis and classified among 
genes worthy of further investigation (Pils et al., 2005; Thomassen et al., 2009). Likewise, a meta-
analysis combining eight datasets of 1200 breast tumors has shown that EFA6D mRNA level is reduced 
in metastasizing breast cancer and therefore suggested as potential metastasis suppressor genes 
(Thomassen et al., 2009) 
 
However, these studies remain simply correlations that were not further explored or validated at the 
protein level in cellular or animal models. In 2006, the first study looking into the role of EFA6 on a 
molecular level in cancer was published. They have suggested that EFA6A overexpression in a human 
glioblastoma cell line promoted migration and invasion via the activation of an Arf6/ERK signaling 
cascade (Li et al., 2006). 
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 Figure 25: EFA6B regulates the apico-basal polarity of mammary tumorigenic cells. 
Exogenous expression of EFA6B promoted the reversion to an epithelial phenotype while its repression 
leads to unorganized aggregates. Immunofluorescence of MCF7 acini grown in MatrigelTM for 5 to 7 
days .Adapted from Zangari et al., 2014. 
 
This study was followed in 2014 by a work led by my research group on the role of EFA6B in breast 
cancer progression (Zangari et al., 2014). Beforehand, a thorough description of the role of EFA6B in 
establishing epithelial cell polarity and tight junctions assembly was conducted  (Klein et al., 2008a; 
Luton, 2005; Luton et al., 2003; Théard et al., 2010). Taking in consideration the importance of these 
characteristics for normal epithelial cells, my research group proceeded to test their hypothesis on a 
possible role of EFA6B in cancer cells. Using MCF7, a weakly tumorigenic mammary cell line, our 
previous data showed that EFA6B exogenous expression restored a normal polarized epithelial 
monolayer of cells grown in 2D on filters, with functional tight junctions. In 3D culture, EFA6B was 
able to revert the intermediate epithelial-mesenchymal morphology of luminal breast cancer cells MCF7 
into a well differentiated apico-basal epithelial phenotype (Figure 25). It resulted in cells organizing 
collectively into normal mammary acini-like structures, with the formation of lumens, and this is by 
contributing to the fusion of vacuolar apical compartments (VAC) in polarized acini. In addition, in vivo, 
the endogenous downregulation of EFA6B/PSD4 at the transcriptomic and proteomic level was found 
to be correlated in human breast cancer to poor prognosis associated to the aggressive claudin-low or 
triple negative subtype (Zangari et al., 2014). 
 
This study clearly showed that the tight junction regulator EFA6B is capable of enhancing the epithelial 
status of cancer cells and therefore its expression might hamper cancer progression. Of note, the lab 
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showed that EFA6B mediates these effects in part by the activation of Arf6 (Zangari et al., 2014), 
suggesting that EFA6B and Arf6 reduced activity/expression are considered pro-tumorigenic.  
 
This conclusion challenges the previous assumptions about the role of Arf6 in cancer. As previously 
presented in the section of “1. 3. Arfs in Cancer”, Arf6 activation or up-regulation has been related to 
cancer progression. However, it is important to keep a critical eye on the cellular models used and the 
stimulation required to see some of Arf6 pro-tumorigenic effects. It is not surprising after all to see that 
such multifunctional proteins like Arf6 and its regulators EFA6 proteins may present opposing roles in 
different pathological contexts and different stages of tumorigenesis. 
 
In support to our data, a recently published article provided evidence that the loss of NUMB expression, 
an activator of EFA6B exchange activity, promotes cell migration and invasion. More specifically, 
NUMB loss allows the formation of membrane protrusions and the acquisition of mesenchymal 
migratory phenotype due to a reduction of EFA6B/Arf6 activity (Zobel et al., 2018). 
 
We believe that our protein of interest, EFA6B may act as a negative regulator of tumorigenesis at early 
stages. My PhD subscribes in the continuity of this work, and proposes further results supporting this 
hypothesis.  
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 Article 1 
1. Objectives of Article 1 
 
1. 1. General context 
“Epithelial integrity and homeostasis are of central importance to survival” (Macara et al., 2014). Indeed, 
epithelial cells make up a large percentage of our bodies; they form a barrier protecting the internal 
organs from external stresses (e.g. skin, airways, etc.) as well as composing our glands (e.g. mammary 
gland, salivary gland, etc.), indispensable for the development and maintenance of a healthy organism. 
Epithelial cells are structurally characterized by their arrangement into cohesive sheets regulated mostly 
by adhesion complexes (as adherens junctions, desmosomes, tight junctions, etc.), the apico-basal 
polarity and the cytoskeleton rearrangement. These properties are essential for epithelial cells to exhibit 
diverse functions, mainly secretory ones, determined by specific differentiation and activation in 
response to their microenvironment stimuli (mechanical tensions, growth factors, hormones, etc.). 
 
Epithelia is subject to active modifications: from developmental stages where they have to undergo 
proliferation, migration and self-organization processes up to adulthood (e.g. tubes, villi, alveoli, etc.). 
Any deregulation provoking the loss of epithelial identity can induce a range of dysfunctions and 
diseases (such as eczema, psoriasis, asthma…) or even lead to the most common human cancers in 
adults, epithelial carcinomas. For instance, in cancer cases, an extreme deregulation of epithelial 
homeostasis leads to metastasis, the resultant of cells disseminating from the primary tumor. Metastasis 
is considered the main cause of cancer patients death and therefore, it is of great interest to understand 
the initiating factors in charge of cancer cells gaining in invasive properties. 
 
While many oncogenic mutations causing growth, proliferation and resistance to apoptosis have been 
identified ("driver mutations"), epigenetic changes or genes specifically regulating the emergence of 
metastatic properties are less easily detectable. We will call the alteration of these genes “secondary 
driver mutations” considering that alone they cannot transform a normal cell however, they will provide 
newly-transformed cells with functional and phenotypical advantages crucial for malignancy. Of note, 
this is different from passenger mutations targeting non-coding region or redundant genes that will not 
contribute to cancer progression. 
During carcinogenesis, these mutations may also influence the fate of the neo-tumor and its orientation 
towards a particular subtype. Thus, identifying such genes alterations and deciphering the associated 
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signaling pathways would provide a preventive and/or predictive tool for clinicians and help find new 
therapeutic targets. 
 
The results of this thesis work fall within this pre-cancerous research: we show that our protein of 
interest, EFA6B, is a non-transforming factor of which loss of expression in normal breast cells promotes 
Cdc42-dependent invasive properties. Thus, we believe that EFA6B might play an antagonist role in the 
progression of cells towards aggressive breast cancers. 
 
1. 2. EFA6 Background 
Following its cloning in 1999, EFA6A has been demonstrated as an exchange factor for Arf6 and to be 
involved in actin cytoskeleton rearrangement (Franco et al., 1999). Similar characterization was shown 
afterward for the other isoforms of EFA6 family. In the scope of this thesis, I have focused on thde 
EFA6B isoform that has been previously described as a tight junction regulator in normal epithelial cells 
(Klein et al., 2008b; Luton, 2005; Luton et al., 2003; Théard et al., 2010). EFA6B is recruited upon E-
cadherin engagement to help assemble and stabilize tight junctions by strengthening the apical actin 
cytoskeleton and excluding TJ proteins from endocytosis to retain them at the cell surface. This 
discovery triggered the curiosity of my research group to investigate the role of EFA6B in a tumorigenic 
context knowing that the loss of polarity and adhesion complexes represents a major milestone in cancer 
metastasis (Zangari et al., 2014). In MCF7 cells incapable of assembling tight junctions, the exogenous 
expression of EFA6B restored a normal apico-basal polarization with the formation of functional tight 
junctions of cells grown on filters in 2D culture. Interestingly, in 3D Matrigel matrix, the overexpression 
of EFA6B reverted the mass aggregate phenotype, typical of weakly tumorigenic mammary cell lines, 
into normal acini with a central lumen, characteristic of a functional mammary epithelial structure. 
 
These results have revealed the capacity of EFA6B to regulate the mesenchymal/epithelial status of 
cells. Indeed, EFA6B expression blocked the entry in epithelial to mesenchymal transition (EMT) 
observed normally in MCF7 cells treated with the transforming growth factor beta (TGF-b). This is the 
first cue indicating a possible role of EFA6B in EMT which opened up new perspectives and areas of 
investigation for our research group. 
 
Lastly, using transcriptomic and immunohistochemistry analyses, a lower expression of EFA6B in 
human breast cancer tumors was correlated to the aggressive claudin-low subtype characterized by an 
EMT signature and a loss of TJ proteins and to poor prognosis of patients (Zangari et al., 2014). 
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1. 3. Working Hypothesis 
To date, EFA6B has shown remarkable functions in epithelial cells ranging from apico-basal polarity, 
apical actin cytoskeleton organisation, to interfering with the EMT process, all of which contribute 
largely to epithelial homeostasis. As suggested by the correlation with BC patients and its different roles, 
disrupting EFA6B expression can lead to dysfunctions during epithelial morphogenesis but also to 
stimulate cancer progression in tumor cells.  
 
Therefore, during my thesis, I was interested in investigating furthermore the impact of the 
loss of expression of EFA6B (as observed in claudin-low patients) on mammary epithelial cells. 
 
Thus, we have generated a CRISPR/Cas9 full knock-out model of EFA6B in normal mammary epithelial 
cells MCF10, considered mainly as basal cells. We also proceeded by establishing a CRISPR/Cas9 KO 
of EFA6B in HMLE cell line, a normal mammary gland population containing luminal progenitors, 
mature luminal cells and basal cells. This will allow us to validate our results in a different mammary 
epithelial cell line but also to investigate any possible differences in EFA6B impacts related to the origin 
of the cell (mainly between luminal and basal, two major epithelial cells of the mammary gland). 
 
We have decided to work in normal cell lines in order to have a more or less clear genetic background 
allowing to unravel the consequences of deleting EFA6B. In addition, knowing that EFA6B and Arf6 
might have different roles according to the stage of cancer, it was interesting to see if their loss in the 
early steps of tumorigenesis gives an advantage to cells. 
 
This thesis work consisted on approaching the impact of EFA6B loss by setting three main objectives:  
 
1. to describe the impact of EFA6B loss on epithelial properties. 
2. to determine if the loss of EFA6B can endow cells with pro-tumoral features and 
eventually drive them towards the claudin-low subtype. 
3. to reveal and decipher the cellular and molecular mechanisms regulated by EFA6B. 
 
As mentioned before, the existing knowledge focus on few driver mutations, while it is of great 
importance to identify pre-cancerous factors or the so-called secondary driver mutations. We 
demonstrate that EFA6B loss can affect the epithelial homeostasis. Hence, the ultimate goal of this 
thesis is to describe the tumor-antagonistic and protective advantages of EFA6B expression. 
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Abstract 
Breast cancer is the second leading cause of cancer death in women worldwide. Primary tumor 
metastasis is responsible for most of the mortality. Despite the benefits of breast cancer targeted 
therapies there is still no effective treatments against metastases. Cancer initiation is caused by 
somatic mutations in oncogenes or tumor suppressor genes, but additional mutations can provide 
selective advantages to the tumor cells to spread into nearby tissue or distant organs and develop 
metastatic cancers. The identification of pro-invasive factors and the comprehension of their 
mechanism of action is therefore of paramount importance. We have recently proposed that EFA6B 
(Exchange Factor for Arf6, B), a tight junction regulator, acts as an antagonist to breast cancer 
development. Loss of expression of EFA6B is correlated with the metastatic Claudin-low breast cancer 
subtype that is characterized by the loss of tight junction and a transcriptomic signature of epithelial-
to-mesenchymal transition (EMT). To establish and identify the pro-tumoral impact of the loss of 
EFA6B we have invalidated the gene PSD4/EFA6B in normal human mammary cells using the 
CRISPR/Cas9 technology. We found that EFA6B depletion is sufficient to induce the formation of 
cellular branched structures in collagen I by collective invasion. It is accompanied by an up-regulation 
of EMT transcription factors, alterations of the matrisome, changes in the integrin (ITG) repertoire and 
increased cell contractility. Consequently, the cells no longer sense the laminin inhibitory signal and 
form ITGB1-based invadopodia enriched with the metalloprotease MMP14 responsible for the matrix 
degradation. The invasion depends on Cdc42 activation and two of its effector pathways Cdc42-MRCK-
pMLC and Cdc42-N-WASP-Arp2/3. Collectively, our results demonstrate a novel negative regulatory 
pathway of collective invasion downstream of EFA6B and open up new therapeutic perspectives for 
breast cancer. 
Introduction 
Epithelial morphogenesis is essential for embryonic development, organogenesis and tissue 
repair (Bryant and Mostov, 2008; Lecuit and Le Goff, 2007; Martin and Parkhurst, 2004). It relies on 
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highly dynamic and conserved processes that help to deform simple epithelial sheets into three-
dimensional structures (Lecuit and Le Goff, 2007). Alteration of these mechanisms can cause major 
developmental defects and diseases such as cancer (Thiery et al., 2009). Most of our knowledge of the 
molecular and cellular mechanisms comes from the study of simple animal models (e.g. C. Elegans and 
Drosophila) but there is still much to discover about more complex organisms such as mammals 
(Fletcher Alexander G. et al., 2017). In this regard, in vitro 3D cell culture models and organoids provide 
valuable support to the studies of genetically modified animals (Bryant and Mostov, 2008; Cheung and 
Ewald, 2014; Drost and Clevers, 2018; Martín‐Belmonte and Rodríguez‐Fraticelli, 2009). 
The control of tissue morphogenesis is based on a combination of cellular mechanisms (Ladoux 
and Mège, 2017; Lecuit and Le Goff, 2007) and on the interaction of the cells with their stromal 
environment that helps to contain physically and shape through reciprocal communication the 
epithelial tissue (Bonnans et al., 2014; Howard and Lu, 2014; Sakakura et al., 2013). The mammary 
gland is an excellent organ model for studying the remodeling of an epithelial tissue because its 
development takes place after birth, during puberty and undergoes cycles of expansion and involution 
with each pregnancy (Shamir and Ewald, 2015). 
The mature epithelial mammary tissue consists of two layers of distinct cells: the apical luminal 
cells that rest on a layer of basal cells or myo-epithelial cells, and a small fraction of progenitor cells. 
The myo-epithelial cells are in direct contact with the basal membrane, composed essentially of 
laminins and collagen IV, which envelops the epithelial bilayer and separates it from the stroma rich in 
fibrillary collagen I, fibronectin and proteoglycans in which are found fibroblasts, adipocytes and cells 
of the immune system. The basic functional unit of breast tissue under development is the terminal 
end bud (TEB), an alveolar structure formed at the end of a duct. The duct is composed of a double 
layer of luminal and basal cells, while the TEB is made of multiple layers of luminal cells surrounded by 
a single layer of basal cells. At puberty, the mammary gland expands by ductal elongation and 
branching morphogenesis while the TEB penetrates the stroma in a tightly regulated mode of collective 
invasion. It is believed that this developmental program is co-opted during breast cancer providing 
mammary tumor cells with metastatic potential (Macias and Hinck, 2012). 
Breast cancer is a major public health issue with half a million deaths worldwide each year, the 
majority of which being due to metastatic dissemination (Bray et al., 2018). Despite the effectiveness 
of therapies for early detected tumors, the treatment of metastatic cancers remains a largely 
unresolved problem. There is therefore an urgent need to better understand the molecular 
mechanisms that regulate invasion in order to develop new treatments. A large number of studies 
have described the cellular and molecular mechanisms that promote or sustain invasion. Much less is 
known about intracellular signaling pathways that transmit negative regulatory signals to block the 
invasive potential of epithelial cells.  
We have recently described the anti-tumor potential of the Arf6 exchange factor, EFA6 
(Zangari et al., 2014). We initially showed that this molecule, by activating Arf6 and interacting with 
effectors through its C-terminal domain, regulates the assembly and maintenance of tight junctions 
(Klein et al., 2008; Luton et al., 2003; Théard et al., 2010). Then, we showed that its level of expression 
determines the epithelial status of mammary cells grown in 3D culture. In particular, the over-
expression of EFA6B in weakly tumoral cells restores a normal epithelial phenotype by stimulating the 
formation of a central lumen and tight junctions (Milanini et al., 2018; Zangari et al., 2014). Finally, in 
breast cancer patients, we observe a correlation between the loss of expression of EFA6B (mRNA and 
protein), the Claudin-Low (Cld-low) cancer sub-type and a reduced survival rate (Zangari et al., 2014). 
To identify the molecular mechanisms by which EFA6B acts as an antagonist to the 
development of breast cancer, we analyzed the consequences of invalidating its gene (PSD4) in normal 
human mammary cells. We have found that EFA6B knock-out mammary cells, of basal or luminal 
origin, grown in 3D matrices developed branched structures by adopting a collective mode of invasion. 
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This invasion is dependent on the formation of integrin 1- and MMP14-enriched invadopods. 
Upstream, the collective invasion is controlled by the activation of an EMT program with a modification 
of the cell-ECM interaction as judged by alterations in the matrisome, changes in the integrin 
repertoire and increased contractility leading to remodeling of the ECM by the EFA6B knock-out cells. 
Downstream of EFA6B, we show that its knock-out activates Cdc42 which in turn elicits two signaling 
pathways:  Cdc42-MRCK-pMLC that regulates contractility, which together with Cdc42-N-WASP-
Arp2/3 is required for invasion. Thus, we have identified a new EFA6B-regulated mechanism of 
collective invasion, which opens up new avenues for the treatment of breast cancer.  
 
 
Results 
 
Loss of EFA6B in MCF10A stimulates invasive branching in collagen I 
To investigate the impact of the loss of expression of EFA6B on breast cancer development, we have 
inactivated the gene (PSD4) encoding for EFA6B in normal human mammary cell line MCF-10A using 
the CRISPR/Cas9 technology. We have performed two separate rounds of PSD4 knock-out using two 
distinct sgRNA targeting the first exon. In total, four out of 250 clones screened by immunoblot for the 
loss of EFA6B protein expression were isolated. The inactivation of PSD4 gene was further confirmed 
by a DNA mismatch endonuclease assay followed by PSD4-targeted genomic and transcript 
sequencing. Fig. 1A shows the characterization of three knock-out clones (clone KO 55, KO 50 and KO 
2) for EFA6B and one heterozygous clonal cell line (Het 2.9), with the latter expressing half of the total 
levels of EFA6B compared to wild-type cells. The expression of EFA6A and EFA6D, the other members 
of EFA6 family expressed in MCF-10A cells, was unaffected. A slight decrease (20%) of Arf6 expression 
was observed (see also Fig. 1C and Fig. 2B) which was also noticed in BC patients whose EFA6B 
expression was decreased (Zangari et al., 2014). The levels of the other Arf proteins, Arf1 and Arf5, 
remained unaffected. More noticeable was the severe reduction of Arf6-GTP (80%) levels indicating 
that EFA6B is a major Arf6-GEF in MCF-10A cells (Fig. 1C).  
EFA6B has been previously recognized as a tight junction and polarity regulator(Klein et al., 2008; Luton 
et al., 2003; Théard et al., 2010). To assess the hallmark property of epithelial cells to polarize and self-
organize in acini the clones were placed in collagen I gels. Control MCF10A cells formed round 
aggregates typical of normal epithelial cells. In contrast, all the homozygous EFA6B KO clones outgrow 
branched structures reminiscent of collective dissemination (Fig. 1B, upper and middle panels).  
Quantification of cell aggregates displaying at least one branched structure (>2 microns) (Fig. 1B, 
bottom panels) showed that KO clones developed 4 times more membrane and cellular protrusions 
than WT MCF10A cells (Fig. 1D).  Re-expression of wild-type EFA6B by lentiviral infection of the KO 
clone 55 was sufficient to recover the formation of normal round aggregates (Fig. 1D, clone RESCUE) 
indicating that the invasive phenotype was specifically a consequence of the loss of EFA6B. Of note, 
the heterozygous (het) 2.9 clone expressing 50% of EFA6B, organized identical branched structures 
and to the same extent than the homozygous KO clones (Fig. 1D). Since exogenous expression of EFA6B 
in EFA6B KO 55 cells rescued the invasive phenotype, we propose that the dominant loss-of-function 
of EFA6B is likely due to haplo-insufficiency. 
 
Loss of EFA6B stimulates invasive branching in luminal and basal mammary sub-populations  
We then set out to determine whether the effect of KO of EFA6B can be generalized to other epithelial 
mammary cells and whether it has a similar impact on the two major mammary epithelial cell subtypes, 
luminal and basal. To address these questions, we used the HMLE human epithelial population as it 
contains luminal progenitors and both mature luminal and basal epithelial cells. Using the EpCAM and 
CD49f cell surface markers, we sorted luminal progenitors (EpCAM+/CD49f+), mature luminal 
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(EpCAM+/CD49f-) and mature basal (EpCAM-/CD49f+) cells (Fig. 2A) and immediately performed 
CRISPR/Cas9 mediated invalidation of PSD4 in each separate population. We obtained one 
homozygous (KO 3) and one heterozygous clone (Het 25) from the luminal progenitor population and 
one homozygous clone ;KO ϭ’’Ϳ froŵ the mature basal population. No clone was obtained from the 
mature luminal population. Similar to MCF10A clones, EFA6B protein expression was undetectable in 
the homozygous HMLE KO ĐloŶes ;KO ϯ aŶd KO ϭ’’Ϳ Đoŵpared to the wild-type population or clones 
;WT Ϯϯ aŶd WT Ϯ’’Ϳ, while the heterozygous clone (Het 25) expressed 50% of its corresponding wild-
type clone (WT 3) (Fig. 2B). The expression of the other isoforms, EFA6A and EFA6D, was unaffected. 
A modest but significant reduction of Arf6 expression was observed in the clones isolated from the 
luminal progenitor population but not in the basal clone. However, neither Arf1 nor Arf5 levels were 
altered. In 3D-collagen culture, HMLE WT clones formed cohesive rounded aggregates while the EFA6B 
homozygous and heterozygous HMLE clones displayed invasive protrusions (Fig. 2C). Overall, the HMLE 
clones displayed a less developed invasive phenotype than the ones isolated from MCF-10A (Fig. 2D). 
In conclusion, EFA6B is a general negative regulator of the invasive properties of epithelial mammary 
cells from both luminal and myo-epithelial origins. The dominant-negative phenotype of the HMLE 
heterozygous clone confirmed our suggestion of classifying EFA6B as an haplo-insufficient tumor 
antagonist gene. This is in agreement with our previous observations in various cell systems showing 
that the levels of EFA6 proteins were critical to their functions (see discussion). Also, in BC patients the 
severity of the histo-clinical data was correlated with the extent of the loss of expression of PSD4 
messengers (Zangari et al., 2014). 
EFA6B knock-out cells stimulate an MMP-14 dependent ECM degradation and invasion 
The branched structures observed in 3D culture in MCF10A and HMLE cell lines upon the loss of EFA6B 
expression resemble phenotypically to branching during mammary morphogenesis or collective 
invasion of cancer cells. Therefore, we next sought to characterize the enzymatic invasive properties 
found to be crucial for cell dissemination in both normal and cancerous contexts. To demonstrate the 
capacities of cells to digest their microenvironment, we first seeded them on fluorescent gelatin 
matrix. In contrast to WT cells, the EFA6B KO 55 clone was capable of degrading the fluorescent gelatin, 
seen as dark spots underneath the cells (Fig. 3A and B). Moreover, we validated their capacity to 
proteolytically cleave collagen fibers by performing immuno-fluorescence analyses using the Col1-3/4C 
antibody that recognizes specifically the digested ends of collagen fibers (Monteiro et al., 2013). As 
shown in Fig. 3C and D, the Col1-3/4C staining was virtually absent around the wild-type aggregates 
while a strong signal was visible along the invasive cellular protrusions extended by the EFA6B KO 55 
cell aggregates. In the search of a potential protease responsible for collagen degradation, we screened 
several candidates using protease inhibitors and found that GM6001, a MMP selective inhibitor, was 
the most effective (data not shown). We thus focused on the MMP-14 that has been described as the 
main metalloprotease involved in mammary gland morphogenesis and breast cancer metastasis 
(Feinberg et al., 2016, 2018; Friedl and Gilmour, 2009; Poincloux et al., 2009). Both, MCCF10WT and 
EFA6B KO 55 cell lines expressed similar protein levels as assessed by immunoblot (Fig. 3E). Using 
specific siRNA for MMP-14 (Fig. 3F), we found that down-regulation of MMP-14 in the EFA6B KO cells 
totally inhibited collagen invasion (Fig. 3G). 
Next, we challenged the invasive capacities of the cells by placing them in a stoichiometric mixture of 
collagen and Matrigel (1/1 mg/ml). Matrigel is composed of laminin molecules, the main components 
of the basal membrane that inhibits epithelial cell invasion (Nguyen-Ngoc et al., 2012). Although 
Matrigel significantly reduced cells invasion, EFA6B KO 55 cells succeeded to form membranous and 
cellular protrusions (Fig. 3H). In 2mg/ml Matrigel, EFA6B KO 55 cells did not present any protrusive 
aggregates (data not shown). However, unlike WT cells that demonstrated a classic polarized structure 
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with lumen formation, the EFA6B KO 55 cells remained disorganized and never formed any lumen (Fig. 
3I). 
In conclusion, the EFA6B KO cells are potent invasive cells that have lost the capacity to polarize in 
response to ECM stimulation. 
EFA6B knock-out promotes a change in the ITG repertoire and stimulates the formation of ITGB1-
based degradative invadopodia 
Maintenance of epithelial cell polarity relies on cues arising from cell-to-cell interaction and cell-to-
ECM adhesion. In fact, EFA6B KO cells remain cohesive but have lost the ability to polarize in Matrigel 
which suggest a deregulation on Cell-ECM signaling level. Transcriptomic profiling of the KO 55 and 
Het 2.9 clones compared to MCF10 WT cells revealed that the matrisome is the main affected group 
of genes with up to 10% (48) of the total altered genes (475) (Supp. Table 1 and Supp. Fig. 1).  
We explored first the protein expression level of the major integrins (ITG) expressed in mammary cells: 
α21, α31, α61 and α64. By combining FACS (Fig. 4A), immunoblot analyses (Fig. 4C) and confocal 
immunofluorescence imaging (Fig. 4E) we found that the EFA6B KO 55 cells had a good reduction of 
subunits α6 (50%) and 4 (36%) expression, whilst those of α2, α3 and 1 were unchanged. To 
determine which integrins were required for EFA6B KO-mediated invasion, we placed spheroids in 
collagen containing control or integrin blocking antibodies and quantified the number of invasive 
protrusions (Fig. 4B). Antibodies against ITGA6, ITGB4 and ITGB3 had no effect. In contrast, antibodies 
against ITGB1 and ITGA2 strongly blocked cell invasion (Fig. 4B). 
The ITGB1-mediated invasion relies on the formation of specialized degradative structures called 
invadopodia (Eddy et al., 2017). We thus searched for the formation of degradative invadopodia in 
MCF10WT and EFA6B KO cells. In EFA6B KO 55 cells, staining for cortactin, a marker enriched in 
invadopodia, revealed the presence of large structures co-stained for F-actin and matching spots of 
digestion of the gelatin (Fig. 4F). In MCF10 WT cells, no degradation of gelatin was visible and the 
cortactin positive spots, not enriched in F-actin, appeared smaller (Fig. 4F). Since the invasion of the 
EFA6B KO 55 cells is dependent on MMP14, we looked for MMP14 enrichment in invadopodia. Cells 
were transiently transfected with MMP14-mCherry plasmids and stained for cortactin. In EFA6B KO 
55, but not WT, cells expressing low levels of MMP14-mCherry presented extensive co-localization 
with cortactin (Fig. 4G). Next, we determined whether ITGB1 was concentrated into the invadopodia. 
Again, we found a large co-localization of ITGB1 with MMP14-mCherry in EFA6B KO 55 but not in 
MCF10 WT cells (Fig. 4H). Altogether, these results demonstrated that the loss of EFA6B led to the 
formation of MMP14-degradative and ITGB1-based invadopodia. 
Next, we investigated the expression of fibronectin (FN) and the mammary laminin (LN) proteins 
LN111, LN332, LN511 and LN521. Immunoblots of whole cell lysate showed no change in the levels of 
FN, LAM2 (LN332) or LAM1 (LN111, LN511) (Fig. 4D). We thus looked at the LN deposited by cells 
grown in 3D-collagen. In both MCF10 WT and EFA6B KO 55 cells, the staining intensity for LAM2 
(LN332) and LAMα5 (LN511, 521) surrounding the cell aggregates were equivalent indicating that the 
production, secretion and deposition of the major LNs were unaffected (Fig. 4I). However, in the KO 
aggregates, LNs were absent at places where cells invaded the collagen (Fig. 4I, arrows).  
We conclude that in the absence of EFA6B, there is a modification of the matrisome and integrin 
repertoire accompanied by the formation of invadopodia, all of which contributes to the collective 
invasion of the EFA6B KO cells. 
EFA6B knock-out induces the expression of EMT transcription factors that promote collective 
invasion of MCF10A and HMLE cells in collagen I. 
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 The inability of cells to polarize and maintain an epithelial phenotype suggested that they may have 
engaged to some extent into an epithelial to mesenchymal transition (EMT). EMT is believed to 
promote invasion by providing cells with migratory and degradative advantages (Heerboth et al., 
2015). We observed that the MCF10 EFA6B KO cells had reduced levels of E-cadherin with an increased 
expression of N-cadherin; a classical EMT cadherin-switch (Fig. 5A). In addition, transcriptomic analysis 
showed alteration of the cell-cell adhesion (Supp. Fig. 1). Knowing that EFA6B is a TJ regulator and its 
expression correlated with the loss of tight junction proteins and the Cld-low BC subtype, we also 
looked at TJ markers and found that Cld1 and Cld3 were strongly reduced in all clones and occludin 
decreased in 3 out 4 clones (Fig. 5A). We also confirmed these results by analyzing the HMLE clones. 
Although, there was no switch of cadherin expression, we noticed a strong increase of VIM 
accompanied by a slight but robust decrease of Cld3 (Fig. 5B). Confocal immunofluorescence analysis 
of MCF10 WT and EFA6B KO 55 cells grown in 3D-collagen confirmed the cadherin switch at cell-cell 
junctions (Fig. 5C). N-cadherin was described to provide weaker homotypic interaction between 
adjacent cells (Cavallaro and Dejana, 2011). We thus assessed the cell-to-cell affinity by using the 
hanging-drop assay in which cells were submitted to gravity in a drop of medium to facilitate cell-cell 
contacts within a monolayer. Lining the bottom of the drop, MCF10 WT cells formed compact 
monolayers while EFA6B KO 55 cells formed lacy monolayers indicative of loose cell-cell contacts (Fig. 
5D). These results indicated that the loss of EFA6B reduced cell-cell adhesion facilitating pro-migratory 
cell movements, while maintaining enough connection between cells to invade through a collective 
mode of invasion. 
We also analyzed by FACS the expression levels of the cell surface markers, EpCAM and CD49f. In the 
EFA6B KO 55 cells, we found an overall decrease of both markers of 66.9±7.2% for EpCAM and 
41.4±9.6% for CD49f together with the emergence of a new population (11,7% of total cells, red gate) 
characterized by a very low EpCAM expression suggestive of a loss of epithelial identity (Fig. 5E). 
Further analysis by RT-qPCR confirmed the switch of E/N-cadherin, and the decrease of CD49f and 
occludin. It also revealed that Cld7 expression was down-regulated confirming the effect on TJ 
components. We also looked at the CK14 which down-regulation was recently shown to mark an 
advanced mesenchymal state in melanoma (Pastushenko et al., 2018) (Fig. 5F). All our results indicated 
that loss of EFA6B had engaged the cells into an EMT program. Thus, we analyzed the expression of 
the known EMT-TF in BC and found a significant increase of SNAI, TWIST1 and ZEB1, and to a lower 
extent of SLUG and TWIST2 (Fig. 5F). Next, we tested the implication of the most relevant EMT-TFs in 
invasion and found that siRNA-mediated down-regulation of Twist1, Snail and Slug but not ZEB1 
blocked the EFA6 KO invasion (Fig. 5G, H). 
We concluded that the knock-out of EFA6B induced the expression of EMT-TFs that promoted EMT 
and collective invasion. 
EFA6B knock-out stimulates cellular contractility and invasion through Cdc42 
Our results showed that loss of EFA6B promotes collective invasion through activation of an EMT 
transcriptional program, alteration of the matrisome including the integrin repertoire. All of these 
modifications can be directly linked to a change in cell contractility behavior. 
We thus explored the contractility capacity of our cells by first looking at the organization of the 
collagen surrounding the cell aggregates by reflectance (Fig. 6A). We did not observe a particular 
orientation of the collagen fibers around the WT cell aggregates. In contrast, reflectance signals 
showed accumulation of collagen fibers at the periphery of invading EFA6B KO 55 cells, and more 
interestingly, a radial distribution of aligned collagen fibers from leading cells. Thin membrane 
filopodial structures were prolonged by collagen fibers detected by reflectance (Fig. 6A, inset arrows). 
We then quantified the contractility activity by using collagen gel contraction assay (Fig. 6B). EFA6AB 
KO cells were at least twice more contractile than their WT counterparts. Cell contractility is dependent 
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upon the activation of the myosin II through the phosphorylation of the myosin light chain (MLC) 
(Vicente-Manzanares et al., 2009). Concomitant with the results of the contraction assay, whole cell 
lysate showed that EFA6B KO 55 cells presented higher levels of pMLC than control cells (Fig. 6C). All 
these observations indicated that the EFA6B KO 55 cells were more contractile that the WT cells. Small 
G proteins of the Rho family are known to control cell contractility (Zegers and Friedl, 2014); thus by 
siRNA-mediated down-regulation (Fig. 6D), we searched for the small G proteins that could mediate 
the augmented contractility of the EFA6B KO 55 cells. Using gel contraction assays, we found that the 
downregulation of Cdc42, but not RhoA or Rac1, altered the contractility of the EFA6B KO 55 cells (Fig. 
6B). Next, we observed that the down-regulation of Cdc42 was the most effective at blocking invasion, 
while again RhoA and Rac1 had no effect (Fig. 6E). Pull-down experiments were conducted to 
determine whether any of the small G proteins were over-activated in the EFA6B KO 55 cells compared 
to WT (Fig. 6F). In agreement with the functional assays, we found an upregulation of activated Cdc42, 
but not of RhoA or Rac1. Overall, these observations point towards a central role for Cdc42 in 
regulating cell contractility and invasion following EFA6B depletion.  
 
 
EFA6B knock-out stimulates cellular contractility and invasion through two Cdc42-dependent 
signaling pathways: Cdc42-MRCK-pMLC and Cdc42-NWASP-Arp2/3 
Cdc42 is known to regulate contractility through the recruitment of kinases that phosphorylate MLC 
(Wilkinson et al., 2005)  and to control invadopodia formation by activating the Arp2/3 complex, a 
regulator of actin dynamics, through N-WASP (Torres and Rosen, 2006). Downstream of Cdc42, the 
myotonic dystrophy-related Cdc42-binding kinases (MRCK)  were shown to phosphorylate directly or 
indirectly the myosin II regulatory light chains (MLC) (Wilkinson et al., 2005). SiRNA experiments 
showed that the combined down-regulation of both MRCK and MRCK in EFA6B KO 55 cells reduced 
both the MLC phosphorylation and cell invasion in collagen I (Fig. 7A). We also analyzed the effect of 
depleting the Ca2+–calmodulin activated myosin light chain kinase (MLCK) that has been proposed to 
act on the cell peripheral acto-myosin cytoskeleton (Vicente-Manzanares et al., 2009). Down-
regulation of MLCK also decreased the MLC phosphorylation but had little effect on invasion indicating 
that MRCK and MLCK regulate separate pools of MLC (Fig. 7B). RhoA activates the Rho-associated 
protein kinases ROCK1 and ROCK2 believed to phosphorylate MLC in a more central area of the cells. 
Knock-down of both ROCK1 and ROCK2 had no effect on either phosphorylation of MLC or invasion 
(Fig. 7C). Thus, in EFA6B KO cells, the activated Cdc42 controls phosphorylation of MLC and invasion in 
an MRCK/-dependent manner. Further, siRNA down-regulation of N-WASP and Arp2/3 inhibited 
invasion (Fig. 7D). Altogether, our results unraveled a new pathway regulated by EFA6B, which controls 
the activation of Cdc42 and two downstream functions: a) contractility through MRCK/ 
phosphorylation of MLC and b) invasion through N-WASP and Arp2/3. 
 
Discussion 
 
During this study, we discovered a novel negative regulatory pathway of the collective invasion 
controlled by the exchange factor of Arf6, EFA6B. In the absence of EFA6B, mammary cells undergo 
EMT, matrisome remodeling and concomitant activation of a Cdc42-dependent signaling pathway that 
controls cell contractility and invasion via the formation of ITGB1-based and MMP14-enriched 
invadopodia. 
 
EFA6B : specificity and haplo-insufficiency 
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The EFA6 family comprises 4 isoforms among which 3 are expressed in mammary epithelial cells at the 
exception of the neuronal specific member EFA6C. In MCF10A cells, compared to EFA6B, EFA6A is 
expressed in similar amount and EFA6D is in large excess (our unpublished results). Since, neither 
EFA6A nor EFA6D levels of expression were affected upon EFA6B knock-out it indicates that neither 
one was able to compensate for the absence of EFA6B. On the other hand, EFA6B re-expression in 
MCF10 EFA6B KO cells was sufficient to revert the invasive phenotype. Thus, in MCF10A cells the EFA6B 
isoform appears to be selectively regulating the invasive properties. The absence of compensation 
between the EFA6 isoforms is a general observation made by us and other groups (Luton et al., 2003; 
Morishige et al., 2008; Théard et al., 2010; Zangari et al., 2014).  All four EFA6 members displaying 
similar Arf6 GEF activities, it suggests that either their subcellular localization is strictly distinct and/or 
that their functions do not depend only on Arf6 activation but on a combination of signals that they 
integrate through their other functional domains. We have already reported evidence of the latter 
model by showing that EFA6 effects on TJ assembly can only be recapitulated by co-expressing an Arf6 
constitutive mutant (Arf6T157N) together with the PH-Cterminus of EFA6 (Klein et al., 2008). Finally, 
the EFA6B substrate Arf6 levels were found to be slightly but reproducibly reduced in MCF10A and 
HMLE (luminal progenitor) cells while the other members of the family Arf1 and Arf5 were unaffected. 
In BC patients of the Cld-low subtype this reduction in Arf6 was also observed indicating that there is 
a specific loop of regulation between EFA6B levels and its substrate Arf6 (Zangari et al., 2014). 
Most interesting is the observation that heterozygous KO clones were as invasive as the homozygous 
ones, emphasizing the importance of the levels of expression of EAF6B in repressing the invasive 
potential of normal mammary cells. This observation is in agreement with many of the results we have 
previously obtained by studying EFA6A and EFA6B in different cellular models that demonstrated that 
the functions of EFA6 proteins are dependent on their expression level. First, using an inducible system 
to control EFA6Avsvg levels of expression in the MDCK cells, we observed that EFA6A stimulating 
effects on the assembly of the TJ is dose-dependent (Luton et al., 2003). Second, at the onset of 
epithelial polarization following the engagement of the E-cadherin molecules, the levels of 
endogenous EFA6B are transiently and dramatically increased at cell-cell contacts to help assemble the 
TJ (Luton et al., 2003; Théard et al., 2010). Third, at steady state the levels of expression of the 
endogenous EFA6B are maintained low by a finely-tuned balance between high rates of protein 
synthesis and degradation by the ubiquitin-proteasome system (Théard et al., 2010). Fourth, although 
the levels of EFA6B at steady state are low, siRNA-mediated down-regulation weakens the TJ indicating 
that a minimal level of EFA6B is necessary to maintain a functional TJ (Théard et al., 2010). Fifth, the 
functional complementation experiments described above indicated that the strength of the signals 
delivered by the two proteins Arf6T157N and EFA6 PHCter needed to be finely equilibrated to mimic 
EFA6 effects suggestive of a stoichiometric control (Klein et al., 2008). Finally, in BC patients we found 
a correlation between the histo-clinical data and the levels of PSD4/EFA6B (Zangari et al., 2014). 
Collectively, these results indicate that the levels of expression of EFA6B are critical to its functions. In 
this manuscript, the results obtained with the knock-out cells deliver a novel information: the 
PSD4/EFA6B gene appears as an haplo-insufficient tumor-antagonist gene. 
Invasive properties 
MCF10A are the most studied normal epithelial human mammary cells. Yet, although they polarize 
around hollow lumens when grown in Matrigel as expected from luminal cells, their transcriptomic 
signature is that of a basal cell line suggesting that these cells may represent a multipotent lineage 
(Neve et al., 2006). To analyze the effect of EFA6B knock-out selectively in basal and luminal cells, we 
carried out the CRISPR/Cas9-mediated knock-out of EFA6B after sorting both populations from the 
immortalized mammary epithelial cells HMLE (Elenbaas et al., 2001). We observed that the two 
isolated homozygous KO clones derived from each population as well as the heterozygous KO luminal 
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clone were all invasive, though the basal EFA6B KO cells appeared slightly less invasive. Further, 
regardless of their basal or luminal origin, the KO cells displayed similar EMT profiles with no sign of E-
Cadh/N-Cadh switch but a strong increase in vimentin and a slight decrease of the Cld3 protein. 
Although based on few clones, our results indicate that EFA6B depletion in luminal and basal cells 
induces EMT and invasion in collagen I. It is admitted that basal breast cancers are more aggressive 
than luminal ones. However, very little is known about how the differentiation state of the cancer cell 
impacts the acquisition of metastatic capacities. The EMT observed in our luminal clones may endow 
them with invasive properties (Cheung et al., 2013). 
A large body of evidence obtained from in vitro and in vivo studies demonstrated that the MMP14 
metalloprotease is instrumental to enabling normal mammary gland development and BC collective 
invasion (Feinberg et al., 2016, 2018; Friedl and Gilmour, 2009; Ghajar and Bissell, 2008). Looking for 
the protease responsible for invasion in MCF10A KO cells, we found that MMP14 was required. Yet, 
the total level of expression is comparable between MCF10A WT and EFA6B KO cells. Since, invasion is 
a regulated process based on the organization of specialized invasive structures called invadopodia, 
we looked at the cell surface distribution of MMP14 and for the presence of invadopodia. In MCF10 
WT cells, the MMP14-mCherry was found mostly in an intracellular peri-nuclear compartment with 
little MMP14 at the cell surface. In contrast, in EFA6B KO cells, the MMP14 was found enriched in large 
dotted structures labelled for ITGB1 and cortactin marking the presence of invadopodia. Hence, EFA6B 
KO cells invade by stimulating the formation of invadopodia enriched in MMP14. 
The fact that our cells display thin filopodia at the front of the leader cells, express MMP14 and sustain 
invasive protrusions in collagen I is reminiscent of a mechanism of invasion by cancer cells. Indeed, the 
collective invasion during mammary tubulogenesis occurs without actin-based protrusions extending 
into ECM (Ewald et al., 2012). Further, MMP14 is not expressed by the normal epithelial cells during 
mammary gland branching but is expressed by the invading BC cells (Feinberg et al., 2018). Finally, 
normal cells would only invade collagen I transiently before producing their basement membrane that 
blocks invasion (Nguyen-Ngoc et al., 2012). 
EFA6B KO cells keep on invading the collagen I even mixed with Matrigel indicating that they do not 
respond to the arrest signal provided by the matrix and/or do not produce a normal matrix. Gene 
profiling expression analyses showed that the EFA6B KO cells had a major change in their matrisome. 
We have made the same observation in MCF7 cells down-regulated for EFA6B using constitutive 
expression of a specific shRNA (our unpublished results). Nevertheless, immunoblot analyses did not 
detect significant changes of expression of the major laminins expressed by our cells. When spheroids 
of MCF10 WT and EFA6B KO cells were placed in collagen I, we observed staining of similar intensities 
for laminins (LAM5 and LAM2) deposited around the core of the spheroids indicating that the KO 
EFA6B cells were capable of producing, secreting and assembling normal levels of laminins. However, 
while MCF10 WT cells did not invade the collagen I passed their basement membrane, the EFA6B KO 
cells disseminated from the spheroids most likely by digesting their basement membrane that was no 
longer recognized as a stop signal. 
 
The Cdc42 signaling pathway 
In MCF10A cells, the absence of EFA6B led to a strong activation of Cdc42 but not Rac1 nor RhoA. In 
vitro and in vivo studies have shown important roles for Cdc42 in regulating diverse cellular processes 
such as cell cycle progression and mitosis, polarity, survival, differentiation and stem cell function 
(Stengel and Zheng, 2011). Transgenic overexpression of Cdc42 in the mammary gland produced 
hyperbranched ductal trees and abnormal acini with altered epithelial-stromal interactions (Bray et 
al., 2013). Although Cdc42 is found hyperactivated in breast tumors (Fritz et al., 1999, 2002), activating 
mutations in Cdc42 have not been found (Rihet et al., 2001) suggesting that its activating pathways 
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must be altered. We propose that loss of expression of EFA6B alters a Cdc42 activating pathway 
contributing to Cdc42 hyperactivation in human BC. 
How is Cdc42 activated upon EFAB KO? In other words, how EFA6B and/or Arf6 activation inhibits 
Cdc42 in non-tumoral cells? The most direct pathway would be through the recruitment of a Cdc42-
GAP of the ARH-GAP family, which members bind to activated Arf-GTP molecules. For instance, 
ARHGAP10 was shown to be recruited by Arf1-GTP in the Golgi to repress Cdc42 functions (Dubois et 
al., 2005). ARHGAP10 appears to be Golgi-specific but other members of the ARHGAP would be good 
candidates to mediate Cdc42 inhibition downstream of EFA6B/Arf6. Alternatively, another 
EFA6B/Arf6-associated signaling pathway may eventually recruit one of the many Cdc42-GAPs to 
mediate its inhibition. Also, indirectly the EMT transcriptional program or change in matrisome may 
have induced the increased expression of a Cdc42-GAP. 
From in vitro studies, Cdc42 is a known pro-invasive protein that can induce the formation of filopodia, 
invadopodia and can regulate cellular contractility (Stengel and Zheng, 2011). We found that knock-
down of Cdc42 abrogates contractility and invasion of the EFA6B KO cells. We determined that Cdc42 
promotes increased contractility through MLC phosphorylation via the MRCK proteins. In contrast, the 
major RhoA/ROCK contractility pathway did not appear to play a major role. Interestingly, ECM rigidity 
and cellular contractility were shown to regulate the formation of invadopodia (Alexander et al., 2008; 
Parekh and Weaver, 2016) suggesting that in EFA6B KO cells Cdc42 activation might facilitate the 
formation of invadopodia by increasing cell contractility. EFA6B knock-out cell contractility may also 
be the consequence of an alteration of the matrisome that might have increased the ECM rigidity, for 
instance through the observed up-regulation of the LOX protein (Table 1). 
Further, Cdc42 plays an essential role in invadopodia formation (Stengel and Zheng, 2011; Yamaguchi 
et al., 2005) and maturation by maintaining the activation of N-WASP-Arp2/3 complex, which 
nucleates actin polymerization (Eddy et al., 2017). In addition, Cdc42 can promote the recruitment of 
MMP14 to the plasma membrane at invadopodia (Castro-Castro et al., 2016). Since the invasion of our 
EFA6B KO cells is dependent on N-WASP, Arp2/3 and MMP14 we propose that Cdc42 is the major 
effector of their invasive behavior. 
 
EFA6B/Arf6 and breast cancer 
Our previous study indicated that the loss of EFA6B expression in BC patients is correlated with poor 
prognosis and the metastatic subtype Claudin-low characterized by the loss of expression of all cell 
junction constituents and an EMT signature (Zangari et al., 2014). Here, we show that the loss of EFA6B 
expression induces an EMT and endows the cells with invasive properties. There have been no genomic 
studies showing EFA6B to be an oncosuppressor, and our orthotopic xenograft experiments of EFA6B 
KO cells in immunosuppressed mice did not lead to the formation of any tumor demonstrating that 
the loss of EFA6B is not a driver mutation. Yet, other so-called secondary driver mutations, although 
non-transforming on their own, can provide selective advantages to transformed cells (Nik-Zainal and 
Morganella, 2017). We propose that the loss of expression or activity of EFA6B is a secondary driver 
mutation that confers invasive properties and high metastatic susceptibility to cancer cells. 
The loss of expression or activity of EFA6B may occur in several ways. In BC, mutations within the 
PSD4/EFA6 gene are very rare and mostly found outside the catalytic site, or within domains not known 
to control its GEF activity or its association with known interactors (Zangari et al., 2014). It therefore 
seems more likely that the loss of EFA6B expression is due to events altering biological processes that 
control its messenger or protein abundance. We propose that the loss of EFA6B expression observed 
in Cld-low tumors is due to either alteration of its regulation by the ubiquitin proteasome system, by 
non-coding RNAs (miRNAs and ceRNAs), or by mutations in its promoter that could mediate haplo-
insufficiency in the event that only one promoter is affected. In any case, our results indicate that 
reduction of EFA6B protein levels below a minimum threshold induces invasive behavior. Yet, we do 
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not exclude that a gradual loss of EFA6B expression may correlate with the progressive acquisition of 
increasing invasive properties. They are now accumulating evidence emphasizing the role of 
heterozygosity in tumor progression and showing that a reduction of the amount of highly 
interconnected proteins, such as EFA6B, may change the networks response resulting in a high amount 
of damage (Berger et al., 2011; Smilenov, 2006). 
In general, Arf6 is considered as a pro-tumoral factor although only few studies provided mechanistic 
details of its contribution. The work from the group of Sabe described a signaling pathway activated 
by the EGF whereby the EGFR would recruit the Arf-GEF BRAG2/GEP100 to activate Arf6, which then 
recruits in cascade the Arf-GAP AMAP1, cortactin and the mesenchymal protein EPB41L5. In vivo, this 
pathway would regulate the invasive properties of EGFR positive BCs (Li et al., 2017; Sabe et al., 2009). 
In TNBCs, the group of Chavrier reported the implication of Arf6 in facilitating the trafficking of the 
MMP14 to the invadopodia through the adaptor JIP3/4 and kinesin 1 (Marchesin et al., 2015). 
However, another study described an opposite effect where Arf6 recruited by NEDD9 would negatively 
control the trafficking of active MMP14 to the cell surface and block invasion (Loskutov et al., 2015). 
More recently, it was found that the endocytic protein Numb controls negatively the acquisition of 
migratory and invasive properties by activating EFA6B/Arf6 in response to growth factors (Zobel et al., 
2018). 
In summary, we found that the depletion of EFA6B stimulates an epithelial-to-mesenchymal transition 
concomitant to an alteration of the matrisome and the acquisition of collective invasive properties. 
The collective invasion of the EFA6B KO cells is dependent on the activation of Cdc42. The activated 
Cdc42 elicits two signaling pathways that first increase cellular contractility dependent on the MRCK 
proteins, and second the formation of invadopodia enriched in N-WASP, Arp2/3 and the protease 
MMP14. Together with others, these results indicate that the loss of EFA6B expression might 
contribute to the high metastatic propensity of Claudin-low breast cancers. A better understanding of 
the molecular mechanisms leading to EFA6B depletion as well as its consequences should offer new 
opportunities to fight breast cancer. 
Methods 
CRISPR/Cas9 knock-out 
Two guided RNAs targeting the exon 1 of human PSD4 were selected from the crispr.mit.edu/ and  
crispor.tefor.net/ websites. The guided RNAs were cloned separately into the vector pSpCas9(BB)-2A-
GFP (PX458 - Addgene) encoding for Cas9 and GFP. Sequences were as follow: PSD4-Z1T8-pX458-FOR1 
forward 5'-3' CACCgaggatccaccggagcctttcg, PSD4-Z1T8-pX458-REV1 reverse 5'-3' 
AAACcgaaaggctccggtggatcctc, PSD4-Z2T36-pX458-FOR2 forward 5'-3' CACCgttctctgagcaaggactcgcc, 
PSD4-Z2T36-pX458-REV2 reverse 5'-3' AAACggcgagtccttgctcagagaac. 
HMLE and MCF10-A cells were first transfected with the two plasmids using Lipofectamin 3000 
;IŶǀitrogeŶͿ aĐĐordiŶg to ŵaŶufaĐturer’s reĐoŵŵeŶdatioŶs. Ϯϰ hours later, GFP positiǀe Đells ǁere 
sorted and cloned in 96 wells culture plates using the BD FACSAria III (BD Biosciences). Knock-out and 
heterozygous clones were screened by immunoblot. Further validation was carried out using the 
Surveyor assay (Integrated DNA Technologies) and genomic sequencing of the targeted sequence. Of 
note, the three different populations of HMLE were sorted according to their expression of EpCAM and 
CD49f as shown in figure 2 before next-day transfection. 
Transient transfection  
Transient transfection was performed using RNAiMAX (Invitrogen) according to the manufacturer 
instructions. All siRNAs were purchased from Dharmacon ON-TARGETplus collection. 
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Stable transfection 
HEK-293T cells were transfected with the human PSD4 containing pLV lentivirus (VB160428-1095xdp 
– Vector Builder) together with the 3rd generation lentiviral packaging plasmid (Addgene):
pMDLG/pRRE (Gag and Pol), pRSV-Rev (Rev), and pMD2.G (VSV-G envelope) using JETPEI (Polypus
Transfection). Supernatants containing the lentiviruses were collected at 48h and 72h post-
transfection. MCF10-A cells were transduced with the filtered supernatants in the presence of 10g/ml of Polybrene (Sigma-Aldrich). Transduced cells were selected with 250 g/ml of G418 (Sigma).
3D culture 
3D culture was performed using Rat tail Collagen I (Corning). The collagen I solution was neutralized 
using 1N NaOH and diluted in PBS to a final concentration of 1mg/ml for the contractility assay, and 
1.5 mg/ml for the invasion assay, otherwise specified. Matrigel (Corning) matrix was used alone at 
2mg/ml for cell polarization or at 1mg/ml mixed to 1mg/ml collagen matrix to measure invasion. 
Contractility assay 
70 l of collagen mixed with human mammary cells (700 cells/l) were plated in 96-well plates, and 
incubated for 30 min at 37°C in 5% CO2 before addition of complete medium. The collagen gels were 
detached from the plastic using a pipet cone. Collagen area was quantified using Image J software. 
Invasion assay 
Cells transfected with siRNA were plated in collagen 24h after transfection. Human mammary 
individual cells (100 cells/l) resuspended in 200 l of collagen were plated in chambered cover glass 
(Lab-Tek, Thermo Fisher Scientific), and incubated for 30 min at 37°C in 5% CO2 before addition of 
complete medium. After 48h, protrusions were quantified using a phase contrast microscope (Leica) 
by counting 100 cellular aggregates per well. Cells with at least one membrane extension of at least 2 
ŵiĐroŶs’ leŶgth ǁere ĐoŶsidered protrusiǀe. 
Immunoblot 
Cells grown on plastic dishes were washed 3 times with phosphate buffered saline (PBS) and lysed with 
a SDS lysis buffer containing 0.5% SDS, 150 mM NaCl, 5 mM EDTA, 20 mM Triethanolamine–HCl pH 
8.1, 1 mM PMSF. The lysate was heated at 95C for 10 minutes and then thoroughly shaken for 15 
minutes. After a 20 minutes centrifugation at 16,000 g at room temperature, supernatant was 
transferred into new tubes containing 5 × Laemmli buffer and further boiled 5 min. For protein 
analysis, cell lysates were loaded into SDS-PAGE and transferred onto a nitrocellulose membrane. 
Membrane blocking and secondary antibodies dilutions were done in PBS 5% non-fat dry milk, primary 
antibodies were diluted in PBS containing 3% BSA. The proteins were revealed by chemiluminescence 
;ECL™, Aŵersham France) using secondary antibodies directly coupled to HRP. The membranes were 
analyzed with the luminescent image analyzer Fusion (VILBER, France). 
Pull down assay 
MCF10-A cells were lysed at 4°C in 0.5% Nonidet P‐40, 20 mM Hepes pH 7.4, 125 mM NaCl, 1 mM 
phenylmethylsulphonyl fluoride (PMSF) and a cocktail of protease inhibitors (Complete, Roche 
Diagnostics). The cleared lysates containing the protein of interest were incubated 4 h at 4°C with 1.5 
μM of the iŶdiĐated GST‐fused proteiŶs aŶd ϯϬ μl of glutathione‐sepharose CL‐4B beads. After three 
washes in lysis buffer, the beads were boiled in Laemmli buffer, submitted to SDS–PAGE and the 
indicated proteins were revealed by immunoblot. To pull-down Arf6GTP, Rac1GTP, Cdc42GTP and 
RhoAGTP, we fused Gst to the Arf6-GTP binding domain of ARHGAP10, the Cdc42/Rac binding domain 
of PAK, or the Rho binding domain of Rhotekin, respectively. 
RNA isolation and RT-qPCR 
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Total mRNA was isolated using the Tri Reagent (Sigma-Aldrich) and treated with AmbionTM Dnase I 
(Invitrogen) following the ŵaŶufaĐturers’ iŶstruĐtioŶs. 2 g of total RNAs was denatured at 65°C for 
10 min and incubated for 1h at 50°C in the presence of 2.5 mM dNTP, 100 U Superscript III (Invitrogen) 
using 0.5 g oligo(dT)15 primer in a total volume of 20 l, followed by an inactivation step of 15 min 
at 70°C. A negative control lacking RT enzyme was also performed in each assay (NRT). A control PCR 
reaction of the reverse transcription was performed with human GAPDH (forward) 
gaacatcatccctgcatcc, (reverse) ccagtgagcttcccgttca primers with Q5 High fidelity DNA polymerase 
according to the standard protocol described by the manufacturer (New England BioLabs®). The PCR 
products obtained after 35 cycles were separated through a 1% agarose gel, visualized under UV after 
staining with ethidium bromide. Real-time PCR was carried out with The LightCycler® 480 SYBR Green 
I Master (Roche Life Science) in triplicates and analyzed using LightCycler® 480 Software, Version 1.5 
(Roche). The expression of each gene was normalized to the HPRT1 housekeeping gene and relative 
levels were calculated on the basis of the comparative cycle threshold Ct method (2-ΔΔCt) where ΔΔCt 
is the difference in Ct between target and reference gene. 
 
Flow cytometry 
Cells were detached using Accutase (STEMCELL technology) and washed 3 times in PFE (PBS, 2mM 
EDTA, 2% Foetal Bovine Serum). The cells were incubated at 4°C for 30 minutes in the presence of the 
indicated antibodies diluted in PFE. After washes, cells resuspended in cold PFE were examined by BD 
LSRII FortessaTM cell analyser. Results were processed using Kaluza or FlowJo softwares.  
 
Fluorescent gelatin degradation assay 
Oregon Green 488-labeled gelatin was obtained from Molecular Probes. Sterilized coverslips (18-mm 
diaŵeterͿ ǁere Đoated ǁith ϱϬ μg/ŵl polǇ-L-lysine for 20 min at RT, washed with PBS, and fixed with 
0.5% glutaraldehyde for 10 minutes. After 3 washes with PBS coverslips were inverted on a 40-μl drop 
of 0.2% fluorescently labeled gelatin in 2% sucrose in PBS and incubated for 10 min at RT. After washing 
with PBS, coverslips were incubated in a 5mg/ml solution of borohydride for 3 min, washed three times 
in PBS, and incubated with 1 ml of complete medium for 30 minutes. 5 x 104 cells per 12-well were 
plated on the fluorescent gelatin-coated coverslips and incubated at 37°C for 48 h. Cells were then 
washed three times with PBS and fixed with 4% PFA for 20 minutes and processed for labeling with 
Texas Red-Phalloidin and DAPI. The coverslips were mounted with Mowiol mounting medium. Cells 
were imaged on a confocal microscope (Leica TCS-SP5). For the quantification of the gelatin 
degradation, the total area of degraded matrix measured with ImageJ software was divided by the 
total area of each phalloidin-labeled cell. A total of 90 cells were analyzed in three independent 
experiments.  
 
Quantification of cellular collagenolysis 
2 x 104 MCF10A cells were re-suspended in 0.2 ml of 2 mg/ml collagen I solution loaded on an LabTek 
8-well chambered cover-glass. After gelling for 1 h at 37°C, a complete DMEM-F12 medium was added, 
and collagen-embedded cells were incubated 48 h at 37°C in 1% CO2. After fixation in 4% PFA for 20 
min, samples were incubated with collagen type I cleavage site antibody (Col1-2/3 C) diluted 1:200 in 
PBS ;ϱ μg/ŵl, Ϯϰ h at ϰ°CͿ, ǁashed eǆteŶsiǀelǇ ǁith PBS, aŶd ĐouŶterstaiŶed ǁith CǇϱ-conjugated anti-
rabbit IgG antibodies, DAPI and Texas Red-phalloidin. Images acquisition was performed with a 
confocal microscope (Leica TCS-SP5) with a 60x oil objective. Quantification of degradation spots was 
performed with a homemade ImageJ program as described by Marchesin et al., 2015. The degradation 
index is the number of degradation spots divided by the number of cells in each cluster present in the 
field. A total of 90 cells clusters were counted in 3 independent experiments. 
 
Integrin antibody blocking assay 
MCF10A cells were detached using trypsin, washed with PBS and re-suspended in complete DMEM-
F12 medium. The cells were then incubated for 30 min at 37°C to allow for recovery of cell surface 
receptors. 5 x 104 cells were re-suspeŶded iŶ Ϭ.Ϯ μl of a Ϯ ŵg/ŵl ĐollageŶ I solutioŶ aŶd control or 
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blocking antibodies were added. Cell suspension was loaded on an 8-well Lab-tek chambered cover-
glass and left to gelify for 1 h at 37°C. Complete DMEM-F12 medium containing the control or blocking 
antibodies was added on top of collagen-embedded cells. The samples were incubated 48 h at 37°C in 
1% CO2. The development of protrusions was quantified as described above by counting 100 cell 
clusters, in 3 independent experiments. 
Immunofluorescence 
Cells were fixed in 4% paraformaldehyde for 20 minutes, washed three times in PBS and permeabilized 
in PBS containing 0.05% saponin, 0.5% horse serum for 30 min at 37°C. Then the cells were incubated 
with primary antibodies over-night and counterstained with appropriate fluorescent secondary 
antibodies, DAPI or phalloidin. Images acquisition was performed with a confocal microscope (Leica 
TCS-SP5) with a 60x oil objective. 
Confocal reflectance microscopy 
MCF10A spheroids were embedded in collagen I for 48 h at 37°C, then spheroids were fixed and IF was 
performed as indicated above. The imaging of the orientation of the collagen matrix fibers was 
performed by confocal reflectance microscopy using a scanning confocal microscope (Leica TCS-SP5). 
The collagen gels were excited with 488 nm laser, and signal between 485 nm and 495 nm was 
collected.  
Statistics 
Experiments were performed at least three times independently. The number of repeats is indicated 
in the legend as (n). Error bars represent ± standard error of the mean (S.E.M) or standard deviation 
(SD) as indicated in the legend. Statistical significance was determined using a Student t-test and one-
way ANOVA, in which P values < 0.05 were considered statistically significant. All statistical analyses 
have been performed with GraphPad Prism software. 
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Figure legends 
Fig1: CRISPR/Cas9-mediated knock-out of the EFA6B encoding gene PSD4 in MCF10A cells induces 
collective invasion in collagen I. A) The MCF10A WT, the homozygous EFA6B KO 55, EFA6B KO 50, 
EFA6B KO 2, the heterozygous EFA6B KO 2.9 and the EFA6B KO 55 over-expressing EFA6B-vsvg cells 
(Rescue) were solubilized in SDS-lysis buffer and the expression of the indicated proteins analyzed by 
immunoblot. Actin served as a loading control B) Representative images of the MCF10A WT, the 
homozygous EFA6B KO 55, the heterozygous EFA6B KO 2.9 and the EFA6B KO 55 over-expressing 
EFA6B-vsvg placed in collagen for 7 days (upper panels) or 2 days (middle and bottom panels). The cells 
were processed for immunofluorescence to label the endogenous F-actin (red) and the nuclei (blue). 
The bottom panels are brightfield phase contrast images of the corresponding immunofluorescence 
images shown in the middle panels. Scale bars 20 m. C) Lysates of MCF10A WT and EFA6B KO 55 cells 
were reacted with Gst or Gst-ABD (Arf6GTP-binding domain of ARHGAP10) prebound to glutathione-
sepharose beads. The whole lysates and bound proteins were analyzed by immunoblotting with an 
anti-Arf6 antibody. D) Quantification of the percentage of cell aggregates with invasive protrusions of 
the indicated cell lines grown in collagen for 2 days. n=6, average ±SD, Student's t-test p values were 
****, p < 0.0001. 
Fig2: CRISPR/Cas9-mediated knock-out of the EFA6B encoding gene PSD4 in HMLE sub-populations 
induces collective invasion in collagen I. A) The cell surface marker EpCAM and CD49f were used to 
sort three epithelial cell populations including the luminal, luminal progenitors and mature basal cells. 
These cells were immediately processed for CRISPR/Cas9-mediated PSD4 knock-out. B) The HMLE WT 
population, the luminal progenitor WT clone 23, heterozygous EFA6B KO 25, homozygous EFA6B KO 3 
aŶd the ŵature ďasal WT ĐloŶe Ϯ”, homozygous EFA6B-KO ϭ” cells were solubilized in SDS-lysis buffer 
and the expression of the indicated proteins analyzed by immunoblot. Actin served as a loading 
control. C) Representative images of the indicated cells grown 5 days in collagen I are shown. The cells 
were processed for immunofluorescence to label the endogenous F-actin (red) and the nuclei (blue). 
Scale bars 20 m. D) Quantification of the percentage of cell aggregates with invasive protrusions of 
the indicated cell lines grown in collagen I for 5 days. n=3, average ±SD, Student's t-test p values were 
* p < 0.05; **, p < 0.01.
Fig3: EFA6B knock-out stimulates matrices degradation and invasion in a MMP14-dependent manner, 
and leads to loss of collective apico-basal polarization in 3D-Matrigel. A) Representative images of 
MCF10WT and EFA6B KO 55 cells placed on Oregon488-gelatin (green) coated coverslips and stained 
for F-actin (red) and nuclei (blue). Areas devoid of fluorescent signal indicate degradation of the 
fluorescent gelatin. Scale bars 20 m. B) Quantification of the gelatin degradation. Values are mean 
degradation area per cell ± SEM. 90 cells were analyzed for each cell population in three independent 
experiments. ****, p < 0.0001. C) Representative images of MCF10WT and EFA6B KO 55 cells grown 
in collagen I for 3 days and stained for cleaved collagen I with the Col1-3/4C antibody (white in middle 
panel and green in left merge panel). The cells were also labelled for F-actin (red) and nuclei (blue). 
Scale bars 20 m. D) Quantification of the collagen degradation. Values are mean degradation index ± 
SEM. 90 cells were analyzed for each cell population in three independent experiments. ***, p < 0.001. 
E) MCF10A WT and EFA6B KO 55 cells were solubilized in SDS-lysis buffer and the expression of MMP14
analyzed by immunoblot. Hsp60 served as a loading control. F) MCF10A WT and EFA6B-KO 55 cells
were transfected with siRNA control or directed against MMP14. 48 h post-transfection, the cells were
solubilized in SDS lysis buffer and the expression of MMP14 was analyzed by immunoblot. Hsp60
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served as a loading control. G) Quantification of the percentage of cell aggregates with invasive 
protrusions of the indicated cell lines grown in collagen I for 2 days. n=4, ****, p < 0.0001. H) 
Quantification of the percentage of cell aggregates with membrane and cell protrusions of the 
indicated cell lines grown in collagen I (1mg/ml) or collagen I/Matrigel (1:1, 1mg/ml) for 4 days. n=3, 
*, p < 0.05; **, p < 0.01; ***, p < 0.001. Right panels show representative images of MCF10WT and 
EFA6B KO 55 cell aggregates grown in collagen I/Matrigel. Arrow points toward a cell protrusion and 
arrowheads to membrane protrusions. I) Representative images of MCF10A WT and EFA6B KO 55 cells 
grown 5 days in Matrigel (2mg/ml). Arrow points to the central lumen (L) only visible in MCF10A WT 
cell aggregates. 
Fig4: EFA6B knock-out promotes a change in the integrin (ITG) repertoire and stimulates the formation 
of ITGB1-based degradative invadopodia. A) Cell surface expression of ITG molecules in MCF10A WT 
and EFA6B KO 55 cells analyzed by FACS. B) Quantification of MCF10A WT and EFA6B-KO 55 cell 
aggregates with invasive protrusions incubated in the presence of pre-immune serum (Ctl) or the 
indicated anti-ITG antibodies for 2 days. Values are percentages of total cell aggregates ± SD. 300 cell 
aggregates were analyzed for each cell population in three independent experiments. *, p < 0.05; **, 
p < 0.01. C, D) MCF10A WT and EFA6B KO 55 cells were solubilized in SDS-lysis buffer and the 
expression of ITGB1 and ITGB4 (C), or LAM2, LAM1 and fibronectin (FN) (D) analyzed by immunoblot. 
Hsp60 served as a loading control. E) Representative images of the indicated spheroids grown 2 days 
in collagen I are shown. The spheroids were processed for immunofluorescence to label the indicated 
ITG. Scale bars 20 m. F) Representative images of the indicated cells grown 2 days on coverslips 
coated with Oregon488-gelatin (green) are shown. The cells were processed for immunofluorescence 
to label cortactin (blue) and F-actin (red). Co-localization in large dots of both markers appears as a 
pink staining at the periphery of EFA6B-KO cells within areas of Oregon488-gelatin degradation. Scale 
bars 20 m. G, H) Representative images of the indicated cells grown 2 days on collagen I-coated 
coverslips are shown. The cells were processed for immunofluorescence to label cortactin (blue) and 
MMP14-mCherry (red) (G), or ITGB1 (blue) and MMP14-mCherry (red) (H). Co-localization of the 
markers appears as an intense pink staining in EFA6B KO 55 cells. Scale bars 20 m. I) Representative 
images of the indicated spheroids grown 4 days in collagen I are shown. The cells were processed for 
immunofluorescence to label the indicated LAM (green) and the nuclei (blue). Arrows point to the 
absence of LAM staining where EFA6B KO 55 cells invade the collagen I. Scale bars 20 m. 
Fig5: EFA6B knock-out induces the expression of EMT transcription factors that promote collective 
invasion of MCF10A and HMLE WT cells in collagen I. A) The MCF10A WT, the homozygous EFA6B KO 
55, EFA6B-KO 50, EFA6B-KO 2 and the heterozygous EFA6B KO 2.9 cells were solubilized in SDS-lysis 
buffer and the expression of the indicated proteins analyzed by immunoblot. Actin served as a loading 
control. B) The HMLE WT population, the luminal progenitor WT clone 23, heterozygous EFA6B KO 25, 
homozygous EFA6B KO ϯ aŶd the ŵature ďasal WT ĐloŶe Ϯ”, homozygous EFA6B-KO ϭ” cells were 
solubilized in SDS-lysis buffer and the expression of the indicated proteins analyzed by immunoblot. 
Actin served as a loading control. C) Representative images of the indicated spheroids grown 2 days in 
collagen I are shown. The cells were processed for immunofluorescence to label E-cadherin or N-
cadherin. Scale bars 20 m. D) Representative brightfield phase contrast images of the indicated cells 
grown 2 days in hanging-drops are shown. Scale bars 20 m. E) The MCF10A WT (blue) and EFA6B-KO 
55 (green) cells were labeled for the cell surface markers EpCAM and CD49f. The red dotted line circles 
a new de-differentiated population EpCAM-/low and CD49flow (11.7%) appearing in the EFA6B KO 55 cell 
line. F) Expression of EMT-associated genes by qPCR analysis in EFA6B KO 55 cells normalized to 
MCF10A WT. G) Quantification of the percentage of aggregates with invasive protrusions of MCF10A 
WT and EFA6B KO 55 cells grown in collagen I for 2 days after transfection of the indicated siRNAs. n=3, 
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average ±SD, Student's t-test p values were * p < 0.05; **, p < 0.01; ****, p < 0.0001, non-significant 
(ns). H) Expression of the indicated EMT-TF genes by qPCR analysis 2 days after transfection of their 
corresponding specific siRNAs in EFA6B KO 55 cells normalized to siCtl. Folds < 1 represent a 
downregulation of gene expression and folds > 1 represent an upregulation of the corresponding gene 
compared to WT cells gene expression. 
Fig6: EFA6B knock-out stimulates cellular contractility and invasion through Cdc42. A) Representative 
images of the MCF10A WT and EFA6B KO 55 spheroids embedded 2 days in collagen I are shown. The 
cells were processed for immunofluorescence to label F-actin (red). The organization of the collagen I 
fibers surrounding the cell aggregates was imaged by confocal reflectance microscopy (green). Scale 
bars 20 m. B) Quantification of the contractility of MCF10A WT (WT) and EFA6B KO 55 (KO) cells 
transfected with a control siRNA, and EFA6B KO 55 cells transfected with the indicated siRNA evaluated 
by a collagen gel contraction assay. Values are mean surface area of the collagen gel ± SEM. n=3, 
Student's t-test p values were * p < 0.05; ** p < 0.01. C) MCF10A WT and EFA6B KO 55 cells were 
solubilized in SDS-lysis buffer and the expression of pMLC and total MLC analyzed by immunoblot. D) 
Two days post-transfection with the indicated siRNAs, EFA6B KO 55 cells were solubilized in SDS-lysis 
buffer and the expression of the corresponding protein analyzed by immunoblot. Hsp60 served as a 
loading control. E) Quantification of the percentage of aggregates with invasive protrusions of EFA6B 
KO 55 cells grown in collagen I for 2 days after transfection of the indicated siRNAs. n=3, average ±SD, 
Student's t-test p values were **** p < 0.0001: ns: non-significant. F) Lysates of MCF10A WT and EFA6B 
KO 55 cells were reacted with Gst, Gst-CRIB (Cdc42GTP- and Rac1GTP-intercating domain of PAK) or 
Gst-RBD (RhoGTP-binding domain of rhotekin) prebound to glutathione-sepharose beads. The whole 
lysates and bound proteins were analyzed by immunoblotting with the indicated antibodies. 
Fig7: EFA6B knock-out stimulates cellular contractility and invasion through two Cdc42-dependent 
signaling pahways: Cdc42-MRCK-pMLC and Cdc42-N-WASP-Arp2/3. A) Left upper panel: Expression of 
MRCK and MRCK genes by qPCR analysis 2 days after transfection of their corresponding specific 
siRNAs alone or in combination in EFA6B KO 55 cells normalized to siCtl. siMRCK+/ indicates the 
gene expression level of MRCK after transfection of siRNAs against both MRCKs. 
siMRCK+/indicates the gene expression level of MRCK after transfection of siRNAs against both 
MRCKs. Right upper panel: two days post-transfection with the indicated siRNAs as in left panel, EFA6B-
KO 55 cells were solubilized in SDS-lysis buffer and the expression of pMLC and total MLC was analyzed 
by immunoblot. Bottom panel: quantification of the percentage of aggregates with invasive 
protrusions of EFA6B KO 55 cells grown in collagen I for 2 days after transfection of the indicated 
siRNAs. n=3, average ±SD, Student's t-test p values were * p < 0.05. B) Upper panel: two days post-
transfection with the indicated siRNAs, EFA6B KO 55 cells were solubilized in SDS-lysis buffer. The 
down-regulation of MLCK and the expression of pMLC compared to total MLC was analyzed by 
immunoblot. The p85 regulatory subunit of the PI3K served as a loading control. Bottom panel: 
quantification of the percentage of aggregates with invasive protrusions of EFA6B KO 55 cells grown 
in collagen I for 2 days after transfection of the indicated siRNAs as in the upper panel. n=3, average 
±SD, Student's t-test p values were non-significant (ns). C) two days post-transfection with the 
indicated siRNAs directed against ROCK1, ROCK2 or both (ROCK1+2), EFA6B KO 55 cells were 
solubilized in SDS-lysis buffer. The expression of the proteins ROCK1 and ROCK2 compared to the 
loading control hsp60, as well as pMLC compared to total MLC was analyzed by immunoblot. Right 
panel: quantification of the percentage of aggregates with invasive protrusions of EFA6B KO 55 cells 
grown in collagen I for 2 days after transfection of the indicated siRNAs as in the upper panel. n=3, 
average ±SD, Student's t-test p values were non-significant (ns). D) Left panel:  two days post-
transfection with N-WASP targeted siRNAs, EFA6B KO 55 cells were solubilized in SDS-lysis buffer. The 
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down-regulation of N-WASP was analyzed by immunoblot. Actin served as a loading control. Right 
panel: quantification of the percentage of aggregates with invasive protrusions of EFA6B KO 55 cells 
grown in collagen I for 2 days after transfection of N-WASP-directed siRNAs. n=3, average ±SD, 
Student's t-test p values were ** p < 0.01; ***, p < 0.001). E) Right panels:  two days post-transfection 
with a specific Arp2/3 siRNA, EFA6B KO 55 cells were solubilized in SDS-lysis buffer. The down-
regulation of Arp2/3 was analyzed by immunoblot. Hsp60 served as a loading control. Quantification 
of the percentage of aggregates with invasive protrusions of EFA6B KO 55 cells grown in collagen I for 
2 days after transfection. n=3, average ±SD. 
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Supplementary Table 1 
Gene symbol Gene description KO 55+Het 2.9 
vs WT 
Matrisome 
category 
ANGPT1 angiopoietin 1 up Secreted Factors 
DCN decorin up Proteoglycans 
SFTPB surfactant protein B up ECM-affiliated protein 
SERPINB4 serpin peptidase inhibitor, clade B, 4 up ECM Regulators 
SERPINB3 serpin peptidase inhibitor, clade B, 3 up ECM Regulators 
HMMR hyaluronan-mediated motility receptor up Glycoprotein receptor 
GDF15 growth differentiation factor 15 up Secreted Factors 
ADAMTS12 ADAM with thrombospondin type 1 motif, 12 up ECM Regulators 
S100A8 S100 calcium binding protein A8 up Secreted Factors 
S100A7 S100 calcium binding protein A7 up Secreted Factors 
CLEC2B C-type lectin domain family 2,  B up ECM-affiliated Protein 
MUC1 mucin 1, cell surface associated up ECM-affiliated protein 
LAMB1 laminin, beta 1 up ECM glycoPn 
SERPINA3 serpin peptidase inhibitor, member 3 up ECM Regulators 
LOX lysyl oxidase up ECM Regulators 
CTSK cathepsin K up ECM Regulators 
CYR61 cysteine-rich, angiogenic inducer, 61 down ECM glycoPn 
FGFBP1 fibroblast growth factor binding protein 1 down secreted factors 
SERPINB2 serpin peptidase inhibitor, clade B, 2 down ECM Regulators 
MMP2 matrix metallopeptidase 2 down ECM Regulators 
CLCF1 cardiotrophin-like cytokine factor 1 down Secreted factors 
INHBA inhibin, beta A down Secreted factors 
THBS1 thrombospondin 1 down ECM glycoPn 
SERPINE1 serpin peptidase inhibitor, clade E, 1 down ECM Regulators 
PLAT plasminogen activator, tissue down ECM regulators 
WNT9A wingless-type, 9A down Secreted factors 
S100A10 S100 calcium binding protein A10 down Secreted Factors 
PXDN peroxidasin homolog down ECM glycoPn 
LAMC2 laminin, gamma 2 down ECM glycoPn 
IL8 interleukin 8 down Secreted Factors 
SMOC1 SPARC related modular calcium binding 1 down ECM glycoPn 
FN1 fibronectin 1 down ECM glycoPn 
PRG2 proteoglycan 2 down Proteoglycans 
LEPREL1 leprecan-like 1 down ECM regulators 
SPARC secreted protein, acidic, cysteine-rich down ECM glycoPn 
TNC tenascin C down ECM glycoPn 
SULF2 sulfatase 2 down ECM Regulators 
FST follistatin down Secreted Factors 
CTSL2 cathepsin L2 down ECM regulators 
S100A2 S100 calcium binding protein A2 down Secreted Factors 
NRG1 neuregulin 1 down Secreted factors 
AREG amphiregulin down Secreted factors 
ADAMTSL5 ADAMTS-like 5 down ECM Regulators 
PLXNA2 plexin A2 down ECM-affilitaed proteins 
SDC1 syndecan 1 down ECM-affilitaed proteins 
S100A3 S100 calcium binding protein A3 down Secreted Factors 
IGFBP7 insulin-like growth factor binding protein 7 down ECM glycoPn 
Gene set enrichment analysis of the Matrisome signature comparing the expression profiles of MCF10A 
EFA6B KO 55 + Het 2.9 cells vs. MCF10A WT cells 
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Core genes
N=39
NES=-2.18
p-value < 2.00E-6
Core genes
N=78
NES=-1.56
p-value < 3.00E-3
A B
CD24 CD24 molecule
TACSTD2 tumor associated calcium signal transducer 2
SOX9 SRY-box 9
CYR61 cysteine rich angiogenic inducer 61
MYL9 myosin light chain 9
PCDH7 protocadherin 7
ITGA4 integrin subunit alpha 4
CLDN1 claudin 1
PTGER4 prostaglandin E receptor 4
FBLIM1 filamin binding LIM protein 1
STK10 serine/threonine kinase 10
FZD8 frizzled class receptor 8
VCL vinculin
IGSF9B immunoglobulin superfamily member 9B
EPCAM epithelial cell adhesion molecule
EOMES eomesodermin
MYH9 myosin heavy chain 9
ACTG1 actin gamma 1
FLNA filamin A
CDH1 cadherin 1
STXBP1 syntaxin binding protein 1
SRF serum response factor
FAT1 FAT atypical cadherin 1
CHD7 chromodomain helicase DNA binding protein 7
FNDC3A fibronectin type III domain containing 3A
NECTIN2 nectin cell adhesion molecule 2
JAG2 jagged 2
CSTA cystatin A
CSRP1 cysteine and glycine rich protein 1
SMAD3 SMAD family member 3
FZD7 frizzled class receptor 7
CELSR2 cadherin EGF LAG seven-pass G-type receptor 2
NECTIN1 nectin cell adhesion molecule 1
CDK6 cyclin dependent kinase 6
FZD5 frizzled class receptor 5
LEF1 lymphoid enhancer binding factor 1
CLDN7 claudin 7
LGALS7B galectin 7B
CELSR1 cadherin EGF LAG seven-pass G-type receptor 1
ZFP36L1 ZFP36 ring finger protein like 1
PIP5K1C phosphatidylinositol-4-phosphate 5-kinase type 1 gamma
PLEKHA7 pleckstrin homology domain containing A7
LCP1 lymphocyte cytosolic protein 1
CADM4 cell adhesion molecule 4
DSC3 desmocollin 3
SRC SRC proto-oncogene, non-receptor tyrosine kinase
JUP junction plakoglobin
CLDN19 claudin 19
CD44 CD44 molecule (Indian blood group)
EZR ezrin
ITGA5 integrin subunit alpha 5
CD276 CD276 molecule
CERCAM cerebral endothelial cell adhesion molecule
CDH3 cadherin 3
PVR poliovirus receptor
PSMB10 proteasome subunit beta 10
FGFRL1 fibroblast growth factor receptor-like 1
ELF4 E74 like ETS transcription factor 4
ITGB5 integrin subunit beta 5
FAT2 FAT atypical cadherin 2
SMAGP small cell adhesion glycoprotein
RC3H1 ring finger and CCCH-type domains 1
FAS Fas cell surface death receptor
PKNOX1 PBX/knotted 1 homeobox 1
NOV nephroblastoma overexpressed
CDSN corneodesmosin
RAP2B RAP2B, member of RAS oncogene family
RELB RELB proto-oncogene, NF-kB subunit
NPTN neuroplastin
CLSTN1 calsyntenin 1
GATA1 GATA binding protein 1
CD58 CD58 molecule
AMIGO1 adhesion molecule with Ig like domain 1
NT5E 5'-nucleotidase ecto
CDK5R1 cyclin dependent kinase 5 regulatory subunit 1
PKP2 plakophilin 2
ITGB4 integrin subunit beta 4
MAPK8 mitogen-activated protein kinase 8
CAPN2 calpain 2
VASP vasodilator-stimulated phosphoprotein
ITGB5 integrin subunit beta 5
COL4A1 collagen, type IV, alpha 1
COL4A6 collagen, type IV, alpha 6
CCND1 cyclin D1
ITGA5 integrin subunit alpha 5
PXN paxillin
VAV2 vav guanine nucleotide exchange factor 2
CD44 CD44 molecule (Indian blood group)
ACTN4 actinin alpha 4
SRC SRC proto-oncogene, non-receptor tyrosine kinase
PDGFA platelet derived growth factor subunit A
HRAS HRas proto-oncogene, GTPase
PIP5K1C phosphatidylinositol-4-phosphate 5-kinase type 1 gamma
CAV2 caveolin 2
ITGA3 integrin subunit alpha 3
CAV1 caveolin 1
ITGA10 integrin subunit alpha 10
CCND2 cyclin D2
ELK1 ELK1, ETS transcription factor
MYL12B myosin light chain 12B
FLNA filamin A
SDC1 syndecan 1
HSPG2 heparan sulfate proteoglycan 2
ACTG1 actin gamma 1
ITGA6 integrin subunit alpha 6
ITGA2 integrin subunit alpha 2
VCL vinculin
ITGB6 integrin subunit beta 6
ZYX zyxin
LAMC2 laminin subunit gamma 2
ITGA4 integrin subunit alpha 4
MYL9 myosin light chain 9
TNC tenascin C
FN1 fibronectin 1
THBS1 thrombospondin 1
Gene symbol Gene name Gene symbol Gene name
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Supp.	Materials	and	Methods:	List	of	Antibodies	
Antigen	 Antibody	source	and	reference	 Application	
MMP-14	 Millipore,	MAB3328	 Immunoblot	
Integrin-β1	 Santa	Cruz,	sc-13590	
Flow	cytometry	
Immunofluorescence	
Integrin-β4	 BD	Biosciences,	611232	
Flow	cytometry	
Immunofluorescence	
Integrin-α2	 Santa	Cruz,	sc-53502	
Flow	cytometry	
Immunofluorescence	
Integrin-α3	 Millipore,	MAB2057	
Flow	cytometry	
Immunofluorescence	
Integrin-α6	 BD	Biosciences,	555734	
Flow	cytometry	
Immunofluorescence	
EpCAM/CD326	 BD	Biosciences,	563181	 Flow	cytometry	
CD49f	 BD	Biosciences,	562582	 Flow	cytometry	
Laminina5	 BIO-RAD,	5620-0436	 Immunofluorescence	
Lamining2	 Santa	Cruz,	sc-25341	 Immunofluorescence	
Immunoblot	
Lamininb1	 R&D	Systems,	MAB25491	 Immunofluorescence	
Lamininb1	 Santa	Cruz,	sc-17763	 Immunoblot	
Col1-3/4C	 Immuno	Globe,	0217-050	 Immunofluorescence	
N-cadherin BD	Biosciences,	610921	
Immunofluorescence	
Immunoblot	
E-cadherin Thermo	Scientific,	33-4000	 Immunofluorescence	
E-cadherin BD	Biosciences,	610182	 Immunoblot	
Vimentin	 Sigma,	V6389	 Immunoblot	
Claudin	1	 ZYMED	Laboratories,	51-9000	 Immunoblot	
Occludin	 Thermo	Scientific,	40-4700	 Immunoblot	
Actin	 Sigma,	A4700	 Immunoblot	
Claudin	3	 Millipore,	2819163	 Immunoblot	
Arf6	 Gift	from	Dr.	Bourgoin	 Immunoblot	
EFA6A	 Gift	from	Dr.	Sakagami	 Immunoblot	
EFA6B	 Sigma,	HPA034722	 Immunoblot	
EFA6D	 Gift	from	Dr.	Sakagami	 Immunoblot	
Hsp60	 Sigma,	SAB4501464	 Immunoblot	
Cdc42	 BD	Biosciences,	610928	 Immunoblot	
N-WASP Cell	Signaling,	4848	 Immunoblot	
Arp2/3	 BD	Biosciences,	612134	 Immunoblot	
MLCK	 Santa	Cruz,	sc-365352	 Immunoblot	
p85	 Millipore,	ABS1856	 Immunoblot	
pMLC	 Cell	Signaling,	3671	&	3675	 Immunoblot	
MLC	 Sigma,	M4401	 Immunoblot	
RhoA	 Santa	Cruz,	sc-418	 Immunoblot	
ROCK	1	 Santa	Cruz,	sc-17794	 Immunoblot	
ROCK	2	 Santa	Cruz,	sc-398519	 Immunoblot	
Rac	1	 BD	Biosciences,	610650	 Immunoblot	
Arf1	 Novus	Biologicals,	NB100-55421	 Immunoblot	
Arf5	 Abnova,	H00000381-M01	 Immunoblot	
Fibronecin	 BD	Biosciences,	610077	 Immunoblot	
Cortactin	 Millipore,	05-180	 Immunoblot	
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3. Discussion of Article 1
In the above section, I presented the major results of my thesis in the form of an article; however, 
kindly note that it is not the final publishable version. Here, I will be discussing on-going and future 
experiments essential to validate some hypothesis proposed and push our research towards more 
complex models (in vivo). 
In the present work, we identified PSD4 (EFA6B) as a secondary oncogenic driver gene providing when 
altered normal cells with invasive properties in a CDC42 dependent manner. 
We showed that the loss of EFA6B was able to strongly deregulate the epithelial homeostasis of normal 
mammary cell lines at different levels. First, deleting EFA6B allowed the formation of invadopodia rich 
in ITGB1 and MMP14. The invasion capacity of these cells is Cdc42 dependent. We suppose that 
EFA6B KO cells invasion is supported by the contractility, and the formation of protrusive branched 
structures ensured most-likely by Cdc42/MRCK and Cdc42/N-WASP/Arp2/3 activation, respectively. 
Second, we showed that the loss of EFA6B is associated with the engagement of EFA6B KO cells in 
EMT, shown by a clear cadherin switch and an upregulation of mesenchymal TFs. Third, coherently 
with EFA6B roles on junction assembly, its deletion prevented MCF10A cells from polarizing correctly 
and forming normal acini with central lumens. Lastly, in agreement with a previous correlation with 
Cld-low BC patients, our EFA6B KO cells presents a decrease in TJ proteins expression, EMT properties 
and invasion capacities consistent with the Cld-low subtype characteristics.  
Taken together, our results suggest that the loss of EFA6B impacts negatively the epithelial integrity of 
normal mammary cells and drive them towards invasiveness. 
I can propose a scenario showing a dual effect of the loss of EFA6B. On one hand the disassembly of 
adhesion complexes induced by the loss of EFA6B leads to the activation of a transcriptional program 
increasing the expression of EMT-TFs. This can result in the detected modifications of the matrisome 
transcriptomics and its receptors (mainly integrins). On the other hand, EFA6B upregulates Cdc42 
activity, promoting the increase in contractility and invadopodia formation. 
It is hard at this stage to define the chronological order of EFA6B loss consequences. Further studies 
and investigations are needed to better understand the order of emergence of these events.  
In the following, I will expose three different experiments that should be performed to better 
elucidate the impact of the loss of EFA6B on normal mammary epithelial cells. First, we need to 
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show the direct link between Cdc42 and invadopodia formation in the KO cells. Second, we will 
tackle the in vivo experiments that I have already started in order to study the role of EFA6B 
deletion on tumor invasion and how can we improve our models. And lastly, how can we use the 
data we have to better stratify BC patient, and find new therapeutic targets. 
Cdc42 and invadopodia: 
The major result of this work is the impressive invasive capacity acquired by normal cells upon the loss 
of EFA6B. Downregulation experiments have clearly shown the leading role of Cdc42 signaling in 
supporting and mediating this phenotype.  
What we actually showed is that downregulating Cdc42 in the KO cells decreased contractility as well 
as the formation of protrusive degradative structures. However, an essential information is missing in 
order to directly link Cdc42 to the formation of invadopodia. Invadopodia are actin-rich specialized 
structures, important for migration and invasion in cancer cells, that are dependent mainly on actin-
regulatory protein. We have already confirmed the presence of invadopodia upon the loss of EFA6B by 
staining for cortactin that co-localized with integrin β1and MMP-14. 
Cdc42 was reported to be important for invadopodia formation by sustaining actin nucleation through 
the recruitment of N-WASP/Arp2/3 (Stengel and Zheng, 2011). First, we need to look for N-
WASP/Arp2/3 localization at the invadopodia level. Second, we will verify if the downregulation of 
Cdc42 alter invadopodia formation quantified using a with cortactin, and N-WASP/Arp2/3 staining, 
characteristic of these structures. 
In vivo models: Unpublished data and perspectives 
We have proposed that the alterations of PSD4 (EFA6B) gene can be considered as a secondary driver 
mutation providing cells with invasive advantages. 
-Transformed or not?
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Figure 26: EFA6B knock-out does not affect cell proliferation in vitro and no differences observed 
in vivo when EFA6B KO is combined with the expression of activated form of the oncogene RAS, 
RASV12. 
A) Cell proliferation of MCF10A WT and EFA6B KO 55 cells measured by FACS using an intracellular
staining CMRA Orange that decreases with each cell division for 5 consecutive days (N=1). B) Cell
proliferation of MCF10A WT and EFA6B KO 55 cells measured by Cell LUNA counter for 6 consecutive 
days (N=1). C) Orthotopic xenografts of MCF10A WT and EFA6B KO 55 cells infected with a lentivirus
expressing RASV12. 800 000 cells were injected in each mammary gland of the fourth pair in NOD/SCID 
female mice. Tumor growth was measured with a caliper (3 mice for each group, N=1).
Indeed, our EFA6B knock-out did not transform MCF10A normal cell line. In vitro, I tested first if cells 
had an increased proliferation or a decrease in apoptosis, two main strategies used by transformed cells 
to form a tumor (Figure 26). I used two techniques to follow cells’ proliferation rates for 5 consequent 
days, first by counting cells grown in 2D culture with the LUNATM cell counter (Logos Biosystems) and 
second by staining cells with the CellTrackerTM Orange CMRA, a fluorescent dye measured by flow 
cytometry. Both methods showed no proliferative differences between WT and EFA6B KO MCF10A 
cells. Apoptosis was examined using the annexin-V staining assay measured as well by flow cytometry. 
Similarly, we had insignificant difference in apoptosis rates between our two MCF10A cell lines (<3%). 
We tested the renewing capacity of KO cells as well using a mammosphere assay that did not show any 
differences with WT cells. Most importantly, when injected in the mammary glands of an 
immunodeficient xenograft mice model (NOD/SCID mice), EFA6B KO and WT MCF10A cells did not 
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show any tumor growth. The result of this in vivo experiment validates that MCF10A normal cells are 
not transformed by the loss of EFA6B. 
The loss of EFA6B is not an oncogenic driver but still has provided cells with remarkable invasive 
capacities. Hence our hypothesis of EFA6B acting when altered as a secondary oncogenic driver, giving 
cells pro-invasive properties. 
-Aim of the in vivo xenografts and the insertion of an oncogene
After revealing these properties in vitro, it was interesting to look at the impact of the loss of EFA6B on
invasion in vivo. Thus, we decided to add an oncogenic gene to our WT and EFA6B KO MCF10A cells
in order to transform them into cancer cells capable of proliferating and forming a primary tumor. The
major goal of this experiment was to see if cells deleted for EFA6B would be more apt of leaving the
primary tumor and invading surrounding tissues or even metastasizing to distant organs. We would
expect that the KO cells having degradative capacities (MMP-14), upregulated contractility and invasive
structures would breach the endogenous physical barriers (basal membrane and the ECM) and ultimately
exhibit secondary site colonization, metastasis. Collected tumors can be then classified by BC subtype.
One can expect that a higher frequency of Cld-low tumors would emerge from the EFA6B KO cells.
-Adapted oncogenic choices
We chose to decrease the expression separately of TP53 and PTEN, two tumor suppressors found in
human breast tumors, especially in Cld-low. Mutations of TP53 are estimated to occur in approximately
20%–30% of breast cancers (Hollstein et al., 1991) and the frequency of PTEN loss is 30%-40% in
sporadic breast cancer (Milella et al., 2015). We also decided expressing RASV12 an activated form of
Ras that has been frequently used in xenograft breast cancer models.
I infected MCF10A cells separately with three lentiviruses carrying each one of the aforementioned 
oncogenes/tumor suppressors. When injected orthotypically in the mammary gland of immunodeficient 
mice, MCF10A WT and EFA6B KO cells downregulated for PTEN or TP53 did not show any tumor 
growth even with 106 cells injected. 
Cells infected with RASV12 injected in the mammary gland of NOD/SCID mice rapidly developed 
primary tumor (Figure 26)(the regulatory tumor size limit (1000mm3) attained in 17 days). The 
oncogenic impact of RASV12 was very intense and we think that it has masked the potential effect 
expected for the cells deleted for EFA6B. The RASV12 WT and KO cells did not show anymore the 
protrusive differences when plated in collagen, collagen mixed with Matrigel or Matrigel alone. The fast 
tumor growth observed in our RASV12 WT and KO cells can be due to the high expression level of 
RASV12. It would be then interesting to select clones having a mild expression of this oncogene. 
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-Other in vivo models’ suggestions:
Our cell models combined with these specific transformative genes did not allow us to investigate the
role of the loss of EFA6B in vivo. Therefore, I think that we need to adapt better our in vivo models by
choosing oncogenes that will have a moderate transformative effect on cells. I can propose two mice
models that will probably allow us to answer our question. First, we can use a syngeneic P53 null mouse
mammary gland transplant model of BALB/c mice suggested to mimic more closely human breast
cancer than other models (Zhang et al., 2008). Here, we will recover the mammary cells downregulated
for P53 and downregulate in vitro EFA6B. Cells KO for both P53 and EFA6B will then be injected in
the clear fat pad of syngeneic wild-type recipient mice. Second, we can test other oncogenes and make
sure to control the amount of transfected viral particles. The ideal oncogene should transform the
MCF10A or HMLE cells in order to see a slow growth of a primary tumor. We can use a combined
deletion of PTEN and P53 that was shown to cluster with human Cld-low (Liu et al., 2014). Another
possibility is to upregulate cyclin E in the HMLE cell line (Morel et al., 2017); of note cyclin E
overexpression was identified in 20%-30% of breast cancer (Keyomarsi et al., 2002). In both models,
we will track tumor growth and the emergence of metastasis and then check if the tumors present a Cld-
low transcriptional signature.
The injection method can be as well reviewed. Previously, I used to inject the cells in the fat pad of the 
mammary gland. Another more precise way in order to see if cells will manage to breach the endogenous 
basal membrane is to inject directly in the nipple and then check for local invasions by 
immunohistochemistry. 
Currently, knock-outs of EFA6 in mice are being established in the laboratory of our collaborator H. 
Sakagami in Japan which will open new possibilities and tools for further studies of these GEFs. 
-How can we use our data to better stratify BC in patients?
In collaboration with the genomic platform of IPC in Marseille and the team of Dr. Daniel Birnbaum,
we are actually trying to further analyze the transcriptional data we have for our EFA6B KO MCF10A
cells. It would be interesting to propose a transcriptomic signature that would help stratify better the
Cld-low patients, especially by integrating the matrisome analysis. Another important analysis would
be to check if we can find an upregulation of Cdc42 signaling pathway signature in the Cld-low patients
who have a downregulation of EFA6B. Moreover, we are interested in finding therapeutic targets for
the Cld-low subtype. Since EFA6B is downregulated, it cannot be used directly targeted. Thus, on the
basis of the transcriptomic data of our EFA6B KO cells combined to that of Cld-low patients, we will
propose, as potential therapeutic targets, a list of genes which expression levels inversely correlate with
the downregulation of EFA6B.
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Article 2 
1. Objectives of Article 2
EFA6 belongs to the EFA6/PSD exchange factors family comprising four different isoforms coded by 
different genes: PSD (EFA6A), PSD4 (EFA6B), PSD2 (EFA6C) and PSD3 (EFA6D). They have similar 
structures with a sec7 catalytic domain responsible for activating Arf6 (GEF activity), a PH domain that 
localize them at the plasma membrane, a variable N-terminal domain for which roles have not yet been 
granted and a conserved C-terminal (Cter) domain that can bind multiple effectors (e.g. actin, β-arrestin, 
etc.). 
Since its discovery, EFA6 effects have always been presented as the resultant of EFA6 exchange activity 
for Arf6 in coordination with EFA6 C-terminal domain activity. Indeed, the formation of actin-based 
membrane ruffles was more enhanced by the exogenous expression of the Ph-Cter of EFA6A than by 
overexpressing an activated mutant of Arf6 (Franco et al., 1999). Knowing the importance of EFA6 
Cterminus per se, our research group was interested in identifying partners that can bind this domain in 
order to further understand and characterize its mechanism of action. For this purpose, a two-hybrid 
screening was conducted with the EFA6A C-ter domain from which actinin was sorted as the best 
candidate. Shortly after, a similar interaction was suggested by Sakagami et al, only on the basis of an 
observation of overlapping staining between EFA6 and α-actinin in dendritic spines of hippocampal 
neurons (Sakagami et al., 2007) 
After validating the binding of actinin to EFA6A in vitro, we were interested in investigating the impact 
of the EFA6B-actinin interaction on cellular physiology, more specifically epithelial polarity and lumen 
formation. 
Indeed, EFA6 was strongly established as a regulator of epithelial cell polarity and cytoskeleton 
rearrangement (Klein et al., 2008a; Luton et al., 2003; Théard et al., 2010; Zangari et al., 2014). In 
addition, we had shown that the overexpression of EFA6B in a tumorigenic mammary cell line restored 
the formation of a normal lumen in 3D culture (Zangari et al., 2014). We know that these effects are in 
part mediated by the activation of Arf6, and by the EFA6 Cter domain. However which effectors are 
engaged by the EFA6 C-terminus to fulfil these functions was not yet determined. 
Interestingly, the non-muscular α-actinin1 (ACTN1) and 4 (ACTN4) had already been associated to the 
apical acto-myosin ring supporting the adherens junctions, but only few studies linked them to tight 
junctions. The apical localization of actinin is close to EFA6 spatial distribution, and therefore both 
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molecules were suspected to have a collaborative role on luminogenesis, a process that requires vesicular 
trafficking, actin cytoskeleton rearrangement and the remodeling of adhesion complexes. 
 
Hence the objective of this work is to identify the role and mechanism of action of this interesting 
interaction between actinin and EFA6 on luminogenesis, in a normal epithelial cell line (MDCK) 
and in another model of weakly tumorigenic epithelial mammary cell line (MCF7). 
 
This project has started few years before my arrival. My contribution consisted in elucidating the role 
and interaction of EFA6B/ACTN1in MCF7 cells (figures 5 and 6).  
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EFA6 proteins regulate lumen formation through α-actinin 1
Julie Milanini1, Racha Fayad1, Mariagrazia Partisani1, Patrick Lecine2,*, Jean-Paul Borg2, Michel Franco1 and
Frédéric Luton1,‡
ABSTRACT
A key step of epithelial morphogenesis is the creation of the lumen.
Luminogenesis by hollowing proceeds through the fusion of apical
vesicles at cell–cell contacts. The small nascent lumens grow through
extension, coalescence and enlargement, coordinated with cell
division, to give rise to a single central lumen. Here, by using
MDCK cells grown in 3D-culture, we show that EFA6A (also known as
PSD) participates in luminogenesis. EFA6A recruits α-actinin 1
(ACTN1) through direct binding. In polarized cells, ACTN1 was found
to be enriched at the tight junction where it acts as a primary effector of
EFA6A for normal luminogenesis. Both proteins are essential for the
lumen extension and enlargement, where they mediate their effect by
regulating the cortical acto-myosin contractility. Finally, ACTN1 was
also found to act as an effector for the isoform EFA6B (also known as
PSD4) in the human mammary tumoral MCF7 cell line. EFA6B
restored the glandular morphology of this tumoral cell line in an
ACTN1-dependent manner. Thus, we identified new regulators of
cyst luminogenesis essential for the proper maturation of a newly-
formed lumen into a single central lumen.
KEY WORDS: Epithelium, Lumen, EFA6, ACTN1, Contractility
INTRODUCTION
During organogenesis, the coordinated establishment of the apico-
basal polarity with the de novo formation of an apical luminal space
is fundamental to the emergence of the different types of epithelia.
In adult organisms, the aptitude of the internal organs, which are
lined with epithelial tissues, to ensure specific functions relies on the
preservation of these characteristics. The failure in doing so is
associated with a large variety of diseases (Blasky et al., 2015; Datta
et al., 2011; Sigurbjörnsdóttir et al., 2014). In particular, these
features are often compromised in carcinomas and tumors are
formed of non-polarized cell aggregates incapable of collectively
organizing a lumen (Martin-Belmonte and Perez-Moreno, 2011;
Tanos and Rodriguez-Boulan, 2008; Wang et al., 2012). However,
compelling tumoral cells to maintain their normal epithelial
phenotype can help them override the power of oncogenes
(DuFort et al., 2011; Weaver et al., 1997). Thus, it is important
to decipher the molecular programs that instruct epithelial cells to
collectively organize around lumens in order to maintain their
physiological homeostasis.
For most epithelial tissues, the de novo formation of a lumen is
generated by hollowing. In this process, apical vesicles are delivered
to a focal point of the cell–cell contact named the apical membrane
initiation site (AMIS) to give rise to the apical plasma membrane
and a facing hollow cavity. The nascent lumen appears first as a
closed elongated space named the pre-apical patch (PAP), which is
limited by tight junctions. The PAP will then open and expand
through a combination of events: the delivery of vesicular
membranes, the repulsion of the apposed membrane by highly
charged molecules, the increase of hydrostatic pressure, the
coalescence of mini-lumens and, eventually, expansion through
cell division. This process is closely synchronized with a profound
rearrangement of the actin cytoskeleton into discrete structures
essential for the attachment of structural and signaling apical
proteins. These proteins will then yield a scaffold to shape the lumen
and form an acto-myosin ring in support of the circumferential
apical junctional complexes (AJCs), which are made of adherens
junctions (AJs) and the apical tight junctions (TJs) that outline the
luminal space (Datta et al., 2011; Sigurbjörnsdóttir et al., 2014). The
organization and functions of the acto-myosin ring attached to the
AJ have been extensively studied (Arnold et al., 2017; Braga, 2016;
Grikscheit and Grosse, 2016; Lecuit and Yap, 2015); however, far
less is known about the actin cytoskeleton associated to the TJ.
Nevertheless, it is likely that both structures are somehow
intermingled within the so-called apical perijunctional acto-
myosin ring (PAMR) (Ebrahim et al., 2013; Sluysmans et al.,
2017). The PAMR is described as a sarcomeric-like belt made of F-
actin bundles containing myosin-II, which confers contractile
properties, and bundling proteins, such as the non-muscle α-
actinins, which stiffen the structure. The balance of both activities is
believed to determine the flexibility of this belt, its
mechanosensitivity and the tension forces exerted on the cell
surface (Foley and Young, 2014; Martin and Goldstein, 2014;
Murrell et al., 2015; Röper, 2015). The existence of a central apical
acto-myosin network with radial contractility has also been reported
(Coravos and Martin, 2016).
The α-actinin (ACTN) family comprises four members, the
muscle ACTN2 and ACTN3, and the non-muscle ACTN1 and
ACTN4, which are expressed in most other cell types. They share a
common primary structure with a N-terminal actin-binding domain
(ABD) and a C-terminal calmodulin-like domain (CAMD)
separated by a central repeat of four spectrin-like domains
(spectrin repeats domain; SRD). ACTN molecules form
antiparallel dimers through their rigid SRD allowing for the cross-
linking of actin filaments by the ABD positioned on either end. In
comparison with the filamin proteins, which orthogonally cross-
link actin filaments, non-muscle ACTNs form linear F-actin
bundles, which increase the stiffness (Jahed et al., 2014; Stossel
et al., 2001). They are believed to contribute to myosin-II-driven
contractility by facilitating force transmission (Le Clainche andReceived 3 August 2017; Accepted 11 December 2017
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Carlier, 2008). ACTNs also act as a mechanical linker between actin
filaments and cell–cell and cell–extracellular matrix (ECM)
adhesion complexes. Besides its structural roles, ACTNs could
also serve to couple actin nucleation to assembly at cell–cell
contacts (Tang and Brieher, 2012) and contribute to the maturation
of cell–ECM focal adhesion by transmitting mechanical forces
(Iskratsch et al., 2014; Jahed et al., 2014; Parsons et al., 2010; Ye
et al., 2014). Both ACTN1 and ACTN4 were found at the apical
acto-myosin ring in association with the AJ (Honda et al., 1998;
Tang and Brieher, 2012), whereas a few studies suggested a link
with the TJ (Chen et al., 2006; Geiger et al., 1979; Nakatsuji et al.,
2008). Nevertheless, the repertoire of ACTN molecules associated
with the various F-actin structures is poorly defined and is made
even more complex by the existence of ACTN1–ACTN4
heterodimers (Foley and Young, 2013). Moreover, it is not
completely clear how ACTNs are recruited to cell–cell contacts.
Thus, much remains to be discovered about the role of ACTNs at the
AJC as well as their role during luminogenesis.
Small G-proteins of the Rho family and their partners are key
regulators in the assembly and maintenance of the PAMR. In
particular, RhoA contributes to the constitution of the contractile
apical acto-myosin array through the localization and activation of
the formin proteins and the activation of the motor protein myosin-II
by the Rho-associated coiled-coil kinase effectors ROCK1 and
ROCK2 (hereafter denoted ROCK) (Arnold et al., 2017; Quiros and
Nusrat, 2014; Sluysmans et al., 2017; Takeichi, 2014). Tension
forces are necessary for the establishment and functioning of the
AJC, as they support the changes in cell shape occurring during
epithelial morphogenesis (Coravos et al., 2017; Lecuit and Yap,
2015; Takeichi, 2014). However, how contractility and its regulators
are impacting epithelial cell luminogenesis is an issue of ongoing
debate.
Another small G-protein that regulates the cortical cytoskeleton is
the ADP ribosylation factor 6 (Arf6). It plays a pivotal role in a wide
variety of cellular events including cell surface trafficking,
phagocytosis, cell–cell adhesion, and tumor cell migration and
invasion (D’Souza-Schorey and Chavrier, 2006; Gillingham and
Munro, 2007; Jaworski, 2007; Sabe et al., 2009; Schweitzer et al.,
2011). In epithelial cells, Arf6 was initially shown to regulate
vesicular trafficking to the apical pole of the cell (Altschuler et al.,
1999) and later to impact the turnover of the AJ (Palacios et al.,
2001, 2002, 2005), the establishment of the TJ (Klein et al., 2008;
Luton et al., 2004), cyst morphogenesis (Tushir et al., 2010) and
HGF-induced tubulogenesis (Tushir and D’Souza-Schorey, 2007).
Consistent with these observations, the exchange factor for Arf6
(EFA6; also known as PSD) was found to be enriched at the apical
pole and at the TJ in fully polarized MDCK cells (Luton et al.,
2004). During early epithelial polarization, EFA6 is recruited to the
cell–cell contact in a manner that is dependent on E-cadherin
engagement, where it contributes to the formation of the TJ by
stabilizing the apical acto-myosin ring (Théard et al., 2010).
Expression of EFA6B (also known as PSD4) in the mammary
tumoral MCF7 cell line restored a normal glandular phenotype, with
the formation of lumens delineated by TJs (Zangari et al., 2014).
Conversely, knockdown of EFA6B expression drives various
mammary cell lines into epithelial-to-mesenchymal transition
(Zangari et al., 2014). In breast cancer patients, the loss of
EF6AB expression is associated with the claudin-low subtype
characterized by the loss of expression of all the TJ components and
a poor prognosis (Zangari et al., 2014).
The EFA6 family consists of four isoforms (EFA6A–EFA6D;
EFA6C is also known as PSD2, and EFA6D as PSD3) sharing a
general structure that comprises a variable N-terminal domain, a
catalytic Sec7 domain bearing the nucleotide exchange activity, a
PH domain responsible for their plasma membrane localization and
a conserved C-terminal region involved in actin cytoskeleton
rearrangement (Derrien et al., 2002; Franco et al., 1999; Sakagami,
2008; Sironi et al., 2009). In a previous study, we found that
mutations that abolish the nucleotide exchange activity or delete the
C-terminal domain abrogated the stimulatory effects of EFA6,
indicating that both Arf6 activation and the C-terminal domain
are necessary for epithelial polarization (Luton et al., 2004).
In addition, complementation experiments demonstrated a finely
tuned cooperation between the two signaling pathways associated
with the activated Arf6 and with the EFA6 C-terminus (Klein et al.,
2008).
In this study, we aimed to determine the signaling pathway
associated to EFA6 C-terminus that contributes to its action on
epithelial morphogenesis. Our data showed that: (1) ACTN1 is a
direct partner of EFA6AC-terminal domain, (2) EFA6A is a crucial
regulator of luminogenesis for which ACTN1 is the major effector,
(3) together, they stimulate the formation and enlargement of a
single lumen with a proper round shape, (4) they act by regulating
cortical acto-myosin contractility, and finally (5) ACTN1 is also a
partner of the EFA6B isoform in the promotion of lumen formation
in the mammary tumoral cells MCF7.
RESULTS
EFA6A binds directly to ACTN1
Looking for functional partners of EFA6A in epithelial cells, we
performed a two-hybrid screen of an epithelial library using the C-
terminus (Cter) of EFA6A as a bait, and identified ACTN1 as the
major interacting protein. A similar result was found by Sakagami
et al. in a previous screen using a neuronal library (Sakagami et al.,
2007). A pulldown assay was used to confirm that the Cter of
EFA6A could bind exogenously expressed ACTN1–GFP (Fig. 1A).
We then further characterized this interaction by assessing whether
the two proteins could bind directly. We found that both
GST–ACTN1 and GST–ACTN4 could pulldown full-length
His–EFA6A (Fig. 1B), and that the central SRD of ACTN1 binds
directly to His–EFA6A (Fig. 1C). In BHK cells, GFP–EFA6A
co-immunoprecipitated endogenous ACTN1 (Fig. 1D), and Myc–
EFA6A re-localized the endogenous ACTN1 to F-actin-enriched
lamellipodia as well as to the cell surface microspikes induced by
Myc–EFA6A (Fig. 1E; Derrien et al., 2002; Macia et al., 2008). We
conclude that, in vitro, ACTN and EFA6A can bind directly through
their respective spectrin and C-terminal domains, and that, in vivo,
EFA6A can recruit the endogenous ACTN1 to cortical F-actin
structures. In agreement with our previous reports (Luton et al.,
2004; Théard et al., 2010; Zangari et al., 2014), during lumen
formation mRFP–EFA6A was transiently found to be enriched at
the AMIS and the opened PAP before its expression at the apical
surface decreased to the low level found in mature cyst (Fig. S1A).
We also examined the localization of ACTN1 and ACTN4
in polarized cysts formed by MDCK cells. ACTN1–GFP was
diffused within the cytoplasm and enriched at the apex of cell-cell
junctions (Fig. S1A). Colocalization of ACTN1–GFP with occludin
(Fig. 1Fa–a″) indicated its accumulation at the TJ. In contrast,
ACTN4–GFP was not consistently observed at the TJ at above the
level of the GFP control (Fig. S1A; Fig. 1Fc–c″). In addition,
ACTN1–GFPwas found to be enriched at the nascent lumen formed
in between two cells and its surrounding TJ (Fig. 1Fb–b″), whereas
ACTN4–GFP was found on the newly formed luminal membrane
and also was enriched along the cell–cell contact (Fig. 1Fd–d″).
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Later, in mature cysts, ACTN4–GFP appeared to be more enriched
in AJs stained for E-cadherin (Fig. S1B). Given the enrichment of
ACTN1 at the TJ, we focused our study on the importance of its role
as an effector of EFA6.
EFA6A recruits ACTN1 in a regulated manner
EFA6A and ACTN1 are cortical actin regulators and both
partially localize to the TJ in polarized epithelial cells; we thus
investigated the mechanism of their direct interaction. ACTN1
could serve as a receptor to recruit EFA6A to the TJ. However,
EFA6A localization to the plasma membrane was shown to rely
on its phosphatidylinositol 4,5-bisphosphate (PIP2)-specific PH
domain and its capacity to bind to F-actin (Macia et al., 2008).
Furthermore, the EFA6A mutant deleted of its C-terminus, which
no longer binds ACTN1, has been shown to localize at the
plasma membrane in a similar manner to the full-length protein
(Franco et al., 1999; Macia et al., 2008). In contrast, as shown
above (Fig. 1E) ACTN1 was re-localized to Myc–EFA6A-
induced membrane ruffles, suggesting that ACTN1 can be used
as an effector of EFA6A in order to remodel the cortical actin
cytoskeleton.
To further analyze the binding of ACTN1 to EFA6A and its
functional properties in living cells, we ectopically expressed
EFA6A away from the plasma membrane. We fused EFA6A to the
mitochondrial-targeting peptide ActA and determined whether
EFA6A–ActAwas capable of re-localizing the endogenous ACTN1
to the outer membrane of mitochondria, from which it is normally
absent. Since ACTN1 binds to the C-terminal domain of EFA6A,
we first studied the EFA6ACter fused to mRFP and ActA (named
hereafter EFA6ACter–mRFP–ActA). As previously observed by
others, depending on the expression rate and construct used, in cells
transfected with ActA chimeras the mitochondrial network tended
to aggregate around the nucleus (Bubeck et al., 1997; Moeller et al.,
2004; Reinhard et al., 1999; Zhang et al., 2009). Nevertheless, all
constructs localized to the mitochondria as assessed by monitoring
colocalization with the mitochondrial protein Hsp60 (also known as
HSPD1) (Fig. S2A). When expressed in BHK cells, EFA6ACter–
mRFP–ActA localized to the mitochondria (Fig. S2A) and recruited
endogenous ACTN1 (Fig. 2A; magnification in Fig. S2B). In
contrast, the control mRFP–ActA construct, which also localized to
the mitochondria (Fig. S2A), did not recruit ACTN1 (Fig. 2A).
Interestingly, the full-length EFA6A–mRFP–ActA localized to the
mitochondria (Fig. S2A) but did not re-localize ACTN1 (Fig. 2A).
This observation suggests that the Cter was not available for ACTN1
binding in the full-length EFA6A. Our previous work indicates that
EFA6A exists in a closed conformation where the Cter is folded
Fig. 1. EFA6A binds directly to ACTN1. (A) Lysate of MDCK cells expressing ACTN1–GFP was reacted with GST, GST–EFA6A or GST–EFA6ACter prebound to
glutathione–sepharose beads. The top arrowhead points to GST–EFA6A and the bottom arrowhead toGST–EFA6ACter. (B) PurifiedGST, GST–ACTN1 andGST–
ACTN4 prebound to glutathione–sepharose beads were reacted with purified (6xHis)–EFA6A. The asterisk highlights a main purification contaminant. (C) Purified
GST, GST–ABD, GST–SRD and GST–CAMD (fragments of ACTN1) prebound to glutathione–sepharose beads were reacted with purified (6xHis)-EFA6A. In A–C,
the input or whole lysate and bound proteins were analyzed by immunoblotting with the indicated antibodies. (D) GFP or GFP–EFA6A expressed in BHK cells were
immunoprecipitated using an anti-GFP antibody and the co-precipitation of endogenous ACTN1 was assessed by immunoblotting. (E) BHK cells expressing
or not expressingMyc–EFA6Awere processed for immunofluorescence and stained forMyc (blue), F-actin (red) and the endogenousACTN1 (ACTN1endo., green).
Arrowheads point to EFA6A-induced lamellipodia where the endogenous ACTN1 is recruited. (F) MDCK cells expressing ACTN1–GFP (green; a–b″) or ACTN4–
GFP (green; c–d″) were processed for immunofluorescence to label the endogenous occludin (red) in mature or nascent lumens. Scale bars: 10 µm.
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back onto the PH domain, preventing its association with the
C-terminus of β-arrestin1 (denoted β-arrestin1Cter), another
EFA6ACter ligand (Macia et al., 2012). To test whether the
EFA6A–mRFP–ActA was in a locked conformation, we co-
expressed β-arrestin1Cter–GFP with EFA6ACter–mRFP–ActA or
the full-length EFA6A–mRFP–ActA constructs. Similar to what
was observed with ACTN1, β-arrestin1Cter–GFP could only bind to
EFA6ACter–mRFP–ActA (Fig. 2B) indicating that the binding of
ACTN1 to EFA6A is regulated, and requires the release of its
C-terminal domain.
Some F-actin staining was observed colocalized together with
EFA6ACter–mRFP–ActA and the endogenous ACTN1 at the
mitochondria (Fig. 2A; magnification in Fig. S2B). When the cells
were treated with Latrunculin A, F-actin was absent from the
mitochondria whereas the endogenous ACTN1 was still efficiently
recruited by EFA6Cter–ActA (Fig. 2C). Thus, independently of the
Fig. 2. EFA6A recruits ACTN1 in a regulated manner. (A) BHK cells expressing EFA6ACter–mRFP–ActA, mRFP–ActA and EFA6A–mRFP–ActA were
processed for immunofluorescence to label the endogenous ACTN1 and F-actin. In merge images, mRFP is colored red, ACTN1 blue and F-actin green. (B) BHK
cells co-expressing β-arrestin1Cter–GFP (green) with EFA6ACter–mRFP–ActA (red) or with the full-length EFA6A–mRFP–ActA (red) were processed for
immunofluorescence to label the endogenous F-actin (blue). (C) BHK cells expressing EFA6ACter–mRFP–ActA were exposed to Latrunculin A (2 µM) for 2 h.
The cells were processed for immunofluorescence to label the endogenous ACTN1 (green) and F-actin (blue). Scale bars: 10 µm.
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presence of F-actin, EFA6A can directly recruit ACTN1, which in
turn might function as an effector to organize EFA6A-regulated
actin-based structures.
Depletion of ACTN1 inhibits normal EFA6A-induced
luminogenesis
We have previously shown that expression of EFA6A tagged with
the G glycoprotein of the vesicular stomatitis virus (VSV-G) (VSV-
G–EFA6A) stimulates apical polarity development and TJ
formation in MDCK cells (Klein et al., 2008; Luton et al., 2004).
To assess the role of ACTN1 as an effector of EFA6A, we analyzed
the effects of its downregulation in cells grown in a 3D-culture
system in Matrigel. Several siRNAs against ACTN1 were tested for
their efficiency to downregulate its expression (Fig. S3A). ACTN1
knockdown was carried out in MDCK cells in which the expression
of VSV-G–EFA6A is under the control of the tetracycline (Dox)-
repressible transactivator (hereafter denoted MDCK-VSV-G–
EFA6A cells) (Luton et al., 2004). Fig. 3A is a representative
immunoblot analysis of ACTN1 depletion and VSV-G–EFA6A
expression in the presence or absence of doxycycline.
We first examined whether EFA6A overexpression stimulated
epithelial polarity in MDCK cells grown in Matrigel over 3 days.
Cysts of homogenous size (from 4 to 15 cells) were analyzed for the
formation of one or multiple lumens and for their shape. They were
also characterized for extension and expansion. Extension refers to
the opening of the lumen to all the cells of the aggregates, while
expansion refers to the enlargement of the luminal space. Upon
VSV-G–EFA6A expression (−Dox) we observed an increase in the
formation of cysts displaying a single central lumen (SCL). In
addition, the luminal space became more round with an almost
doubling (from 23% to 40%) of the SCL, with it displaying a round
shape upon VSV-G–EFA6A expression (Fig. 3B, shaded bars and
upper right panel). In contrast, depletion of ACTN1 in control
conditions (+Dox) reduced the number of cysts with a SCL and
Fig. 3. Depletion of ACTN1 inhibits normal EFA6A-induced luminogenesis. (A) MDCK cells expressing inducible VSV-G–EFA6Awere transfected with siRNA
directed against ACTN1 (siACTN1; #2225) or with control siRNA (siCt), and were grown without or with doxycycline (Dox) to induce or not the expression of VSV-G–
EFA6A, respectively. At 48 h post transfection, the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins was analyzed by
immunoblotting. The p85 regulatory subunit of PI3K served as a loading control. (B) Left, quantification of the percentage of cell aggregates with a SCL (left y-axis).
Shaded areas indicate the percentage of those SCL aggregates with a round lumen (right y-axis). Results are mean±s.d., n=5. Right, representative images
of the four cell types labeled for the nuclei (blue), apical marker PDX (green) and F-actin (red) are shown. The insets display an image of the same lumens stained for
F-actin (red) and the TJmarker occludin (green). Arrowheads point to the TJs. (C) MDCK cells expressing ACTN1S744–GFPwere transfected with siCt or siACTN1
(#2225). Top panel, the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins analyzed by immunoblotting. Hsp60 served as a
loading control. Bottom panel, quantification of the percentage of aggregates with a SCL. No significant difference was measured. Results are mean±s.d., n=3.
(D)Quantification of the percentage of aggregateswithmultilumens or incomplete lumens for the indicated conditions. Results aremean±s.d., n=5. (E)Quantification
of the percentage of aggregates with mini-lumens for the indicated conditions. Representative images of cells depleted in ACTN1, and expressing or not expressing
VSV-G–EFA6A, labeled for the nuclei (blue), the apical marker PDX (green) and F-actin (red). The insets display an image of the same mini-lumens stained
for F-actin (red) and the TJ marker occludin (green). Arrowheads point to the TJ. *P≤0.05; **P≤0.01; ***P≤0.001 (Student’s t-test). Scale bars: 10 µm.
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severely altered the shape of the lumen such that the lumens adopted
an ‘octopus-like’ shape with a small central opening from which
closed or barely opened luminal extensions reached in between the
cells (Fig. 3B, shaded bars and lower left panel). Depletion ofACTN1
in cells expressing VSV-G–EFA6A also impaired enlargement of the
lumens, although the opening was more visible (Fig. 3B, shaded bars
and bottom right panel). Thus, ACTN1 is required for the stimulatory
effects found for EFA6A on SCL formation and on the rounding of
the luminal space of multicellular cysts. However, in all conditions,
the cells remained well polarized as indicated by the correct
localization of the apical podocalyxin (PDX; also known as
PODXL) and basolateral (E-cadherin) markers (Fig. S3B), and by
the basal positioning of the nuclei, the general F-actin organization
and the apical assembly of the TJ (Fig. 3B). To confirm that the
phenotypes induced by the siRNA against ACTN1 (siACTN1) were
due to ACTN1 depletion we carried out a rescue experiment. MDCK
cells expressing anACTN1–GFPwhich is insensitive to the siACTN1
(ACTN1S744–GFP) did not display any defect in lumen formation
upon depletion of the endogenous ACTN1 (Fig. 3C).
The loss of cysts with SCLs in the ACTN1-depleted cells was
counterbalanced by an increase of cell aggregates with multiple
lumens and others with incomplete extension to all of the cells
(Fig. 3D, see Materials and Methods). In both cases, the lumens
displayed the distorted octopus-like shape. The extension defect was
further reflected by a strong increase in the number of aggregates
displaying multiple lumens that only opened in between two cells
(hereafter called mini-lumens) that were often blocked at the PAP
stage with no visible opening (Fig. 3E), which suggests that ACTN1
depletion might favor the early formation of an initial lumen. VSV-
G–EFA6A expression did not significantly alter the phenotypic
changes imposed upon ACTN1-depletion; however, it stimulated
the enlargement and rounding of the mini-lumens blocked at the
two-cell stage (Fig. 3E, right panel). Thus, as opposed towhat is seen
for mature lumens, EFA6A can stimulate the volumetric enlargement
of nascent mini-lumens in an ACTN1-independent manner. Taken
together, these observations suggest that ACTN1 is dispensable for
the formation of the initial lumen in between two cells but is required
later on for its extension and enlargement (see Discussion section for
further comments). In summary, depletion of ACTN1 blocked both
the effects of VSV-G–EFA6A on luminogenesis, that is, the
formation of fully extended SCL and its expansion as regular round
lumen. This suggests that ACTN1 acts as an effector downstream of
EFA6A that is important for luminogenesis.
ACTN1 acts as an effector of EFA6A to promote normal
luminogenesis
If EFA6A controls luminogenesis and ACTN1 acts as an effector,
then EFA6A depletion should hamper luminogenesis, and when
combined with ACTN1 depletion there should have no additional
effect. MDCK-VSV-G–EFA6A cells grown in the absence or
presence of doxycycline were submitted to siRNA against EFA6A
(siEFA6A)-, siACTN1- or simultaneous siEFA6A- and siACTN1-
mediated depletion. The efficient knockdown of the indicated
proteins and the induction of the expression of VSV-G–EFA6A
were analyzed by immunoblotting (Fig. 4A; Fig. S4).
Depletion of the endogenous EFA6A was accompanied by a
reduction in the amount of cell aggregates with a SCL
demonstrating that EFA6A is required for luminogenesis
(Fig. 4B). Expression of the exogenous human VSV-G–EFA6A,
which is insensitive to the canine-specific siRNA, rescued the
normal phenotype, thus controlling for the specificity of EFA6A
knockdown (Fig. 4B). As shown in Fig. 3, ACTN1 depletion
hampered luminogenesis and blocked the VSV-G–EFA6A
stimulation. However, ACTN1 depletion did not have any
additional effect when the endogenous EFA6A was knocked
down (Fig. 4B). In addition, the exogenous expression of VSV-G–
EFA6A in the double knockdown cells could not rescue the normal
phenotype (Fig. 4B). In addition, we analyzed the consequences on
the lumen formation of expressing a mutant of EFA6A deleted of its
C-terminus (EFA6AΔC), which contains the ACTN1-binding site.
Expression of VSV-G–EFA6AΔC impaired normal luminogenesis
and caused the formation of lumens with an octopus-like shape
(Fig. 4C). Although the C-terminus of EFA6A likely interacts with
other molecules, it is important to note that its truncation generated
lumens with shapes that were similar to those observed in ACTN1-
depleted cells. Taken together, these observations indicate that
EFA6A mediates luminogenesis in MDCK cells and that ACTN1 is
a crucial effector for this process.
ACTN1 is an effector of EFA6B for luminogenesis induction in
MCF7 breast cancer cells
We have reported that the EFA6B isoform is an antagonist of breast
cancer development (Zangari et al., 2014). Tumoral MCF7 cells
grown in 3D-culture systems form compact aggregates with no
lumen (Han et al., 2010; Kenny et al., 2007). The exogenous
expression of VSV-G–EFA6B in the tumoral MCF7 cells restores
an epithelial phenotype characterized by the appearance of
aggregates with extended lumens (although not often a SCL),
delineated by functional TJs (Zangari et al., 2014). Thus, we asked
whether ACTN1 was required downstream of EFA6B to contribute
to luminogenesis in MCF7 cells.
We first verified that ACTN1 could also bind to the EFA6B
isoform (Fig. S5). Next, we analyzed the effect of ACTN1 depletion
in both control MCF7 and MCF7-VSV-G–EFA6B cells grown in
Matrigel. An immunoblot analysis demonstrated the efficient
knockdown of ACTN1 in both cell lines (Fig. 5A). We quantified
the number of aggregates with extended lumens opened to at least
four cells, as opposed to mini-lumens opened in between only two
cells. As previously reported, MCF7 control cells do not form cysts
with lumens (Han et al., 2010; Kenny et al., 2007; Zangari et al.,
2014), whereas exogenous expression of VSV-G–EFA6B induced
the formation of cysts with extended lumens (Fig. 5B; Zangari et al.,
2014). We observed that ACTN1 depletion blocked the formation of
extended lumens induced by EFA6B indicating that, in MCF7 cells,
ACTN1 is also a crucial effector of EFA6B-induced lumen
formation (Fig. 5B). In addition, although control MCF7 cell
aggregates did not form extended lumens, in ∼20% of the
aggregates one or several mini-lumens were observed (Fig. 5C,D).
Upon ACTN1 depletion, the number of these mini-lumens
increased in both the VSV-G–EFA6B-expressing and non-
expressing MCF7 cell lines. However, in VSV-G–EFA6B-
expressing cells aggregates the luminal space was enlarged while
inMCF7 controls cells themini-lumenswere seen as PAPs (Fig. 5C,D).
Thus, similar to what we had observed in MDCK cells, ACTN1
depletion facilitates the initial lumen formation in between two cells but
then hampers both extension and enlargement.
EFA6AandACTN1control apical contractility contributing to
luminogenesis
The PAMR and ventral stress fibers (SFs) are sarcomere-like actin-
based structures capable of contractility that have been implicated in
epithelial morphogenesis. Contractile actin bundles are formed by
aligned fibers cross-linked by a periodic distribution of ACTNs that
alternates with myosin-II (Burridge andWittchen, 2013; Sluysmans
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs209361. doi:10.1242/jcs.209361
Jo
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
162
et al., 2017). RhoA and its effectors (ROCK and mDia1) have been
recognized as major regulators of the contractile properties of the
acto-myosin cytoskeletons (Arnold et al., 2017; Quiros and Nusrat,
2014; Sluysmans et al., 2017; Takeichi, 2014). Thus, we tested the
possibility that EFA6A and ACTN1 regulate luminogenesis by
contributing to the PAMR contractility. First, we used an antibody
directed against the phosphorylated regulatory myosin light chain 2
(pMLC, also known as MYL2) as a proxy to evaluate the tension
forces in response to modulating EFA6A and ACTN1 expression.
Fig. 6B shows a representative immunoblot analysis of ACTN1
depletion and VSV-G–EFA6A expression in the presence or
absence of doxycycline. In control cells, the pMLC staining
appeared as small intracellular dots, as well as larger dots located in
proximity to the apical membrane. Under conditions of EFA6A or
ACTN1 depletion, this apical staining disappeared and the pMLC
distribution became more diffuse. Upon VSV-G–EFA6A
expression the proportion of apical pMLC was increased and its
staining was evenly distributed all around the luminal cortex. In
ACTN1-depleted cells, the VSV-G–EFA6A-induced apical
accumulation of pMLC was abrogated (Fig. 6A). These results
suggest that EFA6A can modulate the apical tension forces in an
ACTN1-dependent manner.
We investigated the contribution of ACTN1 by first analyzing the
effect of its depletion on the RhoA-stimulated ventral SFs inMDCK
cells by expressing the N-terminal Myc-tagged constitutively active
mutant of RhoA (Myc–RhoAV14) under the control of the
inducible Tet-off system. The levels of expression of the proteins
in different conditions were analyzed by immunoblotting (Fig. 6C).
We monitored the Myc–RhoAV14-induced SF contractility by
immunofluorescence. We looked at the F-actin organization and the
Fig. 4. ACTN1 acts as an effector of EFA6A to promote normal luminogenesis. (A) MDCK cells expressing inducible VSV-G–EFA6Awere transfected with siRNA
control (siCt), siRNA directed against ACTN1 (siACTN1; #2225) or EFA6A (siEFA6A; #2661), or both siACTN1 and siEFA6A, and then grown without or with
doxycycline (Dox) to induce or not the expression of VSV-G–EFA6A, respectively. At 48 h post transfection the cells were solubilized in SDS lysis buffer and the
expression of the indicated proteins analyzed by immunoblotting. Hsp60 served as a loading control. (B) Quantification of the percentage of cell aggregates with a SCL.
Results aremean±s.d., n=4. (C)MDCKcells expressing inducibleVSV-G–EFA6AΔCwere grownwith orwithout Dox. Top panel, at 48 h post transfection the cellswere
solubilized in SDS lysis buffer and the expression of VSV-G–EFA6AΔC analyzed by immunoblotting. Hsp60 served as a loading control. Middle panel, representative
images of cell aggregates grown with or without Dox labeled for the nuclei (blue), apical marker PDX (green) and F-actin (red). Bottom panel. quantification of the
percentage of cell aggregates with a SCL. Results are mean±s.d., n=3. *P≤0.05; **P≤0.01; ***P≤0.001; N.S., not significant (Student’s t-test). Scale bars: 10 µm.
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contractility status by following the distribution of pMLC and
paxillin, a marker of the focal adhesions (Fig. 6D). As expected, the
expression of Myc–RhoAV14 (−Dox) stimulated the formation of
SFs that appeared as thick bundles of parallel F-actin going across
the whole cell cluster (Fig. 6Db). In Myc–RhoAV14-expressing
cells, pMLC was redistributed all along the SFs (Fig. 6Db′) while in
control cells pMLC was enriched at the periphery of the cell cluster
and excluded from cell–cell contacts (Fig. 6Da′). Concomitantly,
paxillin was re-localized to the periphery of the cell cluster mostly
decorating the focal adhesions at the extremity of the SF (Fig. 6Db″).
As previously observed by others (Oakes et al., 2012), depletion of
ACTN1 in control cells (+Dox) led to the loss of bundles or
shortening of radial F-actin bundles resembling transverse arcs
(Fig. 6Dc). These structures were stained for pMLC, which remained
absent from cell–cell contacts (Fig. 6Dc′). The paxillin signal
increased but was still homogeneously distributed within each cell of
the cluster similar to what was seen in control cells (Fig. 6Dc″).
Depletion of ACTN1 blocked the effects of Myc–RhoAV14, leading
to cells displaying a phenotype that was comparable to that of the
control cells with respect to all three markers (Fig. 6Dd–d″). We
conclude that ACTN1 can balance the contractility status of RhoA-
dependent SFs in MDCK cells.
Interfering with the RhoA–ROCK–myosin-II contractility
pathway has been shown to alter luminogenesis in MDCK cells
(Ferrari et al., 2008; Kim et al., 2015; Rodríguez-Fraticelli et al.,
2012). In particular, under permissive conditions, the
constitutively active RhoAV14 mutant blocks the initial step of
lumen formation (Ferrari et al., 2008). We thus asked whether
ACTN1 depletion could prevent the Myc–RhoAV14 inhibitory
effect on luminogenesis. In our 3D cell culture conditions, Myc–
RhoAV14 expression abrogated lumen formation. The cells
became round and loosely attached, forming aggregates almost
exclusively without lumens and that displayed an inverted
polarity, as judged by the peripheral localization of the apical
PDX marker (Fig. 6E,F). ACTN1 depletion partially rescued the
formation of lumens (Fig. 6E). We observed aggregates with
multilumens or incomplete lumen formation, essentially as mini-
lumens (Fig. 6E). The cells adopted a more cuboidal shape and
formed more-compact aggregates (Fig. 6F). These results suggest
that the knockdown of ACTN1 acts to reduce the strong
Fig. 5. ACTN1 is an effector of EFA6B that acts to induce luminogenesis in the MCF7 breast cancer cell line. (A) Control and VSV-G–EFA6B-expressing
MCF7 cells were transfected with siRNA control (siCt) or siRNA directed against ACTN1 (siACTN1). At 48 h post transfection the cells were solubilized in
SDS lysis buffer and the expression of the indicated proteins analyzed by immunoblotting. Actin served as a loading control. (B) Quantification of the percentage of
the indicated cell aggregates with extended lumens. (C) Quantification of the percentage of the indicated cell aggregates with mini-lumens. Results in B and C
are mean±s.d., n=3. *P≤0.05; ***P≤0.001 (Student’s t-test). (D) Representative images of cells depleted or not for ACTN1 and expressing or not expressing
VSV-G–EFA6B. The cell aggregates were processed for immunofluorescence by labeling cytoskeletal F-actin with fluorescent phalloidin. Arrowheads point to
PAPs. Scale bars: 10 µm.
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Fig. 6. EFA6A and ACTN1 control apical contractility, thereby contributing to luminogenesis. (A,B) MDCK cells expressing inducible VSV-G–EFA6Awere
transfected with siRNA control (siCt), or siRNA directed against ACTN1 (siACTN1; #2225) or EFA6A (siEFA6A; #2661) and then grown without or with doxycycline
(Dox) to induce or not the expression of VSV-G–EFA6A, respectively. (A) Representative images of the aggregates labeled for pMLC, F-actin and the nuclei. Top
panels, pMLC staining alone. Bottom panels show the corresponding merged images; pMLC is colored in green, F-actin in red and the nuclei in blue. Scale bars: 10
µm. (B) At 48 h post transfection the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins analyzed by immunoblotting. Hsp60 served
as a loading control. (C) MDCK cells expressing inducible Myc–RhoAV14 were transfected with siCt or siACTN1 (#2225) and grown with or without doxycycline. At
48 h post transfection the cells were solubilized in SDS lysis buffer and the expression of the indicated proteins was analyzed by immunoblotting. Hsp60 served as a
loading control. (D) MDCK cells expressing inducible Myc–RhoAV14 were transfected with siCt or siACTN1 (#2225) and grown on coverslips with or without
doxycycline. At 48 h post transfection the cells were processed for immunofluorescence and labeled for F-actin (a–d), pMLC (a′–d′) and the focal adhesion protein
paxillin (a″–d″). Scale bars: 20 µm. (E) MDCK cells expressing inducible Myc-RhoAV14 were transfected with siCt or siACTN1 (#2225), and grown with or without
doxycycline inMatrigel.Quantification of the indicated cell aggregates forSCLs,multilumens and incomplete lumens or no lumen is reported in the bar graph.Results
aremean±s.d.,n=3. **P≤0.01; ***P≤0.001 (Student’s t-test). (F)Representative imagesMDCKcellswith inducibleMyc–RhoAV14depletedor not for ACTN1 (#2225)
and grown for 4 days inMatrigel with or without doxycycline. The cell aggregateswere processed for immunofluorescence and labeled for the nuclei (blue), the apical
marker PDX (green) and the F-actin (red). Arrowheads point to PAPs and mini-lumens. Scale bars: 10 µm.
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contractility imposed by Myc–RhoAV14, thus allowing the
initiation of lumen formation. This is in agreement with
previous studies that show that reduction of the myosin-II
contractility stimulates the initial early step of lumen opening at
the two-cell stage (Ferrari et al., 2008; Rodríguez-Fraticelli et al.,
2012). However, the extension and enlargement of the lumens,
which we demonstrate to be dependent on ACTN1, were both still
compromised upon reduction of contractility induced by ACTN1
depletion. Thus, our findings support a model whereby the initial
stage of the lumen formation is facilitated by the absence of ACTN1,
followed by lumen maturation, which is ACTN1 dependent.
Taken together, our data suggest that EFA6A and its effector
ACTN1 contribute to SCL formation through the regulation of the
cell surface tension forces within the cell aggregate.
DISCUSSION
In this study, we aimed to define the role of EFA6, a regulator of
epithelial polarization, in lumen formation by using a 3D epithelial
cell culture system. Given the importance of the reorganization of
the actin cytoskeleton during cystogenesis, we were particularly
interested in deciphering the signaling pathway associated with the
EFA6 C-terminal domain that is capable of remodeling the cortical
actin independently of EFA6 GEF activity.
Searching for partners of EFA6ACter, we find that EFA6A binds
directly to the non-muscular ACTN member ACTN1. We
characterized this interaction in living cells by using a
mitochondrial-targeting system, and observed that it is likely
regulated by the structural conformation of the EFA6AC-terminus.
This observation confirms our previous results obtained with
another EFA6Cter ligand, β-arrestin1 (Macia et al., 2012), and
implies the existence of a common regulatory mechanism whereby
binding to EFA6ACter requires an opening signal. A possible
candidate for mediating this signal is Arf6-GTP, the product of
EFA6A Sec7-dependent nucleotide exchange activity. ARNO (also
known as CYTH2), another Sec7 family guanine nucleotide
exchange factor for Arf1, was shown to adopt an auto-inhibited
conformation where its short C-terminus downstream of the
PH domain interferes with the catalytic Sec7 domain (DiNitto
et al., 2007). Arf6-GTP binds to the PH domain of ARNO and
stimulates, in synergy with plasma membrane lipids, the nucleotide
exchange activity of ARNO on Arf1 (Cohen et al., 2007b; Stalder
et al., 2011). We found that Arf6-GTP binds to the PH-C-terminal
region of EFA6 (Padovani et al., 2014). Thus, by analogy with
ARNO, one could speculate that Arf6-GTP, by binding to the PH
domain of EFA6, could release the C-terminus and allow for
ACTN1 binding.
We had previously reported that EFA6A is present at and
regulates the TJ (Luton et al., 2004; Théard et al., 2010), where we
now find ACTN1. Our results support the hypothesis that it is
EFA6A that recruits ACTN1. The re-localization experiments
performed in the presence of Latrunculin B indicate that the binding
between EFA6A and ACTN1 is independent of F-actin. However,
F-actin is found around the mitochondria together with
EFA6ACter–ActA and ACTN1 suggesting that the EFA6A and
ACTN1 couple could organize actin filament structures or even
contribute to their nucleation, as proposed for ACTN4 at the AJ
(Tang and Brieher, 2012). ARNO was also found to bind directly to
ACTN1, through its C-terminal extremity, to modulate neurite
extension, suggesting that ACTNs could be a general player in the
Arf-regulated actin cytoskeleton (Torii et al., 2012).
Since EFA6A recruits ACTN1, we hypothesized that ACTN1
was acting as its effector. In the past, studying monolayers of
MDCK cells, we had found that overexpression of EFA6A
accelerates the general program of epithelial polarization,
including the assembly of functional TJs (Klein et al., 2008;
Luton et al., 2004). Part of the contribution of EFA6A has been
attributed to its ability to stabilize the PAMR. Here, by using a 3D
cell culture system together with siRNA-mediated depletion, we
show that EFA6A is necessary for normal luminogenesis in MDCK
cells. Conversely, overexpression of EFA6A increased the
proportion of cysts with a SCL and stimulated their enlargement.
Thus, we asked whether ACTN1 was acting as an effector to
transduce some of the effects of EFA6A on luminogenesis. Indeed,
we observed that depletion of ACTN1 blocked the stimulatory effect
of EFA6A on both the formation and enlargement of the round SCL.
In further support of this idea, depletion of ACTN1 had no
additional disruptive impact on cells knocked down for EFA6A.
This addition, expression of a mutant of EFA6A deleted of its
C-terminus, which contains the ACTN1-binding site, impaired
normal luminogenesis. These results demonstrate that ACTN1 is a
crucial effector of EFA6A whose function is to promote normal
luminogenesis.
To understand the roles of ACTN1, we analyzed in detail the
defects induced upon its depletion. In the absence of ACTN1, there
was an increase in cysts with multiple lumens, mostly as mini-
lumens formed between two cells, or cysts with lumens that failed to
extend to all cells. We propose that, in the absence of ACTN1, the
initial fusion event to form a PAP is facilitated; however, the
subsequent coalescence and extension of lumens to all cells of
the aggregate is precluded. In addition, the volumetric growth of
the lumens is impaired. In the ACTN1 knockdown cells, the mini-
lumens appeared to be essentially blocked at the PAP stage and, in
larger cysts, the extended lumens and SCL adopted an octopus-like
shape rather than a nice round hollow. Interestingly, in both MDCK
and MCF7 cells, in the absence of ACTN1, EFA6 overexpression is
capable of rescuing enlargement of the mini-lumens. However, at
later stages EFA6A overexpression cannot rescue the enlargement
because ACTN1 is required as an effector downstream of EFA6.
This implies that the enlargement of the luminal space relies on
different molecular machinery at different stages along the process
of lumen formation. Thus, ACTN1 is dispensable at the initial stage
to create the nascent lumens, but it is essential downstream
of EFA6A at later stages for the coalescence, extension and
enlargement of the lumens.
ACTN1 is an actin-bundling protein known to regulate the
contractility and stiffness of acto-myosin. It competes with myosin-
II to bind F-actin in order to maintain a complementary periodicity,
which results in linear F-actin bundles with contractile properties.
The ratio and distribution of these two proteins determines the
overall contractility and rigidity of F-actin cytoskeletons, including
that of the PARM (Arnold et al., 2017; Ferrari et al., 2008;
Sluysmans et al., 2017). Thus, ACTN1 could act by regulating
tension forces at the surface of the developing lumen. Several
observations support of this hypothesis. First, EFA6A and ACTN1
depletion reduced the amount of apical pMLC, whereas EFA6A
expression stimulated its accumulation at the apical pole in an
ACTN1-dependent manner. Second, upon ACTN1 depletion in
both MDCK and MCF7 cells, we observed two defects: (1) a
stimulatory effect on the initial formation of lumens as indicated by
the rapid accumulation of multiple mini-lumens and, (2) at later
stages, a defect of maturation (coalescence and extension) that leads
to large cysts with several lumens or incomplete lumens. These
results are consistent with a role for ACTN1 on contractility or
stiffness. Indeed, several independent studies have shown that
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decreasing contractility through treatment with blebbistatin, ROCK
inhibitors, or downregulation of LKB1 (also known as STK11), an
upstream regulator of RhoA, stimulates the initial formation of a
lumen at the two-cell stage (Cohen et al., 2007a; Ferrari et al., 2008;
Rodríguez-Fraticelli et al., 2012; Taniguchi et al., 2015). Less
appreciated is the impact of contractility at later stages. We found
that similar to what is seen upon ACTN1 depletion, blebbistatin
leads to large cysts with multiple lumens (our unpublished results).
A similar observation was made by reducing contractility through
depletion of LKB1, which first stimulates the initial formation of
lumens but then prevents their coalescence into a SCL (Rodríguez-
Fraticelli et al., 2012). Third, supplemental evidence for the role of
ACTN1 on contractility came from its effects in RhoAV14-
expressing cells. The small G protein RhoA, through its action
on the apical PAMR, is a general regulator of the assembly and
maintenance of the AJ (Lecuit and Yap, 2015) and TJ (Terry et al.,
2010). We showed that ACTN1-depletion could counterbalance
the RhoAV14-mediated contractility. We also found that
ACTN1-depletion rescued the initial formation of lumens
inhibited by RhoAV14 expression. Taken together, these results
indicate that luminogenesis is regulated by acto-myosin
contractility and stiffness, which should be kept low for the
initial formation of a mini-lumen, and then be increased to allow
for their coalescence and extension to form a SCL in larger
multicellular aggregates.
The implementation of tension forces relies on molecular pickets,
which are usually transmembrane proteins that anchor the acto-
myosin structures. In polarized epithelial cells, the AJ and TJ are
anchor points for the PAMR. It is noteworthy that neither EFA6A
nor ACTN1 appeared to be essential for the assembly and
positioning of the AJ and TJ, nor the establishment and
maintenance of the asymmetry along the apico-basal axis. Thus,
EFA6A and its effector ACTN1 modulate the contractility by
affecting the activity and/or organization of the apical acto-myosin
cytoskeleton and not the anchoring junctional complexes.
Not all the functions of ACTN1 appeared to be mediated through
regulating contractility. ACTN1 depletion prevented the luminal
enlargement, while the inhibition of contractility by inhibiting
myosin-II or LKB1 depletion (Rodríguez-Fraticelli et al., 2012) did
not affect the luminal enlargement. Enlargement has been proposed
to depend on apical membrane transport involving the delivery of
highly charged molecules, hydrostatic pressure mediated by ion
channels and coalescence of multilumens. In ACTN1-depleted
cells, the surface of the apical membrane appears large enough to
accommodate a bigger luminal volume. In addition, the highly
charged PDX protein is properly delivered and coalescence is not
relevant when considering SCLs with an octopus-like shape.
However, ACTN1 could help to retain polycystins, which are
implicated in intercellular mechanotransduction (Li et al.,
2005); Wilson, 2001), as well as ion channels. In fact, many ion
channels have been shown to bind or to require ACTNs in order for
them to be retained at the cell surface (Cukovic et al., 2001; Lu
et al., 2009; Maruoka et al., 2000; Sadeghi et al., 2002; Schnizler
et al., 2009; Wyszynski et al., 1997; Ziane et al., 2010). EFA6A
was also shown to bind the ion channels TWIK1 and Kir3.4
(Decressac et al., 2004; Gong et al., 2007). Furthermore, it has been
reported that ACTN4 regulates the outwards water transport in a
process called regulatory volume decrease in response to osmotic
swelling (Ando-Akatsuka et al., 2012). In summary, together with
EFA6A, the recruitment of ACTN1 to the apical surface might help
stabilize ion channels regulating fluid influx and consequently
lumen enlargement.
Alternatively, ACTN1 could serve to organize a non-contractile
scaffold to help support the spherical architecture of the luminal
membrane. To do so, ACTN1 could participate by bundling F-actin
filaments into rigid structures and/or could serve to link or even
nucleate actin filaments at the AJ or TJ to anchor the luminal actin
cytoskeleton. Such a role has been proposed for ACTN4 at the level
of the AJ (Tang and Brieher, 2012).
Finally, we examined the role of ACTN1 in the human tumoral
mammary cell lineMCF7.When grown in 3D culture, these cells fail
to assemble TJ, form a lumen or polarize (Han et al., 2010; Kenny
et al., 2007; Zangari et al., 2014). Only a small fraction of cell
aggregates display one or several mini-lumens. As shown in the past,
EFA6B expression stimulated the formation of extended lumens and
restored an epithelial-like phenotype. So, in contrast to MDCK cells,
the formation of extended lumens in MCF7 is strictly dependent on
the expression of VSV-G–EFA6B. Thus, these cells make a good
model to study the role of ACTN1 downstream of EFA6B. Indeed,
ACTN1 depletion totally blocked lumen formation, demonstrating
that ACTN1 is a crucial effector for EFA6B in the induction of
luminogenesis. Furthermore, ACTN1-depletion in wild-type MCF7
cells stimulated the formation of multiple mini-lumens that were
blocked at the PAP stage. EFA6B expression did not rescue the
formation of extended lumens but did enlarge their volume. Thus, in
agreement with our observations in MDCK cells, ACTN1 depletion
favors the initial formation of lumens in between two cells but
prevents their coalescence and enlargement.
In conclusion, we show that ACTN1 is an effector of EFA6A and
EFA6B to promote luminogenesis in normal and tumoral cell
models. We propose a scenario whereby, at the onset of
luminogenesis, the acto-myosin contractility and rigidity must be
kept low to relax the sub-membranous actin cytoskeleton where
vesicle fusion occurs at the AMIS. At this stage, EFA6 proteins have
a stimulatory effect on the formation and the enlargement of the
mini-lumens suggesting that it acts through an effector other than
ACTN1; perhaps through Arf6, which has already been shown to be
involved in luminogensis (Tushir et al., 2010; Zangari et al., 2014).
At a later stage, EFA6 proteins recruit ACTN1 to contribute to the
coalescence of the mini-lumens, their extension to neighboring
cells and enlargement.We do not exclude the possibility that EFA6
proteins could recruit other effectors to mediate its effects.
Nevertheless, ACTN1 is certainly a primary effector that might
act by modulating the contractility of the acto-myosin ring and
thereby mediating its effects on coalescence and extension (by
helping to pull the lumens together and breaking through the
junctional complexes). Given these results, the EFA6A–ACTN1
pathway might be important for tubulogenesis occurring through
the cord hollowing mechanism, where multiple mini-lumens
are formed along the tubular structure and subsequently fuse
to coalesce in a single lumen, in a ROCK–myosin II-dependent
manner (Bernascone et al., 2017; Kim et al., 2015;
Sigurbjörnsdóttir et al., 2014).
In summary, we identified and characterized the role of two new
regulators of luminogenesis: EFA6A and ACTN1. ACTN1 behaves
as an effector to transduce the stimulating effect of EFA6A on the
formation of a single and well-expanded central lumen by
facilitating the extension and enlargement stages. The EFA6A–
ACTN1 couple acts, at least in part, by balancing the contractility of
the cortical acto-myosin cytoskeleton. In the tumoral MCF7 cells,
this pathway has the capacity to restore the apico-basal polarization,
TJ assembly and collective cellular organization into a cyst with a
central lumen pointing to new directions for cancer research
and therapy.
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MATERIALS AND METHODS
Cells, media and transfection
BHK cells were grown in Glasgow’s minimum essential medium (GMEM;
Invitrogen, Paris, France) supplemented with 5% heat decomplemented fetal
calf serum (FCS; Biowest-Abcys, Nuaillé, France) and penicillin-
streptomycin (Invitrogen). Transient transfection was performed by
lipofection using JETPEI (Polyplus Transfection, Illkirck, France).
MDCK clone II cells expressing VSV-G–EFA6A, VSV-G–EFA6AΔC
(Luton et al., 2004) or Myc-RhoAV14 (Jou and Nelson, 1998) under the
control of the tetracycline-repressible transactivator were grown in MEM
(Sigma-Aldrich, Saint-Quentin-Fallavier, France), 5% decomplemented
FCS (Biowest-Abcys), penicillin-streptomycin and 20 ng/ml doxycycline.
Expression of EFA6A and RhoAV14 was induced upon removal of
doxycycline. Plasmids and siRNA transfections were performed by
nucleofection (Nucleofector™; Lonza, Köln, Germany). For stable
expression of ACTN1–GFP, ACTN4–GFP and ACTN1S744–GFP, the
cells were selected with geneticin (Invitrogen) 2 days after transfection.
MCF7 and MCF7-VSV-G–EFA6B (Zangari et al., 2014) were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) containing
10% decomplemented FCS (Hyclone™, GE Healthcare, France),
supplemented with insulin, transferrin, selenium, glutamine, sodium
pyruvate,MEMnon-essential amino-acids and penicillin-streptomycin (all
from Invitrogen). Transient transfection was performed by nucleofection.
For 3D cell culture, 104 cells were mixed with 20 µl of 5 mg/ml Matrigel
(BDBiosciences, Le Pont de Claix, France) deposited as a drop on a 12 mm
glass coverslip. The BHK and MCF7 cells were obtained from the ATCC
and authenticated by short tandem repeat profiling by the vendor. The
parental MDCK II cell line was from Dr Keith Mostov (University of
California, San Francisco, USA). MDCK and derived cell lines were tested
for species specificity. Newly thawed cells from frozen stocks were tested
for absence of mycoplasma contamination and used for 10 passages before
replacement.
Antibodies and reagents
Rabbit polyclonal sera specific for EFA6B (HPA034722; Sigma-
Aldrich), occludin (71-1500, Invitrogen), phosphorylated (Thr18/Ser19)
myosin light chain 2 (3674, Cell Signaling Technology, Leiden, The
Netherlands), the PI3K p85 regulatory subunit (ABS234, Millipore,
Molsheim, France), Hsp60 (Ab46798, Abcam, Paris, France), GST (27-
4577-01, GE Healthcare) were used. Mouse monoclonal antibodies
specific for gp135/podocalyxin (3B8; gift from George Ojakian, State
University of New York Downstate Medical Center), the VSV-G tag
(P5D4; Roche Diagnostics, Mannheim, Germany), actin (AC-40; Sigma-
Aldrich), E-cadherin (36; Invitrogen), paxillin (610052, BD
Biosciences), the 6× histidine tag (HIS1; Sigma-Aldrich), the Myc tag
(9E10 and rat hybridoma 3F10; Roche Diagnostics), GFP (7.1, Roche
Diagnostics), ACTN1 (BM75.2; Sigma-Aldrich and H-2; Santa Cruz
Biotechnology, Heidelberg, Germany) were used. The rabbit polyclonal
anti-EFA6A was as described elsewhere (Sakagami et al., 2007). The
horseradish peroxidase (HRP)-coupled and fluorescent probes
(secondary antibodies, phalloidin and DAPI) were from Jackson
ImmunoResearch Labs (Suffolk, UK) and Molecular Probes (Eugene,
Oregon, USA), respectively. Full details of antibodies, including
dilutions used are given in Table S1. All other reagents and chemicals
were from Sigma-Aldrich.
DNA constructs and siRNA
Constructs for the expression of the following proteins have been described
elsewhere: GFP–EFA6A (Decressac et al., 2004), mRFP–EFA6A (Théard
et al., 2010), GST–EFA6A, GST–EFA6ACter (Macia et al., 2008), (6xhis)–
EFA6A (Macia et al., 2008), βarrestin1Cter–GFP (Scott et al., 2002),
the GST–ABD [amino acids (aa) 1–269], GST–SRD (aa 218–749) and
GST–CAMD (aa 713–887) fragments of ACTN1 (Fraley et al., 2003),
ACTN1–GFP (Rajfur et al., 2002), GST–ACTN4 (Khurana et al., 2011),
ACTN4–HA and ACTN4–GFP (Michaud et al., 2006). The GST–ACTN1
construct was prepared by PCR amplification of full-length ACTN1 from
pEGFP-ACTN1 and cloned into EcoR1 and Xho1 sites of the pGEX4T1
using the following primers:5′-GATCGATCGAATTCATGGACCA-
TTATGATTCTCAG-3′ and 5′-TGTATCACTCGAGTTAGAGGTCACT-
CTCGCCGTAC-3′. The siRNA #2225 insensitive ACTN1–GFP was ge-
nerated by introducing silent mutations at positions 2236, 2237 and 2238
(aa Ser744) using the QuikChange mutagenesis kit (Agilent Technologies,
Courtabœuf, France) using the following primers 5′-GCCAAGGGCATC-
TCGCAGGAGCAGATGAATG-3′ and 5′-CATTCATCTGCTCCTGCG-
AGATGCCCTTGGC-3′. The resulting plasmid was termed ACTN1S744–
GFP. Full-length EFA6A and EFA6ACter were cloned into mRFP-N1-
ActA (Benjamin et al., 2010) by PCR amplification at the EcoRI and SacII
sites. Primers used to amplify and clone the full-length EFA6A were 5′-
GATCGATCGAATTCGCCGCCACCATGCCTCTCAAGTCACCTGTG-
3′ and 5′-GATCGATCCCGCGGGGGCTTCCGCCGCCCACTGCC-3′,
and those for the EFA6ACter fragment were 5′-GATCGATCGAATTCG-
CCGCCACCATGTTCTCTGCGCCCCCCTTCC-3′ and 5′-GATCGAT-
CCCGCGGGGGCTTCCGCCGCCCACTGCC-3′. The resulting plasmids
were termed EFA6A–mRFP–ActA and EFA6ACter–mRFP–ActA.
The specific and control siRNAs were designed and obtained from
Eurogentec (Angers, France) and Sigma-Aldrich. The silencing efficiency
of several siRNAs per target was assessed by immunoblotting (Figs S3 and
S4). Knockdown of canine EFA6A and ACTN1 expression in MDCK cells
was carried out using the siRNA #2661 5′-CCUAUCAGAGGCGGAGC-
UA-3′ or #1440 5′-CUCUUUCAGUUGUGUGUUU-3′ and siRNA #2225
5′-GCAUCAGCCAGGAGCAAAU-3′ or #594 5′-GGACGACCCACUC-
ACAAAU-3′, respectively. Knockdown of human ACTN1 expression in
MCF7 cells was carried out using the siRNA #1789 5′-
CCUCAGGAGAUCAAUGGCAAA-3′. Silencing specificity was verified
with control siRNAs, rescue experiments (Fig. 3C and Fig. 4B) and
additional independent siRNA (Fig. S4).
Recombinant proteins, pull-down assay and
immunoprecipitation
The induction and purification of GST constructs with glutathione–
sepharose CL-4B beads (GE Healthcare) was as previously described
(Macia et al., 2008). The N-terminal 6×his–EFA6Awas purified on Ni-NTA
columns according to the manufacturer’s instructions (Qiagen, Courtabœuf,
France). For the GST-EFA6A pull-down from cell lysates, MDCK-
ACTN1–GFP cells were lysed at 4°C in 0.5% Nonidet P-40, 20 mM
Hepes pH 7.4, 125 mM NaCl, 1 mM phenylmethylsulphonyl fluoride
(PMSF) and a cocktail of protease inhibitors (Complete™, Roche
Diagnostics). The cleared lysates were incubated for 4 h at 4°C with
1.5 µM of the indicated GST-fused proteins and 30 µl of glutathione-
sepharose CL-4B beads. After three washes in lysis buffer, the beads were
boiled in Laemmli buffer, submitted to SDS-PAGE and the proteins
revealed by immunoblotting. For the GST pull-down of purified His–
EFA6A, 10 µM of the indicated GST fusion proteins and 10 µM of His–
EFA6Awere incubated together for 2 h at 4°C, and the experiments carried
on as described above. For all GST pulldown experiments, an aliquot of the
mixture was analyzed by SDS-PAGE followed by immunoblotting to
estimate the total amount of the added proteins. For immunoprecipitation,
cells were solubilized in ice-cold Triton X-100 lysis buffer (1% Triton X-
100, 150 mM NaCl, 5 mM EDTA, 20 mM Triethanolamine-HCl pH 8.1
and 1 mM PMSF). After centrifugation for 20 min at 16,000 g at 4°C, the
supernatants were pre-cleared at 4°C for 10 min, centrifuged for 10 min at
16,000 g and combined with protein A–sepharose and the indicated
antibody overnight at 4°C. The beads were then washed three times in
washing buffer (1% Triton X-100, 0.2% SDS, 150 mMNaCl, 5 mMEDTA,
8% sucrose, 1 mM PMSF and the cocktail of protease inhibitors) and
washed once in washing buffer without detergent. The immunoprecipitates
were then resuspended and boiled for 5 min in Laemmli buffer before SDS-
PAGE and immunoblot analysis.
Immunoblotting
Samples were resolved on SDS-PAGE and proteins transferred onto a
nitrocellulose membrane.Membrane blocking (30 min at room temperature)
and antibody dilutions were performed in PBS with 5% non-fat dried milk.
The membranes were incubated overnight at 4°C with the indicated
antibody. The proteins were revealed by chemiluminescence (ECL,
Amersham, GE Healthcare) using secondary antibodies directly coupled
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to HRP. The membranes were analyzed with the luminescent image
analyzer LAS-3000 (Fujifilm, Saint-Quentin-en-Yvelines, France).
Immunofluorescence
Cells were fixed in 4% PFA, the samples processed as previously described
(Luton et al., 2004) and imaged on a confocal microscope (Leica TCS-SP5,
Nanterre, France and Zeiss LSM780, Marly-le-Roi, France). Images were
processed for presentation using NIH Image and Adobe® Photoshop® CS2
software.
Quantification of luminogenesis
Unless specified, all quantifications were from cysts of 4–15 cells obtained
after 48 to 72 h growth in Matrigel. Experiments were repeated at least three
times in triplicate and a minimum of 100 cysts per experimental replicate
were analyzed. Each cell aggregate was scanned by using confocal
microscopy to analyze the shape of the lumens and determine the
presence of a single lumen or multiple lumens. Cysts were classified
within five categories: cysts with a single central opened lumen (SCL), two
or more lumens regardless of their shape (multilumen), with an opened
lumen but that was not extended to all cells (incomplete lumen), with an
optically closed lumen (otherwise named pre-apical patch, PAP), and with
no lumen. Within the SCL class, we discriminated those lumens that were
well enlarged from those that were barely opened and not expanded
displaying an ‘octopus-like’ shape (see Fig. 3B). Note, that cysts with
dividing cells or with lumen-containing cells and/or nuclei were not
included. In addition, a separate quantification was performed for a lumen
opened only in between two cells (mini-lumen) as they fell in the
multilumen, incomplete and optically closed lumen categories (see Fig. 3E).
Enlargement refers to the increase of the luminal volume. When
enlargement was compromised there was an octopus-like lumen.
Extension refers to the opening of a lumen (in general starting in-between
two cells) to all the cells of the cell aggregate or coalescence of multiple
small lumens to eventually form a single lumen. When extension was
compromised it led to an incomplete lumen and/or to the presence of
multiple lumens including mini-lumens (see Fig. 3D,E).
Statistics
The experiments were performed at least three times in triplicate, and data
from all experiments were combined. Values are mean±s.d. Statistical
significance was calculated with a two-tailed Student’s t-test. Non-
significant difference (N.S.) are P>0.05; *P≤0.05; **P≤0.01; ***P≤0.001.
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Figure S1. Subcellular localization of mRFP-EFA6A, ACTN1-GFP and ACTN4-GFP. A) MDCK cells 
expressing mRFP-EFA6A were grown in Matrigel and processed for immunofluorescence to label F-
actin and the nuclei. The top panels show the mRFP-EFA6A staining alone and the bottom panels the 
corresponding merged images with mRFP-EFA6A colored in red, F-actin in green and the nuclei in 
blue. Scale bars 10m. B) MDCK cells expressing GFP, ACTN1-GFP and ACTN4-GFP were grown in 
Matrigel and processed for immunofluorescence.  C) MDCK cells expressing ACTN1-GFP (green; a-a'') 
or ACTN4-GFP (green; b-b'') were processed for immunofluorescence to label the endogenous E-
cadherin (red). Scale bars 10m. 
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Figure S2
Figure S2. A) The mRFP-ActA constructs localized to mitochondria. BHK cells expressing mRFP-ActA, 
EFA6ACter-mRFP-ActA and the full-length EFA6A-mRFP-ActA were processed for 
immunofluorescence to label the endogenous mitochondrial protein Hsp60. In merge images, mRFP 
is colored red and Hsp60 is colored green; thus, yellow pixels indicate co-localization demonstrating 
that the fusion proteins are localized to the mitochondria. B) Co-localization of EFA6ACter-mRFP-
ActA with the endogenous ACTN1 and F-actin. Magnified image of BHK cells expressing EFA6ACter-
mRFP-ActA stained for the endogenous ACTN1 and F-actin. In the merge image, mRFP is colored red, 
ACTN1 is colored blue and F-actin is colored green. Overlap of expression appears white in the merge 
color image and indicates triple co-localization. Scale bars 10m. 
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Figure S3. A) siRNA-mediated ACTN1 depletion. MDCK cells were transfected with siRNA control or 
siRNAs directed against ACTN1. 48 hr post-transfection the cells were solubilized in SDS lysis buffer 
and the expression of ACTN1 analyzed by immunoblot. Actin served as a loading control. B) ACTN1 
depletion does not affect the apico-basal polarity. Inducible vsvg-EFA6A MDCK expressing cells were 
transfected with siRNA control or directed against ACTN1 and grown in the presence or absence of 
doxycycline. At day four, the cells were processed for immunofluorescence and labeled for the nuclei 
(blue), the AJ marker E-cadherin (green) and the apical marker PDX (red). Scale bars 10m. C,D) 
Uncropped images shown in Fig. 3B and Fig. 3E. E) MDCK cells expressing GFP were transfected with 
siRNA control or directed against ACTN1. Top panel: the cells were solubilized in SDS lysis buffer and 
the expression of the indicated proteins analyzed by immunoblot. Hsp60 served as a loading control. 
Bottom panel: quantification of the percentage of aggregates with a SCL. Statistical significance was 
calculated using the Student's t-test. n=3, p<0.01. 
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Figure S4. siRNA-mediated EFA6A depletion. MDCK cells were transfected with siRNA control or 
siRNAs directed against EFA6A. 48 hr post-transfection the cells were solubilized in SDS lysis buffer 
and the expression of EFA6A analyzed by immunoblot. Hsp60 served as a loading control. B-E) 
Experiments presented in Fig. 3A,B,D,E and Fig. 4A,B were repeated with alternate siRNAs directed 
against EFA6A (#1440) or ACTN1 (#594). n=3, p-values of the main results discussed in the text are 
indicated on the graphs. 
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Figure S5. EFA6B binds to ACTN1 SRD. Lysate of MCF-10 cells expressing vsvg-EFA6B was reacted 
with Gst-ACTN1 (A) and Gst-SRD (B) or control Gst (A,B) prebound to glutathione Sepharose 4B 
beads. The input, whole lysate and bound proteins were analyzed by immunoblotting with the 
indicated antibodies. * Main purification contaminant. 
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Table S1. Antibodies used in this study. 
Antigen Antibody source and reference Application Dilution or 
concentration 
EFA6B Sigma-Aldrich, HPA034722 Immunoblotting 1/250 
Occludin Invitrogen, 71-1500 Immunofluorescence 1/100 
pMLC Cell Signaling Technology, 3674 Immunofluorescence 1/50 
p85 Millipore, ABS234 Immunoblotting 1/500 
Hsp60 Abcam, Ab46798 Immunoblotting 1/10,000 
GST GE Healthcare, 27-4577-01 Immunoblotting 1/2,000 
PDX Dr. GK Ojakian, 3B8 ascite Immunofluorescence 1/50 
VSV-G Roche Diagnostics, P5D4 Immunoblotting 1/200 
Actin Sigma-Aldrich, AC-40 Immunoblotting 1/1,000 
E-cadherin Invitrogen, 36 Immunofluorescence 1/200 
Paxillin BD Biosciences, 610052 Immunofluorescence 1/5,000 
6xHis Sigma-Aldrich, HIS1 Immunoblotting 1/3,000 
GFP Roche Diagnostics, 7.1 Immunoblotting 1/5,000 
Myc Roche Diagnostics, 3F10 Immunofluorescence 1/100 
ACTN1 Sigma-Aldrich, BM75.2 Immunoblotting 1/200 
ACTN1 Santa Cruz Biotechnology, H-2 Immunofluorescence 1/100 
EFA6A Dr. H. Sakagami, immunopurified Immunoblotting 10g/ml 
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3. Discussion of Article 2
This work has allowed the identification of EFA6 and ACTN1 as two new regulators of luminogenesis. 
We show that ACTN1 acts as a crucial effector of EFA6A and EFA6B for this process in a normal 
epithelial cell model and a tumorigenic context, respectively. Our findings suggest a scenario whereby 
the initial formation of lumen is ensured by ACTN1-independent EFA6 activity, whereas lumen 
maturation is EFA6-ACTN1-dependent. More specifically, the role of EFA6 in lumen initiation and 
enlargement is facilitated by the absence of ACTN1. Indeed, the formation of mini-lumens required a 
relaxed apical actomyosin contractility in order to allow vesicular fusion important to establish the apical 
plasma membrane. However, the tension forces generated in an EFA6-ACTN1 dependent manner are 
essential to favor the extension and enlargement of mini-lumens into single mature central lumens. 
We can notice that this article revealed not only the role of EFA6A-ACTN1 cascade in luminogenesis 
but also highlighted the fact that both proteins have some independent chronologically different roles 
mediated by probably other effectors in the same process. This notion led us once again to the importance 
of a fine regulation of each and every protein activity. Spatio-temporal protein regulations can be 
achieved through a wide variety of strategies: conformational change, phosphorylation, intermediate 
proteins recruiting, scaffolds, etc. I will discuss hereafter two unpublished results that can give some 
insights on how EFA6 and ACTN1 are regulated. 
Unpublished results and potential new roles of ACTN1 on EFA6 
May ACTN1 be a possible conformational regulator of EFA6? 
After finding that EFA6A binds directly to the non-muscular ACTN1, their interaction was characterize 
using a mitochondrial-targeting system. Notably, only the PH-Cter construction but not the full length 
of EFA6A was able to recruit ACTN1 meaning that EFA6A is likely regulated by the structural 
conformation of its Cter domain. This is in agreement with previous results of the lab on β-arrestin1, 
another effector of EFA6A, suggesting that EFA6 is present in a close conformation where the Cter 
domain is folded on the PH domain (Macia et al., 2012). Thus, the binding of EFA6 to its effectors needs 
an opening signal. In the paper’s discussion, we propose Arf6GTP as a possible candidate for mediating 
the opening signal on the basis of: 1- a published mechanism of activation of the inactivated 
conformation of ARNO, an exchange factor for Arf1 deriving from the same Sec7 family of ArfGEFs, 
by ARf1GTP (Cohen et al., 2007; DiNitto et al., 2007; Stalder et al., 2011) , 2- previous results of our 
research group showing that Arf6GTP can bind the PH-Cter region of EFA6A (Padovani et al., 2014). 
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An unpublished preliminary result complementary to the present work suspects ACTN1 as another 
potential candidate to stimulate the opening of EFA6 closed conformation. Indeed, the PH-Cter region 
of EFA6A managed to bind a conformation sensible effector of EFA6, here the β-arrestin1, only when 
pre-incubated with ACTN1. This suggests that ACTN1 by binding to this EFA6 region could release 
the Cter domain and allow the binding of another effector. 
Thus, ACTN1 might regulate the opening of the PH-Cter region and stimulate EFA6 functions. 
May ACTN1 recruitEFA6 recruiter? 
After seeing that the PH-Cter region of EFA6A can target ACTN1 to the mitochondria, we proposed 
that EFA6A, maintained normally at the apical domain of the cell, is responsible of recruiting the 
ubiquitous ACTN1 which will induce the maturing of mini-lumens. 
Another unpublished piece of data indicated that we cannot exclude the opposite scenario. We found by 
fusing ACTN1 to the mitochondrial-targeting peptide ActA, that ACTN1 is also capable of relocating 
EFA6A to the outer membrane of mitochondria. This experiment suggested that ACTN1 might also 
recruit EFA6A. We think that both scenarios may be actually feasible: in a cell and that both proteins at 
different times can recruit each other. Hence one can imagine that, for example, that ACTN1 normally 
present at the level of newly formed adherens junctions will recruit EFA6 to the adhesion complex in 
order to allow the segregation and formation of tight junctions followed by positive feedback loops 
enhancing the recruitment of actinin through EFA6. 
We believe that EFA6 and actinin collaborate in order to regulate the actin cytoskeleton rearrangement, 
the formation of adhesion complexes and luminogenesis among others. Further understanding of their 
interaction and its regulation can be important not only to better understand these functions essential for 
epithelial establishment and homeostasis, but as well to understand their implications in tumorigenesis. 
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 General discussion 
 
1. General context: 
Understanding how normal cells keep their homeostasis through the intense dynamics of the 
developmental cycles is crucial to better interpret the molecular events inducing breast cancer. 
I have started my introduction by presenting the mammary gland morphogenesis, in which epithelial 
cells communicate with their surrounding stroma in order to orchestrate the formation of a functional 
organ. In fact, the mechanisms described in cancer responsible for its initiation and progression largely 
co-opt the finely regulated complex processes of mammary gland development. For instance, mammary 
cells undergo multiple cycles of proliferation, EMT/MET, migration and invasion by integrating various 
internal and external signals. Even though typically found in cancer cells, these aforementioned 
pathways occur in a regulated manner during development, a key notion differentiating a normal tissue 
from a cancerous one. Regulation includes controlling key epithelial features (apico-basal polarity, 
cohesion between epithelial cells, lumen formation, etc.) responsible for maintaining the overall 
epithelial integrity. Here stands our protein of interest, EFA6B, at the core of these structural features, 
and hence our interest in studying its role in mammary epithelial cells.  
 
So, what did we learn from the present work about the impact of EFA6B in mammary 
epithelial cells? And what is the relevance of this work to breast cancer? 
  
In the course of this PhD work, using the mammary gland as a study model, we have described the 
important role of EFA6B in regulating and maintaining epithelial tissue homeostasis. 
 
In the first article, we show that the loss of EFA6B can severely disrupt the epithelial state of normal 
mammary cells. Indeed, EFA6B KO MCF10A and HMLE cells displayed mesenchymal characteristics 
and invasive capacities. They present significant modifications of their extracellular matrix components 
and their integrin repertoire, and they have lost in part their epithelial status by engaging into EMT 
(upregulation of EMT-TFs, E-cadh/N-cadh switch). EFA6B KOs presented a collective dissemination 
regulated by the activation of Cdc42 responsible for actin nucleation (via N-WASP/Arp2/3) essential 
for invadopodia formation (Yamaguchi et al., 2005). Cdc42 upregulation also contributed to cell 
mobility and invadopodia formation by contracting and aligning the collagen fibers (via MRCK/MLC) 
(Fraley et al., 2015). In support to this conclusion, deleting EFA6B allowed the formation of invasive 
structures, invadopodia, rich in ITGB1 and MMP14. All of these newly acquired properties converge 
into a pro-invasive phenotype. In addition, these results are in agreement with a previous correlation 
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between low level of expression of EFA6B and Cld-low BC patients. In fact, this subtype is 
characterized by high metastatic rates and EMT signature. Thus, the loss of EFA6B may have caused 
the acquisition of the Cld-low invasive properties. 
 
In the second article, consistent with the importance of EFA6 in establishing a normal epithelial tissue, 
we identified α-actinin1 as an effector of EFA6A in normal epithelial cells and EFA6B in a tumorigenic 
mammary cell line, MCF7. We showed that both EFA6B/ACTN1 coordination regulates the 
establishment of apico-basal polarity and luminogenesis, two essential processes for functional epithelia, 
via apical cellular contractility. Similarly, we found that MCF10A KO cells were not able to polarize 
and form a lumen. We can definitely suggest that in the absence of EFA6B, actinin is not recruited to 
the apical acto-myosin cytoskeleton and therefore the absence of contractility, crucial for lumen 
enlargement and maturation. It is interesting to note that actin might also be playing a cooperative role 
with Cdc42 in cells deleted for EFA6B, hence the increased contractility. Further investigations are 
needed to validate these hypotheses. 
 
Altogether, these results strikingly show that the KO of EFA6B is capable of turning normal cells into 
invasive ones, and to modify their microenvironment (contractility, degradative invadopodia, alteration 
of the matrisome). We propose PSD4 (EFA6B) as an invasion-suppressor gene that will preserve cells 
from losing their epithelial features in order to maintain tissue integrity. 
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 Figure 27: Model for signaling pathways mediating EFA6B roles in epithelial cells.  
In mammary epithelial cells, EFA6B activates Arf6 through its sec7 catalytic domain and recruits 
ACTN1 by its C-terminal domain. We suggest that first both effectors will regulate cell contractility 
through apical actin cytoskeleton rearrangement. This contractility is important for tight junctions’ 
assembly that was shown to require EFA6B expression and its activated substrate Arf6 in epithelial 
cells. In parallel, EFA6B/ACTN1 mediated contractility is crucial for the formation of central mature 
lumen, a characteristic of normal acini. The overall functions of EFA6B will ensure the establishment 
and maintenance of the apico-basal polarity in epithelial cells. In the absence of EFA6B, cells acquire 
a degradative invasive phenotype associated with an increased contractility, invadopodia formation and 
alteration of the matrisome. We suggest that EFA6B loss activates two different pathways: a) The 
downregulation of EFA6B causes the disassembly of tight and adherens junctions that is probably 
enhanced by the decreased levels and activity of Arf6 and the lack of ACTN1 recruitment in the absence 
of EFA6B. In this case, components of adherens junctions such as catenins can be translocated to the 
nucleus and stimulate new transcriptional programs that will affect the expression of EMT-TFs. EMT-
TFs have been shown to engage cells in an epithelial-mesenchymal transition but can be also 
responsible for the alteration of the matrisome composition and the integrin expression. Given the role 
of Arf6 in vesicular trafficking, the transport of some integrins can be as well altered in the EFA6B KO 
cells. b) In parallel, EFA6B deletion induced a clear upregulation of Cdc42, that can be mediated by 
one of the members of ARH GAP family. We suggest that the overactivation of Cdc42 stimulates MRCK 
that can phosphorylate the MLC which in turn will increase cellular contractility. In parallel, it will 
stabilize the N-WASP/Arp2/3 complex and enable actin nucleation and polymerization. Contractility 
and actin polymerization where both shown to be important for the formation of invadopodia. The 
collective invasion observed in the absence of EFA6B is the result of both MMP14 rich invadopodia 
that will degrade the ECM and possible changes in the matrix stiffness and density perceived by the new 
repertoire of integrins. Of note, inhibiting any of these two Cdc42 dependent and independent pathways 
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can block invasion. We postulate that both pathways have cooperative functions and therefore are 
crucial for providing invasive advantages for EFA6B KO cells.  
A step back: what is then the importance of EFA6B, in a normal context, on epithelial 
homeostasis? 
Collectively our data suggest that epithelial cells cannot afford to lose EFA6B. It protects normal cells 
from losing their epithelial identity. Here’s some examples of EFA6 proteins functions among others 
that would illustrate their importance. 
First important role for EFA6B in maintaining the epithelial homeostasis is the assembly of TJs and the 
establishment of apico-basal polarity. Indeed, a previous study of our research group shows that 
exogenous expression of EFA6B is able of blocking the TGF-β induced EMT (Zangari et al., 2014), and 
here we show that its absence facilitates an EMT engagement. In fully polarized cells, the presence of 
EFA6B at the TJs might serve to preserve the apico-basal polarity and TJs in place. The disassembly of 
adhesion complexes activates different signaling pathways that can disrupt vital cellular functions. For 
example, E-cadherin, once removed from the plasma membrane, activates transcriptional programs 
mainly translocating β-catenin to the nucleus. Associated to TJs, we can find the transcription factor 
ZONAB that can affect cell proliferation by accumulating in the nucleus (Balda et al., 2003). 
The second aspect, related to the apico-basal polarity, ensured by EFA6B and its effector a-actinin1 
expression is luminogenesis. Luminogenesis is a fundamental property of epithelial cells and tube 
formation, and a key step of the mammary gland development and milk secretion. A deregulation of 
lumen formation can be at the origin of human diseases like polycystic kidney disease, cystic fibrosis 
and certain cancer metastasis (Willenborg and Prekeris, 2011). 
Lastly, EFA6 proteins are believed to coordinate the organization of the actin cytoskeleton and cell 
surface trafficking (endocytosis, exocytosis, secretion, recycling). Taking for instance just the regulation 
of receptors expression on cell surface, EFA6 can cover a wide panel of cellular roles. EFA6A was 
shown to control the recycling of β2 adrenergic receptor, a GPCR implicated in controlling vision, 
insulin secretion, heart muscle contraction, etc. (Boulakirba et al., 2014b; Macia et al., 2012). In another 
project in the lab to which I participated (appendix I), EFA6A appears to be important for rhodopsin 
transport and a key player for ciliogenesis by regulating vesicular fusion, two biological processes 
important for vision (shown in vitro in epithelial retinal cells and in vivo in the retina of mice). 
Being implicated in basic cell functions (actin cytoskeleton organization, cell surface trafficking) and 
providing fundamental properties (epithelial cell junctions, apico-basal polarity, lumen formation) for 
epithelial cells, EFA6 proteins should be given more importance when studying epithelial tissues. 
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The whole of this work leaves some questions unanswered, and opens various perspectives for future 
investigation. I will present some of the possible areas of improvement and some hanging questions that 
we still need to tackle in order to better elucidate the roles of EFA6B and its mechanisms of action. 
Seeing the importance of EFA6B in maintaining epithelial cell physiology, I would like first to discuss 
what could be the upstream regulators allocated to prevent EFA6B downregulation in a normal context. 
Then, I would like to tackle the possible links that exists between EFA6B and its effector Cdc42, an 
interesting area for future research, and to bring up where our results stand in the midst of the 
controversies related to the role of EFA6B substrate, Arf6, in cancer. Lastly, I will try to further elaborate 
on the matrisome modifications induced by EFA6B loss: could it be a consequence or the cause of other 
modifications? And what other components would be interesting to consider? 
 
1. 1. Upstream EFA6B: Regulation at its best 
 
Another compelling discovery from this present work is the importance of the level of expression of 
EFA6B. As seen in both MCF10A and HMLE cell lines, heterozygous clones presented similar invasive 
characteristics to the full EFA6B KO cells. With only half of the expression of EFA6B, cells cannot 
function correctly meaning that a certain level of activity is required to maintain the epithelial 
homeostasis of normal cells. In BC patients, EFA6B is not frequently found mutated which suggests 
that regulatory pathways are responsible for this downregulation. 
 
After these observations, a natural question comes to mind: what regulates the expression levels of 
EFA6B? 
 
Regulation is definitely of extreme importance in this case and our research group has previously shown 
that EFA6B proteins are regulated at the protein level by ubiquitination/deubiquitination cycles. The 
levels of EFA6 are critical for TJs biogenesis and are controlled by the deubiquitinating enzyme USP9x. 
In polarized cells, a low level of EFA6 is maintained by an equilibrium between high protein synthesis 
and constitutive ubiquitination and turn over by the proteasome. However, while establishing new 
contacts, epithelial cells require higher levels of EFA6 guaranteed by the USP9x-mediated 
deubiquitination that protects EFA6 from proteosomal degradation at the nascent cell-cell contact where 
TJs are assembled (Théard et al., 2010). 
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Other cooperative mechanism can be put in place by cells to regulate EFA6B on a transcriptional level. 
First, by looking at the promoter of EFA6B, we noted several consensus sequences that can allow the 
binding of several transcription factors. Second, methylation sites have been observed offering another 
strategy of regulating the transcriptional expression of EFA6B (data not shown). 
 
The level of EFA6B expression seems to be crucial for mediating its protective role against cells gaining 
invasive properties. We can suspect that one of these mechanisms is disrupted in tumor cells expressing 
low EFA6B levels. Understanding better the EFA6B regulation process can help control the invasive 
capacity of tumor cells. 
 
1. 2. Downstream EFA6B: Cdc42 and Arf6 
 
Arf6 and controversies 
EFA6B effects are mediated by the regulation of Arf6 activation, in coordination with the recruitment 
of effector proteins by the C-terminal domain or other domains of EFA6B. In our EFA6B KO cells, we 
have clearly shown a reduced expression and activity of Arf6 which is probably in part responsible for 
the invasive properties present in our cells. In the same line of thoughts, our research group has 
previously shown a downregulation of Arf6 in Cld-low BC patients expressing lower levels of EFA6B. 
According to our data, Arf6 activation is more likely to play a protective role against the cells gaining 
mesenchymal and invasive features. In support to this conclusion, a recent study has identified that the 
downregulation of Arf6 by NEDD9, a maker of invasive and metastatic cancers, increased the pool of 
active MMP-14. Thus, the activation of Arf6 maintains MMP-14 in an inactive state that was correlated 
to a decrease in invasion (Loskutov et al., 2015). 
 
However, this does not fit with the results suggested by two research groups showing mainly that the 
activation of Arf6 is associated with the acquisition of pro-tumorigenic properties manifested by the 
formation of invadopodia and the trafficking of MMP-14 to these structures (Hashimoto et al., 2011, 
2004, 2005; Marchesin et al., 2015a). Importantly, the paper of Hashimoto et al (2004) shows that the 
expression of a constitutively active Arf6 can also reduce the invasion of these cells (Hashimoto et al., 
2004). This suggests that any deregulation of the cycle activation/deactivation of Arf6 can aberrantly 
affect the tumorigenic phenotype of cells. In fact, previous results of the lab have shown that expressing 
a continuously activated Arf6 alone gave opposite results on TJ assembly than when expressed with the 
PH-Cterminal of EFA6 (Klein et al., 2008a). These data suggested that the role of Arf6 should be studied 
in the presence of its exchange factor which mimics a more physiological context. Another explanation 
for the controversies related to Arf6 role in cancer is how invasive the cellular model used is. For 
instance, the overexpression of EFA6B in weakly tumorigenic cell lines (e.g. MCF7) could revert the 
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epithelial phenotype in 3D culture, however, this was not possible in aggressive tumor cells (MDA-
MB231) (Zangari et al., 2014). This suggested that Arf6 might have different roles depending on the 
tumor stage. 
 
Which domains of EFA6B are responsible for the protrusion formation? 
EFA6 family comprise four isoforms and 4 different domains (N-terminal, C-terminal, PH, Sec7) 
(Figure 23). We first confirmed the specificity of EFA6B by generating a rescue clone in MCF10A. 
However, it is important to validate whether EFA6B regulates this protrusive phenotype through the 
activation of Arf6, the C-terminal domain or other domains or by the coordination of both events. The 
most straightforward approach would be to express EFA6B mutants deleted for the different domains 
individually and measure the effect on the formation of the protrusive structures. These experiments are 
planned for the near future in order to validate to what extent Arf6 activation or the C-terminal domain 
alone can revert the invasive features of our EFA6B KO cells. 
 
From EFA6B to Cdc42: what are the missing links? 
The impact of the loss of EFA6B was mediated in part by the remarkable upregulation in Cdc42 activity. 
Interestingly, a study conducted on normal mammary cells overexpressing Cdc42, using in vitro and in 
vivo approaches, presents similar results to our present work: they show that the upregulation of Cdc42 
induces an increase in branching and MMP-14 activity/expression, an increased contractility and more 
importantly stromal alterations (Bray et al., 2013). The most surprising common phenotype is the 
modifications of the stromal components seen upon Cdc42 upregulation. This study validates the effects 
we have upon the loss of EFA6B and the consequences of the upregulation of Cdc42: the loss of EFA6B 
induces the upregulation of Cdc42 that will increase cell contractility, invadopodia formation and 
invasion and lastly, act on the transcriptional level to modify the ECM. Bray et al identified MAPK 
pathway activated in parallel to the upregulation of Cdc42, thus it would be interesting to test if the 
increase of Cdc42 due to the loss of EFA6B has the same effect. 
 
We should note that some characteristics were specific to our model such as the EMT engagement and 
loss of TJs proteins that are probably activated through other pathways, probably by the upregulated 
EMT-TFs or the downregulation of Arf6. 
 
Now, our next target should be to characterize the actors that are regulating Cdc42 activation in the 
absence of EFA6B. A plethora of indirect activation could be possible, however if we want to suggest 
that there is a direct regulator affected by the loss of EFA6B then we have to consider the upstream 
regulators of Cdc42, GEFs and GAPs. Loss of function of Rho GAPs and upregulation of Rho GEFs 
have been observed in various patient tumors. Based on in vitro experiments linking these Rho 
GEFs/GAPs to Cdc42, I can suggest the following potential candidates: from Rho GEFs, the Dbl family 
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GEF ARH GEF7 (β-PIX) is one of the most extensively studied for its roles in cell migration and 
invasion, and from Rho GAPs family srGAP3, a member of the Slit-Robo significantly reduced in a 
panel of breast cancer cell (Arias-Romero and Chernoff, 2013; Lawson and Ridley, 2018). 
More concretely, ARHGAP10, is probably the only Rho GAP for which it was previously shown as an 
effector of Arf1 creating therefore a link between Arf proteins and Rho family, particularly Arf1 to 
Cdc42 (Kumari and Mayor, 2008). I suggest starting by investigating members of the ARHGAP family, 
mainly ARHGAP10, and validate if they are mediating the upregulation of Cdc42 in the absence of 
EFA6B. 
1. 3. EFA6B and the matrisome
Interestingly, the loss of EFA6B have affected the matrisome composition, with 48 out of 475 modified 
genes. It is striking that around 10 % of the transcriptional changes in the EFA6B KO are on the ECM, 
an aspect gaining in importance in cancer research considering the increasing evidence of its impact on 
promoting tumorigenesis. Many candidates seem interesting to further investigate, more specifically the 
upregulation of lysyl oxidase (LOX). LOX has been shown to increase matrix stiffness by crosslinking 
collagen fibers contributing to invadopodia formation (Menon and Beningo, 2011) and to promote tumor 
invasion and metastasis by engaging integrin signaling (Kirschmann et al., 2002; Levental et al., 2009; 
Wan et al., 2013). 
As I mentioned before, on the basis of Bayer et al (2013) study, we can propose that the Cdc42 
upregulation is responsible for these matrisomal changes. However, we should keep in mind that cells 
can always amplify these modifications on the basis of the mechanoreciprocity principle between ECM 
and epithelial cells, meaning that physical forces applied by either side can trigger considerable changes 
[discussed in depth in V.Weaver reviews (Butcher et al., 2009; Paszek and Weaver, 2004)]. Thus, 
inversely, changes in the matrisome may have activated Cdc42. 
We thought that the upregulation of LOX would induce an increase in matrix rigidity that can activate 
some signaling pathways, so we started by testing the YAP/TAZ pathway, shown to respond to stiffness. 
By immunofluorescence in 2D, we did not see any differences in YAP translocation to the nucleus 
(preliminary data). More experiments held on 3D cultured KO cells would help investigate the 
implication of the YAP/TAZ pathway. Another interesting experiment is to put the KO cells in matrixes 
with increasing stiffness and see if our cells are sensitive to matrix rigidity. 
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2. Conclusion 
 
In conclusion, this PhD work allowed us to reveal the importance of EFA6B in maintaining the epithelial 
integrity in normal cells. We have also elucidated the impact of its loss on driving normal cells towards 
invasiveness in a Cdc42 dependent manner. Deleting EFA6B provided mammary epithelial cells with 
contractile and degrading capacities as well as a remarkable modification of their stromal compartment, 
all of which contribute to an invasive advantage. These properties provided by EFA6B loss can be in 
vivo the needed modifications to allow transformed cells to metastasize. EFA6B loss can be classified 
as a secondary driver gene capable of pushing cancer cells a step further in the tumorigenesis process 
and drive them towards invasion. In patients, the downregulation of EFA6B might be in part responsible 
for the evolution of breast cancer tumors into the aggressive claudin-low subtype. 
 
After all, the development of breast cancer treatments is still limited by the lack of complete knowledge 
of the molecular and cellular mechanisms responsible for mammary tumorigenesis. In addition to that, 
it is essential to better understand the microenvironment properties that can affect treatment efficiency. 
Thus, identifying in our EFA6B KO cell model the signaling pathways involved and their regulators 
might disclose new therapeutic targets for invasive breast cancer, more specifically claudin-low.
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Short title: EFA6A controls ciliogenesis 
 
 
Abstract  
 
Ciliogenesis is a coordinated process, initiated at the mother centriole by the formation of a 
large ciliary vesicle through molecular mechanisms that remain unclear. Here, we report that 
EFA6A, an exchange factor for Arf6, controls ciliogenesis at early stage by promoting the 
fusion of small distal appendage vesicles via the recruitment of Arl13b and the exocyst 
complex and by removing the inhibitory protein CP110 from the mother centriole.  At a later 
stage, and similar to Arl13b and Sec10 findings, expression levels of EFA6A regulate the 
length of the cilium. In vivo, EFA6A is essential for visual function, which depends on the 
highly specialized photoreceptor cilium. We show that EFA6A depletion from mouse retina 
resulted in morphological alterations of photoreceptors reminiscent of defects observed in 
retinal ciliopathies. Our results uncover novel fusion machinery comprised of EFA6A, Arl13b 
and the exocyst complex, which controls the assembly, the maintenance and the 
physiological function of primary cilia  
   
 
 
Introduction 
 
 The primary cilium (PC) is a microtubule-based structure found in most eukaryotic 
cells. Originally considered to be a vestigial organelle, it is now the object of intense interest 
because of its essential roles in cell homeostasis and development. Also, defects in PC 
assembly or function cause a wide variety of diseases called ciliopathies. They include 
skeletal defects, limb and digit development disorders, cystic renal diseases, 
neurodevelopmental disorders (cerebellar ataxia, acrocallosal syndrome) and retinal 
degeneration 1-3. Considered as a group, the prevalence rate of ciliopathies is relatively high 
(1 in 2000 adults)4. These disorders are due to mutations in genes that encode proteins 
localized to the PC and which play an important role in its function.  
 The outer segment (OS) of photoreceptor cells is a highly specialized PC that 
converts light signals into an electrical output in a process called phototransduction 5, 6. This 
dynamic cilium is subjected to constant renewal to compensate for the shedding and 
phagocytosis of its distal tip by the retinal pigment epithelium (RPE). Its resident proteins, 
particularly the light sensitive receptor rhodopsin, are continuously transported from the 
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proximal inner segment (IS) to the OS through the connecting cilium (CC). Most of the 
ciliopathies, including Joubert, Meckel, Senior-Loken and Bardet-Biedl syndromes lead to the 
retinal degeneration that is associated with classical disorders such as renal cystic disease, 
obesity, and mental retardation 7. The gene products implicated in these retinal illnesses are 
also expressed in the primary cilium of other tissues, which explains their pleiotropic 
phenotype. 
 The PC is formed at the distal end of the mother centriole (m-centriole) during 
quiescence or the G0 phase of the cell cycle 8-10. The assembly of PC starts with the 
formation of a large ciliary vesicle (CV) docked to the m-centriole as described more than 50 
years ago by Sergei Sorokin 11. This step is followed by the dissociation of the inhibitory 
CP110-CEP97 complex from the distal end allowing axoneme extension and the eventual 
formation of the cilium (reviewed in 8, 10). Clearly the biogenesis of the CV is not fully 
understood. Recent reports describe the presence of small preciliary vesicles docked onto 
the distal appendages (called DAV for distal appendage vesicles) that precede the formation 
of the CV, probably through their fusion12, 13.The DAV fusion is driven by the proteins EHD1/3 
and the SNARE SNAP29, at the very least 12. Then, the ciliary membrane biogenesis and 
extension is achieved by vesicular membrane trafficking controlled by a cascade of small G 
proteins, including Rab11, Rab8 and its Guanine Nucleotide Exchange Factor (GEF) Rabin8 
14-16
. More recently, the exocyst, an octameric protein complex implicated in the tethering and 
fusion of post-Golgi and recycling-compartment-derived vesicles has also been shown to 
control ciliogenesis and ciliary membrane extension 17, 18. Indeed, the exocyst complex 
localizes to the PC, and knockdown of Sec10, one of the eight exocyst subunits, strongly 
inhibits ciliogenesis whereas its overexpression increases PC assembly and length 17, 19. 
Moreover, Sec15, another exocyst subunit, interacts with Rab proteins including Rab8 and 
Rab11 (reviewed in 20). Arl13b is another small G protein that is involved in membrane 
transport, and a set of mutations in the corresponding gene has been linked to the Joubert 
syndrome ciliopathy, indicating that it plays a role in ciliogenesis 21-23. Arl13b regulates the 
ciliary length by controlling ciliary membrane extension 24. In addition, Arl13b acts as an Arl3 
GEF to control the ciliary targeting of lipidated protein cargo, and the assembly of Intra-
Flagellar Transport (IFT) -A and -B complexes required for the intra-cilium transport 25. 
Interestingly, Arl13b directly binds two exocyst complex subunits, Sec5 and Sec8, suggesting 
that Arl13b and the exocyst function together to control ciliary membrane extension via the 
tethering of membrane vesicles 26.  
 The EFA6 family belongs to the Sec7-domain containing proteins that act as 
nucleotide exchange factors for the small G proteins of the Arf group 27. Humans express 
four tissue specific EFA6 isoforms, which are encoded by four different genes 28, 29. While 
they display highly divergent N-terminal domains, they share a common C-terminal structure 
30
. Despite their homology and frequent co-expression, it remains unclear whether the 
different EFA6 proteins play specific or overlapping roles. EFA6A, is mostly expressed in the 
brain, small intestine and colon 30. It controls the endocytic trafficking of different cargos such 
as GPCRs, the transferrin receptor, ion channels 27, 31-33 and the transport of membrane 
vesicles to form the apical lumen in mammary epithelial cells 34. In addition, EFA6A drives 
actin cytoskeleton reorganization, at least in part, by interacting with F-actin and -actinin 35-
37
. Its exogenous expression leads to the formation of membrane ruffles in various cell types, 
the stabilization of the apical actomyosin ring in polarized epithelial cells 27, 30, 38, the 
formation of neurite and dendritic spines 36, 39, 40 and axon regeneration 41.  
Here, we describe the role of EFA6A as an essential regulator of ciliogenesis and 
vision. In human cells, EFA6A is required for the removal of the ciliation inhibitor CP110 and 
acts together with Arl13b and the exocyst complex to assemble the ciliary vesicle by fusion of 
DAVs. In mouse retina, EFA6A controls morphology and electrical activity of the 
photoreceptor OS. Considered together, our results indicate that EFA6A plays a key role in 
photoreceptor function by controlling early steps of ciliogenesis and cilia maintenance. 
 
RESULTS 
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 EFA6A localizes to photoreceptor and RPE cells in mouse retina 
 EFA6A protein is particularly enriched in the brain but its functions in neurons has not 
been clearly established 27. Here, we looked for a role of EFA6A in the mouse retina. First, 
immuno-histochemistry analyses localized the EFA6A protein in RPE cells, the outer and 
inner segments (OS and IS respectively) of the photoreceptors, in some cells of the inner 
nuclear and plexiform layers (INL and IPL) and in ganglion cell layer (GCL) (Fig. 1A and 
Supp. Fig. 1A). EFA6A mRNA localization was subsequently determined by in situ 
hybridization on frozen sections of retinas. In accordance with the immuno-histochemistry 
results, a specific antisense oligonucleotide probe revealed mRNA expression in the 
ganglion cell layer, inner and outer nuclear layers, and in RPE cells to some extent (Supp. 
Fig. 1B). We conclude that EFA6A is present in most cell layers of the retina including 
photoreceptors and RPE. 
 
Depletion of EFA6A leads to morphological alterations in mouse retina 
 EFA6A depletion, obtained by intravitreal siRNA application, was used to explore the 
role of EFA6A on the morphology and ultrastructural organization of the mouse retina. 
EFA6A siRNA efficiency was analyzed by WB and RT-PCR (Supp. Fig.1 C and D). Using 
light microscopy, we observed severe retinal detachment in numerous retinal sections of the 
si-EFA6A-treated groups (Fig. 1B a, b white arrowhead). This was accompanied by the loss 
of some OS (Fig. 1B b black arrowhead) and the loss of nuclei in the outer nuclear layer 
(ONL) (Fig. 1B).  
 Electron microscopy (EM) further confirmed that the photoreceptor OS organization 
was severely disrupted in the siEFA6A injected eyes at day 7 (Fig. 1C a and b). In contrast to 
the control groups, the OS were not regularly aligned and packed (Fig. 1C a,b) and the 
interface with the RPE was not tight (Supp. Fig. 1E a,b). Large holes were observed in the 
OS layer probably as a result of a defect in OS growth (Fig. 1C b white arrowhead). 
Moreover, the alteration to photoreceptor cell structure observed by EM in the siEFA6A-
treated retinas was associated with mislocalization of rhodopsin (Supp. Fig.1F b compared to 
a). Rhodopsin staining was not uniformly distributed throughout the retinas, suggesting 
inhibition of IS to OS transport. This fault in rhodopsin transport can be explained by the 
disorganization of the membrane, or connecting cilium (CC), that joins the inner and the 
outer segments (Fig. 1C b black arrowheads). In fact, the CC was less visible in the 
siEFA6A-treated tissue, compared to the control (Fig.1C b compared to a). Interestingly, in 
further support of these EM observations, acetylated-tubulin staining, which is particularly 
enriched in the CC and in the RPE of control retinas, was significantly disturbed and 
attenuated in siEFA6A-treated retinas (Fig. 1D a, b). 
 Finally, ultrastructural analysis of ONL showed degenerative cell bodies in rod (*) and 
cone photoreceptors (**) in siEFA6A-treated retinas compared to the control (Supp. Fig. 1E 
c, d) indicating that EFA6A depletion resulted in photoreceptor cell degeneration.  
 To summarize, EFA6A depletion in mouse retina provoked profound morphological 
alterations mainly in the outer segment and in the RPE layers. It resulted in the degeneration 
and the loss of photoreceptor outer segments, a mislocalization of rhodopsin, and a loss of 
connecting cilia (Supp. Fig.1G for an illustration). Thus, from these results, we conclude that 
EFA6A plays an important role in organizing the CC and the OS of the photoreceptor cells.  
 
Depletion of EFA6A leads to functional alterations of mouse retina 
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  The modified structural integrity of EFA6A-depleted retinas prompted us to test for 
alterations to their physiological electrical response. To explore the functional status of the 
siEFA6A-treated retinas, we recorded electro-retinograms (ERG) in scotopic (to measure the 
activity of rod cells, Fig. 1E and Fig Supp.2A,B,C) and photopic (to measure the activity of 
cone cells, Fig. 1F and Fig Supp.2D,E,F) conditions seven days after siRNA injection. In all 
cases, ERG showed no alteration between untreated (control) and siRNA-control-treated 
groups. However, siEFA6A-treated retinas exhibited a severe decrease in ERG response 
under both conditions.  
 In scotopic conditions and at high stimuli intensity (1.87 log scot troland.s), the a-
wave amplitude, generated by the rod cells, declined to 38% and 45% at day 7 for siRNA #a 
and #b respectively compared to control (Fig. 1E and Supp. Fig. 2A). These results are 
consistent with a degenerated and dysfunctional photoreceptor layer. The b-wave, which is 
generated by the bipolar cells immediately following the a-wave, was also affected by the 
siEFA6A treatment (Supp. Fig. 2B). The maximum saturated scotopic b-wave (Vmax) was 
significantly reduced (p<0.001); approximately 40% (#a) and 43% (#b) lower at day 7 in the 
siEFA6A-treated groups, compared to the control. However the b/a wave ratio was 
conserved between the four groups (Supp. Fig. 2C), indicating that the degeneration 
preferentially occurs in the outer retina and is not the consequence of degeneration in other 
retinal cells.  
 In photopic conditions, and at high intensity stimuli (1.87 log scot troland.s), the a-
wave amplitudes decreased significantly (p< 0.001) to 31% and 27% at day 7 for siRNA #a 
and #b compared to the control groups (Fig. 1F). Concomitantly, the overall difference in the 
photopic b-wave was also significant (p< 0.001) and the b-wave amplitudes decreased to 
27% and 30% at day 7 in siRNA #a and #b compared to the control groups (Supp. Fig. 2E). 
However the b/a ratio, under photopic condition, was not significantly affected (absence of 
negative-type ERGs b/a wave ratio< 1) by siEFA6A treatment, confirming that photoreceptor 
alteration was the main cause for the decrease in the retinal electrical response (Supp. Fig. 
2F). 
 In conclusion, our data demonstrate that EFA6A is required in vivo for the 
morphological integrity and functional activity of the photoreceptors. 
 
EFA6A controls ciliogenesis 
 As EFA6A depletion from the retina phenocopied ciliopathies i.e. loss of visual activity 
and degeneration of photoreceptor outer segments 42-44, we looked for a role of EFA6A in 
primary cilium biogenesis. We determined the localization of exogeneous EFA6A expressed 
at low levels in hTert-RPE-1 (RPE-1) cells after serum starvation to induce ciliogenesis. In 
addition to its classical plasma membrane localization, EFA6A was detected along the entire 
primary cilium where it colocalized with Arl13b, a protein essential to ciliogenesis and whose 
localization is restricted to the ciliary membrane (Fig. 2A). 
In RPE-1 cells, small interfering RNA (siRNA) mediated depletion of EFA6A strongly 
inhibited ciliogenesis, as assessed by acetylated tubulin staining (70.1% of ciliated cells in 
the control compared to 6.1% in EFA6A siRNA pool treated cells; Fig. 2B and C and 
Supplementary Fig. 3A and B). Similar results were obtained with Arl13b labeling, which 
confirmed that EFA6A depletion affected ciliogenesis (Fig. 2D). In contrast, EFA6A depletion 
did not affect centrosome assembly as controlled by the centrosomal/satellite localization of 
PCM1 (Fig. 2B), nor was Golgi apparatus morphology affected as indicated by p23 labeling 
(Supplementary Fig. 3C). These results suggest a specific role for EFA6A in the assembly of 
the primary cilium. 
200
RPE-1 cells expressed two other EFA6 isoforms, EFA6B and EFA6D (Supplementary 
Fig. 3A, B). Knockdown of either one had no effect on the presence or morphology of primary 
cilia (Fig. 2D, E and Supplementary Fig. 3A, B). This result indicates that ciliogenesis is 
specifically controlled by the EFA6A isoform in RPE-1 cells.  
To determine if EFA6A plays a general role in ciliogenesis and PC maintenance, we 
turned to the MDCK renal epithelial cell model. The exogenous and inducible expression 
(Tet-Off system) of a human vsv-g-tagged EFA6A (Supplementary Fig. 3D) significantly 
increased the percentage of ciliated cells and unexpectedly increased the cilium length as 
well (Fig. 3A, B). The cilia elongation mediated by EFA6A was also observed in MDCK cells 
grown in 3D culture indicating that this stimulatory property also occurs in near physiological 
conditions (Fig. 3C). Furthermore, siRNA-mediated EFA6A depletion inhibited ciliogenesis, 
which was rescued by the expression of the human vsv-g-tagged EFA6A, resistant to the 
canine-specific siRNA (Fig. 3D and Supplementary Fig. 3E).  Thus, cilia-localized EFA6A 
appears to act as a general regulator of ciliogenesis and controls both cilium assembly and 
maintenance.  
EFA6A depletion prevents the removal of CP110 from the m-centriole 
 We investigated the molecular mode of action of EFA6A in ciliogenesis, and given 
that EFA6A depletion totally abolished the formation of primary cilia, we focused on the early 
steps of ciliogenesis.  The CP110 protein caps the distal end of both centrioles and its 
removal from the mother centriole is required for the initiation of ciliogenesis 45. In serum-
starved RPE-1 cells, EFA6A siRNA-treatment significantly increased the proportion of cells 
containing two CP110-capped centrioles (63.4% vs 30.6% in control cells; Fig. 4A a). This 
observation suggested that EFA6A depletion may have blocked cilia formation at least in part 
by inhibiting the dissociation of CP110 from the m-centriole. CP110 removal is known to be 
driven by the centriole distal appendage protein CEP164 and the recruitment of the 
serine/threonine kinase TTBK2 to the sub-distal appendages (for review 46). EFA6A depletion 
did not inhibit the accumulation of either CEP164 or TTBK2 at the centrioles (Fig. 4A b and 
c). These observations indicate that EFA6A does not regulate the localization of CEP164 and 
TTBK2 to the m-centriole. However, in the absence of EFA6A, their recruitment is not 
sufficient to promote the release of the ciliation inhibitor CP110. 
EFA6A controls the fusion of vesicles by regulating the function of Arl13b 
We subsequently considered whether EFA6A depletion could interfere with 
membrane vesicle delivery to the m-centriole. As Arl13b is a membrane ciliary marker that is 
required for ciliary membrane formation and extension, we looked for the presence of Arl13b 
positive structures at the m-centrioles. Using immuno-fluorescence after serum-starvation, 
we observed Arl13b-positive staining close to the centriole in EFA6A-depleted cells (Fig. 4B 
a). This result suggested that, even if it led to the inhibition of PC, EFA6A depletion was not 
preventing the formation or the docking of Arl13b-positive vesicles to the m-centriole.  
To test this hypothesis, we investigated the effect of EFA6A depletion at the 
ultrastructural level by EM on serum-starved RPE-1 cells (Fig. 4B b). Control cells exhibited a 
typical PC comprised of a basal body with distal appendages and a long axoneme 
surrounded by a proximal ciliary pocket 47. In contrast, EFA6A-depleted cells rarely exhibited 
fully assembled cilia or CV-docked basal bodies. In most of the cells small vesicles (between 
50 and 100 nm diameter) were found very close  to the m-centrioles, likely docked to the 
distal appendages (Fig. 4B b, and Fig. 5 G for quantification), which is consistent with the 
Arl13b-positive vesicles observed by immunofluorescence (Fig. 4B a). These vesicles 
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resembled m-centriole-docked DAVs prior to fusion and CV assembly 12. Collectively, our 
data demonstrate a role for EFA6A in the fusion of the DAVs and in the removal of the 
CP110 negative regulator.  
Several lines of evidence prompted us to look for a link between EFA6A and Arl13b. 
Indeed, EFA6A depletion led to the inhibition of ciliogenesis as observed in Arl13b deficient 
cells, and to photoreceptor cells degeneration as noted in patients with the Arl13b-associated 
Joubert Syndrome. Moreover, similar to Arl13b, overexpression of EFA6A increased PC 
length. Using GST pull-down experiments, we demonstrated that full-length EFA6A, and to a 
lesser extent its catalytic Sec7 and PH domains, were able to specifically pull-down Arl13b-
GFP from RPE-1 cell lysate (Fig.5A and Supp. Fig. 4A). GST pull-down experiments with 
purified proteins revealed that the two proteins were able to directly interact (Fig. 5B). EFA6A 
preferentially bound the GTP-loaded form of Arl13b but did not act as an Arl13b-GEF (Supp. 
Fig. 4B, C). We considered whether Arl13b could act downstream of EFA6A. Overexpression 
of Arl13b-GFP partially rescued the inhibition of ciliogenesis induced by EFA6A depletion 
(Fig.5D and E), indicating that a lower amount of EFA6A could be counterbalanced by a 
higher expression of Arl13b. In contrast, EFA6A overexpression could not rescue the 
inhibition of ciliogenesis caused by Arl13b depletion (Supp. Fig. 4D). One explanation could 
be that EFA6A recruits Arl13b to promote the fusion of the DAVs. If this were the case, the 
depletion of Arl13b would lead to the same phenotype as that observed for EFA6A, namely 
an absence of CV but the presence of DAVs in the vicinity of m-centrioles. Indeed, electron 
microscopy imaging showed that, similarly to EFA6A, Arl13b depletion resulted in a majority 
of m-centrioles surrounded with small membrane vesicles (Fig. 5F and G for quantification). 
Our results show that EFA6A interacts with Arl13b to regulate the fusion of DAVs to 
assemble the PC. 
Among the different Arl13b interactors, only the exocyst complex could play a role in 
DAVs fusion. Indeed, the exocyst complex is involved in the tethering and the fusion of 
recycling vesicles and is also known to be required for PC and photoreceptor outer segment 
assembly 17, 18. Interestingly, we observed that EFA6A pull-downed the Sec10 and Exo84 but 
not Exo70 exocyst complex subunits (Fig.5C and Supp. Fig. 4D, E, F). The interaction with 
Sec10 is direct as indicated by the pull-down experiment with the purified proteins (Fig.5B). 
Altogether our data demonstrate that EFA6A and Arl13b, most likely through their interaction 
with the exocyst complex, regulate the fusion of DAVs to form the ciliary vesicle. 
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Discussion 
Biogenesis of the primary cilium is an important and intricate process that has been 
the object of numerous studies. The hierarchical series of events from the conversion of the 
centriole to the cilium extension have been well established, yet the detailed molecular 
mechanisms and the different partners involved in each step are poorly described. Here, we 
describe a novel molecular cascade that regulates primary cilium formation and 
maintenance. 
EFA6A functions in retina activity 
We observed that EFA6A is present in almost all mouse retina cells, including 
photoreceptors and RPE. The localization of EFA6A in photoreceptors has been previously 
reported, but its role in retina function was not addressed 48. Here, we demonstrate that 
EFA6A is required for vision. In mouse retina, EFA6A depletion led to a strong alteration of 
visual electrical activity. ERG analyses indicated that the photoreceptors, both cones and 
rods, were at the root of the defect. The electrical alterations were coupled to morphological 
damage, which was visible in the organization of the photoreceptor cell layer. The 
localization of rhodopsin was markedly affected and the rods were less compact, with a loss 
of outer segments. These alterations could arise from a defect in lipid and protein transport 
toward the cilium and would be compatible with a role for EFA6A in the delivery and the 
fusion of membrane vesicles at the basis of the OS. Moreover, EFA6A depletion resulted in 
the morphological alteration of the connecting cilium as revealed by the loss of tubulin 
acetylation labeling and confirmed at the ultrastructure level by EM. This indicated that 
EFA6A is involved in the assembly and the stability of the connecting cilium. As the latter 
plays a critical function in the transport of proteins toward the outer segment, the 
photoreceptor degeneration observed in the absence of EFA6A might also result from the 
inability to transport key OS components through the deficient connecting cilium. In any case, 
a defect in rhodopsin transport toward the outer segment is a well-described causal 
mechanism for severe diseases, such as autosomal dominant Retinitis Pigmentosa and its 
associated photoreceptor degeneration 7, 49, 50.  
A role for EFA6A in CP110 release and CV formation 
EFA6A depletion in MDCK and RPE1 cell models abolished the formation of PC 
induced by serum starvation.  This demonstrates a conserved and essential role of EFA6A in 
ciliogenesis. More precisely, our data show that EFA6A is required to remove the negative 
regulator, CP110, from the m-centriole and is thus indispensable in the early stages of 
ciliogenesis. The persistence of CP110 could explain the absence of ciliogenesis in EFA6A-
depleted cells. However, EFA6A depletion did not affect the recruitment to the basal body of 
CEP164 or the kinase TTBK2, two proteins required for the removal of CP110. These results 
suggest that EFA6A could either regulate the kinase activity of TTBK2 or control the release 
of CP110 by an unknown mechanism.  
Immuno-fluorescence analyses in EFA6A-depleted cells revealed the accumulation of 
small Arl13b-positive structures in the vicinity of the centrioles. EM studies confirmed the 
presence of small vesicles (DAV) docked or very close to the m-centrioles. These results 
indicate that docking of DAV to the distal appendages of the m-centriole is not an EFA6A-
dependent process. Yet, there was no evidence for a large CV cap at the distal end of the m-
centriole, which indicates that the fusion of the DAVs into a larger CV requires EFA6A. The 
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direct binding of EFA6A to Arl13b and to the exocyst subunit Sec10 could explain the role of 
EFA6A in CV formation. Surprisingly, we found that EFA6A depletion could be bypassed by 
overexpression of Arl13b. This observation suggests that EFA6A may act as an anchor for 
Arl13b. We hypothesize that EFA6A may regulate the formation of a complex between 
Arl13b and the exocyst in order to favor the fusion of the DAV. Arl13b and Arf6, the substrate 
of EFA6, are known to regulate the endocytic recycling traffic 23, 51-53. Moreover, it has been 
shown that Arf6 regulates the post-endocytic recycling through its interaction with Sec10 54. 
Thus, we propose that EFA6A controls the fusion of vesicular membranes during ciliogenesis 
via the formation of a complex including Arf6, Arl13b and the exocyst. 
 Another protein involved in vesicular transport, EHD1/3, was recently found to be 
necessary for CV assembly 12. Much like EFA6A, EHD1 appears to be essential for both the 
fusion of the DAV and the removal of CP110. This suggests the existence of an unexpected 
link whereby the assembly of the CV would control the CP110 release from the m-centriole, a 
crucial step for the subsequent elongation of the axoneme. The authors proposed that 
EHD1/3 regulates the fusion of the DAV through SNAP29, a SNARE membrane fusion 
regulator. To date no connections between EFA6A and EHD proteins nor between EFA6A 
and SNAP29 have been reported. Yet, EHD1 and Arf6 have been implicated in the recycling 
of MHC-I to the plasma membrane 55 suggesting that both proteins could be part of the same 
transport machinery. As the exocyst complex is thought to bridge the v- and t-SNAREs from 
opposing membranes, the interaction between EFA6A and Arl13b would occur prior to the 
interaction between EHD1/3 and the t-SNARE SNAP29.  
 
EFA6A expression controls PC maintenance  
The primary cilium is a dynamic structure whose size and shape is controlled by 
extracellular signals. This is emphasized in the outer segments of photoreceptors cells, 
which are continually renewed to counterbalance cell shedding and RPE phagocytosis. The 
fact that EFA6A depletion in adult mice retina resulted in the alteration of the CC and OS of 
photoreceptors indicates that EFA6A also controls the maintenance of the PC. Analogous to 
its role in DAVs fusion and CV formation, we propose that EFA6A-mediated membrane 
vesicle fusion plays a major role in PC maintenance. It is noteworthy that the overexpression 
of EFA6A (this study), as observed for Arl13b and Sec10 17, 24, increases the cilium length. 
One can speculate that EFA6A and Arl13b regulate the delivery of membrane, through 
interactions with the vesicle tethering exocyst complex, to the base of the growing cilia where 
the exocyst has been found to be enriched 26. It would be now interesting to study a putative 
link between the EFA6A/Arl13b/exocyst machinery and the Rab11/Rabin8/Rab8 equivalent, 
which has been clearly shown to be involved in the delivery of vesicular membrane during 
ciliogenesis (reviewed in 20, 56 ).  
In summary, EFA6A is essential during the initiation steps of ciliogenesis and in the 
control of PC length. EFA6A could assume both of these functions by regulating membrane 
vesicles fusion during ciliogenesis. 
  
Loss of EFA6A function, a cause of ciliopathy?  
 Although ciliopathies are individually relatively rare disorders (incidence of individual 
ciliopathies ranges from around 1 in 1000 for autosomal dominant polycystic kidney disease 
to 1 in 150000 3), taken as a group their high frequency has a significant impact on human 
health. In the absence of effective treatments, they remain a serious public health challenge. 
Mutations in genes that encode cilia components account for most of ciliopathies. Here, we 
have observed that the exogenously expressed EFA6A is localized throughout the primary 
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cilium in RPE-1 cells, and immuno-histochemistry analyses revealed that the endogenous 
EFA6A was abundant in the photoreceptor cell layer of mouse retina. EFA6A was also 
identified in a proteomic analysis of the mouse photoreceptor sensory cilium complex 57. In 
addition to its retinal localization, we found EFA6A to be essential for cilium assembly, as 
well as photoreceptor maintenance and function. We observed that EFA6A depletion in 
retinas leads to progressive degeneration of photoreceptors.  Thus, aberrant alleles of the 
PSD gene, which encodes EFA6A, are a strong candidate for retinal ciliopathies. Given that 
the molecular mechanisms of primary cilium assembly are highly conserved we predict that 
PSD gene mutations will be the source of pleiotropic disorders. We also predict that strong 
alterations in the PSD post-transcriptional gene regulatory mechanisms affecting the cellular 
expression level of EFA6A protein could also lead to ciliopathies. 
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 METHODS 
 
Antibodies and reagents.  
Mouse monoclonal antibodies (mAb) against vsv-g epitope (clone P5D4, Roche Diagnostics 
GmbH, Mannheim, Germany), -Tubulin, -Tubulin, acetylated-Tubulin, syntaxin, PKCα, 
calbindin monoclonal D-28K antibody (Sigma Chemical St. Louis, MO), RPE65 (Novus 
Biological), rhodopsin (Millipore). Rabbit antisera against Arl13b and CP110 (Proteintech 
Europe Manchester, United Kingdom), EFA6B, TTBK2 and CEP164 (Sigma), P23 and 
PCM1 (Abcam). Rat monoclonal anti–Thy1.2 antibody (Abcam). Goat anti-peanut agglutinin 
antibody (Vector Laboratories). Fluorescent conjugated secondary antibodies from donkey 
and cross absorbed for the other species were from Jackson Immuno-Research (West Grove 
PA) or Molecular Probes (Invitrogen, Cergy Pontoise France). DAPI (4', 6-diamidino-2-
phenylindole) was from Sigma. Fluorescent labeled Phalloïdin (Molecular Probes). Purified 
rabbit anti-EFA6A antibodies were prepared against a C-terminal peptide 
(LQPKPSSQPRAQRHS) (Eurogentec). 
 
DNA constructs  
Plasmids encoding vsv-g-tagged EFA6A, EGFP-EFA6A, His-EFA6A, His-EFA6AN, GST-
EFA6A-Sec7, GST-EFA6A, GST-EFA6A-Cter, GST-EFA6A-PHCter and Arf6-His have been 
described elsewhere 35. Plasmid encoding Arl13b-EGFP 58, plasmids encoding GST-
CrArl13b(18-278), called GST-Arl13b in the text, was kindly provided by A. Whittinghofer and 
C. Koerner (MPI Dortmund, Germany). Plasmids encoding, Sec10-mCherry, Exo70-mCherry 
and  Exo84-mCherry were kindly provided by Dr. P. Chavrier (Institut Curie, Paris). 
 
Expression and purification of recombinant proteins  
For the in vitro binding assays, recombinant Arf6 wild-type with a C-terminal hexa-his tag 
(Arf6-His) and recombinant N-terminal his-tagged EFA6AN (His-EFA6AN) were produced 
in Escherichia coli and purified on Ni/NTA resin according manufacturer’s instructions 
(Qiagen). The different GST fusion proteins were also produced in Escherichia coli and 
purified by affinity chromatography on gluthatione sepharose beads (GE Healthcare). After 
elution with glutathione, the purified proteins were dialysed against 20 mM Tris-HCl pH 8.0, 
100 mM NaCl, 1 mM MgCl2, 1 mM DTT, and 10% glycerol (dialysis buffer), and stored at -80 
°C.  
 
 
Cell culture and transfections.  
All cell culture reagents were from Invitrogen/Thermofisher, unless indicated. Filtered FBS 
was from Perbio Thermo Scientific. All cell lines were grown in 10% FBS at 37°C in 5% CO2 
incubator. RPE-1 cells (from ATCC) were cultured in DMEM/F12 (1:1). For cilia formation, 
RPE-1 cells were serum deprived overnight before fixation.  
MDCKII cells stably expressing vsvg tagged-EFA6A under the control of the tetracycline-
repressible transactivator were grown in MEM (Sigma), 5% decomplemented FCS (Biowest-
Abcys), penicillin-streptomycin 100 U/ml and 100 g/ml 38. When indicated cells were grown 
on transparent permeable filters (Costar, Corning, NY) at 2x105 cells/12 mm filter. For 3D cell 
culture, cells were grown in Matrigel (BD Biosciences, San Jose, CA). 2x103 cells were 
mixed with 20 µl of Matrigel and deposited as a drop on a 12 mm glass coverslip placed in a 
24-well plate and fed with regular medium. 
 
siRNAs and mammalian expression constructs.  
SiRNA duplexes (SiGenome smart pool) targeting human Arl13b, Sec10 (ExoC5), EFA6A, 
EFA6B and EFA6D and the four individual siRNA-EFA6A were purchased from Dharmacon. 
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SiRNA control was from Sigma. The siRNA#2661 ccuaucagaggcggagcua targeting the 
canine EFA6A transcript was from Eurogentec. 
Small siRNA targeting mouse EFA6A for intravitreal injection siRNA#1:ccaagugggaauucuu 
and siRNA#2: ggugcuaccgagagac (Eurogentec) 
SiRNA transfection in RPE-1 cells was performed using RNAiMAX (Invitrogen) following the 
manufacturer’s instructions and the transfected cells were incubated for 3 days at 37 °C. 
SiRNA transfection in MDCK cells was performed by nucleofection (AMAXA, Lonza Group 
Ltd, Switzerland) according to the manufacturer’s instructions. 
 
All cDNA transfections were performed with Jet-PEI (Polyplus transfection, Illkirch, France) 
and the transfected cells were incubated for 24 h or 48 h at 37 °C. All cDNAs were amplified 
in DH5 Escherichia coli (Invitrogen) and prepared following the manufacturer’s instructions 
(Qiagen). 
 
RNA isolation, RT-PCR and QRT-PCR. 
Total mRNA was isolated according the Chowynski method using Fast Prep apparatus (Q-
Biogen). 2 g of total RNA was denatured at 65 °C for 10 min and incubated for 1 h at 50 °C 
in presence of 2.5 mM dNTP, 100 U Superscript III (Invitrogen) using 0.5 g oligo(dT)15 
primer in a total volume of 20 l, followed by an inactivation step of 15 min at 70 °C. A 
negative control lacking RT enzyme was also performed in each assay (NRT).  
 
The PCR was performed with mouse EFA6A (forward) atctctgttgcgcccc, (reverse) 
gggcggcggaagccctga and GAPDH (forward) gaacatcatccctgcatcc, (reverse) 
ccagtgagcttcccgttca primers with HotStartTaq DNA polymerase according to the standard 
protocol described by the manufacturer (Q-Biogen). The PCR products obtained after 35 
cycles were separated through a 1% agarose gel, visualized under UV after staining with 
ethidium bromide. The PCR fragments of expected sizes for EFA6A and GAPDH mRNA-
derived PCR products were obtained. 
 
Quantitative real-time PCR was carried out with The LightCycler® 480 SYBR Green I Master 
(Roche Life Science) in triplicate and analyzed using LightCycler® 480 Software, Version 1.5 
(Roche). Primers sequences were as followed:  
Human EFA6A: Forward: AGGGCATGATCCTCTACCTG  
Reverse: ATGCTGATGGCATTCTTGAG  
Canine  EFA6A: Forward: CAACGGGCAGAAAGCAGACC  
Reverse: CTTGAGGTACTCGCCAGCCA  
Human EFA6B: Forward: AGCTGGAAAGTGAGCCAGAT  
Reverse: CAGCAGATGGAGTGTGGTTT  
Human EFA6D: Forward: AAGGCCTTGTCTGAAGAGGA  
Reverse: CTCTGGGCTCTGAGTTTGAA  
Human/Canine GAPDH: Forward: TGCCTCCTGCACCACCAACT  
Reverse: CCCGTTCAGCTCAGGGATGA 
The expression of each gene was normalized to the GAPDH housekeeping gene and relative 
levels were calculated on the basis of the comparative cycle threshold Ct method (2-ΔΔCt) 
where ΔΔCt is the difference in Ct between target and reference gene.  
 
Western blot (WB) analysis. 
Cells were washed twice in PBS then scrapped and resuspended in lysis buffer (20 mM 
TriEthanolAmine pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% sodium dodecyl sulfate and 
protease inhibitor cocktail Complete (Roche)). Cell lysates were centrifuged and 
supernatants were diluted with Laemmli Sample Buffer. The proteins were heat denatured 
and processed by SDS-PAGE, transferred to nitrocellulose membranes, stained with 
Ponceau Red and immunoblotted with the indicated Abs. Proteins were detected with 
SuperSignal western lightning chemiluminescence reagents (ThermoScientific) following the 
manufacturer’s instructions. 
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Analysis of the protein content of siRNA-treated mouse retinas by WB. Retinas were washed 
in PBS and resuspended in Lysis Buffer, boiled for 10 min, sonicated for 10 seconds and 
centrifuged. The resulting lysates were diluted 10 times and the total protein concentrations 
were determined by the Bradford method. Protein samples (40 g/lane) were then analyzed 
as described above.    
 
GST pull-down experiments  
RPE-1 cells were transfected with plasmid encoding GFP-Arl13b, Sec10-mCherry, Exo84-
mCherry or Exo70-mCherry using Jet-PEI reagent. After 24 h, cells were lysed in 50 mM Tris 
pH 8.0, 100 mM NaCl, 10 mM MgCl2, 10% glycerol, 1% Triton-X100, 2  mM DTT and a 
cocktail of protease inhibitors (Roche, Diagnostics GmbH, Mannheim, Germany), and 
centrifuged at 15,000 g for 10 min at 4 °C. Supernatants were incubated with 0.5 M GST 
constructs in the presence of 0.75% BSA and Glutathione Sepharose beads for 4 h at 4 °C.  
For the direct binding assay with purified recombinant proteins, 0.2 µM His-EFA6A was 
incubated in 50 mM Tris pH 8.0, 100 mM NaCl, 10 mM MgCl2, 10% glycerol, 2 mM DTT and 
a cocktail of protease inhibitors with 0.5 µM GST or GST-Arl13b or GST-Sec10 in the 
presence of 0.75% BSA and Glutathione Sepharose beads for 1 h at 25 °C. 
Beads were washed, and bound proteins were eluted using SDS sample buffer and 
separated by SDS-PAGE. Their presence in the eluate was detected by western blotting 
using the anti-tag antibodies. 
 
[35S]GTPS binding assay 
Arf6-His or GST-Arl13b (2 µM) were incubated at 30 °C with [35S]GTPS (20 µM, ~ 2000 
cpm/pmol) in 50 mM Hepes (pH 7.5), 2 mM MgCl2, 100 mM KCl, with azolectin (2 mM) with 
or without (as indicated in the figure legend) His-tagged EFA6A (0.5 µM). At the indicated 
times, samples of 25 µl were removed and measured for radioactivity as described 
previously 27. 
 
Preparation of phospholipid vesicles. 
Large unilamellar vesicles of azolectin were prepared as previously described 59, and 
extruded through a 0.4 µM pore size polycarbonate filter (Isopore, Millipore).  
 
Immunofluorescence and confocal microscopy analysis. 
Cultured cells were fixed on 11 mm round glass coverslips with 3 % paraformaldehyde, and 
processed for immunofluorescence analysis as described previously 60. Confocal microscopy 
analysis was carried out with a Leica TCS-SP5 microscope (Leica Microsystems) or a LSM-
780 (Zeiss). Images were analyzed using Image J and Adobe Photoshop software. 
For centrosomal markers, the cells were fixed in methanol at -20 °C for 4 min, rinsed twice in 
PBS and processed as above. 
 
Transmission Electron Microscopy. 
For ultrastructural analysis, RPE-1 cells were fixed in 1.6% glutaraldehyde in 0.1 M 
phosphate buffer, rinsed in 0.1 M cacodylate buffer, post-fixed for 1 h in 1% osmium tetroxide 
and 1% potassium ferrocyanide in 0.1 M cacodylate buffer to enhance the staining of 
membranes. Cells were rinsed in distilled water, dehydrated in alcohol and lastly embedded 
in epoxy resin. Contrasted ultrathin sections (70 nm) were analyzed using a JEOL 1400 
transmission electron microscope mounted with a Morada Olympus CCD camera. 
 
Quantifications. 
Results are the mean of three to five independent experiments. The error bars represent 
standard deviations within n experiments (n= number of distinct experiments, unless 
otherwise indicated). Statistical significances (p) were calculated using the Student's t test. 
*p<0.05; **p<0.01, ***p<0.001 and ****p<0.0001. 
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For cilium length measurement, fluorescence image stacks of MDCK cells obtained by laser 
scanning confocal microscopy (LSM780, Carl Zeiss, France) were analyzed to measure cilia 
lengths using a custom-built ImageJ macro program. After maximal projection of the stack, 
filtering by "background subtraction", segmentation by thresholding and skeletization of the 
cilia, the length of the skeleton was measured to determine the length of each cilium in the 
image. 
Ethics statement. 
All animal experimental procedures were carried out in accordance with French ethical 
guidelines for laboratory animals (Reference number of the project: 00537.01; Agreement 
number: C061525 -16/04/2015) and approved by the Animal Care Committee.  
Animals. 
Adult male C57BL/6J mice (12 weeks old, Charles River, France) were maintained in clear 
plastic cages and subjected to standard light cycles (12 hours light/12 hours dark cycle) with 
ad libitum access to food and water. Light levels measured from the bottom of cages 
averaged 40 to 50 lux. Mice were acclimated for 2 weeks before experiments. These studies 
were performed in accordance with the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. 
In situ hybridization, immunochemistry and double labeling.  
Mice were dark adapted overnight, anesthetized, and killed by cervical dislocation. Eyes 
were removed, punctured at the limbus, and perfused with ice-cold 4 % paraformaldehyde in 
phosphate-buffered saline (PBS). After 30 min of fixation, the cornea, the lens, and the 
vitreous were removed, and the eyecups were cryoprotected in 20 % sucrose in PBS for 1 
hour and then embedded (Tissue-Tek; Sakura Finetek, Bayer Diagnostic, France) and snap 
frozen in liquid nitrogen-cooled isopentane. Frozen 14 µm sections were then prepared.  
For in situ hybridization, the following antisense oligonucleotide EFA6A was used (5’-GCA-
GGT-AGA-GGA-TCA-TCG-CCT-TGA-GGA-TCC-CGT-GGA-AGC-TCT-TCC-3’). A sense 
oligonucleotide unrelated to EFA6A (5’-GGA-AGA-GCT-TCC-ACG-GGA-TCC-TCA-AGG-
GCA-TGA-TCC-TCT-ACC-TGC-3’) was used as a negative control. The probes were 3’ end-
labeled with digoxigenin (DIG)-UTP by a terminal deoxynucleotidyl transferase. The sections 
were fixed for 20 min in 4% paraformaldehyde in PBS, permeabilized in 0.1% Tween 20 in 
PBS, and rinsed three times in PBS. The sections were acetylated for 10 min in 0.25% acetic 
anhydride and 0.1 M triethanolamine, pH 7.5, prehybridized for 10 min at 37 °C in 4X SSC 
and 12.5% formamide, and hybridized overnight at 42 °C in 4X SSC, 12.5% formamide, 2.5x 
Denhardt’s solution, 250 µg/ml herring sperm DNA, 125 µg/ml yeast tRNA and 22 ng/µl DIG-
labeled probe. The slides were washed briefly with 4X SSC and then washed for 10 min with 
1XSSC. DIG-labeled probes were detected according to the protocol from Roche 
Diagnostics. Briefly, the sections were incubated with anti-DIG-alkaline phosphatase for 2 hr 
at 25 °C, rinsed with washing buffer, and incubated with nitroblue tetrazolium (NBT)–5-
bromo-4-chloro-3-indolyl-phosphate (BCIP) for 2 hr in the dark. 
For immunochemistry, the frozen retinal sections were immediately permeabilized with 0.1% 
Triton X-100 in PBS for 15 minutes, subsequently washed in 1X PBS three times, and 
blocked with 10% horse serum in PBS to avoid nonspecific staining. EFA6A was detected 
with the rabbit anti–EFA6A antibody (1:250) incubated on sections overnight. Detection was 
achieved with FITC labeled anti-rabbit IgG antibody (1:300; Vector Laboratories, Burlingame, 
CA). In double-immunostaining experiments, cell-type marker antibodies were incubated 
overnight at 4 °C and were detected with an indocarbocyanine (Cy-3)–labeled anti–mouse 
IgG (1:300; Invitrogen, Cergy Pontoise, France) or anti–rat IgG (1:400; Invitrogen). Control 
experiments were conducted without primary antibody. Rod and cone inner segments were 
localized, respectively, with anti-rhodopsin and peanut agglutinin antibodies, horizontal cells 
with anti-calbindin, bipolar cells with anti-PKCα, amacrine cells with anti–syntaxin, RPE cells 
with anti-RPE65 and ganglion cells with rat anti–Thy1.2 antibodies. Immunostained retinas 
on slides were mounted in anti-fade solution containing DAPI for nuclear staining 
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(Vectashield; VectorLaboratories). Negative controls were used without primary or secondary 
antibodies (data not shown). Images of retinal sections were acquired and photographed with 
an imaging microscope (Axioplan2; Zeiss, Thornwood, NY) and analyzed by confocal 
microscopy (Zeiss, LSM 780).   
 
Intravitreal injection. 
Wild-type mice of C57BL/6 strain (4-month-old) were anesthetized by intraperitoneal injection 
of ketamine/xylazine (ketamine, 100-125 mg/kg; xylazine, 10-12.5 mg/kg). Intravitreal 
injections were performed under a dissecting microscope with a 33 gauge needle attached to 
a 10 μl glass syringe (Hamilton, France). The needle was positioned 1 mm posterior to the 
limbus and 1 μl of the solution was slowly injected (3-5 sec) into the vitreous chamber of the 
eye using micro-pump (WA 30 second interval was kept before removing the needle).  
Intravitreal injections of siRNA were performed as described in 61. 
 
ERG Recording and Analysis. 
Photopic and scotopic ERGs were performed according to the procedure previously 
described 62. To record conventional ERGs, responses were recorded using a stainless ring 
electrode that made contact with the corneal surface through a thin layer of 0.7% 
methylcellulose. Needle electrodes placed in the cheek and the tail served as reference and 
ground leads, respectively. Responses were differentially amplified (0.3-500 Hz), averaged, 
and stored using a UTAS Big-Shot signal averaging system (LKC Technologies, 
Gaithersburg, MD). In scotopic conditions, ERGs were recorded to flash stimuli ranging from 
-4.72 to 1.87 log (sc td*s) presented, in order of increasing intensity to the dark-adapted eye, 
in an LKC ganzfeld flashes. Cone ERGs were obtained to flash stimuli ranging between -2.32 
to 1.87 log (sc td*s) superimposed on a steady adapting field (44 cd/m2) after a 7-min 
adaptation period (Peachey et al. 1993). The a-wave amplitude was measured from the pre-
stimulus baseline to the trough of the a-wave. The b-wave amplitude was measured from the 
trough of the a-wave to the positive peak. The amplitude of the c-wave was measured from 
the pre-stimulus baseline to the peak of the c-wave. Oscillatory potentials (OPs), which are 
superimposed over the ascending phase of the ERG b-wave, were extracted for the highest 
and the lowest stimulus intensity using EM software with two filtering operations equivalent to 
applying a bandpass filter with corner frequencies of 73 and 500 Hz. For each of the four 
parameters, the data were plotted against flash luminance to generate the scotopic and 
photopic luminance response. Two other parameters were derived from the scotopic and 
photopic luminance response of the b-wave, the V max and logσ. 
 
Histology and transmission electron microscopy. Eyes enucleated from mice killed by 
anesthetic overdose were placed in fresh fixative (2.5% glutaraldehyde, 2% 
paraformaldehyde and 100 mM cacodylate, pH 7.4) for 30 min. Tissues were post fixed with 
1% OsO4 for 1 h and stained with 2% uranyl-acetate for 30 min, dehydrated in a graded 
ethanol series, and infiltrated and embedded in medium (Polybed 812; Polysciences, 
Warrington, PA). Thin sections were cut with an ultramicrotome (MT 7000; Ventana, Tucson, 
AZ), collected onto nickel grids, stained with 2% uranyl acetate and lead citrate, and imaged 
in a transmission electron microscope (Morgagni; FEI, Hillsboro,OR) at 80 Kv. 
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Figure legends. 
 
 
Figure 1. Localization of EFA6A and morphological changes resulting from its depletion in retina. (A) 
Immunolabeling of wild-type retinas with an anti-EFA6A Ab (anti-EFA6A) or an anti-EFA6A Ab after 
incubation with purified EFA6A protein (control) revealed the specific presence of EFA6A in the retinal 
pigment epithelium, in photoreceptors (outer and inner segments), in some cells in the inner nuclear 
and plexiform layer and in the ganglion cell layer. (B) Morphology of siRNA control or siEFA6A-
injected retinas.  Semi-thin retinal sections (1 m) counterstained with methylene blue-azur II of siRNA 
control (a) and siEFA6A (b) treated retinas. Scale bar = 20 µm. (C) Electron micrographs of 
photoreceptor Outer Segments (OS) of siControl (a) or siEFA6A (b) treated retinas illustrating lack of 
well-organized OS accompanied with degeneration in siEFA6A retina. (D) Mislocalisation of acetylated 
tubulin in EFA6A depleted retinas. Immunohistochemical analysis of cryosections of siControl (a) or 
siEFA6A (b) treated retina using acetylated tubulin antibodies (green). DAPI was used to stain the 
nuclei (blue). Scale bars: 20 µm. RPE, retinal pigment epithelium; OS, outer segment; CC, connecting 
cilium; IS, inner segment, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear 
layer IPL, inner plexiform layer; GCL, ganglion cell layer. (E, F) EFA6A depletion on scotopic (E) or 
photopic (F) luminance-response function: Intensity response curve of the dark adapted (E) or of the 
light-adapted (F) ERG a-waves in retina of 3-month-old control mice (black square) or subjected to 
intravitreal injection of siRNA control (gray inverted triangle), siEFA6A#a (black circle) and si-EFA6A#b 
(gray triangle) respectively. Mean amplitude + SD are plotted; n=3 and ***p <0.001).  
 
 
Figure 2. EFA6A controls ciliogenesis in RPE-1 cells. (A) Localization of GFP-EFA6A transiently 
expressed in RPE-1 cells for 48 hours, starved for 24 hours and stained with anti-Arl13b.  (B) EFA6A 
depletion inhibits ciliogenesis without affecting PCM1 localization. Acetylated Tubulin (Ac.T), and 
PCM1 were detected in control or EFA6A siRNA treated RPE-1 serum starved for 24 h. (C) Ciliation 
quantification in 48 h siRNA-treated cells (control, EFA6A si-pool, si#2 and si#4) with 24 h serum 
starvation, followed by staining with acetylated -tubulin and  tubulin antibodies. (Means +/- SD from 
n= 3 to 5 independent experiments are shown, with >200 cells per treatment. For si-pool n=5 and 
p=3.2E-5; for si#2 and si#4 n=3 and p=6.3E-3, and p=6.5E-3 respectively. (D) Analysis of the effect of 
the EFA6 isoform specificity on ciliogenesis. RPE-1 cells were transfected with siRNA control or siRNA 
pool against EFA6A or EFA6B or EFA6D for 48 h, with 24 h serum starvation, followed by staining with 
Arl13b antibodies. (D) Quantification of ciliation is shown. Means +/- SD from 3 to 5 independent 
experiments, t-test p=1.3E-4 for siEFA6A; p=8.2E-2 for siEFA6B, and p=3.6E-2 for siEFA6D. 
 
 
Figure 3. EFA6A overexpression increases cilium length in 2D and 3D culture systems. (A) MDCK 
cells overexpressing (-dox) or not (+dox) vsv-g-EFA6A were grown on polycarbonate filters for 10 
days then fixed and processed for immuno-fluorescence. (B) Quantification of the effect of EFA6A 
overexpression on the number of cilia/cell and the cilium length observed in (A).  Mean ± SD, n=4 for 
Dox and n=5 for no Dox, p=0.4 (NS) for nucleus number, p=6.7E-05 (****) for cil/nucl % and p=0.0004 
(***) for average cilium length (m). (C) Ciliogenesis rescued with human vsv-g EFA6A in MDCK 
treated with siRNA anti-canine EFA6A. MDCK cells were transfected with a control siRNA or a canine 
EFA6A specific siRNA and grown on polycarboante filters. After 10 days, the fully polarized cells were 
processed for immunofluorescence and the primary cilia stained with an anti-Arl13b antibody. The 
experiment was performed three times and data from all three experiments were combined. An 
average of 4000 cells per sample was analyzed for the presence or absence of a cilium. Values are 
mean ± SD, n=3, t-test p=0.001 for siEFA6A +DOX; p=0.04 for siEFA6A -DOX. (D) EFA6A 
overexpression increases cilium size in 3D culture system. MDCK cells overexpressing (-dox) or not 
(+dox) vsv-g-EFA6A were grown in matrigel for 7 days then fixed and processed for immuno-
fluorescence using antibodies anti vsv-g and anti-acetylated -tubulin antibodies.  
 
Figure 4. Knockdown of EFA6A inhibits the maturation of the basal body (A) and the assembly of the 
ciliary vesicle (B). (A) EFA6A depletion prevents CP110 release from the mother centrioles (a) but 
does not impair the recruitment of CEP164 (b) or TTBK2 (c). ). tubulin (-Tub), CP110, CEP164 and 
TTBK2 were detected in control or EFA6A siRNA treated RPE-1 cells with 24 h serum starvation. Error 
bars represent SD (n =3 to 5 independent experiments), p=4.9E-5 for CP110, p=0.8 and 0.6 for 
CEP164 and TTBK2 respectively. (B) EFA6A depletion does not prevent the accumulation of Arl13b 
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positive structures at the centriole (a). tubulin (-Tub) and Arl13b were detected in control or EFA6A 
siRNA treated RPE-1 cells after 24 h serum starvation. Error bars represent SD (n=3 to 5 independent 
experiments), p=0.3. Representative electron micrographs of RPE-1 cells treated with siRNA control 
or EFA6A pool for 48 h with serum starvation for the last 24 h (b). Distal appendage vesicles (DAV) 
are highlighted. 
Figure 5. EFA6A interacts with Arl13b and Sec10 a subunit of the exocyst complex. (A) GST pull-
down of Arl13b-GFP expressed in BHK cells by EFA6A fused to GST. (B) GST pull-down of purified 
His-EFA6A by Arl13b or Sec10 fused to GST. (C) GST pull-down of Sec10-mCherry expressed in 
BHK cells by EFA6A fused to GST. (D) Overexpression of Arl13b-GFP partially rescued the inhibition 
of ciliogenesis induced by EFA6A depletion. RPE-1 cells were transfected or not with pEGFP-Arl13b 
for 24 h and then transfected with siEFA6A for 48 h, with 24 h serum starvation, followed by staining 
with acetylated tubulin or Arl13b antibodies. (D) Quantification of ciliation is shown. Error bars 
represent SD, n =3 p=1.9E-3 for siEFA6A pool treated sample and p=2.2E-2 for the siEFA6A pool-
treated and Arl13b-GFP-expressing sample. (F) Representative electron micrographs of RPE-1 cells 
treated with siRNA control or Arl13b pool for 48 h with serum starvation for the last 24 h. (G) 
Quantification of electron microscopy experiments. Only m-centrioles without elongated cilia are 
quantified (i.e. about 30% of control cells and 90% of the siEFA6A and siARl13b cells as determined 
by immunofluorescence experiments). (H) Model for the role of EFA6A during intracellular ciliogenesis 
(modified from 12)
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EFA6A plays a key role in retinal function by controlling ciliogenesis. 
Partisani et al 
Supplemental Information: 
Figure S1. (A) Confocal immunofluorescence micrographs show, by colabeling with anti-rhodopsin 
(Rho, upper panels), that EFA6A is expressed in OS particularly in connecting cilium (red arrows), 
scale bar 25 µm. Colabeling with Peanut Agglutinin (middle panels) indicates that EFA6A is present in 
the IS and OS segments of cones (arrows). Scale bar, 50 µm. Finally, colabeling with anti-RPE65 
(lower panels) shows the presence of EFA6A in the RPE (arrows). Scale bar, 25 µm. (B) In situ 
hybridization experiments on mouse retina using an EFA6A antisense or sense (as control) probe and 
diaminobenzidine detection. Antisense oligonucleotide probe revealed labeled cells in the ganglion cell 
layer, in the inner and outer nuclear layers and in the retinal pigment epithelium. (C,D) Control of 
EFA6A depletion in mouse retina after 7 days siRNA treatment (by intra-vitreal injection of siRNA) by 
Western blotting (C) or RT-PCR (D). (E) Electron micrographs of RPE cells (a,b), and of outer nuclear 
layer (c,d) of si-RNA control (a,c) or siRNA-EFA6A (b,d) treated retinas illustrating lack of well-
organized OS at the RPE/OS interface and the presence of  some degenerative cell bodies of rod (*) 
and cone photoreceptors (**) in siRNA-EFA6A retina. (F) Mislocalisation of rhodopsin in EFA6A 
depleted retinas. Immunohistochemical analysis of cryosections of si-control (a) or si-EFA6A (b) 
treated retina using rhodopsin (green) antibodies and Peanut Agglutunin (red). DAPI was used to stain 
the nuclei (blue). RPE, retinal pigment epithelium; OS, outer segment; IS, inner segment, ONL, outer 
nuclear layer; CC, connecting cilium. Scale bars: 20 µm. (G) Diagram summarizing the morphological 
alterations observed in siEFA6A-treated retinas. 
Figure S2. (A,B,C) Effect of EFA6A depletion on scotopic luminance-response function: (A) ERG 
profiles obtained at flash intensities ranging from -4.72 to 1.87 log scot td/s in control, siRNA control, 
si-EFA6A#a and si-EFA6A#b groups respectively at day 7 post-injection. Each trace is the average of 
at least nine mice. (B) Intensity response curve of the dark adapted b-waves in retina of 3-month-old 
control mice (black square) or subjected to intravitreal injection of siRNA control (gray inverted 
triangle), siEFA6A#a (black circle) and si-EFA6A#b (gray triangle) respectively. Mean amplitude + SD 
are plotted. (C) The dark-adapted b/a-wave ratio obtained at flash intensities ranging from - 1.12 to 
1.87 log scot td/s in retinas of control mice (black square) and in mice submitted to intravitreal injection 
of siRNA control (red inverted triangle) and si-EFA6A#a (red circle) and si-EFA6A#b (blue triangle) 
respectively at 7-days post-injection. Mean amplitude ± SD are plotted, n=3 and pvalues <0.001). 
(D,E,F) Effect of EFA6A depletion on light-adapted retinas. ERG waveform extracted at 2.2 Hz. (D) 
photopic ERG traces elicited at flash intensities ranging from - 2.32 to 1.87 log scot td/s in retinas of 3-
month-old control mice or submitted to intravitreal injection of siRNA control, si-EFA6A#a and si-
EFA6A#b groups respectively at day 7 post-injection. Each photopic ERG trace represents the 
average of at least nine mice. (E) intensity-response curve of the light-adapted ERG b-waves in retina 
of control (black square), siRNA control (gray inverted triangle), si-EFA6A#a (dark circle) and 
siEFA6A#b (gray triangle). Mean amplitudes ± SD are plotted, n=3 and pvalues <0.001). (F) The light 
adapted b/a-wave ratio obtained at day 7 post-injection and at flash intensities ranging from 0.47 to 
1.87 log scot td/s in retinas of control mice (black square)  and in mice subjected to intravitreal 
injection of siRNA control (red inverted triangle) and si-EFA6A#a (red circle) and si-EFA6A#2 (blue 
triangle) respectively at 7 day post-injection. Mean amplitude ± SD are plotted. 
Figure S3. (A, B) Western blotting (A) or Q-PCR (B) analyses to control the efficiency of siRNA-
mediated depletion of EFA6A, EFA6B and EFA6D in RPE-1 cells after 48h siRNA treatment.  (C) 
EFA6A depletion inhibits ciliogenesis without affecting Golgi apparatus morphology. P23 (Golgi) and 
Arl13b (cilium) were detected in siRNA control or EFA6A siRNA pool treated RPE-1 cells for 48h with 
24h serum starvation. (D) Western blot analysis of vsv-g-EFA6A overexpression in MDCK cells.  (E) 
Q-PCR analysis of the effect of the siRNA anti-canine EFA6A in MDCK cells.
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Figure S4. EFA6A interacts with Arl13b. (A) GST pull-down of Arl13b-GFP expressed in BHK cells 
with different constructs of EFA6A fused to GST. (B) GST pull-down of purified His-EFA6A by Arl13b 
fused to GST and bound to GDP or GTPS. (C) Kinetics of [35S]GTPS binding to purified Arf6-His or
GST-Arl13b in the presence or the absence of EFA6A. (D) Western blotting to control the efficiency of 
siRNA-mediated depletion of Arl13b in RPE-1 cells. (E) Overexpressed GFP-EFA6A did not rescue 
the si-Arl13b mediated inhibition of ciliogenesis in serum-starved RPE-1 cells. (F,G) GST pull-down of 
mCherry tagged Exo84 (E) or Exo70 (F) expressed in BHK cells with different constructs of EFA6A 
fused to GST. (H) GST-EFA6A but not GST-Arl13b pull-downed endogenous Sec10 from BHK cell 
lysate. 
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